1	Persistent	persistent	JJ	_	2	NMOD
2	Amyloidosis	amyloidosis	NN	_	0	ROOT
3	following	follow	VBG	_	2	TMP
4	Suppression	suppression	NN	_	3	PMOD
5	of	of	IN	_	4	NMOD
6	Aβ	aβ	NN	_	7	NMOD
7	Production	production	NN	_	5	PMOD
8	in	in	IN	_	4	LOC
9	a	a	DT	_	11	NMOD
10	Transgenic	transgenic	JJ	_	11	NMOD
11	Model	model	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	Alzheimer	alzheimer	NNP	_	14	NMOD
14	Disease	disease	NN	_	12	PMOD

1	Abstract	abstract	NN	_	0	ROOT

1	Background	background	NN	_	0	ROOT

1	The	the	DT	_	4	NMOD
2	proteases	protease	NNS	_	4	NMOD
3	(	(	-LRB-	_	4	P
4	secretases	secretase	NNS	_	23	SBJ
5	)	)	-RRB-	_	4	P
6	that	that	WDT	_	7	SBJ
7	cleave	cleave	VBP	_	4	NMOD
8	amyloid	amyloid	NN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	β	β	NN	_	12	NMOD
11	(	(	-LRB-	_	12	P
12	Aβ	aβ	NN	_	14	NMOD
13	)	)	-RRB-	_	14	P
14	peptide	peptide	NN	_	7	OBJ
15	from	from	IN	_	7	ADV
16	the	the	DT	_	19	NMOD
17	amyloid	amyloid	NN	_	19	NMOD
18	precursor	precursor	NN	_	19	NMOD
19	protein	protein	NN	_	21	NMOD
20	(	(	-LRB-	_	21	P
21	APP	app	NN	_	15	PMOD
22	)	)	-RRB-	_	23	P
23	have	have	VBP	_	0	ROOT
24	been	be	VBN	_	23	VC
25	the	the	DT	_	26	NMOD
26	focus	focus	NN	_	24	PRD
27	of	of	IN	_	26	NMOD
28	considerable	considerable	JJ	_	29	NMOD
29	investigation	investigation	NN	_	27	PMOD
30	in	in	IN	_	29	NMOD
31	the	the	DT	_	32	NMOD
32	development	development	NN	_	30	PMOD
33	of	of	IN	_	32	NMOD
34	treatments	treatment	NNS	_	33	PMOD
35	for	for	IN	_	34	NMOD
36	Alzheimer	alzheimer	NNP	_	37	NMOD
37	disease	disease	NN	_	35	PMOD
38	.	.	.	_	23	P

1	The	the	DT	_	2	NMOD
2	prediction	prediction	NN	_	3	SBJ
3	has	have	VBZ	_	0	ROOT
4	been	be	VBN	_	3	VC
5	that	that	IN	_	4	PRD
6	reducing	reduce	VBG	_	27	SBJ
7	Aβ	aβ	NN	_	8	NMOD
8	production	production	NN	_	6	OBJ
9	in	in	IN	_	6	LOC
10	the	the	DT	_	11	NMOD
11	brain	brain	NN	_	9	PMOD
12	,	,	,	_	27	P
13	even	even	RB	_	14	PMOD
14	after	after	IN	_	27	TMP
15	the	the	DT	_	16	NMOD
16	onset	onset	NN	_	14	PMOD
17	of	of	IN	_	16	NMOD
18	clinical	clinical	JJ	_	19	NMOD
19	symptoms	symptom	NNS	_	17	PMOD
20	and	and	CC	_	16	COORD
21	the	the	DT	_	22	NMOD
22	development	development	NN	_	20	CONJ
23	of	of	IN	_	22	NMOD
24	associated	associate	VBN	_	25	NMOD
25	pathology	pathology	NN	_	23	PMOD
26	,	,	,	_	27	P
27	will	will	MD	_	5	SUB
28	facilitate	facilitate	VB	_	27	VC
29	the	the	DT	_	30	NMOD
30	repair	repair	NN	_	28	OBJ
31	of	of	IN	_	30	NMOD
32	damaged	damage	VBN	_	33	NMOD
33	tissue	tissue	NN	_	31	PMOD
34	and	and	CC	_	30	COORD
35	removal	removal	NN	_	34	CONJ
36	of	of	IN	_	35	NMOD
37	amyloid	amyloid	NN	_	38	NMOD
38	lesions	lesion	NNS	_	36	PMOD
39	.	.	.	_	3	P

1	However	however	RB	_	14	ADV
2	,	,	,	_	14	P
3	no	no	DT	_	7	NMOD
4	long	long	JJ	_	6	NMOD
5	-	-	HYPH	_	4	P
6	term	term	NN	_	7	NMOD
7	studies	study	NNS	_	14	SBJ
8	using	use	VBG	_	7	NMOD
9	animal	animal	NN	_	10	NMOD
10	models	model	NNS	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	amyloid	amyloid	NN	_	13	NMOD
13	pathology	pathology	NN	_	11	PMOD
14	have	have	VBP	_	0	ROOT
15	yet	yet	RB	_	14	ADV
16	been	be	VBN	_	14	VC
17	performed	perform	VBN	_	16	VC
18	to	to	TO	_	17	PRP
19	test	test	VB	_	18	IM
20	this	this	DT	_	21	NMOD
21	hypothesis	hypothesis	NN	_	19	OBJ
22	.	.	.	_	14	P

1	Methods	method	NNS	_	0	ROOT
2	and	and	CC	_	1	COORD
3	Findings	finding	NNS	_	2	CONJ

1	We	we	PRP	_	2	SBJ
2	have	have	VBP	_	0	ROOT
3	generated	generate	VBN	_	2	VC
4	a	a	DT	_	7	NMOD
5	transgenic	transgenic	JJ	_	7	NMOD
6	mouse	mouse	NN	_	7	NMOD
7	model	model	NN	_	3	OBJ
8	that	that	WDT	_	10	SBJ
9	genetically	genetically	RB	_	10	ADV
10	mimics	mimic	VBZ	_	7	NMOD
11	the	the	DT	_	12	NMOD
12	arrest	arrest	NN	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	Aβ	aβ	NN	_	15	NMOD
15	production	production	NN	_	13	PMOD
16	expected	expect	VBN	_	15	NMOD
17	from	from	IN	_	16	ADV
18	treatment	treatment	NN	_	17	PMOD
19	with	with	IN	_	18	NMOD
20	secretase	secretase	NN	_	21	NMOD
21	inhibitors	inhibitor	NNS	_	19	PMOD
22	.	.	.	_	2	P

1	These	these	DT	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	overexpress	overexpress	VBP	_	0	ROOT
4	mutant	mutant	NN	_	5	NMOD
5	APP	app	NN	_	3	OBJ
6	from	from	IN	_	3	ADV
7	a	a	DT	_	8	NMOD
8	vector	vector	NN	_	6	PMOD
9	that	that	WDT	_	10	SBJ
10	can	can	MD	_	8	NMOD
11	be	be	VB	_	10	VC
12	regulated	regulate	VBN	_	11	VC
13	by	by	IN	_	12	LGS
14	doxycycline	doxycycline	NN	_	13	PMOD
15	.	.	.	_	3	P

1	Under	under	IN	_	12	ADV
2	normal	normal	JJ	_	3	NMOD
3	conditions	condition	NNS	_	1	PMOD
4	,	,	,	_	12	P
5	high	high	JJ	_	7	NMOD
6	-	-	HYPH	_	5	P
7	level	level	NN	_	8	NMOD
8	expression	expression	NN	_	12	SBJ
9	of	of	IN	_	8	NMOD
10	APP	app	NN	_	9	PMOD
11	quickly	quickly	RB	_	12	ADV
12	induces	induce	VBZ	_	0	ROOT
13	fulminant	fulminant	JJ	_	15	NMOD
14	amyloid	amyloid	NN	_	15	NMOD
15	pathology	pathology	NN	_	12	OBJ
16	.	.	.	_	12	P

1	We	we	PRP	_	2	SBJ
2	show	show	VBP	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	doxycycline	doxycycline	NN	_	5	NMOD
5	administration	administration	NN	_	6	SBJ
6	inhibits	inhibit	VBZ	_	3	SUB
7	transgenic	transgenic	JJ	_	9	NMOD
8	APP	app	NN	_	9	NMOD
9	expression	expression	NN	_	6	OBJ
10	by	by	IN	_	6	ADV
11	greater	great	JJR	_	14	NMOD
12	than	than	IN	_	11	QMOD
13	95	0	CD	_	11	QMOD
14	%	%	NN	_	10	PMOD
15	and	and	CC	_	6	COORD
16	reduces	reduce	VBZ	_	15	CONJ
17	Aβ	aβ	NN	_	18	NMOD
18	production	production	NN	_	16	OBJ
19	to	to	IN	_	16	ADV
20	levels	level	NNS	_	19	PMOD
21	found	find	VBN	_	20	NMOD
22	in	in	IN	_	21	LOC
23	nontransgenic	nontransgenic	JJ	_	24	NMOD
24	mice	mouse	NNS	_	22	PMOD
25	.	.	.	_	2	P

1	Suppression	suppression	NN	_	10	SBJ
2	of	of	IN	_	1	NMOD
3	transgenic	transgenic	JJ	_	5	NMOD
4	Aβ	aβ	NN	_	5	NMOD
5	synthesis	synthesis	NN	_	2	PMOD
6	in	in	IN	_	1	NMOD
7	this	this	DT	_	8	NMOD
8	model	model	NN	_	6	PMOD
9	abruptly	abruptly	RB	_	10	MNR
10	halts	halt	VBZ	_	0	ROOT
11	the	the	DT	_	12	NMOD
12	progression	progression	NN	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	amyloid	amyloid	NN	_	15	NMOD
15	pathology	pathology	NN	_	13	PMOD
16	.	.	.	_	10	P

1	However	however	RB	_	9	ADV
2	,	,	,	_	9	P
3	formation	formation	NN	_	9	SBJ
4	and	and	CC	_	3	COORD
5	disaggregation	disaggregation	NN	_	4	CONJ
6	of	of	IN	_	3	NMOD
7	amyloid	amyloid	NN	_	8	NMOD
8	deposits	deposit	NNS	_	6	PMOD
9	appear	appear	VBP	_	0	ROOT
10	to	to	TO	_	9	OPRD
11	be	be	VB	_	10	IM
12	in	in	IN	_	11	PRD
13	disequilibrium	disequilibrium	NN	_	12	PMOD
14	as	as	IN	_	11	PRP
15	the	the	DT	_	16	NMOD
16	plaques	plaque	NNS	_	17	SBJ
17	require	require	VBP	_	14	SUB
18	far	far	RB	_	17	TMP
19	longer	longer	RBR	_	18	AMOD
20	to	to	TO	_	17	OPRD
21	disperse	disperse	VB	_	20	IM
22	than	than	IN	_	18	AMOD
23	to	to	TO	_	22	SUB
24	assemble	assemble	VB	_	23	IM
25	.	.	.	_	9	P

1	Mice	mouse	NNS	_	20	SBJ
2	in	in	IN	_	7	ADV
3	which	which	WDT	_	2	PMOD
4	APP	app	NN	_	5	NMOD
5	synthesis	synthesis	NN	_	6	SBJ
6	was	be	VBD	_	1	NMOD
7	suppressed	suppress	VBN	_	6	VC
8	for	for	IN	_	7	TMP
9	as	as	RB	_	12	QMOD
10	long	long	JJ	_	12	QMOD
11	as	as	IN	_	12	QMOD
12	6	0	CD	_	13	NMOD
13	mo	mo	NN	_	8	PMOD
14	after	after	IN	_	7	TMP
15	the	the	DT	_	16	NMOD
16	formation	formation	NN	_	14	PMOD
17	of	of	IN	_	16	NMOD
18	Aβ	aβ	NN	_	19	NMOD
19	deposits	deposit	NNS	_	17	PMOD
20	retain	retain	VBP	_	0	ROOT
21	a	a	DT	_	24	NMOD
22	considerable	considerable	JJ	_	24	NMOD
23	amyloid	amyloid	NN	_	24	NMOD
24	load	load	NN	_	20	OBJ
25	,	,	,	_	20	P
26	with	with	IN	_	20	ADV
27	little	little	JJ	_	28	NMOD
28	sign	sign	NN	_	26	PMOD
29	of	of	IN	_	28	NMOD
30	active	active	JJ	_	31	NMOD
31	clearance	clearance	NN	_	29	PMOD
32	.	.	.	_	20	P

1	Conclusion	conclusion	NN	_	0	ROOT

1	This	this	DT	_	2	NMOD
2	study	study	NN	_	3	SBJ
3	demonstrates	demonstrate	VBZ	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	amyloid	amyloid	NN	_	6	NMOD
6	lesions	lesion	NNS	_	10	SBJ
7	in	in	IN	_	6	LOC
8	transgenic	transgenic	JJ	_	9	NMOD
9	mice	mouse	NNS	_	7	PMOD
10	are	be	VBP	_	4	SUB
11	highly	highly	RB	_	12	AMOD
12	stable	stable	JJ	_	13	NMOD
13	structures	structure	NNS	_	10	PRD
14	in	in	FW	_	15	AMOD
15	vivo	vivo	FW	_	13	NMOD
16	that	that	WDT	_	17	SBJ
17	are	be	VBP	_	13	NMOD
18	slow	slow	JJ	_	17	PRD
19	to	to	TO	_	18	AMOD
20	disaggregate	disaggregate	VB	_	19	IM
21	.	.	.	_	3	P

1	Our	our	PRP$	_	2	NMOD
2	findings	finding	NNS	_	3	SBJ
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	arresting	arrest	VBG	_	13	SBJ
6	Aβ	aβ	NN	_	7	NMOD
7	production	production	NN	_	5	OBJ
8	in	in	IN	_	5	LOC
9	patients	patient	NNS	_	8	PMOD
10	with	with	IN	_	9	NMOD
11	Alzheimer	alzheimer	NNP	_	12	NMOD
12	disease	disease	NN	_	10	PMOD
13	should	should	MD	_	4	SUB
14	halt	halt	VB	_	13	VC
15	the	the	DT	_	16	NMOD
16	progression	progression	NN	_	14	OBJ
17	of	of	IN	_	16	NMOD
18	pathology	pathology	NN	_	17	PMOD
19	,	,	,	_	4	P
20	but	but	CC	_	4	COORD
21	that	that	IN	_	20	CONJ
22	early	early	JJ	_	23	NMOD
23	treatment	treatment	NN	_	24	SBJ
24	may	may	MD	_	21	SUB
25	be	be	VB	_	24	VC
26	imperative	imperative	JJ	_	25	PRD
27	,	,	,	_	25	P
28	as	as	IN	_	25	PRP
29	it	it	PRP	_	30	SBJ
30	appears	appear	VBZ	_	28	SUB
31	that	that	IN	_	30	OBJ
32	amyloid	amyloid	NN	_	33	NMOD
33	deposits	deposit	NNS	_	38	SBJ
34	,	,	,	_	38	P
35	once	once	IN	_	38	TMP
36	formed	form	VBN	_	35	SUB
37	,	,	,	_	38	P
38	will	will	MD	_	31	SUB
39	require	require	VB	_	38	VC
40	additional	additional	JJ	_	41	NMOD
41	intervention	intervention	NN	_	39	OBJ
42	to	to	TO	_	41	NMOD
43	clear	clear	VB	_	42	IM
44	.	.	.	_	3	P

1	Introduction	introduction	NN	_	0	ROOT

1	Over	over	IN	_	2	QMOD
2	a	a	DT	_	3	NMOD
3	decade	decade	NN	_	4	AMOD
4	ago	ago	RB	_	9	TMP
5	the	the	DT	_	8	NMOD
6	amyloid	amyloid	NN	_	7	NMOD
7	cascade	cascade	NN	_	8	NMOD
8	hypothesis	hypothesis	NN	_	9	SBJ
9	predicted	predict	VBD	_	0	ROOT
10	that	that	IN	_	9	OBJ
11	increased	increase	VBN	_	12	NMOD
12	levels	level	NNS	_	21	SBJ
13	of	of	IN	_	12	NMOD
14	amyloid	amyloid	NN	_	16	NMOD
15	-	-	HYPH	_	14	P
16	β	β	NN	_	18	NMOD
17	(	(	-LRB-	_	18	P
18	Aβ	aβ	NN	_	20	NMOD
19	)	)	-RRB-	_	20	P
20	peptide	peptide	NN	_	13	PMOD
21	lead	lead	VBP	_	10	SUB
22	to	to	IN	_	21	ADV
23	secondary	secondary	JJ	_	24	NMOD
24	pathologies	pathology	NNS	_	22	PMOD
25	that	that	WDT	_	27	SBJ
26	ultimately	ultimately	RB	_	27	ADV
27	culminate	culminate	VBP	_	24	NMOD
28	in	in	IN	_	27	ADV
29	the	the	DT	_	30	NMOD
30	onset	onset	NN	_	28	PMOD
31	of	of	IN	_	30	NMOD
32	Alzheimer	alzheimer	NNP	_	33	NMOD
33	disease	disease	NN	_	35	NMOD
34	(	(	-LRB-	_	35	P
35	AD	ad	NN	_	31	PMOD
36	)	)	-RRB-	_	21	P
37	[	[	-LRB-	_	38	P
38	1	0	CD	_	21	PRN
39	]	]	-RRB-	_	38	P
40	.	.	.	_	9	P

1	Early	early	JJ	_	2	NMOD
2	support	support	NN	_	6	SBJ
3	for	for	IN	_	2	NMOD
4	this	this	DT	_	5	NMOD
5	hypothesis	hypothesis	NN	_	3	PMOD
6	came	come	VBD	_	0	ROOT
7	from	from	IN	_	6	ADV
8	genetic	genetic	JJ	_	9	NMOD
9	studies	study	NNS	_	7	PMOD
10	linking	link	VBG	_	9	NMOD
11	early	early	JJ	_	13	NMOD
12	-	-	HYPH	_	11	P
13	onset	onset	NN	_	14	NMOD
14	AD	ad	NN	_	10	OBJ
15	to	to	IN	_	10	ADV
16	mutations	mutation	NNS	_	15	PMOD
17	in	in	IN	_	16	LOC
18	the	the	DT	_	21	NMOD
19	amyloid	amyloid	NN	_	21	NMOD
20	precursor	precursor	NN	_	21	NMOD
21	protein	protein	NN	_	23	NMOD
22	(	(	-LRB-	_	23	P
23	APP	app	NN	_	17	PMOD
24	)	)	-RRB-	_	23	P
25	,	,	,	_	23	P
26	from	from	IN	_	30	ADV
27	which	which	WDT	_	26	PMOD
28	Aβ	aβ	NN	_	29	SBJ
29	is	be	VBZ	_	23	NMOD
30	derived	derive	VBN	_	29	VC
31	,	,	,	_	23	P
32	and	and	CC	_	23	COORD
33	presenilins	presenilins	NNS	_	34	NMOD
34	1	0	CD	_	32	CONJ
35	and	and	CC	_	34	COORD
36	2	0	CD	_	35	CONJ
37	,	,	,	_	34	P
38	which	which	WDT	_	39	SBJ
39	are	be	VBP	_	34	NMOD
40	interchangeable	interchangeable	JJ	_	41	NMOD
41	components	component	NNS	_	39	PRD
42	of	of	IN	_	41	NMOD
43	a	a	DT	_	45	NMOD
44	endoprotease	endoprotease	NN	_	45	NMOD
45	complex	complex	NN	_	42	PMOD
46	that	that	WDT	_	47	SBJ
47	releases	release	VBZ	_	45	NMOD
48	Aβ	aβ	NN	_	47	OBJ
49	from	from	IN	_	47	ADV
50	APP	app	NN	_	49	PMOD
51	(	(	-LRB-	_	54	P
52	for	for	IN	_	54	ADV
53	review	review	NN	_	52	PMOD
54	see	see	VBP	_	47	PRN
55	[	[	-LRB-	_	54	P
56	2	0	CD	_	58	NMOD
57	,	,	,	_	58	P
58	3	0	CD	_	54	OBJ
59	]	]	-RRB-	_	54	P
60	)	)	-RRB-	_	54	P
61	.	.	.	_	6	P

1	If	if	IN	_	25	ADV
2	,	,	,	_	1	P
3	as	as	IN	_	9	ADV
4	predicted	predict	VBN	_	3	SUB
5	,	,	,	_	9	P
6	overproduction	overproduction	NN	_	9	SBJ
7	of	of	IN	_	6	NMOD
8	Aβ	aβ	NN	_	7	PMOD
9	initiates	initiate	VBZ	_	1	SUB
10	the	the	DT	_	11	NMOD
11	cascade	cascade	NN	_	9	OBJ
12	of	of	IN	_	11	NMOD
13	events	event	NNS	_	12	PMOD
14	leading	lead	VBG	_	13	NMOD
15	to	to	IN	_	14	ADV
16	disease	disease	NN	_	15	PMOD
17	,	,	,	_	25	P
18	then	then	RB	_	25	TMP
19	therapeutic	therapeutic	JJ	_	20	NMOD
20	strategies	strategy	NNS	_	25	SBJ
21	that	that	WDT	_	22	SBJ
22	lower	lower	VBP	_	20	NMOD
23	Aβ	aβ	NN	_	24	NMOD
24	levels	level	NNS	_	22	OBJ
25	should	should	MD	_	0	ROOT
26	either	either	CC	_	27	COORD
27	arrest	arrest	VB	_	25	VC
28	or	or	CC	_	27	COORD
29	reverse	reverse	VB	_	28	CONJ
30	the	the	DT	_	31	NMOD
31	progression	progression	NN	_	27	OBJ
32	from	from	IN	_	31	NMOD
33	peptide	peptide	NN	_	32	PMOD
34	to	to	IN	_	32	PMOD
35	dementia	dementia	NN	_	34	PMOD
36	.	.	.	_	25	P

1	Early	early	JJ	_	2	NMOD
2	evidence	evidence	NN	_	24	SBJ
3	from	from	IN	_	2	NMOD
4	clinical	clinical	JJ	_	5	NMOD
5	trials	trial	NNS	_	3	PMOD
6	of	of	IN	_	5	NMOD
7	antibody	antibody	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	mediated	mediate	VBN	_	10	NMOD
10	clearance	clearance	NN	_	6	PMOD
11	,	,	,	_	10	P
12	one	one	CD	_	10	APPO
13	of	of	IN	_	12	NMOD
14	the	the	DT	_	19	NMOD
15	first	$#ORD#$	JJ	_	19	NMOD
16	Aβ	aβ	NN	_	18	AMOD
17	-	-	HYPH	_	16	P
18	lowering	lower	VBG	_	19	NMOD
19	approaches	approach	NNS	_	13	PMOD
20	tested	test	VBN	_	19	NMOD
21	in	in	IN	_	20	LOC
22	humans	human	NNS	_	21	PMOD
23	,	,	,	_	24	P
24	suggested	suggest	VBD	_	0	ROOT
25	that	that	IN	_	24	OBJ
26	treatments	treatment	NNS	_	32	SBJ
27	designed	design	VBN	_	26	NMOD
28	to	to	TO	_	27	PRP
29	reduce	reduce	VB	_	28	IM
30	amyloid	amyloid	NN	_	31	NMOD
31	burden	burden	NN	_	29	OBJ
32	may	may	MD	_	25	SUB
33	indeed	indeed	RB	_	32	ADV
34	be	be	VB	_	32	VC
35	beneficial	beneficial	JJ	_	34	PRD
36	.	.	.	_	24	P

1	Although	although	IN	_	26	ADV
2	the	the	DT	_	3	NMOD
3	trials	trial	NNS	_	4	SBJ
4	were	be	VBD	_	1	SUB
5	halted	halt	VBN	_	4	VC
6	because	because	IN	_	5	PRP
7	of	of	IN	_	6	PMOD
8	adverse	adverse	JJ	_	9	NMOD
9	effects	effect	NNS	_	6	PMOD
10	in	in	IN	_	9	NMOD
11	a	a	DT	_	12	NMOD
12	subset	subset	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	volunteers	volunteer	NNS	_	13	PMOD
15	[	[	-LRB-	_	18	P
16	4	0	CD	_	18	NMOD
17	,	,	,	_	18	P
18	5	0	CD	_	5	PRN
19	]	]	-RRB-	_	18	P
20	,	,	,	_	26	P
21	further	further	JJ	_	22	NMOD
22	analysis	analysis	NN	_	26	SBJ
23	of	of	IN	_	22	NMOD
24	several	several	JJ	_	25	NMOD
25	patients	patient	NNS	_	23	PMOD
26	found	find	VBD	_	0	ROOT
27	evidence	evidence	NN	_	26	OBJ
28	that	that	IN	_	27	NMOD
29	amyloid	amyloid	NN	_	30	NMOD
30	pathology	pathology	NN	_	40	SBJ
31	,	,	,	_	30	P
32	and	and	CC	_	30	COORD
33	to	to	IN	_	38	NMOD
34	a	a	DT	_	36	NMOD
35	lesser	less	JJR	_	36	NMOD
36	degree	degree	NN	_	33	PMOD
37	cognitive	cognitive	JJ	_	38	NMOD
38	function	function	NN	_	32	CONJ
39	,	,	,	_	40	P
40	was	be	VBD	_	28	SUB
41	improved	improve	VBN	_	40	VC
42	in	in	IN	_	41	ADV
43	proportion	proportion	NN	_	42	PMOD
44	to	to	IN	_	43	NMOD
45	the	the	DT	_	46	NMOD
46	patient	patient	NN	_	48	NMOD
47	's	's	POS	_	46	NMOD
48	titer	titer	NN	_	44	PMOD
49	of	of	IN	_	48	NMOD
50	Aβ	aβ	NN	_	52	AMOD
51	-	-	HYPH	_	50	P
52	specific	specific	JJ	_	53	NMOD
53	antibody	antibody	NN	_	49	PMOD
54	[	[	-LRB-	_	57	P
55	6	0	CD	_	57	NMOD
56	,	,	,	_	57	P
57	7	0	CD	_	41	PRN
58	]	]	-RRB-	_	57	P
59	.	.	.	_	26	P

1	While	while	IN	_	20	ADV
2	this	this	DT	_	3	NMOD
3	approach	approach	NN	_	4	SBJ
4	is	be	VBZ	_	1	SUB
5	promising	promising	JJ	_	4	PRD
6	,	,	,	_	20	P
7	constant	constant	JJ	_	8	NMOD
8	exposure	exposure	NN	_	20	SBJ
9	to	to	IN	_	8	NMOD
10	antibodies	antibody	NNS	_	9	PMOD
11	that	that	WDT	_	12	SBJ
12	recognize	recognize	VBP	_	10	NMOD
13	an	an	DT	_	14	NMOD
14	epitope	epitope	NN	_	12	OBJ
15	highly	highly	RB	_	16	AMOD
16	enriched	enrich	VBN	_	14	NMOD
17	in	in	IN	_	16	LOC
18	the	the	DT	_	19	NMOD
19	brain	brain	NN	_	17	PMOD
20	may	may	MD	_	0	ROOT
21	have	have	VB	_	20	VC
22	unexpected	unexpected	JJ	_	24	NMOD
23	side	side	NN	_	24	NMOD
24	effects	effect	NNS	_	21	OBJ
25	that	that	WDT	_	26	SBJ
26	will	will	MD	_	24	NMOD
27	limit	limit	VB	_	26	VC
28	its	its	PRP$	_	32	NMOD
29	long	long	JJ	_	31	NMOD
30	-	-	HYPH	_	29	P
31	term	term	NN	_	32	NMOD
32	use	use	NN	_	27	OBJ
33	.	.	.	_	20	P

1	An	an	DT	_	3	NMOD
2	alternative	alternative	JJ	_	3	NMOD
3	approach	approach	NN	_	14	SBJ
4	that	that	WDT	_	5	SBJ
5	is	be	VBZ	_	3	NMOD
6	being	be	VBG	_	5	VC
7	actively	actively	RB	_	6	MNR
8	pursued	pursue	VBN	_	6	VC
9	for	for	IN	_	8	PRP
10	future	future	JJ	_	11	NMOD
11	treatment	treatment	NN	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	AD	ad	NN	_	12	PMOD
14	seeks	seek	VBZ	_	0	ROOT
15	to	to	TO	_	14	OPRD
16	lower	lower	VB	_	15	IM
17	Aβ	aβ	NN	_	18	NMOD
18	levels	level	NNS	_	16	OBJ
19	by	by	IN	_	16	MNR
20	limiting	limit	VBG	_	19	PMOD
21	its	its	PRP$	_	22	NMOD
22	production	production	NN	_	20	OBJ
23	from	from	IN	_	20	ADV
24	the	the	DT	_	26	NMOD
25	precursor	precursor	NN	_	26	NMOD
26	protein	protein	NN	_	27	NMOD
27	APP	app	NN	_	23	PMOD
28	.	.	.	_	14	P

1	Peptide	peptide	NN	_	2	NMOD
2	Aβ	aβ	NN	_	3	SBJ
3	is	be	VBZ	_	0	ROOT
4	released	release	VBN	_	3	VC
5	from	from	IN	_	4	ADV
6	APP	app	NN	_	5	PMOD
7	by	by	IN	_	4	LGS
8	the	the	DT	_	9	NMOD
9	action	action	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	two	two	CD	_	12	NMOD
12	enzymes	enzyme	NNS	_	10	PMOD
13	,	,	,	_	12	P
14	the	the	DT	_	22	NMOD
15	β	β	NN	_	17	NMOD
16	-	-	HYPH	_	15	P
17	APP	app	NN	_	18	AMOD
18	cleaving	cleave	VBG	_	19	NMOD
19	enzyme	enzyme	NN	_	22	NMOD
20	1	0	CD	_	19	NMOD
21	(	(	-LRB-	_	22	P
22	BACE1	bace0	NN	_	12	APPO
23	)	)	-RRB-	_	22	P
24	and	and	CC	_	22	COORD
25	γ	γ	SYM	_	27	P
26	-	-	HYPH	_	27	P
27	secretase	secretase	NN	_	24	CONJ
28	,	,	,	_	12	P
29	which	which	WDT	_	30	SBJ
30	cleave	cleave	VBP	_	12	NMOD
31	the	the	DT	_	32	NMOD
32	holoprotein	holoprotein	NN	_	30	OBJ
33	at	at	IN	_	30	LOC
34	the	the	DT	_	40	NMOD
35	N	n	NN	_	40	NMOD
36	-	-	HYPH	_	35	P
37	and	and	CC	_	35	COORD
38	C	c	NN	_	37	CONJ
39	-	-	HYPH	_	35	P
40	termini	terminus	NNS	_	33	PMOD
41	of	of	IN	_	40	NMOD
42	Aβ	aβ	NN	_	41	PMOD
43	,	,	,	_	4	P
44	respectively	respectively	RB	_	4	ADV
45	.	.	.	_	3	P

1	Several	several	JJ	_	2	NMOD
2	inhibitors	inhibitor	NNS	_	7	SBJ
3	of	of	IN	_	2	NMOD
4	γ	γ	SYM	_	6	P
5	-	-	HYPH	_	6	P
6	secretase	secretase	NN	_	3	PMOD
7	have	have	VBP	_	0	ROOT
8	already	already	RB	_	7	ADV
9	been	be	VBN	_	7	VC
10	produced	produce	VBN	_	9	VC
11	[	[	-LRB-	_	14	P
12	8	0	CD	_	14	NMOD
13	,	,	,	_	14	P
14	9	0	CD	_	10	PRN
15	]	]	-RRB-	_	14	P
16	,	,	,	_	7	P
17	and	and	CC	_	7	COORD
18	small	small	JJ	_	20	NMOD
19	molecule	molecule	NN	_	20	NMOD
20	inhibitors	inhibitor	NNS	_	28	SBJ
21	of	of	IN	_	20	NMOD
22	β	β	NN	_	24	NMOD
23	-	-	HYPH	_	22	P
24	APP	app	NN	_	25	AMOD
25	cleaving	cleave	VBG	_	26	NMOD
26	enzyme	enzyme	NN	_	21	PMOD
27	1	0	CD	_	26	NMOD
28	are	be	VBP	_	17	CONJ
29	currently	currently	RB	_	28	TMP
30	being	be	VBG	_	28	VC
31	developed	develop	VBN	_	30	VC
32	[	[	-LRB-	_	35	P
33	10	0	CD	_	35	NMOD
34	,	,	,	_	35	P
35	11	0	CD	_	31	PRN
36	]	]	-RRB-	_	35	P
37	.	.	.	_	7	P

1	The	the	DT	_	5	NMOD
2	long	long	JJ	_	4	NMOD
3	-	-	HYPH	_	2	P
4	term	term	NN	_	5	NMOD
5	effectiveness	effectiveness	NN	_	18	SBJ
6	of	of	IN	_	5	NMOD
7	this	this	DT	_	8	NMOD
8	approach	approach	NN	_	6	PMOD
9	in	in	IN	_	5	LOC
10	either	either	CC	_	11	COORD
11	humans	human	NNS	_	9	PMOD
12	or	or	CC	_	11	COORD
13	model	model	NN	_	14	NMOD
14	systems	system	NNS	_	12	CONJ
15	,	,	,	_	18	P
16	however	however	RB	_	18	ADV
17	,	,	,	_	18	P
18	has	have	VBZ	_	0	ROOT
19	not	not	RB	_	18	ADV
20	been	be	VBN	_	18	VC
21	reported	report	VBN	_	20	VC
22	.	.	.	_	18	P

1	Although	although	IN	_	39	ADV
2	loss	loss	NN	_	11	SBJ
3	of	of	IN	_	2	NMOD
4	β	β	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	APP	app	NN	_	7	AMOD
7	cleaving	cleave	VBG	_	10	NMOD
8	enzyme	enzyme	NN	_	10	NMOD
9	1	0	CD	_	8	NMOD
10	function	function	NN	_	3	PMOD
11	can	can	MD	_	1	SUB
12	prevent	prevent	VB	_	11	VC
13	the	the	DT	_	14	NMOD
14	development	development	NN	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	plaques	plaque	NNS	_	15	PMOD
17	in	in	IN	_	12	LOC
18	transgenic	transgenic	JJ	_	20	NMOD
19	mouse	mouse	NN	_	20	NMOD
20	models	model	NNS	_	17	PMOD
21	for	for	IN	_	20	NMOD
22	AD	ad	NN	_	21	PMOD
23	(	(	-LRB-	_	24	P
24	F.	f.	NNP	_	12	CIT
25	Laird	laird	NNP	_	24	DEP
26	,	,	,	_	24	P
27	H.	h.	NNP	_	24	DEP
28	Cai	cai	NNP	_	24	DEP
29	,	,	,	_	24	P
30	P.	p.	NNP	_	24	DEP
31	C.	c.	NNP	_	24	DEP
32	Wong	wong	NNP	_	24	DEP
33	,	,	,	_	24	P
34	personal	personal	JJ	_	24	DEP
35	communication	communication	NN	_	24	DEP
36	)	)	-RRB-	_	24	P
37	,	,	,	_	39	P
38	it	it	PRP	_	39	SBJ
39	is	be	VBZ	_	0	ROOT
40	not	not	RB	_	39	ADV
41	known	know	VBN	_	39	VC
42	whether	whether	IN	_	41	OBJ
43	the	the	DT	_	44	NMOD
44	brain	brain	NN	_	45	SBJ
45	can	can	MD	_	42	SUB
46	clear	clear	VB	_	45	VC
47	pre-existing	pre-existing	JJ	_	49	NMOD
48	amyloid	amyloid	NN	_	49	NMOD
49	deposits	deposit	NNS	_	46	OBJ
50	once	once	IN	_	46	TMP
51	production	production	NN	_	54	SBJ
52	of	of	IN	_	51	NMOD
53	Aβ	aβ	NN	_	52	PMOD
54	has	have	VBZ	_	50	SUB
55	been	be	VBN	_	54	VC
56	suppressed	suppress	VBN	_	55	VC
57	.	.	.	_	39	P

1	Clearly	clearly	RB	_	8	ADV
2	,	,	,	_	8	P
3	the	the	DT	_	7	NMOD
4	amyloid	amyloid	NN	_	6	AMOD
5	-	-	HYPH	_	4	P
6	lowering	lower	VBG	_	7	NMOD
7	approach	approach	NN	_	8	SBJ
8	should	should	MD	_	0	ROOT
9	be	be	VB	_	8	VC
10	rigorously	rigorously	RB	_	9	MNR
11	examined	examine	VBN	_	9	VC
12	in	in	IN	_	11	LOC
13	animal	animal	NN	_	14	NMOD
14	models	model	NNS	_	12	PMOD
15	before	before	IN	_	11	TMP
16	these	these	DT	_	17	NMOD
17	reagents	reagent	NNS	_	18	SBJ
18	are	be	VBP	_	15	SUB
19	tested	test	VBN	_	18	VC
20	in	in	IN	_	19	LOC
21	patients	patient	NNS	_	20	PMOD
22	.	.	.	_	8	P

1	However	however	RB	_	13	ADV
2	,	,	,	_	13	P
3	the	the	DT	_	6	NMOD
4	chemical	chemical	JJ	_	6	NMOD
5	secretase	secretase	NN	_	6	NMOD
6	inhibitors	inhibitor	NNS	_	13	SBJ
7	most	most	RBS	_	8	AMOD
8	likely	likely	JJ	_	6	NMOD
9	to	to	TO	_	8	AMOD
10	reach	reach	VB	_	9	IM
11	human	human	JJ	_	12	NMOD
12	trials	trial	NNS	_	10	OBJ
13	are	be	VBP	_	0	ROOT
14	still	still	RB	_	13	TMP
15	in	in	IN	_	13	PRD
16	development	development	NN	_	15	PMOD
17	.	.	.	_	13	P

1	Therefore	therefore	RB	_	4	ADV
2	,	,	,	_	4	P
3	we	we	PRP	_	4	SBJ
4	developed	develop	VBD	_	0	ROOT
5	a	a	DT	_	7	NMOD
6	mouse	mouse	NN	_	7	NMOD
7	model	model	NN	_	4	OBJ
8	of	of	IN	_	7	NMOD
9	Alzheimer	alzheimer	NNP	_	11	NMOD
10	-	-	HYPH	_	9	P
11	type	type	NN	_	12	NMOD
12	amyloid	amyloid	NN	_	8	PMOD
13	that	that	WDT	_	14	SBJ
14	expresses	express	VBZ	_	12	NMOD
15	a	a	DT	_	18	NMOD
16	controllable	controllable	JJ	_	18	NMOD
17	APP	app	NN	_	18	NMOD
18	transgene	transgene	NN	_	14	OBJ
19	.	.	.	_	4	P

1	This	this	DT	_	2	NMOD
2	system	system	NN	_	13	SBJ
3	,	,	,	_	2	P
4	commonly	commonly	RB	_	5	ADV
5	known	know	VBN	_	2	NMOD
6	as	as	IN	_	5	ADV
7	the	the	DT	_	11	NMOD
8	tet	tet	NN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	off	off	NN	_	11	NMOD
11	system	system	NN	_	6	PMOD
12	,	,	,	_	13	P
13	can	can	MD	_	0	ROOT
14	be	be	VB	_	13	VC
15	regulated	regulate	VBN	_	14	VC
16	by	by	IN	_	15	LGS
17	analogs	analog	NNS	_	16	PMOD
18	of	of	IN	_	17	NMOD
19	tetracycline	tetracycline	NN	_	18	PMOD
20	administered	administer	VBN	_	19	NMOD
21	in	in	IN	_	20	LOC
22	food	food	NN	_	21	PMOD
23	or	or	CC	_	22	COORD
24	water	water	NN	_	23	CONJ
25	[	[	-LRB-	_	28	P
26	12	0	CD	_	28	NMOD
27	,	,	,	_	28	P
28	13	0	CD	_	15	PRN
29	]	]	-RRB-	_	28	P
30	.	.	.	_	13	P

1	The	the	DT	_	4	NMOD
2	strong	strong	JJ	_	4	NMOD
3	expression	expression	NN	_	4	NMOD
4	levels	level	NNS	_	32	SBJ
5	produced	produce	VBN	_	4	NMOD
6	with	with	IN	_	5	ADV
7	the	the	DT	_	11	NMOD
8	tet	tet	NN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	off	off	NN	_	11	NMOD
11	vectors	vector	NNS	_	6	PMOD
12	,	,	,	_	11	P
13	combined	combine	VBN	_	11	NMOD
14	with	with	IN	_	13	ADV
15	the	the	DT	_	16	NMOD
16	ability	ability	NN	_	14	PMOD
17	to	to	TO	_	16	NMOD
18	reduce	reduce	VB	_	17	IM
19	this	this	DT	_	20	NMOD
20	expression	expression	NN	_	18	OBJ
21	by	by	IN	_	18	EXT
22	several	several	JJ	_	23	NMOD
23	orders	order	NNS	_	21	PMOD
24	of	of	IN	_	23	NMOD
25	magnitude	magnitude	NN	_	24	PMOD
26	with	with	IN	_	18	MNR
27	tetracycline	tetracycline	NN	_	26	PMOD
28	[	[	-LRB-	_	29	P
29	14	0	CD	_	18	PRN
30	]	]	-RRB-	_	29	P
31	,	,	,	_	32	P
32	allowed	allow	VBD	_	0	ROOT
33	for	for	IN	_	32	ADV
34	a	a	DT	_	36	NMOD
35	stringent	stringent	JJ	_	36	NMOD
36	test	test	NN	_	33	PMOD
37	of	of	IN	_	36	NMOD
38	how	how	WRB	_	48	MNR
39	a	a	DT	_	43	NMOD
40	highly	highly	RB	_	41	AMOD
41	effective	effective	JJ	_	43	NMOD
42	pharmaceutical	pharmaceutical	JJ	_	43	NMOD
43	inhibitor	inhibitor	NN	_	47	SBJ
44	of	of	IN	_	43	NMOD
45	Aβ	aβ	NN	_	46	NMOD
46	production	production	NN	_	44	PMOD
47	would	would	MD	_	37	PMOD
48	impact	impact	VB	_	47	VC
49	the	the	DT	_	50	NMOD
50	progression	progression	NN	_	48	OBJ
51	of	of	IN	_	50	NMOD
52	amyloid	amyloid	NN	_	53	NMOD
53	pathology	pathology	NN	_	51	PMOD
54	and	and	CC	_	47	COORD
55	whether	whether	IN	_	54	CONJ
56	reversal	reversal	NN	_	60	SBJ
57	of	of	IN	_	56	NMOD
58	these	these	DT	_	59	NMOD
59	lesions	lesion	NNS	_	57	PMOD
60	might	might	MD	_	55	SUB
61	be	be	VB	_	60	VC
62	possible	possible	JJ	_	61	PRD
63	following	follow	VBG	_	61	TMP
64	such	such	JJ	_	63	PMOD
65	treatment	treatment	NN	_	64	PMOD
66	.	.	.	_	32	P

1	Methods	method	NNS	_	0	ROOT

1	Transgene	transgene	NN	_	2	NMOD
2	Construction	construction	NN	_	0	ROOT

1	We	we	PRP	_	2	SBJ
2	created	create	VBD	_	0	ROOT
3	a	a	DT	_	19	NMOD
4	tetracycline	tetracycline	NN	_	6	AMOD
5	-	-	HYPH	_	4	P
6	responsive	responsive	JJ	_	19	NMOD
7	chimeric	chimeric	JJ	_	19	NMOD
8	mouse	mouse	NN	_	19	NMOD
9	/	/	HYPH	_	8	P
10	human	human	JJ	_	8	NMOD
11	APP695Swedish	app0swedish	NN	_	13	NMOD
12	/	/	HYPH	_	11	P
13	Indiana	indiana	NNP	_	17	NMOD
14	(	(	-LRB-	_	17	P
15	swe	swe	NN	_	17	NMOD
16	/	/	HYPH	_	15	P
17	ind	ind	NN	_	19	NMOD
18	)	)	-RRB-	_	19	P
19	vector	vector	NN	_	2	OBJ
20	by	by	IN	_	2	MNR
21	replacing	replace	VBG	_	20	PMOD
22	the	the	DT	_	24	NMOD
23	promoter	promoter	NN	_	24	NMOD
24	region	region	NN	_	21	OBJ
25	of	of	IN	_	24	NMOD
26	the	the	DT	_	28	NMOD
27	moPrP.XhoI	moprp.xhoi	NN	_	28	NMOD
28	vector	vector	NN	_	25	PMOD
29	(	(	-LRB-	_	31	P
30	also	also	RB	_	31	ADV
31	known	know	VBN	_	21	PRN
32	as	as	IN	_	31	ADV
33	pPrPpE1	pprppe0	NN	_	37	NMOD
34	/	/	HYPH	_	33	P
35	E2	e0	NN	_	37	NMOD
36	,	,	,	_	37	P
37	3sal	0sal	NN	_	32	PMOD
38	[	[	-LRB-	_	39	P
39	15	0	CD	_	31	PRN
40	]	]	-RRB-	_	39	P
41	)	)	-RRB-	_	31	P
42	with	with	IN	_	21	ADV
43	the	the	DT	_	47	NMOD
44	tetracycline	tetracycline	NN	_	46	AMOD
45	-	-	HYPH	_	44	P
46	responsive	responsive	JJ	_	47	NMOD
47	promoter	promoter	NN	_	42	PMOD
48	of	of	IN	_	47	NMOD
49	pTetSplice	ptetsplice	NN	_	48	PMOD
50	(	(	-LRB-	_	52	P
51	Life	life	NNP	_	52	NMOD
52	Technologies	technology	NNP	_	49	PRN
53	,	,	,	_	52	P
54	Rockville	rockville	NNP	_	52	APPO
55	,	,	,	_	54	P
56	Maryland	maryland	NNP	_	54	APPO
57	,	,	,	_	56	P
58	United	united	NNP	_	59	NMOD
59	States	state	NNP	_	56	APPO
60	)	)	-RRB-	_	52	P
61	,	,	,	_	21	P
62	and	and	CC	_	21	COORD
63	then	then	RB	_	64	TMP
64	ligating	ligate	VBG	_	62	CONJ
65	mouse	mouse	NN	_	66	NMOD
66	APP	app	NN	_	64	OBJ
67	with	with	IN	_	64	MNR
68	a	a	DT	_	71	NMOD
69	humanized	humanized	JJ	_	71	NMOD
70	Aβ	aβ	NN	_	71	NMOD
71	domain	domain	NN	_	75	NMOD
72	(	(	-LRB-	_	75	P
73	mo	mo	NN	_	75	NMOD
74	/	/	HYPH	_	73	P
75	huAPP695	huapp0	NN	_	77	NMOD
76	)	)	-RRB-	_	77	P
77	cDNA	cdna	NN	_	67	PMOD
78	into	into	IN	_	64	LOC
79	the	the	DT	_	81	NMOD
80	new	new	JJ	_	81	NMOD
81	vector	vector	NN	_	78	PMOD
82	.	.	.	_	2	P

1	We	we	PRP	_	2	SBJ
2	began	begin	VBD	_	0	ROOT
3	by	by	IN	_	2	MNR
4	cloning	clone	VBG	_	3	PMOD
5	the	the	DT	_	9	NMOD
6	tetracycline	tetracycline	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	responsive	responsive	JJ	_	9	NMOD
9	promoter	promoter	NN	_	4	OBJ
10	(	(	-LRB-	_	12	P
11	bp	bp	NN	_	12	NMOD
12	6	0	CD	_	9	PRN
13	–	–	SYM	_	14	P
14	481	0	CD	_	12	NMOD
15	)	)	-RRB-	_	12	P
16	from	from	IN	_	4	ADV
17	pTetSplice	ptetsplice	NN	_	16	PMOD
18	by	by	IN	_	17	NMOD
19	PCR	pcr	NN	_	18	PMOD
20	using	use	VBG	_	19	NMOD
21	primers	primer	NNS	_	20	OBJ
22	that	that	WDT	_	23	SBJ
23	added	add	VBD	_	21	NMOD
24	external	external	JJ	_	28	NMOD
25	BamHI	bamhi	NN	_	28	NMOD
26	and	and	CC	_	25	COORD
27	NotI	noti	NN	_	26	CONJ
28	sites	site	NNS	_	23	OBJ
29	to	to	IN	_	23	ADV
30	the	the	DT	_	33	NMOD
31	5	0	CD	_	33	NMOD
32	′	′	SYM	_	31	P
33	end	end	NN	_	29	PMOD
34	and	and	CC	_	23	COORD
35	a	a	DT	_	37	NMOD
36	BamHI	bamhi	NN	_	37	NMOD
37	site	site	NN	_	34	GAP
38	to	to	IN	_	37	ADV
39	the	the	DT	_	42	NMOD
40	3	0	CD	_	42	NMOD
41	′	′	SYM	_	40	P
42	end	end	NN	_	38	PMOD
43	,	,	,	_	2	P
44	while	while	IN	_	2	ADV
45	destroying	destroy	VBG	_	44	SUB
46	XhoI	xhoi	NN	_	49	NMOD
47	and	and	CC	_	46	COORD
48	BamHI	bamhi	NN	_	47	CONJ
49	sites	site	NNS	_	45	OBJ
50	within	within	IN	_	49	NMOD
51	the	the	DT	_	52	NMOD
52	promoter	promoter	NN	_	50	PMOD
53	(	(	-LRB-	_	71	P
54	forward	forward	NN	_	71	DEP
55	:	:	:	_	54	P
56	GCC	gcc	NN	_	69	NMOD
57	GGA	gga	NN	_	69	NMOD
58	TCC	tcc	NN	_	69	NMOD
59	GCG	gcg	NN	_	69	NMOD
60	GCC	gcc	NN	_	69	NMOD
61	GCC	gcc	NN	_	69	NMOD
62	GTC	gtc	NN	_	69	NMOD
63	GAG	gag	NN	_	69	NMOD
64	TTT	ttt	NN	_	69	NMOD
65	ACC	acc	NN	_	69	NMOD
66	ACT	act	NN	_	69	NMOD
67	CCC	ccc	NN	_	69	NMOD
68	TAT	tat	NN	_	69	NMOD
69	C	c	NN	_	54	DEP
70	;	;	:	_	71	P
71	reverse	reverse	NN	_	45	PRN
72	:	:	:	_	71	P
73	GCC	gcc	NN	_	83	NMOD
74	GGA	gga	NN	_	83	NMOD
75	TCC	tcc	NN	_	83	NMOD
76	ACT	act	NN	_	83	NMOD
77	CTA	cta	NN	_	83	NMOD
78	GAA	gaa	NN	_	83	NMOD
79	GAT	gat	NN	_	83	NMOD
80	CCC	ccc	NN	_	83	NMOD
81	CGG	cgg	NN	_	83	NMOD
82	GTA	gta	NN	_	83	NMOD
83	CCG	ccg	NN	_	71	DEP
84	)	)	-RRB-	_	71	P
85	.	.	.	_	2	P

1	We	we	PRP	_	3	SBJ
2	then	then	RB	_	3	TMP
3	isolated	isolate	VBD	_	0	ROOT
4	the	the	DT	_	6	NMOD
5	moPrP.XhoI	moprp.xhoi	NN	_	6	NMOD
6	intron	intron	NN	_	3	OBJ
7	by	by	IN	_	3	MNR
8	amplification	amplification	NN	_	7	PMOD
9	with	with	IN	_	8	NMOD
10	primers	primer	NNS	_	9	PMOD
11	that	that	WDT	_	12	SBJ
12	added	add	VBD	_	10	NMOD
13	an	an	DT	_	16	NMOD
14	external	external	JJ	_	16	NMOD
15	BamHI	bamhi	NN	_	16	NMOD
16	site	site	NN	_	12	OBJ
17	to	to	IN	_	12	ADV
18	the	the	DT	_	21	NMOD
19	5	0	CD	_	21	NMOD
20	′	′	SYM	_	19	P
21	end	end	NN	_	17	PMOD
22	of	of	IN	_	21	NMOD
23	exon	exon	NN	_	22	PMOD
24	1	0	CD	_	23	NMOD
25	and	and	CC	_	12	COORD
26	ran	run	VBD	_	25	CONJ
27	through	through	IN	_	26	ADV
28	the	the	DT	_	30	NMOD
29	Asp718	asp0	NN	_	30	NMOD
30	site	site	NN	_	27	PMOD
31	of	of	IN	_	30	NMOD
32	exon	exon	NN	_	31	PMOD
33	2	0	CD	_	32	NMOD
34	(	(	-LRB-	_	48	P
35	forward	forward	NN	_	48	DEP
36	:	:	:	_	35	P
37	GCC	gcc	NN	_	46	NMOD
38	GGA	gga	NN	_	46	NMOD
39	TCC	tcc	NN	_	46	NMOD
40	GAT	gat	NN	_	46	NMOD
41	CAG	cag	NN	_	46	NMOD
42	CAG	cag	NN	_	46	NMOD
43	ACC	acc	NN	_	46	NMOD
44	GAT	gat	NN	_	46	NMOD
45	TCT	tct	NN	_	46	NMOD
46	GG	gg	NN	_	35	DEP
47	;	;	:	_	48	P
48	reverse	reverse	NN	_	30	PRN
49	:	:	:	_	48	P
50	GCC	gcc	NN	_	58	NMOD
51	GGT	ggt	NN	_	58	NMOD
52	ACC	acc	NN	_	58	NMOD
53	ACT	act	NN	_	58	NMOD
54	AGG	agg	NN	_	58	NMOD
55	AAG	aag	NN	_	58	NMOD
56	GCA	gca	NN	_	58	NMOD
57	GAA	gaa	NN	_	58	NMOD
58	TGC	tgc	NN	_	48	DEP
59	)	)	-RRB-	_	48	P
60	.	.	.	_	3	P

1	This	this	DT	_	6	NMOD
2	2	0	CD	_	4	NMOD
3	-	-	HYPH	_	2	P
4	kb	kb	NN	_	6	NMOD
5	intron	intron	NN	_	6	NMOD
6	fragment	fragment	NN	_	7	SBJ
7	was	be	VBD	_	0	ROOT
8	cloned	clone	VBN	_	7	VC
9	into	into	IN	_	8	LOC
10	a	a	DT	_	13	NMOD
11	TA	ta	NN	_	12	NMOD
12	cloning	cloning	NN	_	13	NMOD
13	vector	vector	NN	_	9	PMOD
14	(	(	-LRB-	_	15	P
15	Invitrogen	invitrogen	NNP	_	13	PRN
16	,	,	,	_	15	P
17	Carlsbad	carlsbad	NNP	_	15	APPO
18	,	,	,	_	17	P
19	California	california	NNP	_	17	APPO
20	,	,	,	_	19	P
21	United	united	NNP	_	22	NMOD
22	States	state	NNP	_	19	APPO
23	)	)	-RRB-	_	15	P
24	,	,	,	_	8	P
25	then	then	RB	_	26	TMP
26	excised	excise	VBN	_	8	CONJ
27	by	by	IN	_	26	MNR
28	Asp718	asp0	NN	_	29	NMOD
29	digestion	digestion	NN	_	27	PMOD
30	and	and	CC	_	26	COORD
31	ligated	ligate	VBN	_	30	CONJ
32	to	to	IN	_	31	ADV
33	the	the	DT	_	38	NMOD
34	6.8	0	CD	_	36	NMOD
35	-	-	HYPH	_	34	P
36	kb	kb	NN	_	38	NMOD
37	Asp718	asp0	NN	_	38	NMOD
38	fragment	fragment	NN	_	32	PMOD
39	of	of	IN	_	38	NMOD
40	moPrP.XhoI	moprp.xhoi	NN	_	39	PMOD
41	containing	contain	VBG	_	38	NMOD
42	exon	exon	NN	_	41	OBJ
43	2	0	CD	_	42	NMOD
44	,	,	,	_	42	P
45	exon	exon	NN	_	42	CONJ
46	3	0	CD	_	45	NMOD
47	,	,	,	_	45	P
48	the	the	DT	_	51	NMOD
49	3	0	CD	_	51	NMOD
50	′	′	SYM	_	49	P
51	UTR	utr	NN	_	45	CONJ
52	,	,	,	_	51	P
53	and	and	CC	_	51	COORD
54	pBluescript	pbluescript	NN	_	53	CONJ
55	to	to	TO	_	8	PRP
56	generate	generate	VB	_	55	IM
57	an	an	DT	_	59	NMOD
58	intermediate	intermediate	JJ	_	59	NMOD
59	vector	vector	NN	_	56	OBJ
60	with	with	IN	_	56	MNR
61	all	all	DT	_	63	NMOD
62	three	three	CD	_	63	NMOD
63	exons	exon	NNS	_	60	PMOD
64	and	and	CC	_	63	COORD
65	a	a	DT	_	67	NMOD
66	central	central	JJ	_	67	NMOD
67	intron	intron	NN	_	64	CONJ
68	but	but	CC	_	63	COORD
69	no	no	DT	_	70	NMOD
70	promoter	promoter	NN	_	68	CONJ
71	.	.	.	_	7	P

1	This	this	DT	_	2	NMOD
2	vector	vector	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	then	then	RB	_	3	TMP
5	opened	open	VBN	_	3	VC
6	at	at	IN	_	5	LOC
7	the	the	DT	_	9	NMOD
8	BamHI	bamhi	NN	_	9	NMOD
9	site	site	NN	_	6	PMOD
10	introduced	introduce	VBN	_	9	NMOD
11	by	by	IN	_	10	LGS
12	the	the	DT	_	15	NMOD
13	intron	intron	NN	_	15	NMOD
14	cloning	cloning	NN	_	15	NMOD
15	primer	primer	NN	_	11	PMOD
16	,	,	,	_	5	P
17	and	and	CC	_	5	COORD
18	ligated	ligate	VBN	_	17	CONJ
19	to	to	IN	_	18	ADV
20	the	the	DT	_	29	NMOD
21	0.5	0	CD	_	23	NMOD
22	-	-	HYPH	_	21	P
23	kb	kb	NN	_	29	NMOD
24	BamHI	bamhi	NN	_	26	NMOD
25	-	-	HYPH	_	24	P
26	cut	cut	NN	_	29	NMOD
27	tetracycline	tetracycline	NN	_	28	NMOD
28	promoter	promoter	NN	_	29	NMOD
29	fragment	fragment	NN	_	19	PMOD
30	.	.	.	_	3	P

1	This	this	DT	_	2	NMOD
2	ligation	ligation	NN	_	3	SBJ
3	generated	generate	VBD	_	0	ROOT
4	a	a	DT	_	8	NMOD
5	9.3	0	CD	_	7	NMOD
6	-	-	HYPH	_	5	P
7	kb	kb	NN	_	8	NMOD
8	vector	vector	NN	_	3	OBJ
9	encoding	encode	VBG	_	8	NMOD
10	the	the	DT	_	12	NMOD
11	tetracycline	tetracycline	NN	_	12	NMOD
12	promoter	promoter	NN	_	9	OBJ
13	from	from	IN	_	12	NMOD
14	pTetSplice	ptetsplice	NN	_	13	PMOD
15	with	with	IN	_	9	MNR
16	two	two	CD	_	17	NMOD
17	exons	exon	NNS	_	15	PMOD
18	,	,	,	_	17	P
19	one	one	CD	_	20	NMOD
20	intron	intron	NN	_	17	CONJ
21	,	,	,	_	20	P
22	and	and	CC	_	20	COORD
23	the	the	DT	_	27	NMOD
24	original	original	JJ	_	27	NMOD
25	3	0	CD	_	27	NMOD
26	′	′	SYM	_	25	P
27	UTR	utr	NN	_	22	CONJ
28	of	of	IN	_	27	NMOD
29	the	the	DT	_	31	NMOD
30	moPrP.XhoI	moprp.xhoi	NN	_	31	NMOD
31	vector	vector	NN	_	28	PMOD
32	,	,	,	_	17	P
33	all	all	RB	_	34	ADV
34	carried	carry	VBN	_	17	NMOD
35	in	in	IN	_	34	LOC
36	the	the	DT	_	39	NMOD
37	pBluescript	pbluescript	NNP	_	38	NMOD
38	cloning	cloning	NN	_	39	NMOD
39	vector	vector	NN	_	35	PMOD
40	.	.	.	_	3	P

1	We	we	PRP	_	2	SBJ
2	incorporated	incorporate	VBD	_	43	DEP
3	the	the	DT	_	15	NMOD
4	Swedish	swedish	NNP	_	15	NMOD
5	(	(	-LRB-	_	8	P
6	KM570	km0	NN	_	8	NMOD
7	/	/	HYPH	_	6	P
8	571NL	0nl	NN	_	4	PRN
9	)	)	-RRB-	_	8	P
10	and	and	CC	_	4	COORD
11	Indiana	indiana	NNP	_	10	CONJ
12	(	(	-LRB-	_	13	P
13	V617F	v0f	NN	_	11	PRN
14	)	)	-RRB-	_	13	P
15	mutations	mutation	NNS	_	2	OBJ
16	into	into	IN	_	2	ADV
17	the	the	DT	_	21	NMOD
18	mo	mo	NN	_	20	NMOD
19	/	/	HYPH	_	18	P
20	huAPP695	huapp0	NN	_	21	NMOD
21	cDNA	cdna	NN	_	16	PMOD
22	(	(	-LRB-	_	21	P
23	in	in	IN	_	21	LOC
24	BS	b	NN	_	26	NMOD
25	-	-	HYPH	_	24	P
26	KS	k	NN	_	23	PMOD
27	)	)	-RRB-	_	2	P
28	by	by	IN	_	2	MNR
29	PCR	pcr	NN	_	28	PMOD
30	using	use	VBG	_	2	MNR
31	a	a	DT	_	35	NMOD
32	four	four	CD	_	34	NMOD
33	-	-	HYPH	_	32	P
34	primer	primer	NN	_	35	NMOD
35	strategy	strategy	NN	_	30	OBJ
36	:	:	:	_	43	P
37	first	$#ORD#$	RB	_	43	TMP
38	,	,	,	_	43	P
39	two	two	CD	_	42	NMOD
40	partially	partially	RB	_	41	AMOD
41	overlapping	overlap	VBG	_	42	NMOD
42	products	product	NNS	_	43	SBJ
43	were	be	VBD	_	0	ROOT
44	generated	generate	VBN	_	43	VC
45	in	in	IN	_	44	ADV
46	separate	separate	JJ	_	47	NMOD
47	reactions	reaction	NNS	_	45	PMOD
48	using	use	VBG	_	44	MNR
49	primers	primer	NNS	_	48	OBJ
50	that	that	WDT	_	51	SBJ
51	encode	encode	VBP	_	49	NMOD
52	the	the	DT	_	54	NMOD
53	desired	desire	VBN	_	54	NMOD
54	mutations	mutation	NNS	_	51	OBJ
55	(	(	-LRB-	_	85	P
56	Swedish	swedish	NNP	_	57	NMOD
57	forward	forward	NN	_	85	DEP
58	:	:	:	_	57	P
59	GGA	gga	NN	_	70	NMOD
60	GAT	gat	NN	_	70	NMOD
61	CTC	ctc	NN	_	70	NMOD
62	TGA	tga	NN	_	70	NMOD
63	AGT	agt	NN	_	70	NMOD
64	GAA	gaa	NN	_	70	NMOD
65	TCT	tct	NN	_	70	NMOD
66	GGA	gga	NNP	_	70	NMOD
67	TGC	tgc	NNP	_	70	NMOD
68	AGA	aga	NNP	_	70	NMOD
69	ATT	att	NNP	_	70	NMOD
70	CCG	ccg	NN	_	57	DEP
71	/	/	HYPH	_	57	P
72	Indiana	indiana	NNP	_	73	NMOD
73	reverse	reverse	NN	_	57	DEP
74	:	:	:	_	73	P
75	GGG	ggg	NN	_	82	NMOD
76	TGA	tga	NN	_	82	NMOD
77	TGA	tga	NN	_	82	NMOD
78	AAA	aaa	NN	_	82	NMOD
79	TCA	tca	NN	_	82	NMOD
80	CGG	cgg	NN	_	82	NMOD
81	TTG	ttg	NN	_	82	NMOD
82	C	c	NN	_	73	DEP
83	;	;	:	_	85	P
84	Indiana	indiana	NNP	_	85	NMOD
85	forward	forward	NN	_	51	PRN
86	:	:	:	_	85	P
87	CAA	caa	NN	_	96	NMOD
88	CCG	ccg	NN	_	96	NMOD
89	TGA	tga	NN	_	96	NMOD
90	TTT	ttt	NN	_	96	NMOD
91	TCA	tca	NN	_	96	NMOD
92	TCA	tca	NN	_	96	NMOD
93	CCC	ccc	NN	_	96	NMOD
94	TGG	tgg	NN	_	96	NMOD
95	/	/	HYPH	_	94	P
96	M13	m0	NN	_	85	DEP
97	reverse	reverse	RB	_	96	NMOD
98	)	)	-RRB-	_	85	P
99	.	.	.	_	43	P

1	The	the	DT	_	4	NMOD
2	two	two	CD	_	4	NMOD
3	PCR	pcr	NN	_	4	NMOD
4	products	product	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	ligated	ligate	VBN	_	5	VC
7	,	,	,	_	6	P
8	digested	digest	VBN	_	6	DEP
9	with	with	IN	_	6	MNR
10	BglII	bglii	NN	_	9	PMOD
11	and	and	CC	_	10	COORD
12	ApaI	apai	NN	_	11	CONJ
13	and	and	CC	_	5	COORD
14	cloned	clone	VBN	_	13	CONJ
15	back	back	RB	_	14	ADV
16	into	into	IN	_	14	ADV
17	the	the	DT	_	26	NMOD
18	original	original	JJ	_	26	NMOD
19	mo	mo	NN	_	25	NMOD
20	/	/	HYPH	_	19	P
21	huAPP695	huapp0	NN	_	25	NMOD
22	-	-	HYPH	_	21	P
23	BS	b	NN	_	25	NMOD
24	-	-	HYPH	_	23	P
25	KS	k	NN	_	26	NMOD
26	vector	vector	NN	_	16	PMOD
27	.	.	.	_	5	P

1	Finally	finally	RB	_	8	TMP
2	,	,	,	_	8	P
3	the	the	DT	_	7	NMOD
4	new	new	JJ	_	7	NMOD
5	APP695swe	app0swe	NN	_	7	NMOD
6	/	/	HYPH	_	5	P
7	ind	ind	NN	_	8	SBJ
8	was	be	VBD	_	0	ROOT
9	subcloned	subcloned	VBN	_	8	VC
10	into	into	IN	_	9	LOC
11	the	the	DT	_	13	NMOD
12	XhoI	xhoi	NN	_	13	NMOD
13	site	site	NN	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	19	NMOD
16	moPrP	moprp	NN	_	18	NMOD
17	-	-	HYPH	_	16	P
18	tetP	tetp	NN	_	19	NMOD
19	vector	vector	NN	_	14	PMOD
20	from	from	IN	_	9	DIR
21	above	above	RB	_	20	PMOD
22	to	to	TO	_	9	PRP
23	complete	complete	VB	_	22	IM
24	the	the	DT	_	25	NMOD
25	construct	construct	NN	_	23	OBJ
26	.	.	.	_	8	P

1	Pronuclear	pronuclear	JJ	_	2	NMOD
2	Injection	injection	NN	_	0	ROOT
3	,	,	,	_	2	P
4	Screening	screening	NN	_	2	CONJ
5	of	of	IN	_	4	NMOD
6	Founders	founder	NNS	_	5	PMOD
7	,	,	,	_	4	P
8	and	and	CC	_	4	COORD
9	Maintenance	maintenance	NN	_	8	CONJ
10	of	of	IN	_	9	NMOD
11	the	the	DT	_	12	NMOD
12	Lines	line	NNS	_	10	PMOD

1	The	the	DT	_	11	NMOD
2	moPrP	moprp	NN	_	10	NMOD
3	-	-	HYPH	_	2	P
4	tetP	tetp	NN	_	10	NMOD
5	-	-	HYPH	_	4	P
6	mo	mo	NN	_	10	NMOD
7	/	/	HYPH	_	6	P
8	huAPP695swe	huapp0swe	NN	_	10	NMOD
9	/	/	HYPH	_	8	P
10	ind	ind	NN	_	11	NMOD
11	vector	vector	NN	_	12	SBJ
12	was	be	VBD	_	0	ROOT
13	linearized	linearize	VBN	_	12	VC
14	and	and	CC	_	12	COORD
15	the	the	DT	_	17	NMOD
16	pBluescript	pbluescript	NNP	_	17	NMOD
17	domain	domain	NN	_	18	SBJ
18	excised	excise	VBN	_	14	GAP
19	by	by	IN	_	18	MNR
20	digestion	digestion	NN	_	19	PMOD
21	with	with	IN	_	20	NMOD
22	NotI	noti	NN	_	21	PMOD
23	.	.	.	_	12	P

1	The	the	DT	_	3	NMOD
2	purified	purify	VBN	_	3	NMOD
3	vector	vector	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	injected	inject	VBN	_	4	VC
6	into	into	IN	_	5	DIR
7	the	the	DT	_	8	NMOD
8	pronucleus	pronucleus	NN	_	6	PMOD
9	of	of	IN	_	8	NMOD
10	fertilized	fertilize	VBN	_	11	NMOD
11	eggs	egg	NNS	_	9	PMOD
12	from	from	IN	_	11	NMOD
13	C57BL	c0bl	NN	_	17	NMOD
14	/	/	HYPH	_	13	P
15	6J	0j	NN	_	17	NMOD
16	×	×	SYM	_	17	P
17	C3HeJ	c0hej	NN	_	19	NMOD
18	F1	f0	NN	_	19	NMOD
19	matings	mating	NNS	_	12	PMOD
20	.	.	.	_	4	P

1	Founder	founder	NN	_	2	NMOD
2	animals	animal	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	screened	screen	VBN	_	3	VC
5	for	for	IN	_	4	ADV
6	the	the	DT	_	7	NMOD
7	presence	presence	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	the	the	DT	_	10	NMOD
10	transgene	transgene	NN	_	8	PMOD
11	by	by	IN	_	4	MNR
12	three	three	CD	_	14	NMOD
13	-	-	HYPH	_	12	P
14	way	way	NN	_	15	NMOD
15	PCR	pcr	NN	_	11	PMOD
16	using	use	VBG	_	4	MNR
17	the	the	DT	_	27	NMOD
18	S36	s0	NN	_	27	NMOD
19	and	and	CC	_	18	COORD
20	PrP	prp	NN	_	26	NMOD
21	-	-	HYPH	_	20	P
22	S	s	NN	_	26	NMOD
23	/	/	HYPH	_	22	P
24	PrP	prp	NN	_	26	NMOD
25	-	-	HYPH	_	24	P
26	AS	a	NN	_	19	CONJ
27	primers	primer	NNS	_	16	OBJ
28	described	describe	VBN	_	27	NMOD
29	below	below	RB	_	28	ADV
30	.	.	.	_	3	P

1	Transgene	transgene	NN	_	3	AMOD
2	-	-	HYPH	_	1	P
3	positive	positive	JJ	_	4	NMOD
4	founders	founder	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	bred	breed	VBN	_	5	VC
7	to	to	IN	_	6	ADV
8	animals	animal	NNS	_	7	PMOD
9	expressing	express	VBG	_	8	NMOD
10	the	the	DT	_	12	NMOD
11	tetracycline	tetracycline	NN	_	12	NMOD
12	transactivator	transactivator	NN	_	14	NMOD
13	(	(	-LRB-	_	14	P
14	tTA	tta	NN	_	9	OBJ
15	)	)	-RRB-	_	6	P
16	under	under	IN	_	6	MNR
17	control	control	NN	_	16	PMOD
18	of	of	IN	_	17	NMOD
19	the	the	DT	_	28	NMOD
20	calcium	calcium	NN	_	22	NMOD
21	-	-	HYPH	_	20	P
22	calmodulin	calmodulin	NN	_	24	NMOD
23	kinase	kinase	NN	_	24	NMOD
24	IIα	iiα	NN	_	28	NMOD
25	(	(	-LRB-	_	28	P
26	CaMKIIα	camkiiα	NN	_	28	NMOD
27	)	)	-RRB-	_	28	P
28	promoter	promoter	NN	_	18	PMOD
29	obtained	obtain	VBN	_	28	NMOD
30	from	from	IN	_	29	ADV
31	Jackson	jackson	NNP	_	32	NMOD
32	Laboratory	laboratory	NNP	_	30	PMOD
33	[	[	-LRB-	_	34	P
34	16	0	CD	_	32	PRN
35	]	]	-RRB-	_	34	P
36	(	(	-LRB-	_	45	P
37	Bar	bar	NNP	_	38	NMOD
38	Harbor	harbor	NNP	_	45	DEP
39	,	,	,	_	38	P
40	Maine	maine	NNP	_	38	APPO
41	,	,	,	_	40	P
42	United	united	NNP	_	43	NMOD
43	States	state	NNP	_	40	APPO
44	;	;	:	_	45	P
45	stock	stock	NN	_	29	PRN
46	#	#	SYM	_	45	P
47	3010	0	CD	_	45	NMOD
48	;	;	:	_	45	P
49	B6	b0	NN	_	45	DEP
50	;	;	:	_	45	P
51	CBA	cba	NN	_	59	NMOD
52	-	-	HYPH	_	51	P
53	TgN	tgn	NN	_	59	NMOD
54	[	[	-LRB-	_	59	P
55	Camk2a	camk0a	NN	_	59	NMOD
56	-	-	HYPH	_	55	P
57	tTA	tta	NN	_	59	NMOD
58	]	]	-RRB-	_	59	P
59	1Mmay	0mmay	NN	_	45	DEP
60	)	)	-RRB-	_	45	P
61	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	colony	colony	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	thereafter	thereafter	RB	_	3	TMP
5	maintained	maintain	VBN	_	3	VC
6	by	by	IN	_	5	MNR
7	crossing	cross	VBG	_	6	PMOD
8	single	single	JJ	_	13	NMOD
9	transgenic	transgenic	JJ	_	13	NMOD
10	tTA	tta	NN	_	13	NMOD
11	and	and	CC	_	10	COORD
12	APP	app	NN	_	11	CONJ
13	offspring	offspring	NN	_	7	OBJ
14	for	for	IN	_	7	ADV
15	each	each	DT	_	14	PMOD
16	of	of	IN	_	15	NMOD
17	the	the	DT	_	20	NMOD
18	four	four	CD	_	20	NMOD
19	APP	app	NN	_	20	NMOD
20	lines	line	NNS	_	16	PMOD
21	.	.	.	_	3	P

1	All	all	DT	_	2	NMOD
2	mice	mouse	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	provided	provide	VBN	_	3	VC
5	fresh	fresh	JJ	_	6	NMOD
6	food	food	NN	_	4	OBJ
7	and	and	CC	_	6	COORD
8	water	water	NN	_	7	CONJ
9	ad	ad	FW	_	10	AMOD
10	libitum	libitum	FW	_	4	MNR
11	.	.	.	_	3	P

1	Animal	animal	NN	_	2	NMOD
2	protocols	protocol	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	approved	approve	VBN	_	3	VC
5	by	by	IN	_	4	LGS
6	both	both	DT	_	10	NMOD
7	the	the	DT	_	10	NMOD
8	Johns	john	NNP	_	10	NMOD
9	Hopkins	hopkins	NNP	_	10	NMOD
10	University	university	NNP	_	22	NMOD
11	and	and	CC	_	10	COORD
12	the	the	DT	_	14	NMOD
13	California	california	NNP	_	14	NMOD
14	Institute	institute	NNP	_	11	CONJ
15	of	of	IN	_	14	NMOD
16	Technology	technology	NNP	_	15	PMOD
17	Institutional	institutional	NNP	_	18	NMOD
18	Animal	animal	NNP	_	19	NMOD
19	Care	care	NNP	_	22	NMOD
20	and	and	CC	_	19	COORD
21	Use	use	NNP	_	20	CONJ
22	Committees	committee	NNP	_	5	PMOD
23	.	.	.	_	3	P

1	Doxycycline	doxycycline	NN	_	2	NMOD
2	Administration	administration	NN	_	0	ROOT

1	Doxycycline	doxycycline	NN	_	3	NMOD
2	(	(	-LRB-	_	3	P
3	dox	dox	NN	_	5	SBJ
4	)	)	-RRB-	_	3	P
5	was	be	VBD	_	0	ROOT
6	administered	administer	VBN	_	5	VC
7	through	through	IN	_	6	MNR
8	commercially	commercially	RB	_	9	AMOD
9	available	available	JJ	_	13	NMOD
10	dox	dox	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	containing	contain	VBG	_	13	NMOD
13	chow	chow	NN	_	7	PMOD
14	(	(	-LRB-	_	15	P
15	BioServ	bioserv	NNP	_	6	PRN
16	,	,	,	_	15	P
17	Frenchtown	frenchtown	NNP	_	15	APPO
18	,	,	,	_	17	P
19	New	new	NNP	_	20	NMOD
20	Jersey	jersey	NNP	_	17	APPO
21	,	,	,	_	20	P
22	United	united	NNP	_	23	NMOD
23	States	state	NNP	_	20	APPO
24	)	)	-RRB-	_	15	P
25	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	chow	chow	NN	_	3	SBJ
3	contained	contain	VBD	_	29	DEP
4	200	0	CD	_	5	NMOD
5	mg	mg	NN	_	3	OBJ
6	/	/	SYM	_	7	P
7	kg	kg	NN	_	5	NMOD
8	of	of	IN	_	5	NMOD
9	antibiotic	antibiotic	JJ	_	8	PMOD
10	;	;	:	_	29	P
11	based	base	VBN	_	29	ADV
12	on	on	IN	_	11	PMOD
13	estimated	estimate	VBN	_	14	NMOD
14	consumption	consumption	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	5	0	CD	_	17	NMOD
17	g	g	NN	_	15	PMOD
18	per	per	IN	_	17	NMOD
19	mouse	mouse	NN	_	18	PMOD
20	per	per	IN	_	17	TMP
21	day	day	NN	_	20	PMOD
22	,	,	,	_	29	P
23	the	the	DT	_	25	NMOD
24	expected	expect	VBN	_	25	NMOD
25	dose	dose	NN	_	29	SBJ
26	to	to	IN	_	25	NMOD
27	each	each	DT	_	28	NMOD
28	animal	animal	NN	_	26	PMOD
29	was	be	VBD	_	0	ROOT
30	1	0	CD	_	31	NMOD
31	mg	mg	NN	_	32	NMOD
32	dox	dox	NN	_	29	PRD
33	per	per	IN	_	32	TMP
34	day	day	NN	_	33	PMOD
35	.	.	.	_	29	P

1	The	the	DT	_	6	NMOD
2	average	average	JJ	_	6	NMOD
3	25	0	CD	_	5	NMOD
4	-	-	HYPH	_	3	P
5	g	g	NN	_	6	NMOD
6	animal	animal	NN	_	8	SBJ
7	therefore	therefore	RB	_	8	ADV
8	received	receive	VBD	_	0	ROOT
9	40	0	CD	_	10	NMOD
10	μg	μg	NN	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	dox	dox	NN	_	11	PMOD
13	per	per	IN	_	10	NMOD
14	gram	gram	NN	_	16	NMOD
15	body	body	NN	_	16	NMOD
16	weight	weight	NN	_	13	PMOD
17	per	per	IN	_	10	TMP
18	day	day	NN	_	17	PMOD
19	.	.	.	_	8	P

1	Chow	chow	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	changed	change	VBN	_	2	VC
4	1	0	CD	_	7	NMOD
5	–	–	SYM	_	4	P
6	2	0	CD	_	4	QMOD
7	times	time	NNS	_	3	TMP
8	per	per	IN	_	7	TMP
9	week	week	NN	_	8	PMOD
10	to	to	TO	_	3	PRP
11	prevent	prevent	VB	_	10	IM
12	breakdown	breakdown	NN	_	11	OBJ
13	of	of	IN	_	12	NMOD
14	the	the	DT	_	15	NMOD
15	antibiotic	antibiotic	NN	_	13	PMOD
16	.	.	.	_	2	P

1	Genotyping	genotyping	NN	_	0	ROOT

1	Offspring	offspring	NN	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	genotyped	genotyped	VBN	_	2	VC
4	for	for	IN	_	3	ADV
5	the	the	DT	_	6	NMOD
6	presence	presence	NN	_	4	PMOD
7	of	of	IN	_	6	NMOD
8	each	each	DT	_	9	NMOD
9	transgene	transgene	NN	_	7	PMOD
10	by	by	IN	_	3	MNR
11	PCR	pcr	NN	_	12	NMOD
12	amplification	amplification	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	genomic	genomic	JJ	_	15	NMOD
15	DNA	dna	NN	_	13	PMOD
16	extracted	extract	VBN	_	15	NMOD
17	from	from	IN	_	16	ADV
18	a	a	DT	_	23	NMOD
19	5	0	CD	_	21	NMOD
20	-	-	HYPH	_	19	P
21	mm	mm	NN	_	23	NMOD
22	tail	tail	NN	_	23	NMOD
23	biopsy	biopsy	NN	_	17	PMOD
24	.	.	.	_	2	P

1	Tails	tail	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	heated	heat	VBN	_	2	VC
4	to	to	IN	_	3	ADV
5	95	0	CD	_	6	NMOD
6	°C	°c	NN	_	4	PMOD
7	for	for	IN	_	3	TMP
8	45	0	CD	_	9	NMOD
9	min	min	NN	_	7	PMOD
10	in	in	IN	_	3	LOC
11	250	0	CD	_	12	NMOD
12	μl	μl	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	50	0	CD	_	15	NMOD
15	mM	mm	NN	_	16	NMOD
16	NaOH	naoh	NN	_	13	PMOD
17	,	,	,	_	3	P
18	vortexed	vortexed	VBN	_	3	VC
19	,	,	,	_	3	P
20	then	then	RB	_	21	TMP
21	neutralized	neutralize	VBN	_	3	VC
22	with	with	IN	_	21	MNR
23	an	an	DT	_	25	NMOD
24	equal	equal	JJ	_	25	NMOD
25	volume	volume	NN	_	22	PMOD
26	of	of	IN	_	25	NMOD
27	0.5	0	CD	_	28	NMOD
28	M	m	NN	_	31	NMOD
29	Tris	tris	NN	_	31	NMOD
30	-	-	HYPH	_	29	P
31	HCl	hcl	NN	_	26	PMOD
32	(	(	-LRB-	_	33	P
33	pH	ph	NN	_	31	PRN
34	5.5	0	CD	_	33	NMOD
35	)	)	-RRB-	_	33	P
36	.	.	.	_	2	P

1	Debris	debris	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	sedimented	sediment	VBN	_	2	VC
4	by	by	IN	_	3	MNR
5	centrifugation	centrifugation	NN	_	4	PMOD
6	,	,	,	_	2	P
7	and	and	CC	_	2	COORD
8	3	0	CD	_	9	NMOD
9	μl	μl	NN	_	12	SBJ
10	of	of	IN	_	9	NMOD
11	supernatant	supernatant	NN	_	10	PMOD
12	was	be	VBD	_	7	CONJ
13	used	use	VBN	_	12	VC
14	for	for	IN	_	13	PRP
15	amplification	amplification	NN	_	14	PMOD
16	.	.	.	_	2	P

1	Genotyping	genotyping	VBG	_	7	SBJ
2	for	for	IN	_	1	NMOD
3	APP	app	NN	_	6	NMOD
4	and	and	CC	_	3	COORD
5	tTA	tta	NN	_	4	CONJ
6	transgenes	transgene	NNS	_	2	PMOD
7	was	be	VBD	_	0	ROOT
8	performed	perform	VBN	_	7	VC
9	in	in	IN	_	8	ADV
10	the	the	DT	_	13	NMOD
11	same	same	JJ	_	13	NMOD
12	PCR	pcr	NN	_	13	NMOD
13	reaction	reaction	NN	_	9	PMOD
14	,	,	,	_	8	P
15	using	use	VBG	_	8	MNR
16	five	five	CD	_	18	NMOD
17	separate	separate	JJ	_	18	NMOD
18	primers	primer	NNS	_	15	OBJ
19	.	.	.	_	7	P

1	APP	app	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	amplified	amplify	VBN	_	2	VC
4	using	use	VBG	_	3	MNR
5	forward	forward	RB	_	7	NMOD
6	primer	primer	NN	_	7	NMOD
7	S36	s0	NN	_	4	OBJ
8	located	locate	VBN	_	7	NMOD
9	in	in	IN	_	8	LOC
10	the	the	DT	_	13	NMOD
11	3	0	CD	_	13	NMOD
12	′	′	SYM	_	11	P
13	end	end	NN	_	9	PMOD
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	17	NMOD
16	APP	app	NN	_	17	NMOD
17	cDNA	cdna	NN	_	14	PMOD
18	(	(	-LRB-	_	27	P
19	CCG	ccg	NN	_	27	NMOD
20	AGA	aga	NN	_	27	NMOD
21	TCT	tct	NN	_	27	NMOD
22	CTG	ctg	NN	_	27	NMOD
23	AAG	aag	NN	_	27	NMOD
24	TGA	tga	NN	_	27	NMOD
25	AGA	aga	NN	_	27	NMOD
26	TGG	tgg	NN	_	27	NMOD
27	ATG	atg	NN	_	17	PRN
28	)	)	-RRB-	_	27	P
29	and	and	CC	_	7	COORD
30	reverse	reverse	JJ	_	36	NMOD
31	primer	primer	NN	_	36	NMOD
32	PrP	prp	NN	_	36	NMOD
33	-	-	HYPH	_	32	P
34	AS	a	NN	_	36	NMOD
35	-	-	HYPH	_	34	P
36	J	j	NN	_	29	CONJ
37	located	locate	VBN	_	36	NMOD
38	in	in	IN	_	37	LOC
39	the	the	DT	_	42	NMOD
40	3	0	CD	_	42	NMOD
41	′	′	SYM	_	40	P
42	UTR	utr	NN	_	38	PMOD
43	of	of	IN	_	42	NMOD
44	the	the	DT	_	45	NMOD
45	vector	vector	NN	_	43	PMOD
46	(	(	-LRB-	_	54	P
47	CCA	cca	NN	_	54	NMOD
48	AGC	agc	NN	_	54	NMOD
49	CTA	cta	NN	_	54	NMOD
50	GAC	gac	NN	_	54	NMOD
51	CAC	cac	NN	_	54	NMOD
52	GAG	gag	NN	_	54	NMOD
53	AAT	aat	NN	_	54	NMOD
54	GC	gc	NN	_	42	PRN
55	)	)	-RRB-	_	54	P
56	.	.	.	_	2	P

1	The	the	DT	_	3	NMOD
2	tTA	tta	NN	_	3	NMOD
3	transgene	transgene	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	detected	detect	VBN	_	4	VC
6	using	use	VBG	_	5	MNR
7	a	a	DT	_	9	NMOD
8	primer	primer	NN	_	9	NMOD
9	set	set	NN	_	6	OBJ
10	that	that	WDT	_	11	SBJ
11	amplified	amplify	VBD	_	9	NMOD
12	across	across	IN	_	11	LOC
13	its	its	PRP$	_	15	NMOD
14	two	two	CD	_	15	NMOD
15	subdomains	subdomains	NNS	_	12	PMOD
16	with	with	IN	_	11	MNR
17	tet	tet	NN	_	16	PMOD
18	forward	forward	RB	_	17	NMOD
19	located	locate	VBN	_	17	NMOD
20	within	within	IN	_	19	LOC
21	the	the	DT	_	24	NMOD
22	Tn10	tn0	NN	_	23	NMOD
23	tetracycline	tetracycline	NN	_	24	NMOD
24	repressor	repressor	NN	_	20	PMOD
25	(	(	-LRB-	_	33	P
26	CGC	cgc	NN	_	33	NMOD
27	TGT	tgt	NN	_	33	NMOD
28	GGG	ggg	NN	_	33	NMOD
29	GCA	gca	NN	_	33	NMOD
30	TTT	ttt	NN	_	33	NMOD
31	TAC	tac	NN	_	33	NMOD
32	TTT	ttt	NN	_	33	NMOD
33	AG	ag	NN	_	24	PRN
34	)	)	-RRB-	_	33	P
35	and	and	CC	_	19	COORD
36	tet	tet	NN	_	35	GAP
37	reverse	reverse	JJ	_	36	NMOD
38	within	within	IN	_	36	LOC
39	the	the	DT	_	41	NMOD
40	HSV1	hsv0	NN	_	41	NMOD
41	VP16	vp0	NN	_	38	PMOD
42	(	(	-LRB-	_	49	P
43	CAT	cat	NN	_	49	NMOD
44	GTC	gtc	NN	_	49	NMOD
45	CAG	cag	NN	_	49	NMOD
46	ATC	atc	NN	_	49	NMOD
47	GAA	gaa	NN	_	49	NMOD
48	ATC	atc	NN	_	49	NMOD
49	GTC	gtc	NN	_	41	PRN
50	)	)	-RRB-	_	49	P
51	.	.	.	_	4	P

1	All	all	DT	_	2	NMOD
2	reactions	reaction	NNS	_	11	SBJ
3	,	,	,	_	11	P
4	whether	whether	IN	_	11	ADV
5	transgene	transgene	NN	_	7	AMOD
6	-	-	HYPH	_	5	P
7	positive	positive	JJ	_	4	SUB
8	or	or	CC	_	7	COORD
9	not	not	RB	_	8	CONJ
10	,	,	,	_	11	P
11	amplified	amplify	VBD	_	0	ROOT
12	a	a	DT	_	13	NMOD
13	segment	segment	NN	_	11	OBJ
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	19	NMOD
16	endogenous	endogenous	JJ	_	19	NMOD
17	prion	prion	NN	_	19	NMOD
18	protein	protein	NN	_	19	NMOD
19	gene	gene	NN	_	14	PMOD
20	as	as	IN	_	11	ADV
21	a	a	DT	_	22	NMOD
22	control	control	NN	_	20	PMOD
23	for	for	IN	_	22	NMOD
24	DNA	dna	NN	_	25	NMOD
25	quality	quality	NN	_	23	PMOD
26	using	use	VBG	_	11	MNR
27	a	a	DT	_	29	NMOD
28	forward	forward	JJ	_	29	NMOD
29	primer	primer	NN	_	26	OBJ
30	,	,	,	_	29	P
31	PrP	prp	NN	_	35	NMOD
32	-	-	HYPH	_	31	P
33	S	s	NN	_	35	NMOD
34	-	-	HYPH	_	33	P
35	J	j	NN	_	29	APPO
36	,	,	,	_	29	P
37	specific	specific	JJ	_	29	NMOD
38	to	to	IN	_	37	AMOD
39	the	the	DT	_	44	NMOD
40	mouse	mouse	NN	_	44	NMOD
41	PrP	prp	NN	_	44	NMOD
42	open	open	JJ	_	43	NMOD
43	reading	reading	NN	_	44	NMOD
44	frame	frame	NN	_	38	PMOD
45	(	(	-LRB-	_	53	P
46	GGG	ggg	NN	_	53	NMOD
47	ACT	act	NN	_	53	NMOD
48	ATG	atg	NN	_	53	NMOD
49	TGG	tgg	NN	_	53	NMOD
50	ACT	act	NN	_	53	NMOD
51	GAT	gat	NN	_	53	NMOD
52	GTC	gtc	NN	_	53	NMOD
53	GG	gg	NN	_	44	PRN
54	)	)	-RRB-	_	53	P
55	and	and	CC	_	29	COORD
56	a	a	DT	_	58	NMOD
57	reverse	reverse	JJ	_	58	NMOD
58	primer	primer	NN	_	55	CONJ
59	,	,	,	_	58	P
60	PrP	prp	NN	_	64	NMOD
61	-	-	HYPH	_	60	P
62	AS	a	NN	_	64	NMOD
63	-	-	HYPH	_	62	P
64	J	j	NN	_	58	APPO
65	,	,	,	_	58	P
66	shared	share	VBN	_	58	NMOD
67	by	by	IN	_	66	LGS
68	the	the	DT	_	71	NMOD
69	3	0	CD	_	71	NMOD
70	′	′	SYM	_	69	P
71	UTR	utr	NN	_	67	PMOD
72	of	of	IN	_	71	NMOD
73	the	the	DT	_	76	NMOD
74	endogenous	endogenous	JJ	_	76	NMOD
75	PrP	prp	NN	_	76	NMOD
76	gene	gene	NN	_	72	PMOD
77	and	and	CC	_	76	COORD
78	the	the	DT	_	80	NMOD
79	transgene	transgene	NN	_	80	NMOD
80	vector	vector	NN	_	77	CONJ
81	.	.	.	_	11	P

1	Amplification	amplification	NN	_	2	NMOD
2	reactions	reaction	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	run	run	VBN	_	3	VC
5	for	for	IN	_	4	ADV
6	37	0	CD	_	7	NMOD
7	cycles	cycle	NNS	_	5	PMOD
8	at	at	IN	_	4	ADV
9	94	0	CD	_	10	NMOD
10	°C	°c	NN	_	8	PMOD
11	for	for	IN	_	4	TMP
12	30	0	CD	_	13	NMOD
13	s	s	NN	_	11	PMOD
14	,	,	,	_	4	P
15	64	0	CD	_	16	NMOD
16	°C	°c	NN	_	4	GAP
17	for	for	IN	_	16	TMP
18	1	0	CD	_	19	NMOD
19	min	min	NN	_	17	PMOD
20	,	,	,	_	16	P
21	and	and	CC	_	16	COORD
22	72	0	CD	_	23	NMOD
23	°C	°c	NN	_	21	GAP
24	for	for	IN	_	23	TMP
25	1	0	CD	_	26	NMOD
26	min	min	NN	_	24	PMOD
27	.	.	.	_	3	P

1	All	all	DT	_	2	NMOD
2	samples	sample	NNS	_	10	SBJ
3	,	,	,	_	2	P
4	transgenic	transgenic	JJ	_	2	NMOD
5	and	and	CC	_	4	COORD
6	wild	wild	JJ	_	8	NMOD
7	-	-	HYPH	_	6	P
8	type	type	NN	_	5	CONJ
9	,	,	,	_	10	P
10	gave	give	VBD	_	0	ROOT
11	a	a	DT	_	15	NMOD
12	750	0	CD	_	14	NMOD
13	-	-	HYPH	_	12	P
14	bp	bp	NN	_	15	NMOD
15	product	product	NN	_	10	OBJ
16	from	from	IN	_	15	NMOD
17	the	the	DT	_	20	NMOD
18	endogenous	endogenous	JJ	_	20	NMOD
19	PrP	prp	NN	_	20	NMOD
20	gene	gene	NN	_	16	PMOD
21	.	.	.	_	10	P

1	The	the	DT	_	3	NMOD
2	APP	app	NN	_	3	NMOD
3	transgene	transgene	NN	_	4	SBJ
4	yielded	yield	VBD	_	15	DEP
5	an	an	DT	_	7	NMOD
6	additional	additional	JJ	_	7	NMOD
7	band	band	NN	_	4	OBJ
8	at	at	IN	_	7	NMOD
9	400	0	CD	_	10	NMOD
10	bp	bp	NN	_	8	PMOD
11	;	;	:	_	15	P
12	the	the	DT	_	14	NMOD
13	tTA	tta	NN	_	14	NMOD
14	product	product	NN	_	15	SBJ
15	fell	fall	VBD	_	0	ROOT
16	in	in	RB	_	17	AMOD
17	between	between	RB	_	15	ADV
18	at	at	IN	_	15	LOC
19	480	0	CD	_	20	NMOD
20	bp	bp	NN	_	18	PMOD
21	.	.	.	_	15	P

1	Immunoblotting	immunoblotting	NN	_	3	NMOD
2	/	/	HYPH	_	1	P
3	Quantitation	quantitation	NN	_	0	ROOT

1	Frozen	freeze	VBN	_	6	NMOD
2	cortical	cortical	JJ	_	6	NMOD
3	or	or	CC	_	2	COORD
4	whole	whole	JJ	_	5	NMOD
5	forebrain	forebrain	NN	_	3	CONJ
6	tissue	tissue	NN	_	7	SBJ
7	was	be	VBD	_	0	ROOT
8	homogenized	homogenize	VBN	_	7	VC
9	by	by	IN	_	8	MNR
10	sonication	sonication	NN	_	9	PMOD
11	in	in	IN	_	8	LOC
12	five	five	CD	_	13	NMOD
13	volumes	volume	NNS	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	phosphate	phosphate	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	buffered	buffer	VBN	_	18	NMOD
18	saline	saline	NN	_	20	NMOD
19	(	(	-LRB-	_	20	P
20	PBS	pb	NN	_	14	PMOD
21	)	)	-RRB-	_	8	P
22	with	with	IN	_	8	MNR
23	5	0	CD	_	24	NMOD
24	mM	mm	NN	_	28	NMOD
25	EDTA	edta	NN	_	28	NMOD
26	and	and	CC	_	25	COORD
27	protease	protease	NN	_	26	CONJ
28	inhibitors	inhibitor	NNS	_	22	PMOD
29	(	(	-LRB-	_	32	P
30	Mammalian	mammalian	JJ	_	32	NMOD
31	cell	cell	NN	_	32	NMOD
32	cocktail	cocktail	NN	_	28	PRN
33	,	,	,	_	32	P
34	Sigma	sigma	NNP	_	32	APPO
35	,	,	,	_	34	P
36	St.	st.	NNP	_	37	NMOD
37	Louis	louis	NNP	_	34	APPO
38	,	,	,	_	37	P
39	Missouri	missouri	NNP	_	37	APPO
40	,	,	,	_	39	P
41	United	united	NNP	_	42	NMOD
42	States	state	NNP	_	39	APPO
43	)	)	-RRB-	_	32	P
44	,	,	,	_	8	P
45	using	use	VBG	_	8	MNR
46	a	a	DT	_	48	NMOD
47	probe	probe	NN	_	48	NMOD
48	sonicator	sonicator	NN	_	45	OBJ
49	set	set	VBN	_	48	NMOD
50	to	to	IN	_	49	ADV
51	50	0	CD	_	52	NMOD
52	%	%	NN	_	53	NMOD
53	output	output	NN	_	50	PMOD
54	(	(	-LRB-	_	55	P
55	TEKMAR	tekmar	NNP	_	48	PRN
56	,	,	,	_	55	P
57	Cincinnati	cincinnati	NNP	_	55	APPO
58	,	,	,	_	57	P
59	Ohio	ohio	NNP	_	57	APPO
60	,	,	,	_	59	P
61	United	united	NNP	_	62	NMOD
62	States	state	NNP	_	59	APPO
63	)	)	-RRB-	_	55	P
64	.	.	.	_	7	P

1	After	after	IN	_	17	TMP
2	dilution	dilution	NN	_	1	PMOD
3	with	with	IN	_	2	NMOD
4	an	an	DT	_	6	NMOD
5	equal	equal	JJ	_	6	NMOD
6	volume	volume	NN	_	3	PMOD
7	of	of	IN	_	6	NMOD
8	PBS	pb	NN	_	12	NMOD
9	/	/	HYPH	_	8	P
10	EDTA	edta	NN	_	12	NMOD
11	/	/	HYPH	_	10	P
12	protease	protease	NN	_	13	NMOD
13	inhibitor	inhibitor	NN	_	7	PMOD
14	,	,	,	_	17	P
15	the	the	DT	_	16	NMOD
16	samples	sample	NNS	_	17	SBJ
17	were	be	VBD	_	0	ROOT
18	centrifuged	centrifuge	VBN	_	17	VC
19	briefly	briefly	RB	_	18	TMP
20	and	and	CC	_	17	COORD
21	the	the	DT	_	22	NMOD
22	supernatant	supernatant	NN	_	23	SBJ
23	used	use	VBN	_	20	GAP
24	for	for	IN	_	23	PRP
25	analysis	analysis	NN	_	24	PMOD
26	.	.	.	_	17	P

1	Fifty	fifty	CD	_	2	NMOD
2	micrograms	microgram	NNS	_	4	NMOD
3	(	(	-LRB-	_	4	P
4	6E10	0e0	NN	_	17	SBJ
5	and	and	CC	_	4	COORD
6	CT15	ct0	NN	_	5	CONJ
7	)	)	-RRB-	_	4	P
8	or	or	CC	_	4	COORD
9	5	0	CD	_	10	NMOD
10	μg	μg	NN	_	12	NMOD
11	(	(	-LRB-	_	12	P
12	22C11	0c0	NN	_	8	CONJ
13	)	)	-RRB-	_	12	P
14	of	of	IN	_	4	NMOD
15	brain	brain	NN	_	16	NMOD
16	homogenate	homogenate	NN	_	14	PMOD
17	was	be	VBD	_	0	ROOT
18	loaded	load	VBN	_	17	VC
19	per	per	IN	_	18	ADV
20	lane	lane	NN	_	19	PMOD
21	onto	onto	IN	_	18	ADV
22	7.5	0	CD	_	23	NMOD
23	%	%	NN	_	40	NMOD
24	,	,	,	_	23	P
25	10	0	CD	_	26	NMOD
26	%	%	NN	_	23	CONJ
27	–	–	SYM	_	29	P
28	20	0	CD	_	29	NMOD
29	%	%	NN	_	26	NMOD
30	,	,	,	_	26	P
31	or	or	CC	_	26	COORD
32	4	0	CD	_	33	NMOD
33	%	%	NN	_	31	CONJ
34	–	–	SYM	_	36	P
35	20	0	CD	_	36	NMOD
36	%	%	NN	_	33	NMOD
37	Tris	tris	NN	_	40	NMOD
38	-	-	HYPH	_	37	P
39	HCl	hcl	NN	_	40	NMOD
40	PAGE	page	NN	_	41	NMOD
41	gels	gel	NNS	_	21	PMOD
42	(	(	-LRB-	_	46	P
43	Bio	bio	NNP	_	45	NMOD
44	-	-	HYPH	_	43	P
45	Rad	rad	NNP	_	46	NMOD
46	Laboratories	laboratory	NNP	_	41	PRN
47	,	,	,	_	46	P
48	Hercules	hercules	NNP	_	46	APPO
49	,	,	,	_	48	P
50	California	california	NNP	_	48	APPO
51	,	,	,	_	50	P
52	United	united	NNP	_	53	NMOD
53	States	state	NNP	_	50	APPO
54	)	)	-RRB-	_	46	P
55	and	and	CC	_	18	COORD
56	electrophoresed	electrophoresed	VBN	_	55	CONJ
57	for	for	IN	_	56	TMP
58	several	several	JJ	_	59	NMOD
59	hours	hour	NNS	_	57	PMOD
60	in	in	IN	_	56	LOC
61	1	0	CD	_	69	NMOD
62	×	×	SYM	_	61	P
63	Tris	tris	NN	_	69	NMOD
64	-	-	HYPH	_	63	P
65	glycine	glycine	NN	_	69	NMOD
66	–	–	HYPH	_	65	P
67	sodium	sodium	NN	_	69	NMOD
68	dodecyl	dodecyl	NN	_	69	NMOD
69	sulfate	sulfate	NN	_	75	NMOD
70	(	(	-LRB-	_	75	P
71	1	0	CD	_	75	NMOD
72	×	×	SYM	_	71	P
73	TG	tg	NN	_	75	NMOD
74	-	-	HYPH	_	73	P
75	SDS	sd	NN	_	77	NMOD
76	)	)	-RRB-	_	77	P
77	buffer	buffer	NN	_	60	PMOD
78	(	(	-LRB-	_	83	P
79	6E10	0e0	NN	_	83	DEP
80	and	and	CC	_	79	COORD
81	22C11	0c0	NN	_	80	CONJ
82	;	;	:	_	83	P
83	Amresco	amresco	NNP	_	77	PRN
84	,	,	,	_	83	P
85	Solon	solon	NNP	_	83	APPO
86	,	,	,	_	85	P
87	Ohio	ohio	NNP	_	85	APPO
88	,	,	,	_	87	P
89	United	united	NNP	_	90	NMOD
90	States	state	NNP	_	87	APPO
91	)	)	-RRB-	_	83	P
92	or	or	CC	_	77	COORD
93	1	0	CD	_	100	NMOD
94	×	×	SYM	_	93	P
95	Tris	tris	NN	_	99	NMOD
96	-	-	HYPH	_	95	P
97	tricine	tricine	NN	_	99	NMOD
98	-	-	HYPH	_	97	P
99	SDS	sd	NN	_	100	NMOD
100	buffer	buffer	NN	_	92	CONJ
101	(	(	-LRB-	_	104	P
102	CT15	ct0	NN	_	104	DEP
103	;	;	:	_	104	P
104	Invitrogen	invitrogen	NNP	_	100	PRN
105	,	,	,	_	104	P
106	Carlsbad	carlsbad	NNP	_	104	APPO
107	,	,	,	_	106	P
108	California	california	NNP	_	106	APPO
109	,	,	,	_	108	P
110	United	united	NNP	_	111	NMOD
111	States	state	NNP	_	108	APPO
112	)	)	-RRB-	_	104	P
113	.	.	.	_	17	P

1	Proteins	protein	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	transferred	transfer	VBN	_	2	VC
4	overnight	overnight	RB	_	3	TMP
5	to	to	IN	_	3	ADV
6	0.45	0	CD	_	8	NMOD
7	-	-	HYPH	_	6	P
8	μm	μm	NN	_	10	NMOD
9	Optitran	optitran	NNP	_	10	NMOD
10	nitrocellulose	nitrocellulose	NN	_	5	PMOD
11	(	(	-LRB-	_	12	P
12	Schleicher	schleicher	NNP	_	10	PRN
13	and	and	CC	_	12	COORD
14	Schuell	schuell	NNP	_	13	CONJ
15	,	,	,	_	12	P
16	Keene	keene	NNP	_	12	APPO
17	,	,	,	_	16	P
18	New	new	NNP	_	19	NMOD
19	Hampshire	hampshire	NNP	_	16	APPO
20	,	,	,	_	19	P
21	United	united	NNP	_	22	NMOD
22	States	state	NNP	_	19	APPO
23	)	)	-RRB-	_	12	P
24	in	in	IN	_	3	LOC
25	1	0	CD	_	28	NMOD
26	×	×	SYM	_	25	P
27	TG	tg	NN	_	28	NMOD
28	buffer	buffer	NN	_	24	PMOD
29	(	(	-LRB-	_	30	P
30	Amresco	amresco	NNP	_	28	PRN
31	)	)	-RRB-	_	30	P
32	.	.	.	_	2	P

1	Blots	blot	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	blocked	block	VBN	_	2	VC
4	in	in	IN	_	3	LOC
5	PBS	pb	NN	_	4	PMOD
6	containing	contain	VBG	_	5	NMOD
7	5	0	CD	_	8	NMOD
8	%	%	NN	_	12	NMOD
9	nonfat	nonfat	JJ	_	11	NMOD
10	dry	dry	JJ	_	11	NMOD
11	milk	milk	NN	_	12	NMOD
12	powder	powder	NN	_	6	OBJ
13	,	,	,	_	3	P
14	and	and	CC	_	3	COORD
15	incubated	incubate	VBN	_	14	CONJ
16	for	for	IN	_	15	TMP
17	3	0	CD	_	18	NMOD
18	h	h	NN	_	16	PMOD
19	at	at	IN	_	15	ADV
20	room	room	NN	_	21	NMOD
21	temperature	temperature	NN	_	19	PMOD
22	in	in	IN	_	15	LOC
23	blocking	blocking	NN	_	24	NMOD
24	solution	solution	NN	_	22	PMOD
25	with	with	IN	_	24	NMOD
26	one	one	CD	_	25	PMOD
27	of	of	IN	_	26	NMOD
28	the	the	DT	_	30	NMOD
29	following	follow	VBG	_	30	NMOD
30	antibodies	antibody	NNS	_	34	NMOD
31	:	:	:	_	34	P
32	mouse	mouse	NN	_	34	NMOD
33	monoclonal	monoclonal	JJ	_	34	NMOD
34	22C11	0c0	NN	_	27	PMOD
35	(	(	-LRB-	_	46	P
36	kind	kind	JJ	_	37	NMOD
37	gift	gift	NN	_	46	DEP
38	of	of	IN	_	37	NMOD
39	Konrad	konrad	NNP	_	40	NMOD
40	Beyreuther	beyreuther	NNP	_	38	PMOD
41	and	and	CC	_	40	COORD
42	Andreas	andreas	NNP	_	43	NMOD
43	Weidemann	weidemann	NNP	_	41	CONJ
44	;	;	:	_	46	P
45	[	[	-LRB-	_	46	P
46	17	0	CD	_	34	PRN
47	]	]	-RRB-	_	46	P
48	)	)	-RRB-	_	46	P
49	diluted	dilute	VBN	_	34	NMOD
50	1	0	CD	_	49	EXT
51	:	:	SYM	_	52	P
52	1,000	0	CD	_	50	NMOD
53	,	,	,	_	34	P
54	mouse	mouse	NN	_	56	NMOD
55	monoclonal	monoclonal	JJ	_	56	NMOD
56	6E10	0e0	NN	_	34	CONJ
57	(	(	-LRB-	_	59	P
58	Signet	signet	NNP	_	59	NMOD
59	Laboratories	laboratory	NNP	_	56	PRN
60	,	,	,	_	59	P
61	Dedham	dedham	NNP	_	59	APPO
62	,	,	,	_	61	P
63	Massachusetts	massachusetts	NNP	_	61	APPO
64	,	,	,	_	63	P
65	United	united	NNP	_	66	NMOD
66	States	state	NNP	_	63	APPO
67	)	)	-RRB-	_	59	P
68	diluted	dilute	VBN	_	56	NMOD
69	1	0	CD	_	68	EXT
70	:	:	SYM	_	71	P
71	2,500	0	CD	_	69	NMOD
72	,	,	,	_	56	P
73	rabbit	rabbit	NN	_	81	NMOD
74	polyclonal	polyclonal	JJ	_	81	NMOD
75	anti-superoxide	anti-superoxide	JJ	_	81	NMOD
76	dismutase	dismutase	NN	_	81	NMOD
77	1	0	CD	_	81	NMOD
78	(	(	-LRB-	_	81	P
79	m	m	NN	_	81	NMOD
80	/	/	HYPH	_	79	P
81	hSOD1	hsod0	NN	_	56	CONJ
82	)	)	-RRB-	_	81	P
83	[	[	-LRB-	_	84	P
84	18	0	CD	_	81	PRN
85	]	]	-RRB-	_	84	P
86	diluted	dilute	VBN	_	81	NMOD
87	1	0	CD	_	86	EXT
88	:	:	SYM	_	89	P
89	2,500	0	CD	_	87	NMOD
90	to	to	IN	_	87	NMOD
91	1	0	CD	_	90	PMOD
92	:	:	SYM	_	93	P
93	4,000	0	CD	_	91	NMOD
94	,	,	,	_	81	P
95	or	or	CC	_	81	COORD
96	rabbit	rabbit	NN	_	98	NMOD
97	polyclonal	polyclonal	JJ	_	98	NMOD
98	CT15	ct0	NN	_	95	CONJ
99	(	(	-LRB-	_	101	P
100	kind	kind	JJ	_	101	NMOD
101	gift	gift	NN	_	98	PRN
102	of	of	IN	_	101	NMOD
103	Ed	ed	NNP	_	104	NMOD
104	Koo	koo	NNP	_	102	PMOD
105	;	;	:	_	101	P
106	[	[	-LRB-	_	107	P
107	19	0	CD	_	101	PRN
108	]	]	-RRB-	_	107	P
109	)	)	-RRB-	_	101	P
110	diluted	dilute	VBN	_	98	NMOD
111	1	0	CD	_	110	EXT
112	:	:	SYM	_	113	P
113	1,000	0	CD	_	111	NMOD
114	.	.	.	_	2	P

1	Subsequently	subsequently	RB	_	5	TMP
2	,	,	,	_	5	P
3	the	the	DT	_	4	NMOD
4	blots	blot	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	washed	wash	VBN	_	5	VC
7	with	with	IN	_	6	MNR
8	PBS	pb	NN	_	7	PMOD
9	containing	contain	VBG	_	8	NMOD
10	0.1	0	CD	_	11	NMOD
11	%	%	NN	_	12	NMOD
12	Tween	tween	NN	_	9	OBJ
13	-	-	HYPH	_	12	P
14	20	0	CD	_	12	NMOD
15	,	,	,	_	6	P
16	and	and	CC	_	6	COORD
17	then	then	RB	_	18	TMP
18	incubated	incubate	VBN	_	16	CONJ
19	with	with	IN	_	18	MNR
20	either	either	CC	_	21	COORD
21	goat	goat	NN	_	31	NMOD
22	anti-mouse	anti-mouse	JJ	_	21	NMOD
23	–	–	HYPH	_	21	P
24	or	or	CC	_	21	COORD
25	goat	goat	NN	_	24	CONJ
26	anti-rabbit	anti-rabbit	JJ	_	25	NMOD
27	–	–	HYPH	_	21	P
28	HRP	hrp	NN	_	29	AMOD
29	conjugated	conjugate	VBN	_	31	NMOD
30	secondary	secondary	JJ	_	31	NMOD
31	antibody	antibody	NN	_	19	PMOD
32	diluted	dilute	VBN	_	31	NMOD
33	1	0	CD	_	32	EXT
34	:	:	SYM	_	35	P
35	1,000	0	CD	_	33	NMOD
36	in	in	IN	_	32	LOC
37	blocking	blocking	NN	_	38	NMOD
38	solution	solution	NN	_	36	PMOD
39	.	.	.	_	5	P

1	After	after	IN	_	15	TMP
2	several	several	JJ	_	4	NMOD
3	additional	additional	JJ	_	4	NMOD
4	rinses	rinse	NNS	_	1	PMOD
5	in	in	IN	_	4	LOC
6	PBS	pb	NN	_	5	PMOD
7	with	with	IN	_	4	NMOD
8	0.1	0	CD	_	10	NMOD
9	%	%	NN	_	8	QMOD
10	Tween	tween	NN	_	7	PMOD
11	-	-	HYPH	_	10	P
12	20	0	CD	_	10	NMOD
13	,	,	,	_	15	P
14	blots	blot	NNS	_	15	SBJ
15	were	be	VBD	_	0	ROOT
16	developed	develop	VBN	_	15	VC
17	with	with	IN	_	16	MNR
18	enhanced	enhance	VBN	_	20	NMOD
19	chemiluminescence	chemiluminescence	NN	_	20	NMOD
20	reagent	reagent	NN	_	17	PMOD
21	and	and	CC	_	16	COORD
22	imaged	image	VBN	_	21	CONJ
23	with	with	IN	_	22	MNR
24	the	the	DT	_	31	NMOD
25	Bio	bio	NNP	_	27	NMOD
26	-	-	HYPH	_	25	P
27	Rad	rad	NNP	_	30	NMOD
28	Molecular	molecular	NNP	_	30	NMOD
29	Imager	imager	NNP	_	30	NMOD
30	FX	fx	NNP	_	31	NMOD
31	system	system	NN	_	23	PMOD
32	.	.	.	_	15	P

1	Staining	staining	NN	_	2	NMOD
2	intensity	intensity	NN	_	6	SBJ
3	within	within	IN	_	2	NMOD
4	each	each	DT	_	5	NMOD
5	lane	lane	NN	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	quantified	quantify	VBN	_	6	VC
8	using	use	VBG	_	7	MNR
9	the	the	DT	_	14	NMOD
10	Quantity	quantity	NNP	_	14	NMOD
11	One	one	CD	_	10	NMOD
12	image	image	NN	_	13	NMOD
13	analysis	analysis	NN	_	14	NMOD
14	software	software	NN	_	8	OBJ
15	(	(	-LRB-	_	18	P
16	Molecular	molecular	NNP	_	17	NMOD
17	Imager	imager	NNP	_	18	NMOD
18	FX	fx	NNP	_	14	PRN
19	,	,	,	_	18	P
20	Bio	bio	NNP	_	22	NMOD
21	-	-	HYPH	_	20	P
22	Rad	rad	NNP	_	23	NMOD
23	Laboratories	laboratory	NNP	_	18	APPO
24	)	)	-RRB-	_	18	P
25	.	.	.	_	6	P

1	Background	background	NN	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	calculated	calculate	VBN	_	2	VC
4	from	from	IN	_	3	ADV
5	across	across	IN	_	4	PMOD
6	the	the	DT	_	7	NMOD
7	image	image	NN	_	5	PMOD
8	and	and	CC	_	3	COORD
9	subtracted	subtract	VBN	_	8	CONJ
10	from	from	IN	_	9	ADV
11	the	the	DT	_	13	NMOD
12	entire	entire	JJ	_	13	NMOD
13	file	file	NN	_	10	PMOD
14	.	.	.	_	2	P

1	The	the	DT	_	3	NMOD
2	signal	signal	NN	_	3	NMOD
3	intensity	intensity	NN	_	15	SBJ
4	for	for	IN	_	3	NMOD
5	each	each	DT	_	6	NMOD
6	band	band	NN	_	4	PMOD
7	(	(	-LRB-	_	13	P
8	corrected	correct	VBN	_	10	NMOD
9	signal	signal	NN	_	10	NMOD
10	intensity	intensity	NN	_	13	NMOD
11	×	×	SYM	_	13	P
12	pixel	pixel	NN	_	13	NMOD
13	number	number	NN	_	3	PRN
14	)	)	-RRB-	_	13	P
15	was	be	VBD	_	0	ROOT
16	then	then	RB	_	15	TMP
17	calculated	calculate	VBN	_	15	VC
18	using	use	VBG	_	17	MNR
19	the	the	DT	_	22	NMOD
20	Volume	volume	NN	_	21	NMOD
21	report	report	NN	_	22	NMOD
22	tool	tool	NN	_	18	OBJ
23	.	.	.	_	15	P

1	Slot	slot	NN	_	2	NMOD
2	Blot	blot	NN	_	4	NMOD
3	mRNA	mrna	NN	_	4	NMOD
4	Analysis	analysis	NN	_	0	ROOT

1	Five	five	CD	_	2	NMOD
2	micrograms	microgram	NNS	_	28	SBJ
3	per	per	IN	_	2	NMOD
4	sample	sample	NN	_	3	PMOD
5	of	of	IN	_	4	NMOD
6	total	total	JJ	_	7	NMOD
7	RNA	rna	NN	_	5	PMOD
8	extracted	extract	VBN	_	7	NMOD
9	from	from	IN	_	8	ADV
10	fresh	fresh	JJ	_	12	AMOD
11	-	-	HYPH	_	10	P
12	frozen	freeze	VBN	_	13	NMOD
13	brain	brain	NN	_	9	PMOD
14	,	,	,	_	13	P
15	liver	liver	NN	_	13	CONJ
16	,	,	,	_	15	P
17	kidney	kidney	NN	_	15	CONJ
18	,	,	,	_	17	P
19	heart	heart	NN	_	17	CONJ
20	,	,	,	_	19	P
21	lung	lung	NN	_	19	CONJ
22	,	,	,	_	21	P
23	spleen	spleen	NN	_	21	CONJ
24	,	,	,	_	23	P
25	and	and	CC	_	23	COORD
26	skeletal	skeletal	JJ	_	27	NMOD
27	muscle	muscle	NN	_	25	CONJ
28	was	be	VBD	_	0	ROOT
29	vacuum	vacuum	NN	_	31	DEP
30	-	-	HYPH	_	29	P
31	filtered	filter	VBN	_	28	VC
32	through	through	IN	_	31	MNR
33	0.45	0	CD	_	35	NMOD
34	-	-	HYPH	_	33	P
35	μm	μm	NN	_	37	NMOD
36	Optitran	optitran	NNP	_	37	NMOD
37	nitrocellulose	nitrocellulose	NN	_	32	PMOD
38	.	.	.	_	28	P

1	After	after	IN	_	13	TMP
2	several	several	JJ	_	3	NMOD
3	washes	wash	NNS	_	1	PMOD
4	through	through	IN	_	3	NMOD
5	the	the	DT	_	6	NMOD
6	manifold	manifold	NN	_	4	PMOD
7	with	with	IN	_	3	NMOD
8	10	0	CD	_	10	NMOD
9	×	×	SYM	_	8	P
10	SSC	ssc	NN	_	7	PMOD
11	,	,	,	_	13	P
12	blots	blot	NNS	_	13	SBJ
13	were	be	VBD	_	0	ROOT
14	UV	uv	NN	_	16	DEP
15	-	-	HYPH	_	14	P
16	cross-linked	cross-linked	VBN	_	13	VC
17	and	and	CC	_	16	COORD
18	probed	probe	VBN	_	17	CONJ
19	with	with	IN	_	18	MNR
20	a	a	DT	_	30	NMOD
21	radiolabeled	radiolabeled	VBN	_	30	NMOD
22	∼	∼	SYM	_	23	P
23	350	0	CD	_	25	NMOD
24	-	-	HYPH	_	23	P
25	bp	bp	NN	_	30	NMOD
26	BglII	bglii	NN	_	28	NMOD
27	–	–	HYPH	_	26	P
28	XhoI	xhoi	NN	_	30	NMOD
29	cDNA	cdna	NN	_	30	NMOD
30	fragment	fragment	NN	_	19	PMOD
31	of	of	IN	_	30	NMOD
32	mo	mo	NN	_	34	NMOD
33	/	/	HYPH	_	32	P
34	huAPP695	huapp0	NN	_	35	NMOD
35	cDNA	cdna	NN	_	31	PMOD
36	.	.	.	_	13	P

1	After	after	IN	_	35	TMP
2	hybridizing	hybridize	VBG	_	1	PMOD
3	overnight	overnight	RB	_	2	TMP
4	at	at	IN	_	2	ADV
5	65	0	CD	_	6	NMOD
6	°C	°c	NN	_	4	PMOD
7	in	in	IN	_	2	LOC
8	1	0	CD	_	9	NMOD
9	%	%	NN	_	10	NMOD
10	BSA	bsa	NN	_	28	NMOD
11	/	/	HYPH	_	10	P
12	1	0	CD	_	13	NMOD
13	mM	mm	NN	_	14	NMOD
14	EDTA	edta	NN	_	28	NMOD
15	/	/	HYPH	_	14	P
16	0.5	0	CD	_	17	NMOD
17	M	m	NN	_	20	NMOD
18	sodium	sodium	NN	_	20	NMOD
19	phosphate	phosphate	NN	_	20	NMOD
20	buffer	buffer	NN	_	28	NMOD
21	(	(	-LRB-	_	22	P
22	pH	ph	NN	_	20	PRN
23	7.2	0	CD	_	22	NMOD
24	)	)	-RRB-	_	22	P
25	/	/	HYPH	_	20	P
26	7	0	CD	_	27	NMOD
27	%	%	NN	_	28	NMOD
28	SDS	sd	NN	_	7	PMOD
29	[	[	-LRB-	_	30	P
30	20	0	CD	_	28	PRN
31	]	]	-RRB-	_	30	P
32	,	,	,	_	35	P
33	the	the	DT	_	34	NMOD
34	blots	blot	NNS	_	35	SBJ
35	were	be	VBD	_	0	ROOT
36	washed	wash	VBN	_	35	VC
37	twice	twice	RB	_	36	TMP
38	at	at	IN	_	36	ADV
39	65	0	CD	_	40	NMOD
40	°C	°c	NN	_	38	PMOD
41	for	for	IN	_	36	TMP
42	30	0	CD	_	43	NMOD
43	min	min	NN	_	44	NMOD
44	each	each	DT	_	41	PMOD
45	in	in	IN	_	36	LOC
46	0.1	0	CD	_	47	NMOD
47	%	%	NN	_	48	NMOD
48	BSA	bsa	NN	_	66	NMOD
49	/	/	HYPH	_	48	P
50	1	0	CD	_	51	NMOD
51	mM	mm	NN	_	52	NMOD
52	EDTA	edta	NN	_	66	NMOD
53	/	/	HYPH	_	52	P
54	40	0	CD	_	55	NMOD
55	mM	mm	NN	_	58	NMOD
56	sodium	sodium	NN	_	58	NMOD
57	phosphate	phosphate	NN	_	58	NMOD
58	buffer	buffer	NN	_	66	NMOD
59	(	(	-LRB-	_	60	P
60	pH	ph	NN	_	58	PRN
61	7.2	0	CD	_	60	NMOD
62	)	)	-RRB-	_	60	P
63	/	/	HYPH	_	58	P
64	5	0	CD	_	65	NMOD
65	%	%	NN	_	66	NMOD
66	SDS	sd	NN	_	45	PMOD
67	before	before	IN	_	36	TMP
68	two	two	CD	_	73	NMOD
69	final	final	JJ	_	73	NMOD
70	30	0	CD	_	72	NMOD
71	-	-	HYPH	_	70	P
72	min	min	NN	_	73	NMOD
73	washes	wash	NNS	_	67	PMOD
74	at	at	IN	_	73	NMOD
75	65	0	CD	_	76	NMOD
76	°C	°c	NN	_	74	PMOD
77	with	with	IN	_	73	NMOD
78	1	0	CD	_	79	NMOD
79	mM	mm	NN	_	80	NMOD
80	EDTA	edta	NN	_	94	NMOD
81	/	/	HYPH	_	80	P
82	40	0	CD	_	83	NMOD
83	mM	mm	NN	_	86	NMOD
84	sodium	sodium	NN	_	86	NMOD
85	phosphate	phosphate	NN	_	86	NMOD
86	buffer	buffer	NN	_	94	NMOD
87	(	(	-LRB-	_	88	P
88	pH	ph	NN	_	86	PRN
89	7.2	0	CD	_	88	NMOD
90	)	)	-RRB-	_	88	P
91	/	/	HYPH	_	86	P
92	1	0	CD	_	93	NMOD
93	%	%	NN	_	94	NMOD
94	SDS	sd	NN	_	77	PMOD
95	.	.	.	_	35	P

1	Blots	blot	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	wrapped	wrap	VBN	_	2	VC
4	wet	wet	JJ	_	3	ADV
5	and	and	CC	_	3	COORD
6	exposed	expose	VBN	_	5	CONJ
7	to	to	IN	_	6	ADV
8	phosphorscreens	phosphorscreens	NNS	_	7	PMOD
9	overnight	overnight	RB	_	6	TMP
10	at	at	IN	_	6	ADV
11	room	room	NN	_	12	NMOD
12	temperature	temperature	NN	_	10	PMOD
13	.	.	.	_	2	P

1	Amyloid	amyloid	NN	_	2	NMOD
2	Histology	histology	NN	_	0	ROOT

1	Mice	mouse	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	euthanized	euthanized	VBN	_	2	VC
4	by	by	IN	_	3	MNR
5	ether	ether	NN	_	6	NMOD
6	inhalation	inhalation	NN	_	4	PMOD
7	and	and	CC	_	2	COORD
8	brains	brain	NNS	_	9	SBJ
9	removed	remove	VBN	_	7	GAP
10	for	for	IN	_	9	PRP
11	immersion	immersion	NN	_	12	NMOD
12	fixation	fixation	NN	_	10	PMOD
13	in	in	IN	_	12	LOC
14	4	0	CD	_	15	NMOD
15	%	%	NN	_	16	NMOD
16	paraformaldehyde	paraformaldehyde	NN	_	20	NMOD
17	/	/	HYPH	_	16	P
18	1	0	CD	_	20	NMOD
19	×	×	SYM	_	18	P
20	PBS	pb	NN	_	13	PMOD
21	.	.	.	_	2	P

1	After	after	IN	_	11	TMP
2	48	0	CD	_	3	NMOD
3	h	h	NN	_	1	PMOD
4	in	in	IN	_	3	NMOD
5	fixative	fixative	JJ	_	4	PMOD
6	at	at	IN	_	3	NMOD
7	4	0	CD	_	8	NMOD
8	°C	°c	NN	_	6	PMOD
9	,	,	,	_	11	P
10	brains	brain	NNS	_	11	SBJ
11	were	be	VBD	_	0	ROOT
12	transferred	transfer	VBN	_	11	VC
13	to	to	IN	_	12	ADV
14	PBS	pb	NN	_	13	PMOD
15	,	,	,	_	12	P
16	dehydrated	dehydrate	VBN	_	12	CONJ
17	in	in	IN	_	16	LOC
18	alcohols	alcohol	NNS	_	17	PMOD
19	,	,	,	_	16	P
20	treated	treat	VBN	_	16	CONJ
21	with	with	IN	_	20	MNR
22	cedarwood	cedarwood	NN	_	23	NMOD
23	oil	oil	NN	_	21	PMOD
24	and	and	CC	_	23	COORD
25	methylsalicylate	methylsalicylate	NN	_	24	CONJ
26	,	,	,	_	20	P
27	and	and	CC	_	20	COORD
28	embedded	embed	VBN	_	27	CONJ
29	in	in	IN	_	28	LOC
30	paraffin	paraffin	NN	_	29	PMOD
31	for	for	IN	_	28	PRP
32	sectioning	section	VBG	_	31	PMOD
33	.	.	.	_	11	P

1	Hirano	hirano	NN	_	3	NMOD
2	silver	silver	NN	_	3	NMOD
3	stain	stain	NN	_	0	ROOT

1	Silver	silver	NN	_	3	NMOD
2	impregnation	impregnation	NN	_	3	NMOD
3	histology	histology	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	performed	perform	VBN	_	4	VC
6	on	on	IN	_	5	ADV
7	10	0	CD	_	9	NMOD
8	-	-	HYPH	_	7	P
9	μm	μm	NN	_	13	NMOD
10	paraffin	paraffin	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	embedded	embed	VBN	_	13	NMOD
13	sections	section	NNS	_	6	PMOD
14	by	by	IN	_	5	MNR
15	Hirano	hirano	NNP	_	17	NMOD
16	's	's	POS	_	15	NMOD
17	modification	modification	NN	_	14	PMOD
18	of	of	IN	_	17	NMOD
19	the	the	DT	_	21	NMOD
20	Bielschowsky	bielschowsky	NNP	_	21	NMOD
21	method	method	NN	_	18	PMOD
22	[	[	-LRB-	_	23	P
23	21	0	CD	_	5	PRN
24	]	]	-RRB-	_	23	P
25	.	.	.	_	4	P

1	Briefly	briefly	RB	_	4	TMP
2	,	,	,	_	4	P
3	sections	section	NNS	_	4	SBJ
4	were	be	VBD	_	0	ROOT
5	deparaffinized	deparaffinized	VBN	_	4	VC
6	through	through	IN	_	5	MNR
7	xylene	xylene	NN	_	6	PMOD
8	and	and	CC	_	7	COORD
9	alcohols	alcohol	NNS	_	8	CONJ
10	into	into	IN	_	5	LOC
11	tap	tap	NN	_	12	NMOD
12	water	water	NN	_	10	PMOD
13	before	before	IN	_	5	TMP
14	being	be	VBG	_	13	PMOD
15	placed	place	VBN	_	14	VC
16	into	into	IN	_	15	LOC
17	fresh	fresh	JJ	_	22	NMOD
18	20	0	CD	_	19	NMOD
19	%	%	NN	_	22	NMOD
20	silver	silver	NN	_	22	NMOD
21	nitrate	nitrate	NN	_	22	NMOD
22	solution	solution	NN	_	16	PMOD
23	for	for	IN	_	15	TMP
24	20	0	CD	_	25	NMOD
25	min	min	NN	_	23	PMOD
26	.	.	.	_	4	P

1	After	after	IN	_	10	TMP
2	being	be	VBG	_	1	PMOD
3	washed	wash	VBN	_	2	VC
4	thoroughly	thoroughly	RB	_	3	MNR
5	with	with	IN	_	3	ADV
6	distilled	distilled	JJ	_	7	NMOD
7	water	water	NN	_	5	PMOD
8	,	,	,	_	10	P
9	slides	slide	NNS	_	10	SBJ
10	were	be	VBD	_	0	ROOT
11	immersed	immerse	VBN	_	10	VC
12	in	in	IN	_	11	LOC
13	20	0	CD	_	14	NMOD
14	%	%	NN	_	17	NMOD
15	silver	silver	NN	_	16	NMOD
16	nitrate	nitrate	NN	_	17	NMOD
17	solution	solution	NN	_	12	PMOD
18	titrated	titrate	VBN	_	17	NMOD
19	with	with	IN	_	18	MNR
20	fresh	fresh	JJ	_	22	NMOD
21	ammonium	ammonium	NN	_	22	NMOD
22	hydroxide	hydroxide	NN	_	19	PMOD
23	.	.	.	_	10	P

1	After	after	IN	_	6	TMP
2	20	0	CD	_	3	NMOD
3	min	min	NN	_	1	PMOD
4	,	,	,	_	6	P
5	slides	slide	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	washed	wash	VBN	_	6	VC
8	with	with	IN	_	7	MNR
9	ammonia	ammonia	NN	_	10	NMOD
10	water	water	NN	_	8	PMOD
11	before	before	IN	_	7	TMP
12	being	be	VBG	_	11	PMOD
13	individually	individually	RB	_	12	MNR
14	developed	develop	VBN	_	12	VC
15	with	with	IN	_	14	MNR
16	100	0	CD	_	17	NMOD
17	μl	μl	NN	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	developer	developer	NN	_	18	PMOD
20	(	(	-LRB-	_	22	P
21	20	0	CD	_	22	NMOD
22	ml	ml	NN	_	19	PRN
23	of	of	IN	_	22	NMOD
24	37	0	CD	_	25	NMOD
25	%	%	NN	_	26	NMOD
26	formaldehyde	formaldehyde	NN	_	23	PMOD
27	,	,	,	_	22	P
28	100	0	CD	_	29	NMOD
29	ml	ml	NN	_	22	CONJ
30	of	of	IN	_	29	NMOD
31	distilled	distilled	JJ	_	32	NMOD
32	water	water	NN	_	30	PMOD
33	,	,	,	_	29	P
34	50	0	CD	_	35	NMOD
35	μl	μl	NN	_	29	CONJ
36	of	of	IN	_	35	NMOD
37	concentrated	concentrate	VBN	_	39	NMOD
38	nitric	nitric	JJ	_	39	NMOD
39	acid	acid	NN	_	36	PMOD
40	,	,	,	_	35	P
41	and	and	CC	_	35	COORD
42	0.5	0	CD	_	43	NMOD
43	g	g	NN	_	41	CONJ
44	of	of	IN	_	43	NMOD
45	citric	citric	JJ	_	46	NMOD
46	acid	acid	NN	_	44	PMOD
47	)	)	-RRB-	_	22	P
48	added	add	VBN	_	17	NMOD
49	to	to	IN	_	48	ADV
50	50	0	CD	_	51	NMOD
51	ml	ml	NN	_	49	PMOD
52	of	of	IN	_	51	NMOD
53	titrated	titrate	VBN	_	56	NMOD
54	silver	silver	NN	_	55	NMOD
55	nitrate	nitrate	NN	_	56	NMOD
56	solution	solution	NN	_	52	PMOD
57	.	.	.	_	6	P

1	Slides	slide	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	then	then	RB	_	2	TMP
4	rinsed	rinse	VBN	_	2	VC
5	in	in	IN	_	4	LOC
6	tap	tap	NN	_	7	NMOD
7	water	water	NN	_	5	PMOD
8	,	,	,	_	4	P
9	fixed	fix	VBN	_	4	CONJ
10	in	in	IN	_	9	LOC
11	5	0	CD	_	12	NMOD
12	%	%	NN	_	14	NMOD
13	sodium	sodium	NN	_	14	NMOD
14	thiosulfate	thiosulfate	NN	_	10	PMOD
15	,	,	,	_	9	P
16	and	and	CC	_	9	COORD
17	dehydrated	dehydrate	VBN	_	16	CONJ
18	through	through	IN	_	17	MNR
19	alcohols	alcohol	NNS	_	18	PMOD
20	and	and	CC	_	19	COORD
21	xylene	xylene	NN	_	20	CONJ
22	.	.	.	_	2	P

1	Thioflavin	thioflavin	NN	_	3	NMOD
2	-	-	HYPH	_	1	P
3	S	s	NN	_	4	NMOD
4	staining	staining	NN	_	0	ROOT

1	Following	follow	VBG	_	16	TMP
2	deparaffinization	deparaffinization	NN	_	1	PMOD
3	of	of	IN	_	2	NMOD
4	sections	section	NNS	_	3	PMOD
5	through	through	IN	_	2	NMOD
6	xylene	xylene	NN	_	5	PMOD
7	and	and	CC	_	6	COORD
8	alcohols	alcohol	NNS	_	7	CONJ
9	,	,	,	_	16	P
10	amyloid	amyloid	NN	_	11	NMOD
11	impregnation	impregnation	NN	_	16	SBJ
12	with	with	IN	_	11	NMOD
13	thioflavin	thioflavin	NN	_	15	NMOD
14	-	-	HYPH	_	13	P
15	S	s	NN	_	12	PMOD
16	was	be	VBD	_	0	ROOT
17	performed	perform	VBN	_	16	VC
18	according	accord	VBG	_	17	ADV
19	to	to	IN	_	18	PMOD
20	the	the	DT	_	22	NMOD
21	Guntern	guntern	NN	_	22	NMOD
22	modification	modification	NN	_	19	PMOD
23	of	of	IN	_	22	NMOD
24	the	the	DT	_	26	NMOD
25	standard	standard	JJ	_	26	NMOD
26	protocol	protocol	NN	_	23	PMOD
27	.	.	.	_	16	P

1	Slides	slide	NNS	_	8	SBJ
2	holding	hold	VBG	_	1	NMOD
3	10	0	CD	_	5	NMOD
4	-	-	HYPH	_	3	P
5	μm	μm	NN	_	7	NMOD
6	paraffin	paraffin	NN	_	7	NMOD
7	sections	section	NNS	_	2	OBJ
8	were	be	VBD	_	0	ROOT
9	washed	wash	VBN	_	8	VC
10	twice	twice	RB	_	9	TMP
11	in	in	IN	_	9	LOC
12	distilled	distilled	JJ	_	13	NMOD
13	water	water	NN	_	11	PMOD
14	,	,	,	_	9	P
15	then	then	RB	_	16	TMP
16	immersed	immerse	VBN	_	9	VC
17	for	for	IN	_	16	TMP
18	5	0	CD	_	19	NMOD
19	min	min	NN	_	17	PMOD
20	in	in	IN	_	16	LOC
21	a	a	DT	_	26	NMOD
22	0.25	0	CD	_	23	NMOD
23	%	%	NN	_	26	NMOD
24	potassium	potassium	NN	_	26	NMOD
25	permanganate	permanganate	NN	_	26	NMOD
26	solution	solution	NN	_	20	PMOD
27	,	,	,	_	16	P
28	followed	follow	VBN	_	16	ADV
29	by	by	IN	_	28	LGS
30	5	0	CD	_	31	NMOD
31	min	min	NN	_	29	PMOD
32	in	in	IN	_	31	LOC
33	a	a	DT	_	43	NMOD
34	1	0	CD	_	35	NMOD
35	%	%	NN	_	37	NMOD
36	potassium	potassium	NN	_	37	NMOD
37	metabisulfate	metabisulfate	NN	_	42	NMOD
38	/	/	HYPH	_	37	P
39	1	0	CD	_	40	NMOD
40	%	%	NN	_	42	NMOD
41	oxalic	oxalic	JJ	_	42	NMOD
42	acid	acid	NN	_	43	NMOD
43	solution	solution	NN	_	32	PMOD
44	.	.	.	_	8	P

1	After	after	IN	_	6	TMP
2	this	this	DT	_	3	NMOD
3	preparation	preparation	NN	_	1	PMOD
4	,	,	,	_	6	P
5	slides	slide	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	placed	place	VBN	_	6	VC
8	into	into	IN	_	7	LOC
9	a	a	DT	_	17	NMOD
10	filtered	filter	VBN	_	17	NMOD
11	aqueous	aqueous	JJ	_	17	NMOD
12	0.02	0	CD	_	13	NMOD
13	%	%	NN	_	17	NMOD
14	thioflavin	thioflavin	NN	_	16	NMOD
15	-	-	HYPH	_	14	P
16	S	s	NN	_	17	NMOD
17	solution	solution	NN	_	8	PMOD
18	(	(	-LRB-	_	22	P
19	Chroma	chroma	NNP	_	21	NMOD
20	-	-	HYPH	_	19	P
21	Gesellschaft	gesellschaft	NNP	_	22	NMOD
22	Schmid	schmid	NNP	_	17	PRN
23	,	,	,	_	22	P
24	Kongen	kongen	NNP	_	22	APPO
25	,	,	,	_	24	P
26	Germany	germany	NNP	_	24	APPO
27	)	)	-RRB-	_	22	P
28	for	for	IN	_	7	TMP
29	8	0	CD	_	30	NMOD
30	min	min	NN	_	28	PMOD
31	.	.	.	_	6	P

1	Excess	excess	JJ	_	2	NMOD
2	stain	stain	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	removed	remove	VBN	_	3	VC
5	by	by	IN	_	4	LGS
6	two	two	CD	_	8	NMOD
7	brief	brief	JJ	_	8	NMOD
8	rinses	rinse	NNS	_	5	PMOD
9	in	in	IN	_	8	NMOD
10	80	0	CD	_	11	NMOD
11	%	%	NN	_	12	NMOD
12	ethanol	ethanol	NN	_	9	PMOD
13	,	,	,	_	8	P
14	then	then	RB	_	15	TMP
15	two	two	CD	_	8	APPO
16	in	in	IN	_	15	LOC
17	distilled	distilled	JJ	_	18	NMOD
18	water	water	NN	_	16	PMOD
19	,	,	,	_	8	P
20	after	after	IN	_	24	TMP
21	which	which	WDT	_	20	PMOD
22	slides	slide	NNS	_	23	SBJ
23	were	be	VBD	_	8	NMOD
24	finished	finish	VBN	_	23	VC
25	in	in	IN	_	24	LOC
26	aqueous	aqueous	JJ	_	28	NMOD
27	mounting	mounting	NN	_	28	NMOD
28	medium	medium	NN	_	25	PMOD
29	for	for	IN	_	24	PRP
30	florescence	florescence	NN	_	31	NMOD
31	photomicrography	photomicrography	NN	_	29	PMOD
32	.	.	.	_	3	P

1	Ubiquitin	ubiquitin	NN	_	0	ROOT
2	,	,	,	_	1	P
3	glial	glial	JJ	_	6	NMOD
4	fibrillary	fibrillary	JJ	_	6	NMOD
5	acidic	acidic	JJ	_	6	NMOD
6	protein	protein	NN	_	1	CONJ
7	,	,	,	_	6	P
8	and	and	CC	_	6	COORD
9	Aβ	aβ	NN	_	10	NMOD
10	immunohistochemistry	immunohistochemistry	NN	_	8	CONJ

1	Prior	prior	JJ	_	2	PMOD
2	to	to	IN	_	6	TMP
3	immunostaining	immunostaining	NN	_	2	PMOD
4	,	,	,	_	6	P
5	slides	slide	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	deparaffinized	deparaffinized	VBN	_	6	VC
8	by	by	IN	_	7	MNR
9	oven	oven	NN	_	10	NMOD
10	heating	heating	NN	_	8	PMOD
11	followed	follow	VBN	_	7	TMP
12	by	by	IN	_	11	LGS
13	immersion	immersion	NN	_	12	PMOD
14	in	in	IN	_	13	LOC
15	xylene	xylene	NN	_	14	PMOD
16	.	.	.	_	6	P

1	After	after	IN	_	13	TMP
2	rehydration	rehydration	NN	_	1	PMOD
3	through	through	IN	_	2	NMOD
4	graded	grade	VBN	_	5	NMOD
5	alcohols	alcohol	NNS	_	3	PMOD
6	into	into	IN	_	2	LOC
7	tap	tap	NN	_	8	NMOD
8	water	water	NN	_	6	PMOD
9	,	,	,	_	13	P
10	endogenous	endogenous	JJ	_	12	NMOD
11	peroxidase	peroxidase	NN	_	12	NMOD
12	activity	activity	NN	_	13	SBJ
13	was	be	VBD	_	0	ROOT
14	quenched	quench	VBN	_	13	VC
15	by	by	IN	_	14	LGS
16	incubation	incubation	NN	_	15	PMOD
17	with	with	IN	_	16	NMOD
18	3	0	CD	_	19	NMOD
19	%	%	NN	_	21	NMOD
20	hydrogen	hydrogen	NN	_	21	NMOD
21	peroxide	peroxide	NN	_	17	PMOD
22	in	in	IN	_	16	LOC
23	methanol	methanol	NN	_	22	PMOD
24	.	.	.	_	13	P

1	Slides	slide	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	microwaved	microwave	VBN	_	2	VC
4	for	for	IN	_	3	TMP
5	5	0	CD	_	8	NMOD
6	–	–	SYM	_	5	P
7	7	0	CD	_	5	QMOD
8	min	min	NN	_	4	PMOD
9	in	in	IN	_	3	LOC
10	water	water	NN	_	9	PMOD
11	,	,	,	_	3	P
12	cooled	cool	VBN	_	3	VC
13	for	for	IN	_	12	TMP
14	5	0	CD	_	15	NMOD
15	min	min	NN	_	13	PMOD
16	,	,	,	_	3	P
17	then	then	RB	_	18	TMP
18	washed	wash	VBN	_	3	VC
19	in	in	IN	_	18	LOC
20	TBS	tb	NN	_	19	PMOD
21	.	.	.	_	2	P

1	Nonspecific	nonspecific	JJ	_	2	NMOD
2	staining	staining	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	blocked	block	VBN	_	3	VC
5	for	for	IN	_	4	TMP
6	1	0	CD	_	7	NMOD
7	h	h	NN	_	5	PMOD
8	with	with	IN	_	4	MNR
9	3	0	CD	_	10	NMOD
10	%	%	NN	_	13	NMOD
11	normal	normal	JJ	_	13	NMOD
12	goat	goat	NN	_	13	NMOD
13	serum	serum	NN	_	8	PMOD
14	and	and	CC	_	13	COORD
15	0.1	0	CD	_	16	NMOD
16	%	%	NN	_	19	NMOD
17	Triton	triton	NN	_	19	NMOD
18	-	-	HYPH	_	17	P
19	X	x	NN	_	14	CONJ
20	100	0	CD	_	19	NMOD
21	in	in	IN	_	13	LOC
22	TBS	tb	NN	_	21	PMOD
23	.	.	.	_	3	P

1	Slides	slide	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	then	then	RB	_	2	TMP
4	placed	place	VBN	_	2	VC
5	into	into	IN	_	4	LOC
6	primary	primary	JJ	_	7	NMOD
7	antibody	antibody	NN	_	5	PMOD
8	(	(	-LRB-	_	39	P
9	rabbit	rabbit	NN	_	13	NMOD
10	anti-Aβ	anti-aβ	JJ	_	13	NMOD
11	peptide	peptide	NN	_	13	NMOD
12	polyclonal	polyclonal	JJ	_	13	NMOD
13	antibody	antibody	NN	_	39	DEP
14	,	,	,	_	13	P
15	Zymed	zymed	NNP	_	16	NMOD
16	Laboratories	laboratory	NNP	_	13	APPO
17	,	,	,	_	16	P
18	South	south	NNP	_	20	NMOD
19	San	san	NNP	_	20	NMOD
20	Francisco	francisco	NNP	_	16	APPO
21	,	,	,	_	20	P
22	California	california	NNP	_	20	APPO
23	,	,	,	_	22	P
24	United	united	NNP	_	25	NMOD
25	States	state	NNP	_	22	APPO
26	;	;	:	_	39	P
27	rabbit	rabbit	NN	_	39	NMOD
28	anti-ubiquitin	anti-ubiquitin	JJ	_	27	NMOD
29	and	and	CC	_	27	COORD
30	rabbit	rabbit	NN	_	29	CONJ
31	anti–glial	anti–glial	JJ	_	30	NMOD
32	fibrillary	fibrillary	JJ	_	34	NMOD
33	acidic	acidic	JJ	_	34	NMOD
34	protein	protein	NN	_	36	NMOD
35	(	(	-LRB-	_	36	P
36	GFAP	gfap	NN	_	39	NMOD
37	)	)	-RRB-	_	39	P
38	polyclonal	polyclonal	JJ	_	39	NMOD
39	antibodies	antibody	NNS	_	7	PRN
40	,	,	,	_	39	P
41	Dako	dako	NNP	_	39	APPO
42	,	,	,	_	41	P
43	Carpinteria	carpinteria	NNP	_	41	APPO
44	,	,	,	_	43	P
45	California	california	NNP	_	43	APPO
46	,	,	,	_	45	P
47	United	united	NNP	_	48	NMOD
48	States	state	NNP	_	45	APPO
49	)	)	-RRB-	_	39	P
50	diluted	dilute	VBN	_	7	NMOD
51	1	0	CD	_	50	ADV
52	:	:	SYM	_	53	P
53	500	0	CD	_	51	NMOD
54	in	in	IN	_	50	LOC
55	TBS	tb	NN	_	54	PMOD
56	with	with	IN	_	50	MNR
57	2	0	CD	_	58	NMOD
58	%	%	NN	_	61	NMOD
59	normal	normal	JJ	_	61	NMOD
60	goat	goat	NN	_	61	NMOD
61	serum	serum	NN	_	56	PMOD
62	and	and	CC	_	4	COORD
63	incubated	incubate	VBN	_	62	CONJ
64	overnight	overnight	RB	_	63	TMP
65	at	at	IN	_	63	ADV
66	room	room	NN	_	67	NMOD
67	temperature	temperature	NN	_	65	PMOD
68	.	.	.	_	2	P

1	After	after	IN	_	15	TMP
2	being	be	VBG	_	1	PMOD
3	washed	wash	VBN	_	2	VC
4	of	of	IN	_	3	ADV
5	excess	excess	JJ	_	7	NMOD
6	primary	primary	JJ	_	7	NMOD
7	antibody	antibody	NN	_	4	PMOD
8	with	with	IN	_	3	MNR
9	several	several	JJ	_	10	NMOD
10	changes	change	NNS	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	TBS	tb	NN	_	11	PMOD
13	,	,	,	_	15	P
14	slides	slide	NNS	_	15	SBJ
15	were	be	VBD	_	0	ROOT
16	incubated	incubate	VBN	_	15	VC
17	with	with	IN	_	16	MNR
18	either	either	CC	_	24	COORD
19	the	the	DT	_	24	NMOD
20	Vectastain	vectastain	NNP	_	21	NMOD
21	Elite	elite	NNP	_	24	NMOD
22	anti-rabbit	anti-rabbit	JJ	_	24	NMOD
23	secondary	secondary	JJ	_	24	NMOD
24	system	system	NN	_	17	PMOD
25	(	(	-LRB-	_	29	P
26	anti-Aβ	anti-aβ	JJ	_	29	DEP
27	;	;	:	_	29	P
28	Vector	vector	NNP	_	29	NMOD
29	Laboratories	laboratory	NNP	_	24	PRN
30	,	,	,	_	29	P
31	Burlingame	burlingame	NNP	_	29	APPO
32	,	,	,	_	31	P
33	California	california	NNP	_	31	APPO
34	,	,	,	_	33	P
35	United	united	NNP	_	36	NMOD
36	States	state	NNP	_	33	APPO
37	)	)	-RRB-	_	29	P
38	or	or	CC	_	24	COORD
39	peroxidase	peroxidase	NN	_	42	NMOD
40	/	/	HYPH	_	39	P
41	anti-peroxidase	anti-peroxidase	JJ	_	39	NMOD
42	reagents	reagent	NNS	_	38	CONJ
43	(	(	-LRB-	_	49	P
44	anti-ubitquitin	anti-ubitquitin	JJ	_	49	DEP
45	and	and	CC	_	44	COORD
46	anti-GFAP	anti-gfap	JJ	_	45	CONJ
47	;	;	:	_	49	P
48	Sternberger	sternberger	NNP	_	49	NMOD
49	Monoclonals	monoclonal	NNPS	_	42	PRN
50	,	,	,	_	49	P
51	Lutherville	lutherville	NNP	_	49	APPO
52	,	,	,	_	51	P
53	Maryland	maryland	NNP	_	51	APPO
54	,	,	,	_	53	P
55	United	united	NNP	_	56	NMOD
56	States	state	NNP	_	53	APPO
57	)	)	-RRB-	_	49	P
58	according	accord	VBG	_	16	MNR
59	to	to	IN	_	58	PMOD
60	the	the	DT	_	61	NMOD
61	manufacturers	manufacturer	NNS	_	63	NMOD
62	'	'	POS	_	61	NMOD
63	directions	direction	NNS	_	59	PMOD
64	.	.	.	_	15	P

1	Antibody	antibody	NN	_	2	NMOD
2	binding	binding	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	visualized	visualize	VBN	_	3	VC
5	with	with	IN	_	4	MNR
6	diaminobenzidene	diaminobenzidene	NN	_	5	PMOD
7	,	,	,	_	3	P
8	and	and	CC	_	3	COORD
9	sections	section	NNS	_	10	SBJ
10	were	be	VBD	_	8	CONJ
11	counterstained	counterstained	VBN	_	10	VC
12	with	with	IN	_	11	MNR
13	hematoxylin	hematoxylin	NN	_	12	PMOD
14	.	.	.	_	3	P

1	Filter	filter	NN	_	3	NMOD
2	Trap	trap	NN	_	3	NMOD
3	Assay	assay	NN	_	0	ROOT

1	An	an	DT	_	2	NMOD
2	aliquot	aliquot	NN	_	12	SBJ
3	of	of	IN	_	2	NMOD
4	each	each	DT	_	6	NMOD
5	cortical	cortical	JJ	_	6	NMOD
6	homogenate	homogenate	NN	_	3	PMOD
7	used	use	VBN	_	6	NMOD
8	for	for	IN	_	7	PRP
9	Western	western	NNP	_	10	NMOD
10	blotting	blotting	NN	_	8	PMOD
11	above	above	RB	_	7	ADV
12	was	be	VBD	_	0	ROOT
13	partially	partially	RB	_	12	ADV
14	solubilized	solubilized	VBN	_	12	VC
15	by	by	IN	_	14	MNR
16	the	the	DT	_	17	NMOD
17	addition	addition	NN	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	SDS	sd	NN	_	18	PMOD
20	to	to	IN	_	14	ADV
21	a	a	DT	_	23	NMOD
22	final	final	JJ	_	23	NMOD
23	concentration	concentration	NN	_	20	PMOD
24	of	of	IN	_	23	NMOD
25	1	0	CD	_	26	NMOD
26	%	%	NN	_	24	PMOD
27	.	.	.	_	12	P

1	Serial	serial	JJ	_	5	NMOD
2	1	0	CD	_	5	NMOD
3	:	:	SYM	_	4	P
4	2	0	CD	_	2	NMOD
5	dilutions	dilution	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	made	make	VBN	_	6	VC
8	with	with	IN	_	7	MNR
9	1	0	CD	_	11	NMOD
10	×	×	SYM	_	9	P
11	PBS	pb	NN	_	15	NMOD
12	/	/	HYPH	_	11	P
13	1	0	CD	_	14	NMOD
14	%	%	NN	_	15	NMOD
15	SDS	sd	NN	_	8	PMOD
16	,	,	,	_	6	P
17	and	and	CC	_	6	COORD
18	100	0	CD	_	19	NMOD
19	μl	μl	NN	_	23	SBJ
20	of	of	IN	_	19	NMOD
21	each	each	DT	_	22	NMOD
22	dilution	dilution	NN	_	20	PMOD
23	was	be	VBD	_	17	CONJ
24	then	then	RB	_	23	TMP
25	vacuum	vacuum	NN	_	27	DEP
26	-	-	HYPH	_	25	P
27	filtered	filter	VBN	_	23	VC
28	through	through	IN	_	27	DIR
29	a	a	DT	_	36	NMOD
30	pre-wet	pre-wet	JJ	_	36	NMOD
31	0.22	0	CD	_	33	NMOD
32	-	-	HYPH	_	31	P
33	μm	μm	NN	_	36	NMOD
34	cellulose	cellulose	NN	_	36	NMOD
35	acetate	acetate	NN	_	36	NMOD
36	membrane	membrane	NN	_	28	PMOD
37	(	(	-LRB-	_	38	P
38	Schleicher	schleicher	NNP	_	36	PRN
39	and	and	CC	_	38	COORD
40	Schuell	schuell	NNP	_	39	CONJ
41	)	)	-RRB-	_	38	P
42	[	[	-LRB-	_	43	P
43	22	0	CD	_	27	PRN
44	]	]	-RRB-	_	43	P
45	.	.	.	_	6	P

1	Each	each	DT	_	2	NMOD
2	well	well	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	washed	wash	VBN	_	3	VC
5	several	several	JJ	_	6	NMOD
6	times	time	NNS	_	4	OBJ
7	with	with	IN	_	4	MNR
8	PBS	pb	NN	_	7	PMOD
9	,	,	,	_	4	P
10	after	after	IN	_	14	TMP
11	which	which	WDT	_	10	PMOD
12	blots	blot	NNS	_	13	SBJ
13	were	be	VBD	_	4	TMP
14	incubated	incubate	VBN	_	13	VC
15	overnight	overnight	RB	_	14	TMP
16	with	with	IN	_	14	MNR
17	polyclonal	polyclonal	JJ	_	19	NMOD
18	anti-Aβ	anti-aβ	JJ	_	19	NMOD
19	antibody	antibody	NN	_	16	PMOD
20	(	(	-LRB-	_	22	P
21	Zymed	zymed	NNP	_	22	NMOD
22	Laboratories	laboratory	NNP	_	19	PRN
23	)	)	-RRB-	_	22	P
24	diluted	dilute	VBN	_	19	NMOD
25	1	0	CD	_	24	EXT
26	:	:	SYM	_	27	P
27	600	0	CD	_	25	NMOD
28	in	in	IN	_	24	LOC
29	a	a	DT	_	31	NMOD
30	blocking	blocking	NN	_	31	NMOD
31	solution	solution	NN	_	28	PMOD
32	of	of	IN	_	31	NMOD
33	1	0	CD	_	35	NMOD
34	×	×	SYM	_	33	P
35	TBS	tb	NN	_	41	NMOD
36	/	/	HYPH	_	35	P
37	5	0	CD	_	38	NMOD
38	%	%	NN	_	41	NMOD
39	nonfat	nonfat	JJ	_	41	NMOD
40	dry	dry	JJ	_	41	NMOD
41	milk	milk	NN	_	42	NMOD
42	powder	powder	NN	_	32	PMOD
43	.	.	.	_	3	P

1	After	after	IN	_	24	TMP
2	washing	wash	VBG	_	1	PMOD
3	the	the	DT	_	4	NMOD
4	blots	blot	NNS	_	2	OBJ
5	three	three	CD	_	6	NMOD
6	times	time	NNS	_	2	TMP
7	for	for	IN	_	2	ADV
8	10	0	CD	_	9	NMOD
9	min	min	NN	_	10	NMOD
10	each	each	DT	_	7	PMOD
11	in	in	IN	_	2	LOC
12	1	0	CD	_	14	NMOD
13	×	×	SYM	_	12	P
14	TBS	tb	NN	_	18	NMOD
15	/	/	HYPH	_	14	P
16	0.1	0	CD	_	17	NMOD
17	%	%	NN	_	18	NMOD
18	Tween	tween	NN	_	11	PMOD
19	-	-	HYPH	_	18	P
20	20	0	CD	_	18	NMOD
21	,	,	,	_	24	P
22	the	the	DT	_	23	NMOD
23	membrane	membrane	NN	_	24	SBJ
24	was	be	VBD	_	0	ROOT
25	incubated	incubate	VBN	_	24	VC
26	for	for	IN	_	25	TMP
27	1	0	CD	_	28	NMOD
28	h	h	NN	_	26	PMOD
29	with	with	IN	_	25	MNR
30	HRP	hrp	NN	_	32	AMOD
31	-	-	HYPH	_	30	P
32	conjugated	conjugate	VBN	_	34	NMOD
33	protein	protein	NN	_	34	NMOD
34	A	a	NN	_	29	PMOD
35	(	(	-LRB-	_	36	P
36	Sigma	sigma	NNP	_	34	PRN
37	)	)	-RRB-	_	36	P
38	diluted	dilute	VBN	_	34	NMOD
39	1	0	CD	_	38	OBJ
40	:	:	SYM	_	41	P
41	5,000	0	CD	_	39	NMOD
42	in	in	IN	_	38	LOC
43	blocking	blocking	NN	_	44	NMOD
44	solution	solution	NN	_	42	PMOD
45	.	.	.	_	24	P

1	The	the	DT	_	2	NMOD
2	membranes	membrane	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	again	again	RB	_	3	TMP
5	washed	wash	VBN	_	3	VC
6	three	three	CD	_	7	NMOD
7	times	time	NNS	_	5	TMP
8	with	with	IN	_	5	MNR
9	1	0	CD	_	11	NMOD
10	×	×	SYM	_	9	P
11	TBS	tb	NN	_	15	NMOD
12	/	/	HYPH	_	11	P
13	0.1	0	CD	_	14	NMOD
14	%	%	NN	_	15	NMOD
15	Tween	tween	NN	_	8	PMOD
16	-	-	HYPH	_	15	P
17	20	0	CD	_	15	NMOD
18	,	,	,	_	5	P
19	before	before	IN	_	5	TMP
20	antibody	antibody	NN	_	21	NMOD
21	binding	binding	NN	_	22	SBJ
22	was	be	VBD	_	19	SUB
23	detected	detect	VBN	_	22	VC
24	with	with	IN	_	23	MNR
25	enhanced	enhance	VBN	_	26	NMOD
26	chemiluminescence	chemiluminescence	NN	_	24	PMOD
27	(	(	-LRB-	_	28	P
28	PerkinElmer	perkinelmer	NNP	_	23	PRN
29	,	,	,	_	28	P
30	Boston	boston	NNP	_	28	APPO
31	,	,	,	_	30	P
32	Massachusetts	massachusetts	NNP	_	30	APPO
33	,	,	,	_	32	P
34	United	united	NNP	_	35	NMOD
35	States	state	NNP	_	32	APPO
36	)	)	-RRB-	_	28	P
37	.	.	.	_	3	P

1	Digital	digital	JJ	_	2	NMOD
2	images	image	NNS	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	each	each	DT	_	5	NMOD
5	blot	blot	NN	_	3	PMOD
6	were	be	VBD	_	0	ROOT
7	captured	capture	VBN	_	6	VC
8	with	with	IN	_	7	MNR
9	a	a	DT	_	15	NMOD
10	Molecular	molecular	JJ	_	11	NMOD
11	Imager	imager	NNP	_	12	NMOD
12	FX	fx	NNP	_	15	NMOD
13	gel	gel	NN	_	14	NMOD
14	documentation	documentation	NN	_	15	NMOD
15	system	system	NN	_	8	PMOD
16	,	,	,	_	6	P
17	and	and	CC	_	6	COORD
18	the	the	DT	_	19	NMOD
19	intensity	intensity	NN	_	23	SBJ
20	of	of	IN	_	19	NMOD
21	Aβ	aβ	NN	_	22	NMOD
22	staining	staining	NN	_	20	PMOD
23	was	be	VBD	_	17	CONJ
24	quantified	quantify	VBN	_	23	VC
25	using	use	VBG	_	24	MNR
26	Quantity	quantity	NNP	_	30	NMOD
27	One	one	CD	_	26	NMOD
28	image	image	NN	_	29	NMOD
29	analysis	analysis	NN	_	30	NMOD
30	software	software	NN	_	25	OBJ
31	.	.	.	_	6	P

1	Aβ	aβ	NN	_	2	NMOD
2	ELISA	elisa	NN	_	0	ROOT

1	An	an	DT	_	2	NMOD
2	aliquot	aliquot	NN	_	12	SBJ
3	of	of	IN	_	2	NMOD
4	cortical	cortical	JJ	_	5	NMOD
5	homogenate	homogenate	NN	_	3	PMOD
6	generated	generate	VBN	_	5	NMOD
7	for	for	IN	_	6	PRP
8	Western	western	NNP	_	9	NMOD
9	analysis	analysis	NN	_	7	PMOD
10	described	describe	VBN	_	9	NMOD
11	above	above	RB	_	10	ADV
12	was	be	VBD	_	0	ROOT
13	subjected	subject	VBN	_	12	VC
14	to	to	IN	_	13	ADV
15	a	a	DT	_	20	NMOD
16	three	three	CD	_	18	NMOD
17	-	-	HYPH	_	16	P
18	step	step	NN	_	20	NMOD
19	sequential	sequential	JJ	_	20	NMOD
20	extraction	extraction	NN	_	14	PMOD
21	using	use	VBG	_	13	MNR
22	PBS	pb	NN	_	21	OBJ
23	,	,	,	_	22	P
24	2	0	CD	_	25	NMOD
25	%	%	NN	_	26	NMOD
26	SDS	sd	NN	_	22	CONJ
27	,	,	,	_	26	P
28	and	and	CC	_	26	COORD
29	70	0	CD	_	30	NMOD
30	%	%	NN	_	34	NMOD
31	formic	formic	JJ	_	32	NMOD
32	acid	acid	NN	_	34	NMOD
33	(	(	-LRB-	_	34	P
34	FA	fa	NN	_	28	CONJ
35	)	)	-RRB-	_	12	P
36	.	.	.	_	12	P

1	At	at	IN	_	7	ADV
2	each	each	DT	_	3	NMOD
3	step	step	NN	_	1	PMOD
4	,	,	,	_	7	P
5	the	the	DT	_	6	NMOD
6	sample	sample	NN	_	7	SBJ
7	was	be	VBD	_	0	ROOT
8	sonicated	sonicated	VBN	_	7	VC
9	in	in	IN	_	8	LOC
10	appropriate	appropriate	JJ	_	11	NMOD
11	buffer	buffer	NN	_	9	PMOD
12	and	and	CC	_	8	COORD
13	centrifuged	centrifuge	VBN	_	12	CONJ
14	at	at	IN	_	13	ADV
15	100,000g	0g	CD	_	14	PMOD
16	for	for	IN	_	13	TMP
17	30	0	CD	_	18	NMOD
18	min	min	NN	_	16	PMOD
19	(	(	-LRB-	_	26	P
20	1	0	CD	_	25	NMOD
21	-	-	HYPH	_	20	P
22	to	to	IN	_	20	QMOD
23	1.5	0	CD	_	20	QMOD
24	-	-	HYPH	_	20	P
25	mo	mo	NN	_	26	NMOD
26	samples	sample	NNS	_	18	PRN
27	)	)	-RRB-	_	26	P
28	or	or	CC	_	18	COORD
29	60	0	CD	_	30	NMOD
30	min	min	NN	_	28	CONJ
31	(	(	-LRB-	_	38	P
32	6	0	CD	_	37	NMOD
33	-	-	HYPH	_	32	P
34	to	to	IN	_	32	QMOD
35	12	0	CD	_	32	QMOD
36	-	-	HYPH	_	32	P
37	mo	mo	NN	_	38	NMOD
38	samples	sample	NNS	_	30	PRN
39	)	)	-RRB-	_	38	P
40	at	at	IN	_	13	ADV
41	4	0	CD	_	42	NMOD
42	°C	°c	NN	_	40	PMOD
43	as	as	IN	_	13	MNR
44	previously	previously	RB	_	45	TMP
45	described	describe	VBN	_	43	SUB
46	[	[	-LRB-	_	47	P
47	23	0	CD	_	13	PRN
48	–	–	SYM	_	49	P
49	25	0	CD	_	47	NMOD
50	]	]	-RRB-	_	47	P
51	.	.	.	_	7	P

1	The	the	DT	_	2	NMOD
2	supernatant	supernatant	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	removed	remove	VBN	_	3	VC
5	for	for	IN	_	4	PRP
6	analysis	analysis	NN	_	5	PMOD
7	,	,	,	_	3	P
8	and	and	CC	_	3	COORD
9	the	the	DT	_	10	NMOD
10	pellet	pellet	NN	_	11	SBJ
11	was	be	VBD	_	8	CONJ
12	sonicated	sonicated	VBN	_	11	VC
13	in	in	IN	_	12	LOC
14	the	the	DT	_	16	NMOD
15	next	next	JJ	_	16	NMOD
16	solution	solution	NN	_	13	PMOD
17	in	in	IN	_	12	MNR
18	sequence	sequence	NN	_	17	PMOD
19	.	.	.	_	3	P

1	The	the	DT	_	5	NMOD
2	2	0	CD	_	3	NMOD
3	%	%	NN	_	5	NMOD
4	SDS	sd	NN	_	5	NMOD
5	extracts	extract	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	diluted	dilute	VBN	_	6	VC
8	in	in	IN	_	7	LOC
9	EC	ec	NN	_	10	NMOD
10	buffer	buffer	NN	_	8	PMOD
11	,	,	,	_	6	P
12	and	and	CC	_	6	COORD
13	the	the	DT	_	15	NMOD
14	FA	fa	NN	_	15	NMOD
15	extracts	extract	NNS	_	16	SBJ
16	neutralized	neutralize	VBN	_	12	GAP
17	with	with	IN	_	16	MNR
18	1M	0m	NN	_	22	NMOD
19	Tris	tris	NN	_	22	NMOD
20	-	-	HYPH	_	19	P
21	phosphate	phosphate	NN	_	22	NMOD
22	buffer	buffer	NN	_	17	PMOD
23	(	(	-LRB-	_	24	P
24	pH	ph	NN	_	22	PRN
25	11	0	CD	_	24	NMOD
26	)	)	-RRB-	_	24	P
27	then	then	RB	_	28	TMP
28	diluted	dilute	VBD	_	16	VC
29	with	with	IN	_	28	MNR
30	EC	ec	NN	_	31	NMOD
31	buffer	buffer	NN	_	29	PMOD
32	prior	prior	JJ	_	33	PMOD
33	to	to	IN	_	28	TMP
34	testing	testing	NN	_	33	PMOD
35	.	.	.	_	6	P

1	Human	human	JJ	_	2	NMOD
2	Aβ	aβ	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	measured	measure	VBN	_	3	VC
5	in	in	IN	_	4	ADV
6	each	each	DT	_	7	NMOD
7	fraction	fraction	NN	_	5	PMOD
8	using	use	VBG	_	4	MNR
9	BAN50	ban0	NN	_	8	OBJ
10	for	for	IN	_	8	ADV
11	capture	capture	NN	_	10	PMOD
12	(	(	-LRB-	_	16	P
13	epitope	epitope	NN	_	16	NMOD
14	Aβ1	aβ0	NN	_	16	NMOD
15	–	–	HYPH	_	14	P
16	16	0	NN	_	11	PRN
17	)	)	-RRB-	_	16	P
18	and	and	CC	_	8	COORD
19	BA27	ba0	NN	_	18	GAP
20	and	and	CC	_	19	COORD
21	BC05	bc0	NN	_	20	CONJ
22	for	for	IN	_	19	ADV
23	detection	detection	NN	_	22	PMOD
24	(	(	-LRB-	_	29	P
25	Aβ40	aβ0	NN	_	29	DEP
26	and	and	CC	_	25	COORD
27	Aβ42	aβ0	NN	_	26	CONJ
28	,	,	,	_	29	P
29	respectively	respectively	RB	_	23	PRN
30	)	)	-RRB-	_	29	P
31	(	(	-LRB-	_	34	P
32	Takeda	takeda	NNP	_	34	NMOD
33	Chemical	chemical	NNP	_	34	NMOD
34	Industries	industry	NNPS	_	23	PRN
35	,	,	,	_	34	P
36	Osaka	osaka	NNP	_	34	APPO
37	,	,	,	_	36	P
38	Japan	japan	NNP	_	36	APPO
39	)	)	-RRB-	_	34	P
40	.	.	.	_	3	P

1	Total	total	JJ	_	2	NMOD
2	Aβ	aβ	NN	_	17	SBJ
3	(	(	-LRB-	_	14	P
4	mouse	mouse	NN	_	14	DEP
5	+	+	SYM	_	4	P
6	human	human	JJ	_	4	NMOD
7	;	;	:	_	14	P
8	1	0	CD	_	13	NMOD
9	-	-	HYPH	_	8	P
10	to	to	IN	_	8	QMOD
11	1.5	0	CD	_	8	QMOD
12	-	-	HYPH	_	8	P
13	mo	mo	NN	_	14	NMOD
14	samples	sample	NNS	_	2	PRN
15	only	only	RB	_	14	NMOD
16	)	)	-RRB-	_	14	P
17	was	be	VBD	_	0	ROOT
18	measured	measure	VBN	_	17	VC
19	in	in	IN	_	18	ADV
20	each	each	DT	_	21	NMOD
21	fraction	fraction	NN	_	19	PMOD
22	using	use	VBG	_	18	MNR
23	BNT77	bnt0	NN	_	22	OBJ
24	for	for	IN	_	22	ADV
25	capture	capture	NN	_	24	PMOD
26	(	(	-LRB-	_	28	P
27	epitope	epitope	NN	_	28	NMOD
28	Aβ11	aβ0	NN	_	25	PRN
29	–	–	HYPH	_	28	P
30	28	0	CD	_	28	NMOD
31	)	)	-RRB-	_	28	P
32	and	and	CC	_	22	COORD
33	BA27	ba0	NN	_	32	GAP
34	and	and	CC	_	33	COORD
35	BC05	bc0	NN	_	34	CONJ
36	for	for	IN	_	33	ADV
37	detection	detection	NN	_	36	PMOD
38	.	.	.	_	17	P

1	All	all	DT	_	2	NMOD
2	values	value	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	calculated	calculate	VBN	_	3	VC
5	as	as	IN	_	4	ADV
6	picomoles	picomoles	NNS	_	5	PMOD
7	per	per	IN	_	6	NMOD
8	gram	gram	NN	_	7	PMOD
9	based	base	VBN	_	4	PRP
10	on	on	IN	_	9	PMOD
11	the	the	DT	_	13	NMOD
12	initial	initial	JJ	_	13	NMOD
13	weight	weight	NN	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	cortical	cortical	JJ	_	16	NMOD
16	tissue	tissue	NN	_	14	PMOD
17	.	.	.	_	3	P

1	Activity	activity	NN	_	2	NMOD
2	Monitoring	monitoring	NN	_	0	ROOT

1	Daily	daily	JJ	_	3	NMOD
2	basal	basal	JJ	_	3	NMOD
3	activity	activity	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	studied	study	VBN	_	4	VC
6	in	in	IN	_	5	LOC
7	28	0	CD	_	19	NMOD
8	CaMKIIα	camkiiα	NN	_	16	NMOD
9	-	-	HYPH	_	8	P
10	tTA	tta	NN	_	16	NMOD
11	×	×	SYM	_	16	P
12	tet	tet	NN	_	16	NMOD
13	-	-	HYPH	_	12	P
14	APPswe	appswe	NN	_	16	NMOD
15	/	/	HYPH	_	14	P
16	ind	ind	NN	_	19	NMOD
17	line	line	NN	_	19	NMOD
18	107	0	CD	_	17	NMOD
19	mice	mouse	NNS	_	6	PMOD
20	between	between	IN	_	21	QMOD
21	4	0	CD	_	24	NMOD
22	and	and	CC	_	21	COORD
23	5	0	CD	_	22	CONJ
24	mo	mo	NN	_	19	TMP
25	of	of	IN	_	24	NMOD
26	age	age	NN	_	25	PMOD
27	.	.	.	_	4	P

1	Animals	animal	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	separated	separate	VBN	_	2	VC
4	into	into	IN	_	3	LOC
5	individual	individual	JJ	_	6	NMOD
6	cages	cage	NNS	_	4	PMOD
7	immediately	immediately	RB	_	8	PMOD
8	before	before	IN	_	3	TMP
9	the	the	DT	_	10	NMOD
10	start	start	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	each	each	DT	_	13	NMOD
13	experiment	experiment	NN	_	11	PMOD
14	(	(	-LRB-	_	17	P
15	n	n	NN	_	17	SBJ
16	=	=	SYM	_	17	P
17	3	0	CD	_	3	PRN
18	–	–	SYM	_	17	P
19	6	0	CD	_	17	QMOD
20	per	per	IN	_	17	NMOD
21	genotype	genotype	NN	_	20	PMOD
22	untreated	untreated	JJ	_	21	NMOD
23	,	,	,	_	17	P
24	2	0	CD	_	17	APPO
25	–	–	SYM	_	24	P
26	5	0	CD	_	24	QMOD
27	per	per	IN	_	24	NMOD
28	genotype	genotype	NN	_	27	PMOD
29	dox	dox	NN	_	31	DEP
30	-	-	HYPH	_	29	P
31	reared	rear	VBN	_	28	NMOD
32	)	)	-RRB-	_	17	P
33	.	.	.	_	2	P

1	The	the	DT	_	2	NMOD
2	cages	cage	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	placed	place	VBN	_	3	VC
5	inside	inside	IN	_	4	LOC
6	activity	activity	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	monitoring	monitor	VBG	_	9	NMOD
9	frames	frame	NNS	_	5	PMOD
10	designed	design	VBN	_	9	NMOD
11	to	to	TO	_	10	PRP
12	count	count	VB	_	11	IM
13	every	every	DT	_	14	NMOD
14	time	time	NN	_	12	OBJ
15	the	the	DT	_	16	NMOD
16	animal	animal	NN	_	17	SBJ
17	passed	pass	VBN	_	14	NMOD
18	through	through	IN	_	17	DIR
19	one	one	CD	_	18	PMOD
20	of	of	IN	_	19	NMOD
21	three	three	CD	_	22	NMOD
22	photobeams	photobeams	NNS	_	20	PMOD
23	spanning	span	VBG	_	22	NMOD
24	the	the	DT	_	25	NMOD
25	width	width	NN	_	23	OBJ
26	of	of	IN	_	25	NMOD
27	the	the	DT	_	28	NMOD
28	cage	cage	NN	_	26	PMOD
29	(	(	-LRB-	_	32	P
30	San	san	NNP	_	31	NMOD
31	Diego	diego	NNP	_	32	NMOD
32	Instruments	instrument	NNP	_	17	PRN
33	,	,	,	_	32	P
34	San	san	NNP	_	35	NMOD
35	Diego	diego	NNP	_	32	APPO
36	,	,	,	_	35	P
37	California	california	NNP	_	35	APPO
38	,	,	,	_	37	P
39	United	united	NNP	_	40	NMOD
40	States	state	NNP	_	37	APPO
41	)	)	-RRB-	_	32	P
42	.	.	.	_	3	P

1	Experiments	experiment	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	started	start	VBN	_	2	VC
4	midway	midway	RB	_	5	PMOD
5	through	through	IN	_	3	TMP
6	the	the	DT	_	8	NMOD
7	light	light	NN	_	8	NMOD
8	phase	phase	NN	_	5	PMOD
9	of	of	IN	_	8	NMOD
10	the	the	DT	_	11	NMOD
11	day	day	NN	_	9	PMOD
12	,	,	,	_	2	P
13	and	and	CC	_	2	COORD
14	data	datum	NNS	_	15	SBJ
15	were	be	VBD	_	13	CONJ
16	collected	collect	VBN	_	15	VC
17	in	in	IN	_	16	LOC
18	1	0	CD	_	20	NMOD
19	-	-	HYPH	_	18	P
20	h	h	NN	_	21	NMOD
21	bins	bin	NNS	_	17	PMOD
22	for	for	IN	_	16	TMP
23	the	the	DT	_	26	NMOD
24	following	following	JJ	_	26	NMOD
25	48	0	CD	_	26	NMOD
26	h	h	NN	_	22	PMOD
27	.	.	.	_	2	P

1	Testing	testing	NN	_	2	NMOD
2	rooms	room	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	maintained	maintain	VBN	_	3	VC
5	on	on	IN	_	4	ADV
6	the	the	DT	_	15	NMOD
7	same	same	JJ	_	15	NMOD
8	13	0	CD	_	11	NMOD
9	:	:	SYM	_	10	P
10	11	0	CD	_	8	NMOD
11	h	h	NN	_	15	NMOD
12	day	day	NN	_	15	NMOD
13	:	:	SYM	_	14	P
14	night	night	NN	_	12	NMOD
15	cycle	cycle	NN	_	5	PMOD
16	as	as	IN	_	15	NMOD
17	the	the	DT	_	21	NMOD
18	main	main	JJ	_	21	NMOD
19	animal	animal	NN	_	20	NMOD
20	housing	housing	NN	_	21	NMOD
21	areas	area	NNS	_	16	PMOD
22	and	and	CC	_	3	COORD
23	were	be	VBD	_	22	CONJ
24	closed	close	VBN	_	23	VC
25	to	to	IN	_	24	ADV
26	entry	entry	NN	_	25	PMOD
27	during	during	IN	_	24	TMP
28	the	the	DT	_	29	NMOD
29	experiment	experiment	NN	_	27	PMOD
30	.	.	.	_	3	P

1	Statistical	statistical	JJ	_	2	NMOD
2	Analyses	analysis	NNS	_	0	ROOT

1	Statistical	statistical	JJ	_	2	NMOD
2	analyses	analysis	NNS	_	14	SBJ
3	of	of	IN	_	2	NMOD
4	protein	protein	NN	_	5	NMOD
5	expression	expression	NN	_	3	PMOD
6	,	,	,	_	5	P
7	ELISA	elisa	NN	_	8	NMOD
8	data	datum	NNS	_	5	CONJ
9	,	,	,	_	8	P
10	and	and	CC	_	8	COORD
11	filter	filter	NN	_	12	NMOD
12	trap	trap	NN	_	13	NMOD
13	assays	assay	NNS	_	10	CONJ
14	were	be	VBD	_	0	ROOT
15	performed	perform	VBN	_	14	VC
16	by	by	IN	_	15	MNR
17	ANOVA	anova	NN	_	16	PMOD
18	with	with	IN	_	15	MNR
19	Tukey	tukey	NNP	_	27	NMOD
20	's	's	POS	_	19	NMOD
21	honest	honest	JJ	_	27	NMOD
22	significant	significant	JJ	_	27	NMOD
23	difference	difference	NN	_	27	NMOD
24	post	post	FW	_	26	NMOD
25	-	-	HYPH	_	24	P
26	hoc	hoc	FW	_	27	NMOD
27	test	test	NN	_	18	PMOD
28	applied	apply	VBN	_	27	NMOD
29	to	to	IN	_	28	ADV
30	significant	significant	JJ	_	32	NMOD
31	main	main	JJ	_	32	NMOD
32	effects	effect	NNS	_	29	PMOD
33	or	or	CC	_	32	COORD
34	interactions	interaction	NNS	_	33	CONJ
35	(	(	-LRB-	_	36	P
36	Statistica	statistica	NNP	_	15	PRN
37	6.0	0	CD	_	36	NMOD
38	,	,	,	_	36	P
39	StatSoft	statsoft	NNP	_	36	APPO
40	,	,	,	_	39	P
41	Tulsa	tulsa	NNP	_	39	APPO
42	,	,	,	_	41	P
43	Oklahoma	oklahoma	NNP	_	41	APPO
44	,	,	,	_	43	P
45	United	united	NNP	_	46	NMOD
46	States	state	NNP	_	43	APPO
47	)	)	-RRB-	_	36	P
48	.	.	.	_	14	P

1	In	in	IN	_	16	ADV
2	cases	case	NNS	_	1	PMOD
3	of	of	IN	_	2	NMOD
4	positively	positively	RB	_	5	AMOD
5	skewed	skew	VBN	_	7	NMOD
6	data	datum	NNS	_	7	NMOD
7	distribution	distribution	NN	_	3	PMOD
8	,	,	,	_	16	P
9	log10	log0	NN	_	11	NMOD
10	(	(	-LRB-	_	11	P
11	x	x	NN	_	15	NMOD
12	+	+	SYM	_	11	P
13	0.5	0	CD	_	11	NMOD
14	)	)	-RRB-	_	11	P
15	transformation	transformation	NN	_	16	SBJ
16	was	be	VBD	_	0	ROOT
17	applied	apply	VBN	_	16	VC
18	to	to	IN	_	17	ADV
19	the	the	DT	_	21	NMOD
20	raw	raw	JJ	_	21	NMOD
21	data	datum	NNS	_	18	PMOD
22	before	before	IN	_	17	TMP
23	submitting	submit	VBG	_	22	PMOD
24	them	them	PRP	_	23	OBJ
25	to	to	IN	_	23	ADV
26	ANOVA	anova	NN	_	25	PMOD
27	.	.	.	_	16	P

1	Results	result	NNS	_	0	ROOT

1	We	we	PRP	_	2	SBJ
2	used	use	VBD	_	0	ROOT
3	the	the	DT	_	8	NMOD
4	tet	tet	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	off	off	NN	_	8	NMOD
7	transgene	transgene	NN	_	8	NMOD
8	system	system	NN	_	2	OBJ
9	to	to	TO	_	2	PRP
10	express	express	VB	_	9	IM
11	a	a	DT	_	14	NMOD
12	double	double	JJ	_	14	NMOD
13	mutant	mutant	NN	_	14	NMOD
14	version	version	NN	_	24	NMOD
15	of	of	IN	_	14	NMOD
16	chimeric	chimeric	JJ	_	19	NMOD
17	mo	mo	NN	_	19	NMOD
18	/	/	HYPH	_	17	P
19	huAPP695	huapp0	NN	_	15	PMOD
20	(	(	-LRB-	_	24	P
21	swe	swe	NN	_	24	NMOD
22	/	/	HYPH	_	21	P
23	ind	ind	NN	_	24	NMOD
24	KM570	km0	NN	_	10	OBJ
25	,	,	,	_	24	P
26	571NL	0nl	NN	_	24	CONJ
27	,	,	,	_	26	P
28	and	and	CC	_	26	COORD
29	V617F	v0f	NN	_	28	CONJ
30	)	)	-RRB-	_	10	P
31	from	from	IN	_	10	ADV
32	a	a	DT	_	36	NMOD
33	tetracycline	tetracycline	NN	_	35	AMOD
34	-	-	HYPH	_	33	P
35	responsive	responsive	JJ	_	36	NMOD
36	promoter	promoter	NN	_	31	PMOD
37	[	[	-LRB-	_	40	P
38	12	0	CD	_	40	NMOD
39	,	,	,	_	40	P
40	13	0	CD	_	10	PRN
41	]	]	-RRB-	_	40	P
42	.	.	.	_	2	P

1	Transgenic	transgenic	JJ	_	2	NMOD
2	APP	app	NN	_	3	NMOD
3	expression	expression	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	activated	activate	VBN	_	4	VC
6	by	by	IN	_	5	MNR
7	crossing	cross	VBG	_	6	PMOD
8	the	the	DT	_	12	NMOD
9	APPswe	appswe	NN	_	11	NMOD
10	/	/	HYPH	_	9	P
11	ind	ind	NN	_	12	NMOD
12	mice	mouse	NNS	_	7	OBJ
13	to	to	IN	_	7	ADV
14	animals	animal	NNS	_	13	PMOD
15	producing	produce	VBG	_	14	NMOD
16	tTA	tta	NN	_	15	OBJ
17	under	under	IN	_	15	ADV
18	control	control	NN	_	17	PMOD
19	of	of	IN	_	18	NMOD
20	the	the	DT	_	22	NMOD
21	CaMKIIα	camkiiα	NN	_	22	NMOD
22	promoter	promoter	NN	_	19	PMOD
23	[	[	-LRB-	_	24	P
24	16	0	CD	_	15	PRN
25	]	]	-RRB-	_	24	P
26	.	.	.	_	4	P

1	After	after	IN	_	8	TMP
2	initial	initial	JJ	_	3	NMOD
3	screening	screening	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	founders	founder	NNS	_	4	PMOD
6	,	,	,	_	8	P
7	we	we	PRP	_	8	SBJ
8	identified	identify	VBD	_	0	ROOT
9	four	four	CD	_	10	NMOD
10	lines	line	NNS	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	tet	tet	NN	_	16	NMOD
13	-	-	HYPH	_	12	P
14	APPswe	appswe	NN	_	16	NMOD
15	/	/	HYPH	_	14	P
16	ind	ind	NN	_	17	NMOD
17	mice	mouse	NNS	_	11	PMOD
18	that	that	WDT	_	19	SBJ
19	produced	produce	VBD	_	10	NMOD
20	very	very	RB	_	21	AMOD
21	high	high	JJ	_	22	NMOD
22	levels	level	NNS	_	19	OBJ
23	of	of	IN	_	22	NMOD
24	transgene	transgene	NN	_	25	NMOD
25	product	product	NN	_	23	PMOD
26	in	in	IN	_	19	LOC
27	offspring	offspring	NN	_	26	PMOD
28	coexpressing	coexpressing	VBG	_	27	NMOD
29	tTA	tta	NN	_	28	OBJ
30	(	(	-LRB-	_	31	P
31	Figures	figure	NNS	_	19	PRN
32	1	0	CD	_	31	NMOD
33	and	and	CC	_	31	COORD
34	Figure	figure	NN	_	35	NMOD
35	S1	s0	NN	_	33	CONJ
36	)	)	-RRB-	_	31	P
37	.	.	.	_	8	P

1	Compared	compare	VBN	_	32	ADV
2	to	to	IN	_	1	PMOD
3	a	a	DT	_	7	NMOD
4	standard	standard	JJ	_	7	NMOD
5	APP	app	NN	_	7	NMOD
6	transgenic	transgenic	JJ	_	7	NMOD
7	line	line	NN	_	2	PMOD
8	used	use	VBN	_	7	NMOD
9	for	for	IN	_	8	PRP
10	previous	previous	JJ	_	12	NMOD
11	amyloid	amyloid	NN	_	12	NMOD
12	studies	study	NNS	_	9	PMOD
13	by	by	IN	_	12	NMOD
14	our	our	PRP$	_	15	NMOD
15	laboratory	laboratory	NN	_	13	PMOD
16	(	(	-LRB-	_	27	P
17	line	line	NN	_	18	NMOD
18	C3	c0	NN	_	27	DEP
19	–	–	HYPH	_	18	P
20	3	0	CD	_	18	NMOD
21	;	;	:	_	27	P
22	[	[	-LRB-	_	27	P
23	15	0	CD	_	27	NMOD
24	,	,	,	_	27	P
25	26	0	CD	_	27	NMOD
26	,	,	,	_	27	P
27	27	0	CD	_	8	PRN
28	]	]	-RRB-	_	27	P
29	)	)	-RRB-	_	27	P
30	,	,	,	_	32	P
31	we	we	PRP	_	32	SBJ
32	estimated	estimate	VBD	_	0	ROOT
33	that	that	IN	_	32	OBJ
34	the	the	DT	_	37	NMOD
35	four	four	CD	_	37	NMOD
36	controllable	controllable	JJ	_	37	NMOD
37	lines	line	NNS	_	38	SBJ
38	produce	produce	VBP	_	33	SUB
39	transgenic	transgenic	JJ	_	41	NMOD
40	APP	app	NN	_	41	NMOD
41	protein	protein	NN	_	38	OBJ
42	at	at	IN	_	38	ADV
43	10	0	CD	_	42	PMOD
44	-	-	HYPH	_	43	P
45	to	to	IN	_	43	QMOD
46	30-fold	0-fold	RB	_	43	QMOD
47	over	over	IN	_	43	AMOD
48	endogenous	endogenous	JJ	_	49	NMOD
49	levels	level	NNS	_	47	PMOD
50	(	(	-LRB-	_	52	P
51	Figure	figure	NN	_	52	NMOD
52	S1	s0	NN	_	38	PRN
53	)	)	-RRB-	_	52	P
54	.	.	.	_	32	P

1	This	this	DT	_	2	NMOD
2	estimate	estimate	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	confirmed	confirm	VBN	_	3	VC
5	by	by	IN	_	4	LGS
6	direct	direct	JJ	_	7	NMOD
7	comparison	comparison	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	APP	app	NN	_	10	NMOD
10	levels	level	NNS	_	8	PMOD
11	in	in	IN	_	7	LOC
12	nontransgenic	nontransgenic	JJ	_	18	NMOD
13	and	and	CC	_	12	COORD
14	tet	tet	NN	_	16	NMOD
15	-	-	HYPH	_	14	P
16	off	off	NN	_	13	CONJ
17	APP	app	NN	_	18	NMOD
18	mice	mouse	NNS	_	11	PMOD
19	using	use	VBG	_	4	MNR
20	an	an	DT	_	21	NMOD
21	antibody	antibody	NN	_	19	OBJ
22	that	that	WDT	_	23	SBJ
23	recognizes	recognize	VBZ	_	21	NMOD
24	both	both	CC	_	26	COORD
25	endogenous	endogenous	JJ	_	26	NMOD
26	APP	app	NN	_	23	OBJ
27	(	(	-LRB-	_	26	P
28	and	and	CC	_	26	COORD
29	amyloid	amyloid	NN	_	33	NMOD
30	precursor	precursor	NN	_	32	AMOD
31	-	-	HYPH	_	30	P
32	like	like	JJ	_	33	NMOD
33	protein	protein	NN	_	28	CONJ
34	2	0	CD	_	33	NMOD
35	)	)	-RRB-	_	26	P
36	and	and	CC	_	26	COORD
37	the	the	DT	_	39	NMOD
38	transgenic	transgenic	JJ	_	39	NMOD
39	protein	protein	NN	_	36	CONJ
40	(	(	-LRB-	_	46	P
41	monoclonal	monoclonal	JJ	_	43	NMOD
42	antibody	antibody	NN	_	43	NMOD
43	22C11	0c0	NN	_	46	DEP
44	;	;	:	_	46	P
45	Figure	figure	NN	_	46	NMOD
46	1D	0d	NN	_	39	PRN
47	)	)	-RRB-	_	46	P
48	.	.	.	_	3	P

1	Importantly	importantly	RB	_	13	ADV
2	,	,	,	_	13	P
3	all	all	DT	_	6	NMOD
4	four	four	CD	_	6	NMOD
5	new	new	JJ	_	6	NMOD
6	lines	line	NNS	_	13	SBJ
7	of	of	IN	_	6	NMOD
8	tet	tet	NN	_	10	NMOD
9	-	-	HYPH	_	8	P
10	off	off	NN	_	12	NMOD
11	APP	app	NN	_	12	NMOD
12	mice	mouse	NNS	_	7	PMOD
13	showed	show	VBD	_	0	ROOT
14	nearly	nearly	RB	_	15	AMOD
15	complete	complete	JJ	_	16	NMOD
16	suppression	suppression	NN	_	13	OBJ
17	of	of	IN	_	16	NMOD
18	the	the	DT	_	19	NMOD
19	transgene	transgene	NN	_	17	PMOD
20	following	follow	VBG	_	13	TMP
21	dox	dox	NN	_	22	NMOD
22	treatment	treatment	NN	_	20	PMOD
23	(	(	-LRB-	_	24	P
24	Figures	figure	NNS	_	13	PRN
25	1	0	CD	_	24	NMOD
26	and	and	CC	_	24	COORD
27	Figure	figure	NN	_	28	NMOD
28	S1	s0	NN	_	26	CONJ
29	)	)	-RRB-	_	24	P
30	.	.	.	_	13	P

1	We	we	PRP	_	2	SBJ
2	focused	focus	VBD	_	0	ROOT
3	on	on	IN	_	2	ADV
4	one	one	CD	_	3	PMOD
5	of	of	IN	_	4	NMOD
6	the	the	DT	_	8	NMOD
7	four	four	CD	_	8	NMOD
8	lines	line	NNS	_	5	PMOD
9	,	,	,	_	4	P
10	line	line	NN	_	4	APPO
11	107	0	CD	_	10	NMOD
12	,	,	,	_	2	P
13	to	to	TO	_	2	PRP
14	examine	examine	VB	_	13	IM
15	in	in	IN	_	14	ADV
16	more	more	JJR	_	17	NMOD
17	detail	detail	NN	_	15	PMOD
18	the	the	DT	_	20	NMOD
19	time	time	NN	_	20	NMOD
20	dependence	dependence	NN	_	14	OBJ
21	and	and	CC	_	20	COORD
22	extent	extent	NN	_	21	CONJ
23	of	of	IN	_	22	NMOD
24	transgene	transgene	NN	_	25	NMOD
25	suppression	suppression	NN	_	23	PMOD
26	following	follow	VBG	_	20	TMP
27	either	either	CC	_	31	COORD
28	acute	acute	JJ	_	31	NMOD
29	or	or	CC	_	28	COORD
30	chronic	chronic	JJ	_	29	CONJ
31	treatment	treatment	NN	_	26	PMOD
32	with	with	IN	_	31	NMOD
33	dox	dox	NN	_	32	PMOD
34	.	.	.	_	2	P

1	Two	two	CD	_	5	NMOD
2	dox	dox	NN	_	4	AMOD
3	-	-	HYPH	_	2	P
4	treated	treat	VBN	_	5	NMOD
5	groups	group	NNS	_	6	SBJ
6	were	be	VBD	_	56	DEP
7	compared	compare	VBN	_	6	VC
8	to	to	IN	_	7	ADV
9	two	two	CD	_	11	NMOD
10	untreated	untreated	JJ	_	11	NMOD
11	groups	group	NNS	_	8	PMOD
12	:	:	:	_	56	P
13	one	one	CD	_	14	NMOD
14	group	group	NN	_	17	SBJ
15	of	of	IN	_	14	NMOD
16	mice	mouse	NNS	_	15	PMOD
17	was	be	VBD	_	56	DEP
18	born	bear	VBN	_	17	VC
19	and	and	CC	_	18	COORD
20	raised	raise	VBN	_	19	CONJ
21	on	on	IN	_	18	ADV
22	dox	dox	NN	_	21	PMOD
23	,	,	,	_	56	P
24	a	a	DT	_	26	NMOD
25	second	$#ORD#$	JJ	_	26	NMOD
26	group	group	NN	_	27	SBJ
27	was	be	VBD	_	56	DEP
28	treated	treat	VBN	_	27	VC
29	with	with	IN	_	28	MNR
30	dox	dox	NN	_	29	PMOD
31	for	for	IN	_	28	TMP
32	2	0	CD	_	33	NMOD
33	wk	wk	NN	_	31	PMOD
34	starting	start	VBG	_	28	TMP
35	at	at	IN	_	34	ADV
36	1	0	CD	_	37	NMOD
37	mo	mo	NN	_	35	PMOD
38	of	of	IN	_	37	NMOD
39	age	age	NN	_	38	PMOD
40	(	(	-LRB-	_	46	P
41	4	0	CD	_	42	NMOD
42	wk	wk	NN	_	46	NMOD
43	+	+	SYM	_	46	P
44	2	0	CD	_	45	NMOD
45	wk	wk	NN	_	46	NMOD
46	dox	dox	NN	_	28	PRN
47	)	)	-RRB-	_	46	P
48	;	;	:	_	56	P
49	two	two	CD	_	51	NMOD
50	untreated	untreated	JJ	_	51	NMOD
51	groups	group	NNS	_	56	SBJ
52	kept	keep	VBN	_	51	NMOD
53	on	on	IN	_	52	ADV
54	normal	normal	JJ	_	55	NMOD
55	chow	chow	NN	_	53	PMOD
56	were	be	VBD	_	0	ROOT
57	harvested	harvest	VBN	_	56	VC
58	at	at	IN	_	57	TMP
59	either	either	CC	_	60	COORD
60	4	0	CD	_	63	NMOD
61	or	or	CC	_	60	COORD
62	6	0	CD	_	61	CONJ
63	wk	wk	NN	_	58	PMOD
64	of	of	IN	_	63	NMOD
65	age	age	NN	_	64	PMOD
66	.	.	.	_	56	P

1	Animals	animal	NNS	_	7	SBJ
2	born	bear	VBN	_	1	NMOD
3	and	and	CC	_	2	COORD
4	raised	raise	VBN	_	3	CONJ
5	on	on	IN	_	2	ADV
6	dox	dox	NN	_	5	PMOD
7	harbored	harbor	VBD	_	0	ROOT
8	no	no	DT	_	10	NMOD
9	transgenic	transgenic	JJ	_	10	NMOD
10	APP	app	NN	_	7	OBJ
11	(	(	-LRB-	_	13	P
12	Figure	figure	NN	_	13	NMOD
13	1A	0a	NN	_	7	PRN
14	)	)	-RRB-	_	13	P
15	.	.	.	_	7	P

1	Following	follow	VBG	_	14	TMP
2	as	as	RB	_	5	QMOD
3	little	little	JJ	_	5	QMOD
4	as	as	IN	_	5	QMOD
5	2	0	CD	_	6	NMOD
6	wk	wk	NN	_	1	PMOD
7	of	of	IN	_	6	NMOD
8	dox	dox	NN	_	9	NMOD
9	treatment	treatment	NN	_	7	PMOD
10	,	,	,	_	14	P
11	transgenic	transgenic	JJ	_	13	NMOD
12	APP	app	NN	_	13	NMOD
13	expression	expression	NN	_	14	SBJ
14	was	be	VBD	_	0	ROOT
15	reduced	reduce	VBN	_	14	VC
16	by	by	IN	_	15	EXT
17	more	more	JJR	_	20	NMOD
18	than	than	IN	_	17	QMOD
19	95	0	CD	_	17	QMOD
20	%	%	NN	_	16	PMOD
21	compared	compare	VBN	_	15	ADV
22	to	to	IN	_	21	PMOD
23	pre-dox	pre-dox	JJ	_	24	NMOD
24	levels	level	NNS	_	22	PMOD
25	.	.	.	_	14	P

1	The	the	DT	_	3	NMOD
2	residual	residual	JJ	_	3	NMOD
3	expression	expression	NN	_	9	SBJ
4	remaining	remain	VBG	_	3	NMOD
5	in	in	IN	_	4	LOC
6	acutely	acutely	RB	_	7	AMOD
7	treated	treat	VBN	_	8	NMOD
8	mice	mouse	NNS	_	5	PMOD
9	represents	represent	VBZ	_	0	ROOT
10	less	less	JJR	_	13	NMOD
11	than	than	IN	_	10	QMOD
12	4	0	CD	_	10	QMOD
13	%	%	NN	_	9	OBJ
14	of	of	IN	_	13	NMOD
15	the	the	DT	_	17	NMOD
16	transgenic	transgenic	JJ	_	17	NMOD
17	protein	protein	NN	_	14	PMOD
18	produced	produce	VBN	_	17	NMOD
19	in	in	IN	_	18	ADV
20	the	the	DT	_	21	NMOD
21	absence	absence	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	dox	dox	NN	_	22	PMOD
24	(	(	-LRB-	_	26	P
25	Figure	figure	NN	_	26	NMOD
26	1C	0c	NN	_	18	PRN
27	)	)	-RRB-	_	26	P
28	,	,	,	_	9	P
29	and	and	CC	_	9	COORD
30	likely	likely	RB	_	31	ADV
31	results	result	VBZ	_	29	CONJ
32	from	from	IN	_	31	ADV
33	slight	slight	JJ	_	34	NMOD
34	leakage	leakage	NN	_	32	PMOD
35	at	at	IN	_	34	NMOD
36	the	the	DT	_	37	NMOD
37	level	level	NN	_	35	PMOD
38	of	of	IN	_	37	NMOD
39	transcription	transcription	NN	_	38	PMOD
40	(	(	-LRB-	_	43	P
41	data	datum	NNS	_	43	SBJ
42	not	not	RB	_	43	ADV
43	shown	show	VBN	_	31	PRN
44	)	)	-RRB-	_	43	P
45	.	.	.	_	9	P

1	Importantly	importantly	RB	_	23	ADV
2	,	,	,	_	23	P
3	the	the	DT	_	5	NMOD
4	total	total	JJ	_	5	NMOD
5	amount	amount	NN	_	23	SBJ
6	of	of	IN	_	5	NMOD
7	APP	app	NN	_	6	PMOD
8	(	(	-LRB-	_	9	P
9	endogenous	endogenous	JJ	_	7	PRN
10	plus	plus	CC	_	9	COORD
11	transgenic	transgenic	JJ	_	10	CONJ
12	)	)	-RRB-	_	9	P
13	and	and	CC	_	7	COORD
14	related	related	JJ	_	15	NMOD
15	APLPs	aplps	NNS	_	13	CONJ
16	in	in	IN	_	5	LOC
17	both	both	CC	_	18	COORD
18	acute	acute	JJ	_	22	NMOD
19	and	and	CC	_	18	COORD
20	chronically	chronically	RB	_	21	AMOD
21	treated	treat	VBN	_	19	CONJ
22	animals	animal	NNS	_	16	PMOD
23	was	be	VBD	_	0	ROOT
24	statistically	statistically	RB	_	25	AMOD
25	indistinguishable	indistinguishable	JJ	_	23	PRD
26	from	from	IN	_	25	AMOD
27	that	that	DT	_	26	PMOD
28	in	in	IN	_	27	LOC
29	nontransgenic	nontransgenic	JJ	_	30	NMOD
30	mice	mouse	NNS	_	28	PMOD
31	(	(	-LRB-	_	42	P
32	Figure	figure	NN	_	33	NMOD
33	1D	0d	NN	_	42	DEP
34	;	;	:	_	42	P
35	statistical	statistical	JJ	_	36	NMOD
36	analyses	analysis	NNS	_	42	SBJ
37	for	for	IN	_	36	NMOD
38	experiments	experiment	NNS	_	37	PMOD
39	throughout	throughout	IN	_	38	NMOD
40	the	the	DT	_	41	NMOD
41	study	study	NN	_	39	PMOD
42	are	be	VBP	_	23	PRN
43	presented	present	VBN	_	42	VC
44	in	in	IN	_	43	ADV
45	the	the	DT	_	48	NMOD
46	accompanying	accompany	VBG	_	48	NMOD
47	figure	figure	NN	_	48	NMOD
48	legends	legend	NNS	_	44	PMOD
49	)	)	-RRB-	_	42	P
50	.	.	.	_	23	P

1	To	to	TO	_	24	PRP
2	ensure	ensure	VB	_	1	IM
3	that	that	IN	_	2	OBJ
4	Aβ	aβ	NN	_	5	NMOD
5	production	production	NN	_	6	SBJ
6	was	be	VBD	_	3	SUB
7	suppressed	suppress	VBN	_	6	VC
8	in	in	IN	_	7	ADV
9	concert	concert	NN	_	8	PMOD
10	with	with	IN	_	9	NMOD
11	the	the	DT	_	15	NMOD
12	dox	dox	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	mediated	mediate	VBN	_	15	NMOD
15	inhibition	inhibition	NN	_	10	PMOD
16	of	of	IN	_	15	NMOD
17	its	its	PRP$	_	18	NMOD
18	precursor	precursor	NN	_	21	NMOD
19	APPswe	appswe	NN	_	21	NMOD
20	/	/	HYPH	_	19	P
21	ind	ind	NN	_	16	PMOD
22	,	,	,	_	24	P
23	we	we	PRP	_	24	SBJ
24	measured	measure	VBD	_	0	ROOT
25	Aβ40	aβ0	NN	_	28	NMOD
26	and	and	CC	_	25	COORD
27	Aβ42	aβ0	NN	_	26	CONJ
28	levels	level	NNS	_	24	OBJ
29	by	by	IN	_	24	MNR
30	ELISA	elisa	NN	_	29	PMOD
31	in	in	IN	_	24	LOC
32	forebrain	forebrain	NN	_	33	NMOD
33	homogenates	homogenate	NNS	_	31	PMOD
34	from	from	IN	_	33	NMOD
35	young	young	JJ	_	39	NMOD
36	tet	tet	NN	_	38	NMOD
37	-	-	HYPH	_	36	P
38	off	off	NN	_	39	NMOD
39	animals	animal	NNS	_	34	PMOD
40	.	.	.	_	24	P

1	At	at	IN	_	9	TMP
2	1	0	CD	_	3	NMOD
3	mo	mo	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	age	age	NN	_	4	PMOD
6	,	,	,	_	9	P
7	the	the	DT	_	8	NMOD
8	mice	mouse	NNS	_	9	SBJ
9	lacked	lack	VBD	_	0	ROOT
10	visible	visible	JJ	_	12	NMOD
11	amyloid	amyloid	NN	_	12	NMOD
12	aggregates	aggregate	NNS	_	9	OBJ
13	that	that	WDT	_	14	SBJ
14	might	might	MD	_	12	NMOD
15	act	act	VB	_	14	VC
16	as	as	IN	_	15	ADV
17	an	an	DT	_	19	NMOD
18	intractable	intractable	JJ	_	19	NMOD
19	reservoir	reservoir	NN	_	16	PMOD
20	of	of	IN	_	19	NMOD
21	peptide	peptide	NN	_	20	PMOD
22	remaining	remain	VBG	_	19	NMOD
23	in	in	IN	_	22	LOC
24	the	the	DT	_	25	NMOD
25	brain	brain	NN	_	23	PMOD
26	after	after	IN	_	31	TMP
27	the	the	DT	_	28	NMOD
28	transgene	transgene	NN	_	29	SBJ
29	had	have	VBD	_	22	TMP
30	been	be	VBN	_	29	VC
31	suppressed	suppress	VBN	_	30	VC
32	.	.	.	_	9	P

1	To	to	TO	_	23	PRP
2	further	far	RB	_	1	ADV
3	ensure	ensure	VB	_	1	IM
4	we	we	PRP	_	5	SBJ
5	could	could	MD	_	3	OBJ
6	detect	detect	VB	_	5	VC
7	any	any	DT	_	10	NMOD
8	such	such	JJ	_	10	NMOD
9	insoluble	insoluble	JJ	_	10	NMOD
10	aggregates	aggregate	NNS	_	6	OBJ
11	that	that	WDT	_	12	SBJ
12	might	might	MD	_	10	NMOD
13	bias	bias	VB	_	12	VC
14	our	our	PRP$	_	15	NMOD
15	measure	measure	NN	_	13	OBJ
16	of	of	IN	_	15	NMOD
17	changes	change	NNS	_	16	PMOD
18	in	in	IN	_	13	ADV
19	peptide	peptide	NN	_	20	NMOD
20	synthesis	synthesis	NN	_	18	PMOD
21	,	,	,	_	23	P
22	we	we	PRP	_	23	SBJ
23	performed	perform	VBD	_	0	ROOT
24	a	a	DT	_	29	NMOD
25	sequential	sequential	JJ	_	29	NMOD
26	three	three	CD	_	28	NMOD
27	-	-	HYPH	_	26	P
28	step	step	NN	_	29	NMOD
29	extraction	extraction	NN	_	23	OBJ
30	with	with	IN	_	29	NMOD
31	PBS	pb	NN	_	30	PMOD
32	,	,	,	_	31	P
33	2	0	CD	_	34	NMOD
34	%	%	NN	_	35	NMOD
35	SDS	sd	NN	_	31	CONJ
36	,	,	,	_	35	P
37	and	and	CC	_	35	COORD
38	70	0	CD	_	39	NMOD
39	%	%	NN	_	40	NMOD
40	FA	fa	NN	_	37	CONJ
41	that	that	WDT	_	42	SBJ
42	would	would	MD	_	29	NMOD
43	separate	separate	VB	_	42	VC
44	peptides	peptide	NNS	_	43	OBJ
45	by	by	IN	_	43	MNR
46	solubility	solubility	NN	_	45	PMOD
47	.	.	.	_	23	P

1	We	we	PRP	_	2	SBJ
2	compared	compare	VBD	_	0	ROOT
3	the	the	DT	_	4	NMOD
4	levels	level	NNS	_	2	OBJ
5	of	of	IN	_	4	NMOD
6	human	human	JJ	_	7	NMOD
7	transgene	transgene	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	derived	derive	VBN	_	10	NMOD
10	Aβ40	aβ0	NN	_	5	PMOD
11	and	and	CC	_	10	COORD
12	Aβ42	aβ0	NN	_	11	CONJ
13	in	in	IN	_	4	LOC
14	untreated	untreated	JJ	_	15	NMOD
15	mice	mouse	NNS	_	13	PMOD
16	at	at	IN	_	4	TMP
17	4	0	CD	_	20	NMOD
18	and	and	CC	_	17	COORD
19	6	0	CD	_	18	CONJ
20	wk	wk	NN	_	16	PMOD
21	of	of	IN	_	20	NMOD
22	age	age	NN	_	21	PMOD
23	to	to	IN	_	2	ADV
24	animals	animal	NNS	_	23	PMOD
25	that	that	WDT	_	26	SBJ
26	had	have	VBD	_	24	NMOD
27	either	either	CC	_	26	COORD
28	been	be	VBN	_	27	CONJ
29	born	bear	VBN	_	28	VC
30	and	and	CC	_	29	COORD
31	raised	raise	VBN	_	30	CONJ
32	on	on	IN	_	29	ADV
33	dox	dox	NN	_	32	PMOD
34	or	or	CC	_	26	COORD
35	that	that	WDT	_	36	SBJ
36	had	have	VBD	_	34	CONJ
37	been	be	VBN	_	36	VC
38	left	leave	VBN	_	37	VC
39	untreated	untreated	JJ	_	38	OPRD
40	for	for	IN	_	38	TMP
41	4	0	CD	_	42	NMOD
42	wk	wk	NN	_	40	PMOD
43	and	and	CC	_	38	COORD
44	then	then	RB	_	45	TMP
45	placed	place	VBN	_	43	CONJ
46	on	on	IN	_	45	ADV
47	dox	dox	NN	_	48	NMOD
48	chow	chow	NN	_	46	PMOD
49	for	for	IN	_	45	TMP
50	2	0	CD	_	51	NMOD
51	wk	wk	NN	_	49	PMOD
52	prior	prior	JJ	_	53	PMOD
53	to	to	IN	_	51	TMP
54	harvest	harvest	NN	_	53	PMOD
55	(	(	-LRB-	_	70	P
56	the	the	DT	_	58	NMOD
57	same	same	JJ	_	58	NMOD
58	groups	group	NNS	_	70	DEP
59	described	describe	VBN	_	58	NMOD
60	above	above	RB	_	59	ADV
61	for	for	IN	_	59	ADV
62	immunoblot	immunoblot	NN	_	63	NMOD
63	analysis	analysis	NN	_	61	PMOD
64	of	of	IN	_	63	NMOD
65	APPswe	appswe	NN	_	67	NMOD
66	/	/	HYPH	_	65	P
67	ind	ind	NN	_	68	NMOD
68	levels	level	NNS	_	64	PMOD
69	,	,	,	_	70	P
70	line	line	NN	_	45	PRN
71	107	0	CD	_	70	NMOD
72	)	)	-RRB-	_	70	P
73	.	.	.	_	2	P

1	Consistent	consistent	JJ	_	23	ADV
2	with	with	IN	_	1	AMOD
3	the	the	DT	_	4	NMOD
4	reduction	reduction	NN	_	2	PMOD
5	in	in	IN	_	4	NMOD
6	full	full	JJ	_	8	NMOD
7	-	-	HYPH	_	6	P
8	length	length	NN	_	12	NMOD
9	APPswe	appswe	NN	_	11	NMOD
10	/	/	HYPH	_	9	P
11	ind	ind	NN	_	12	NMOD
12	synthesis	synthesis	NN	_	5	PMOD
13	shown	show	VBN	_	4	NMOD
14	by	by	IN	_	13	LGS
15	immunoblot	immunoblot	NN	_	14	PMOD
16	(	(	-LRB-	_	17	P
17	see	see	VB	_	1	PRN
18	Figure	figure	NN	_	17	OBJ
19	1	0	CD	_	18	NMOD
20	)	)	-RRB-	_	17	P
21	,	,	,	_	23	P
22	we	we	PRP	_	23	SBJ
23	found	find	VBD	_	0	ROOT
24	that	that	IN	_	23	OBJ
25	transgene	transgene	NN	_	27	AMOD
26	-	-	HYPH	_	25	P
27	derived	derive	VBN	_	29	NMOD
28	Aβ	aβ	NN	_	29	NMOD
29	levels	level	NNS	_	30	SBJ
30	were	be	VBD	_	24	SUB
31	completely	completely	RB	_	30	ADV
32	suppressed	suppress	VBN	_	30	VC
33	in	in	IN	_	32	LOC
34	animals	animal	NNS	_	33	PMOD
35	born	bear	VBN	_	34	NMOD
36	and	and	CC	_	35	COORD
37	raised	raise	VBN	_	36	CONJ
38	on	on	IN	_	35	ADV
39	dox	dox	NN	_	38	PMOD
40	,	,	,	_	30	P
41	and	and	CC	_	30	COORD
42	were	be	VBD	_	41	CONJ
43	sharply	sharply	RB	_	42	ADV
44	reduced	reduce	VBN	_	42	VC
45	following	follow	VBG	_	44	TMP
46	acute	acute	JJ	_	52	NMOD
47	(	(	-LRB-	_	49	P
48	2	0	CD	_	49	NMOD
49	wk	wk	NN	_	46	PRN
50	)	)	-RRB-	_	49	P
51	antibiotic	antibiotic	JJ	_	52	NMOD
52	treatment	treatment	NN	_	45	PMOD
53	.	.	.	_	23	P

1	Compared	compare	VBN	_	18	ADV
2	to	to	IN	_	1	PMOD
3	the	the	DT	_	4	NMOD
4	levels	level	NNS	_	2	PMOD
5	in	in	IN	_	4	LOC
6	untreated	untreated	JJ	_	12	NMOD
7	4	0	CD	_	9	NMOD
8	-	-	HYPH	_	7	P
9	wk	wk	NN	_	11	AMOD
10	-	-	HYPH	_	9	P
11	old	old	JJ	_	12	NMOD
12	mice	mouse	NNS	_	5	PMOD
13	,	,	,	_	18	P
14	PBS	pb	NN	_	16	AMOD
15	-	-	HYPH	_	14	P
16	soluble	soluble	JJ	_	17	NMOD
17	Aβ42	aβ0	NN	_	18	SBJ
18	dropped	drop	VBD	_	0	ROOT
19	by	by	IN	_	18	EXT
20	95.2	0	CD	_	21	NMOD
21	%	%	NN	_	19	PMOD
22	following	follow	VBG	_	18	TMP
23	2	0	CD	_	24	NMOD
24	wk	wk	NN	_	22	PMOD
25	of	of	IN	_	24	NMOD
26	dox	dox	NN	_	27	NMOD
27	treatment	treatment	NN	_	25	PMOD
28	and	and	CC	_	18	COORD
29	by	by	IN	_	28	GAP-EXT
30	99.2	0	CD	_	31	NMOD
31	%	%	NN	_	29	PMOD
32	with	with	IN	_	29	ADV
33	chronic	chronic	JJ	_	34	NMOD
34	treatment	treatment	NN	_	32	PMOD
35	(	(	-LRB-	_	37	P
36	Figure	figure	NN	_	37	NMOD
37	2A	0a	NN	_	29	PRN
38	)	)	-RRB-	_	37	P
39	.	.	.	_	18	P

1	Similarly	similarly	RB	_	7	ADV
2	,	,	,	_	7	P
3	SDS	sd	NN	_	5	AMOD
4	-	-	HYPH	_	3	P
5	soluble	soluble	JJ	_	6	NMOD
6	Aβ42	aβ0	NN	_	7	SBJ
7	decreased	decrease	VBD	_	0	ROOT
8	by	by	IN	_	7	EXT
9	75.2	0	CD	_	10	NMOD
10	%	%	NN	_	8	PMOD
11	and	and	CC	_	10	COORD
12	94.8	0	CD	_	13	NMOD
13	%	%	NN	_	11	CONJ
14	following	follow	VBG	_	7	ADV
15	2	0	CD	_	17	NMOD
16	-	-	HYPH	_	15	P
17	wk	wk	NN	_	21	NMOD
18	or	or	CC	_	17	COORD
19	lifelong	lifelong	JJ	_	18	CONJ
20	dox	dox	NN	_	21	NMOD
21	treatment	treatment	NN	_	14	PMOD
22	(	(	-LRB-	_	24	P
23	Figure	figure	NN	_	24	NMOD
24	2B	0b	NN	_	7	PRN
25	)	)	-RRB-	_	24	P
26	.	.	.	_	7	P

1	Only	only	RB	_	4	NMOD
2	the	the	DT	_	4	NMOD
3	FA	fa	NN	_	4	NMOD
4	fraction	fraction	NN	_	5	SBJ
5	revealed	reveal	VBD	_	0	ROOT
6	a	a	DT	_	11	NMOD
7	small	small	JJ	_	11	NMOD
8	dox	dox	NN	_	10	AMOD
9	-	-	HYPH	_	8	P
10	resistant	resistant	JJ	_	11	NMOD
11	pool	pool	NN	_	5	OBJ
12	of	of	IN	_	11	NMOD
13	peptide	peptide	NN	_	12	PMOD
14	in	in	IN	_	11	LOC
15	acutely	acutely	RB	_	16	AMOD
16	treated	treat	VBN	_	17	NMOD
17	animals	animal	NNS	_	14	PMOD
18	that	that	WDT	_	21	SBJ
19	we	we	PRP	_	20	SBJ
20	believe	believe	VBP	_	11	NMOD
21	represents	represent	VBZ	_	20	OBJ
22	stable	stable	JJ	_	24	NMOD
23	predeposit	predeposit	JJ	_	24	NMOD
24	aggregates	aggregate	NNS	_	21	OBJ
25	that	that	WDT	_	26	SBJ
26	have	have	VBP	_	24	NMOD
27	already	already	RB	_	26	ADV
28	accumulated	accumulate	VBN	_	26	VC
29	by	by	IN	_	28	TMP
30	4	0	CD	_	31	NMOD
31	wk	wk	NN	_	29	PMOD
32	of	of	IN	_	31	NMOD
33	age	age	NN	_	32	PMOD
34	when	when	WRB	_	37	TMP
35	treatment	treatment	NN	_	36	SBJ
36	was	be	VBD	_	28	TMP
37	begun	begin	VBN	_	36	VC
38	(	(	-LRB-	_	40	P
39	Figure	figure	NN	_	40	NMOD
40	2C	0c	NN	_	5	PRN
41	)	)	-RRB-	_	40	P
42	.	.	.	_	5	P

1	Indeed	indeed	RB	_	11	ADV
2	,	,	,	_	11	P
3	animals	animal	NNS	_	11	SBJ
4	that	that	WDT	_	5	SBJ
5	were	be	VBD	_	3	NMOD
6	born	bear	VBN	_	5	VC
7	and	and	CC	_	6	COORD
8	raised	raise	VBN	_	7	CONJ
9	on	on	IN	_	6	ADV
10	dox	dox	NN	_	9	PMOD
11	did	do	VBD	_	0	ROOT
12	not	not	RB	_	11	ADV
13	harbor	harbor	VB	_	11	VC
14	this	this	DT	_	15	NMOD
15	reservoir	reservoir	NN	_	13	OBJ
16	of	of	IN	_	15	NMOD
17	treatment	treatment	NN	_	19	AMOD
18	-	-	HYPH	_	17	P
19	resistant	resistant	JJ	_	20	NMOD
20	peptide	peptide	NN	_	16	PMOD
21	,	,	,	_	13	P
22	with	with	IN	_	13	ADV
23	96.3	0	CD	_	24	NMOD
24	%	%	NN	_	25	AMOD
25	less	less	JJR	_	26	NMOD
26	Aβ42	aβ0	NN	_	22	PMOD
27	than	than	IN	_	26	NMOD
28	untreated	untreated	JJ	_	34	NMOD
29	4	0	CD	_	31	NMOD
30	-	-	HYPH	_	29	P
31	wk	wk	NN	_	33	AMOD
32	-	-	HYPH	_	31	P
33	old	old	JJ	_	34	NMOD
34	mice	mouse	NNS	_	27	PMOD
35	.	.	.	_	11	P

1	Measurement	measurement	NN	_	18	SBJ
2	of	of	IN	_	1	NMOD
3	total	total	JJ	_	4	NMOD
4	Aβ	aβ	NN	_	2	PMOD
5	in	in	IN	_	1	LOC
6	chronically	chronically	RB	_	7	AMOD
7	treated	treat	VBN	_	8	NMOD
8	mice	mouse	NNS	_	5	PMOD
9	,	,	,	_	1	P
10	including	include	VBG	_	1	NMOD
11	endogenous	endogenous	JJ	_	16	NMOD
12	and	and	CC	_	11	COORD
13	transgene	transgene	NN	_	15	AMOD
14	-	-	HYPH	_	13	P
15	derived	derive	VBN	_	12	CONJ
16	peptide	peptide	NN	_	10	PMOD
17	,	,	,	_	18	P
18	demonstrated	demonstrate	VBD	_	0	ROOT
19	that	that	IN	_	18	OBJ
20	Aβ	aβ	NN	_	21	NMOD
21	levels	level	NNS	_	28	SBJ
22	in	in	IN	_	21	LOC
23	tet	tet	NN	_	25	NMOD
24	-	-	HYPH	_	23	P
25	off	off	NN	_	27	NMOD
26	APP	app	NN	_	27	NMOD
27	mice	mouse	NNS	_	22	PMOD
28	were	be	VBD	_	19	SUB
29	reduced	reduce	VBN	_	28	VC
30	to	to	IN	_	29	ADV
31	the	the	DT	_	32	NMOD
32	level	level	NN	_	30	PMOD
33	of	of	IN	_	32	NMOD
34	endogenous	endogenous	JJ	_	35	NMOD
35	peptide	peptide	NN	_	33	PMOD
36	found	find	VBN	_	32	NMOD
37	in	in	IN	_	36	LOC
38	nontransgenic	nontransgenic	JJ	_	39	NMOD
39	animals	animal	NNS	_	37	PMOD
40	(	(	-LRB-	_	42	P
41	Figure	figure	NN	_	42	NMOD
42	2D	0d	NN	_	29	PRN
43	)	)	-RRB-	_	42	P
44	.	.	.	_	18	P

1	Taken	take	VBN	_	18	ADV
2	together	together	RB	_	1	ADV
3	with	with	IN	_	1	ADV
4	the	the	DT	_	6	NMOD
5	immunoblotting	immunoblotting	NN	_	6	NMOD
6	data	datum	NNS	_	3	PMOD
7	for	for	IN	_	6	NMOD
8	full	full	JJ	_	10	NMOD
9	-	-	HYPH	_	8	P
10	length	length	NN	_	13	NMOD
11	APPswe	appswe	NN	_	13	NMOD
12	/	/	HYPH	_	11	P
13	ind	ind	NN	_	7	PMOD
14	,	,	,	_	18	P
15	the	the	DT	_	17	NMOD
16	ELISA	elisa	NN	_	17	NMOD
17	measurements	measurement	NNS	_	18	SBJ
18	indicate	indicate	VBP	_	0	ROOT
19	that	that	IN	_	18	OBJ
20	dox	dox	NN	_	22	AMOD
21	-	-	HYPH	_	20	P
22	mediated	mediate	VBN	_	23	NMOD
23	suppression	suppression	NN	_	30	SBJ
24	of	of	IN	_	23	NMOD
25	transgenic	transgenic	JJ	_	29	NMOD
26	APPswe	appswe	NN	_	28	NMOD
27	/	/	HYPH	_	26	P
28	ind	ind	NN	_	29	NMOD
29	synthesis	synthesis	NN	_	24	PMOD
30	leads	lead	VBZ	_	19	SUB
31	to	to	IN	_	30	ADV
32	parallel	parallel	JJ	_	33	NMOD
33	reduction	reduction	NN	_	31	PMOD
34	of	of	IN	_	33	NMOD
35	Aβ	aβ	NN	_	36	NMOD
36	levels	level	NNS	_	34	PMOD
37	.	.	.	_	18	P

1	The	the	DT	_	3	NMOD
2	ELISA	elisa	NN	_	3	NMOD
3	data	datum	NNS	_	5	SBJ
4	also	also	RB	_	5	ADV
5	confirmed	confirm	VBD	_	0	ROOT
6	that	that	IN	_	5	OBJ
7	incorporation	incorporation	NN	_	14	SBJ
8	of	of	IN	_	7	NMOD
9	the	the	DT	_	13	NMOD
10	Swedish	swedish	JJ	_	13	NMOD
11	and	and	CC	_	10	COORD
12	Indiana	indiana	NNP	_	11	CONJ
13	mutations	mutation	NNS	_	8	PMOD
14	led	lead	VBD	_	6	SUB
15	to	to	IN	_	14	ADV
16	high	high	JJ	_	17	NMOD
17	levels	level	NNS	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	Aβ42	aβ0	NN	_	18	PMOD
20	,	,	,	_	17	P
21	which	which	WDT	_	24	SBJ
22	we	we	PRP	_	23	SBJ
23	predicted	predict	VBD	_	17	NMOD
24	would	would	MD	_	23	OBJ
25	induce	induce	VB	_	24	VC
26	rapid	rapid	JJ	_	28	NMOD
27	plaque	plaque	NN	_	28	NMOD
28	formation	formation	NN	_	25	OBJ
29	in	in	IN	_	25	LOC
30	untreated	untreated	JJ	_	31	NMOD
31	animals	animal	NNS	_	29	PMOD
32	.	.	.	_	5	P

1	Histological	histological	JJ	_	2	PRN
2	characterization	characterization	NN	_	18	SBJ
3	of	of	IN	_	2	NMOD
4	double	double	JJ	_	17	NMOD
5	transgenic	transgenic	JJ	_	17	NMOD
6	(	(	-LRB-	_	13	P
7	CaMKIIα	camkiiα	NN	_	13	NMOD
8	-	-	HYPH	_	7	P
9	tTA	tta	NN	_	13	NMOD
10	×	×	SYM	_	13	P
11	tet	tet	NN	_	13	NMOD
12	-	-	HYPH	_	11	P
13	APPswe	appswe	NN	_	17	PRN
14	/	/	HYPH	_	13	P
15	ind	ind	JJ	_	13	NMOD
16	)	)	-RRB-	_	13	P
17	mice	mouse	NNS	_	3	PMOD
18	revealed	reveal	VBD	_	0	ROOT
19	early	early	JJ	_	21	NMOD
20	-	-	HYPH	_	19	P
21	onset	onset	NN	_	23	NMOD
22	amyloid	amyloid	NN	_	23	NMOD
23	formation	formation	NN	_	18	OBJ
24	in	in	IN	_	18	ADV
25	all	all	DT	_	28	NMOD
26	four	four	CD	_	28	NMOD
27	new	new	JJ	_	28	NMOD
28	lines	line	NNS	_	24	PMOD
29	.	.	.	_	18	P

1	Amyloid	amyloid	NN	_	2	NMOD
2	plaques	plaque	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	seen	see	VBN	_	3	VC
5	in	in	IN	_	4	LOC
6	mice	mouse	NNS	_	5	PMOD
7	as	as	RB	_	8	AMOD
8	young	young	JJ	_	6	NMOD
9	as	as	IN	_	8	AMOD
10	8	0	CD	_	11	NMOD
11	wk	wk	NN	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	age	age	NN	_	12	PMOD
14	(	(	-LRB-	_	17	P
15	data	datum	NNS	_	17	SBJ
16	not	not	RB	_	17	ADV
17	shown	show	VBN	_	4	PRN
18	)	)	-RRB-	_	17	P
19	.	.	.	_	3	P

1	Plaques	plaque	NNS	_	2	SBJ
2	were	be	VBD	_	0	ROOT
3	limited	limit	VBN	_	2	VC
4	to	to	IN	_	3	ADV
5	the	the	DT	_	6	NMOD
6	forebrain	forebrain	NN	_	4	PMOD
7	,	,	,	_	6	P
8	including	include	VBG	_	6	NMOD
9	the	the	DT	_	10	NMOD
10	cortex	cortex	NN	_	8	PMOD
11	,	,	,	_	10	P
12	hippocampus	hippocampus	NN	_	10	CONJ
13	,	,	,	_	12	P
14	olfactory	olfactory	JJ	_	15	NMOD
15	bulb	bulb	NN	_	12	CONJ
16	,	,	,	_	15	P
17	and	and	CC	_	15	COORD
18	striatum	striatum	NN	_	17	CONJ
19	,	,	,	_	6	P
20	where	where	WRB	_	27	LOC
21	the	the	DT	_	23	NMOD
22	CaMKIIα	camkiiα	NN	_	23	NMOD
23	promoter	promoter	NN	_	24	SBJ
24	is	be	VBZ	_	6	NMOD
25	known	know	VBN	_	24	VC
26	to	to	TO	_	25	OPRD
27	be	be	VB	_	26	IM
28	most	most	RBS	_	29	AMOD
29	active	active	JJ	_	27	PRD
30	[	[	-LRB-	_	33	P
31	16	0	CD	_	33	NMOD
32	,	,	,	_	33	P
33	28	0	CD	_	25	PRN
34	]	]	-RRB-	_	33	P
35	(	(	-LRB-	_	37	P
36	Figure	figure	NN	_	37	NMOD
37	S2	s0	NN	_	3	PRN
38	)	)	-RRB-	_	37	P
39	.	.	.	_	2	P

1	By	by	IN	_	9	TMP
2	6	0	CD	_	3	NMOD
3	mo	mo	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	age	age	NN	_	4	PMOD
6	,	,	,	_	9	P
7	amyloid	amyloid	NN	_	8	NMOD
8	burden	burden	NN	_	9	SBJ
9	became	become	VBD	_	0	ROOT
10	severe	severe	JJ	_	9	PRD
11	,	,	,	_	9	P
12	covering	cover	VBG	_	9	ADV
13	large	large	JJ	_	14	NMOD
14	areas	area	NNS	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	the	the	DT	_	17	NMOD
17	cortex	cortex	NN	_	15	PMOD
18	and	and	CC	_	17	COORD
19	hippocampus	hippocampus	NN	_	18	CONJ
20	(	(	-LRB-	_	22	P
21	Figure	figure	NN	_	22	NMOD
22	S3	s0	NN	_	12	PRN
23	)	)	-RRB-	_	22	P
24	.	.	.	_	9	P

1	No	no	DT	_	2	NMOD
2	lesions	lesion	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	seen	see	VBN	_	3	VC
5	in	in	IN	_	4	LOC
6	the	the	DT	_	7	NMOD
7	cerebellum	cerebellum	NN	_	5	PMOD
8	or	or	CC	_	7	COORD
9	brain	brain	NN	_	10	NMOD
10	stem	stem	NN	_	8	CONJ
11	even	even	RB	_	12	PMOD
12	at	at	IN	_	4	TMP
13	late	late	JJ	_	14	NMOD
14	ages	age	NNS	_	12	PMOD
15	,	,	,	_	4	P
16	consistent	consistent	JJ	_	4	ADV
17	with	with	IN	_	16	AMOD
18	CaMKIIα	camkiiα	NN	_	20	AMOD
19	-	-	HYPH	_	18	P
20	controlled	control	VBN	_	22	NMOD
21	transgene	transgene	NN	_	22	NMOD
22	expression	expression	NN	_	17	PMOD
23	.	.	.	_	3	P

1	Unlike	unlike	IN	_	23	ADV
2	what	what	WP	_	3	SBJ
3	is	be	VBZ	_	1	PMOD
4	thought	think	VBN	_	3	VC
5	to	to	TO	_	4	OPRD
6	occur	occur	VB	_	5	IM
7	in	in	IN	_	6	LOC
8	the	the	DT	_	10	NMOD
9	human	human	JJ	_	10	NMOD
10	disease	disease	NN	_	7	PMOD
11	,	,	,	_	23	P
12	the	the	DT	_	15	NMOD
13	first	$#ORD#$	JJ	_	15	NMOD
14	visible	visible	JJ	_	15	NMOD
15	plaques	plaque	NNS	_	23	SBJ
16	in	in	IN	_	15	LOC
17	the	the	DT	_	22	NMOD
18	tet	tet	NN	_	20	NMOD
19	-	-	HYPH	_	18	P
20	off	off	NN	_	22	NMOD
21	APP	app	NN	_	22	NMOD
22	mice	mouse	NNS	_	16	PMOD
23	are	be	VBP	_	0	ROOT
24	fibrillar	fibrillar	JJ	_	26	AMOD
25	-	-	HYPH	_	24	P
26	cored	core	VBN	_	27	NMOD
27	deposits	deposit	NNS	_	23	PRD
28	.	.	.	_	23	P

1	We	we	PRP	_	2	SBJ
2	have	have	VBP	_	0	ROOT
3	noted	note	VBN	_	2	VC
4	the	the	DT	_	7	NMOD
5	same	same	JJ	_	7	NMOD
6	early	early	JJ	_	7	NMOD
7	appearance	appearance	NN	_	3	OBJ
8	of	of	IN	_	7	NMOD
9	cored	core	VBN	_	10	NMOD
10	deposits	deposit	NNS	_	8	PMOD
11	in	in	IN	_	7	LOC
12	other	other	JJ	_	13	NMOD
13	lines	line	NNS	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	APP	app	NN	_	17	NMOD
16	transgenic	transgenic	JJ	_	17	NMOD
17	mice	mouse	NNS	_	14	PMOD
18	that	that	WDT	_	19	SBJ
19	harbor	harbor	VBP	_	13	NMOD
20	the	the	DT	_	22	NMOD
21	Swedish	swedish	JJ	_	22	NMOD
22	mutation	mutation	NN	_	19	OBJ
23	[	[	-LRB-	_	24	P
24	27	0	CD	_	3	PRN
25	]	]	-RRB-	_	24	P
26	.	.	.	_	2	P

1	Diffuse	diffuse	NN	_	2	NMOD
2	plaques	plaque	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	apparent	apparent	JJ	_	3	PRD
5	in	in	IN	_	3	LOC
6	6	0	CD	_	8	NMOD
7	-	-	HYPH	_	6	P
8	mo	mo	NN	_	10	AMOD
9	-	-	HYPH	_	8	P
10	old	old	JJ	_	14	NMOD
11	tTA	tta	NN	_	13	NMOD
12	/	/	HYPH	_	11	P
13	APP	app	NN	_	14	NMOD
14	mice	mouse	NNS	_	5	PMOD
15	,	,	,	_	3	P
16	and	and	CC	_	3	COORD
17	became	become	VBD	_	16	CONJ
18	relatively	relatively	RB	_	19	AMOD
19	abundant	abundant	JJ	_	17	PRD
20	by	by	IN	_	17	TMP
21	9	0	CD	_	22	NMOD
22	mo	mo	NN	_	20	PMOD
23	of	of	IN	_	22	NMOD
24	age	age	NN	_	23	PMOD
25	.	.	.	_	3	P

1	At	at	IN	_	12	TMP
2	older	old	JJR	_	3	NMOD
3	ages	age	NNS	_	8	NMOD
4	(	(	-LRB-	_	8	P
5	9	0	CD	_	8	NMOD
6	–	–	SYM	_	5	P
7	12	0	CD	_	5	QMOD
8	mo	mo	NN	_	1	PMOD
9	)	)	-RRB-	_	12	P
10	amyloid	amyloid	NN	_	11	NMOD
11	deposits	deposit	NNS	_	12	SBJ
12	were	be	VBD	_	0	ROOT
13	visible	visible	JJ	_	12	PRD
14	in	in	IN	_	12	LOC
15	the	the	DT	_	16	NMOD
16	thalamus	thalamus	NN	_	14	PMOD
17	,	,	,	_	16	P
18	which	which	WDT	_	19	SBJ
19	has	have	VBZ	_	16	NMOD
20	also	also	RB	_	19	ADV
21	been	be	VBN	_	19	VC
22	observed	observe	VBN	_	21	VC
23	in	in	IN	_	22	LOC
24	mice	mouse	NNS	_	23	PMOD
25	expressing	express	VBG	_	24	NMOD
26	mutant	mutant	NN	_	27	NMOD
27	APP	app	NN	_	25	OBJ
28	via	via	IN	_	25	MNR
29	the	the	DT	_	33	NMOD
30	Thy	thy	NN	_	33	NMOD
31	-	-	HYPH	_	30	P
32	1	0	CD	_	30	NMOD
33	promoter	promoter	NN	_	28	PMOD
34	.	.	.	_	12	P

1	The	the	DT	_	2	NMOD
2	presence	presence	NN	_	9	SBJ
3	of	of	IN	_	2	NMOD
4	amyloid	amyloid	NN	_	5	NMOD
5	pathology	pathology	NN	_	3	PMOD
6	in	in	IN	_	2	LOC
7	this	this	DT	_	8	NMOD
8	region	region	NN	_	6	PMOD
9	has	have	VBZ	_	0	ROOT
10	been	be	VBN	_	9	VC
11	attributed	attribute	VBN	_	10	VC
12	to	to	IN	_	11	ADV
13	axonal	axonal	JJ	_	14	NMOD
14	transport	transport	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	APP	app	NN	_	18	NMOD
17	/	/	HYPH	_	16	P
18	Aβ	aβ	NN	_	15	PMOD
19	to	to	IN	_	14	NMOD
20	the	the	DT	_	21	NMOD
21	terminals	terminal	NNS	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	cortical	cortical	JJ	_	24	NMOD
24	neurons	neuron	NNS	_	22	PMOD
25	in	in	IN	_	21	LOC
26	the	the	DT	_	27	NMOD
27	thalamus	thalamus	NN	_	25	PMOD
28	[	[	-LRB-	_	29	P
29	29	0	CD	_	11	PRN
30	]	]	-RRB-	_	29	P
31	.	.	.	_	9	P

1	Most	most	RBS	_	2	AMOD
2	importantly	importantly	RB	_	17	ADV
3	,	,	,	_	17	P
4	only	only	RB	_	7	NMOD
5	double	double	JJ	_	6	AMOD
6	transgenic	transgenic	JJ	_	7	NMOD
7	mice	mouse	NNS	_	17	SBJ
8	,	,	,	_	7	P
9	expressing	express	VBG	_	7	NMOD
10	both	both	CC	_	15	COORD
11	the	the	DT	_	15	NMOD
12	tTA	tta	NN	_	15	NMOD
13	and	and	CC	_	12	COORD
14	APP	app	NN	_	13	CONJ
15	transgenes	transgene	NNS	_	9	OBJ
16	,	,	,	_	17	P
17	developed	develop	VBD	_	0	ROOT
18	amyloid	amyloid	NN	_	19	NMOD
19	lesions	lesion	NNS	_	17	OBJ
20	.	.	.	_	17	P

1	Single	single	JJ	_	2	AMOD
2	transgenic	transgenic	JJ	_	3	NMOD
3	mice	mouse	NNS	_	10	SBJ
4	up	up	IN	_	6	QMOD
5	to	to	IN	_	6	QMOD
6	15	0	CD	_	7	NMOD
7	mo	mo	NN	_	3	TMP
8	of	of	IN	_	7	NMOD
9	age	age	NN	_	8	PMOD
10	showed	show	VBD	_	0	ROOT
11	no	no	DT	_	12	NMOD
12	sign	sign	NN	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	pathology	pathology	NN	_	13	PMOD
15	(	(	-LRB-	_	17	P
16	Figure	figure	NN	_	17	NMOD
17	S3	s0	NN	_	10	PRN
18	)	)	-RRB-	_	17	P
19	.	.	.	_	10	P

1	Similarly	similarly	RB	_	5	ADV
2	,	,	,	_	5	P
3	amyloid	amyloid	NN	_	4	NMOD
4	pathology	pathology	NN	_	5	SBJ
5	can	can	MD	_	0	ROOT
6	be	be	VB	_	5	VC
7	completely	completely	RB	_	6	ADV
8	prevented	prevent	VBN	_	6	VC
9	in	in	IN	_	8	LOC
10	double	double	JJ	_	11	AMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	animals	animal	NNS	_	9	PMOD
13	born	bear	VBN	_	12	NMOD
14	and	and	CC	_	13	COORD
15	raised	raise	VBN	_	14	CONJ
16	on	on	IN	_	13	ADV
17	dox	dox	NN	_	16	PMOD
18	.	.	.	_	5	P

1	Animals	animal	NNS	_	19	SBJ
2	from	from	IN	_	1	NMOD
3	our	our	PRP$	_	6	NMOD
4	highest	high	JJS	_	5	AMOD
5	expressing	express	VBG	_	6	NMOD
6	line	line	NN	_	8	NMOD
7	(	(	-LRB-	_	8	P
8	line	line	NN	_	2	PMOD
9	885	0	CD	_	8	NMOD
10	)	)	-RRB-	_	1	P
11	maintained	maintain	VBN	_	1	NMOD
12	on	on	IN	_	11	ADV
13	dox	dox	NN	_	12	PMOD
14	for	for	IN	_	11	TMP
15	up	up	IN	_	14	PMOD
16	to	to	IN	_	15	PMOD
17	1	0	CD	_	18	NMOD
18	y	y	NN	_	16	PMOD
19	harbored	harbor	VBD	_	0	ROOT
20	no	no	DT	_	22	NMOD
21	amyloid	amyloid	NN	_	22	NMOD
22	pathology	pathology	NN	_	19	OBJ
23	(	(	-LRB-	_	26	P
24	data	datum	NNS	_	26	SBJ
25	not	not	RB	_	26	ADV
26	shown	show	VBN	_	22	PRN
27	)	)	-RRB-	_	22	P
28	,	,	,	_	19	P
29	indicating	indicate	VBG	_	19	ADV
30	that	that	IN	_	29	OBJ
31	residual	residual	JJ	_	32	NMOD
32	leakage	leakage	NN	_	41	SBJ
33	of	of	IN	_	32	NMOD
34	transgene	transgene	NN	_	35	NMOD
35	expression	expression	NN	_	33	PMOD
36	in	in	IN	_	32	NMOD
37	the	the	DT	_	38	NMOD
38	presence	presence	NN	_	36	PMOD
39	of	of	IN	_	38	NMOD
40	dox	dox	NN	_	39	PMOD
41	does	do	VBZ	_	30	SUB
42	not	not	RB	_	41	ADV
43	provide	provide	VB	_	41	VC
44	sufficient	sufficient	JJ	_	46	NMOD
45	Aβ	aβ	NN	_	46	NMOD
46	peptide	peptide	NN	_	43	OBJ
47	to	to	TO	_	46	NMOD
48	induce	induce	VB	_	47	IM
49	amyloid	amyloid	NN	_	50	NMOD
50	formation	formation	NN	_	48	OBJ
51	even	even	RB	_	52	PMOD
52	over	over	IN	_	48	TMP
53	long	long	JJ	_	54	NMOD
54	periods	period	NNS	_	52	PMOD
55	.	.	.	_	19	P

1	To	to	TO	_	12	PRP
2	mimic	mimic	VB	_	1	IM
3	therapeutic	therapeutic	JJ	_	4	NMOD
4	intervention	intervention	NN	_	2	OBJ
5	with	with	IN	_	2	MNR
6	inhibitors	inhibitor	NNS	_	5	PMOD
7	of	of	IN	_	6	NMOD
8	Aβ	aβ	NN	_	9	NMOD
9	production	production	NN	_	7	PMOD
10	,	,	,	_	12	P
11	we	we	PRP	_	12	SBJ
12	raised	raise	VBD	_	0	ROOT
13	a	a	DT	_	14	NMOD
14	group	group	NN	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	25	0	CD	_	19	NMOD
17	double	double	JJ	_	18	AMOD
18	transgenic	transgenic	JJ	_	19	NMOD
19	mice	mouse	NNS	_	15	PMOD
20	(	(	-LRB-	_	26	P
21	CaMKIIα	camkiiα	NN	_	25	NMOD
22	-	-	HYPH	_	21	P
23	tTA	tta	NN	_	25	NMOD
24	×	×	SYM	_	25	P
25	APP	app	NN	_	26	NMOD
26	line	line	NN	_	19	PRN
27	107	0	CD	_	26	NMOD
28	)	)	-RRB-	_	26	P
29	on	on	IN	_	12	ADV
30	normal	normal	JJ	_	31	NMOD
31	food	food	NN	_	29	PMOD
32	until	until	IN	_	12	TMP
33	6	0	CD	_	34	NMOD
34	mo	mo	NN	_	32	PMOD
35	of	of	IN	_	34	NMOD
36	age	age	NN	_	35	PMOD
37	,	,	,	_	12	P
38	when	when	WRB	_	40	TMP
39	we	we	PRP	_	40	SBJ
40	knew	know	VBD	_	12	TMP
41	amyloid	amyloid	NN	_	42	NMOD
42	formation	formation	NN	_	43	SBJ
43	was	be	VBD	_	40	OBJ
44	already	already	RB	_	43	ADV
45	well	well	RB	_	46	AMOD
46	underway	underway	JJ	_	43	PRD
47	in	in	IN	_	43	LOC
48	the	the	DT	_	49	NMOD
49	brain	brain	NN	_	47	PMOD
50	.	.	.	_	12	P

1	At	at	IN	_	9	TMP
2	6	0	CD	_	3	NMOD
3	mo	mo	NN	_	1	PMOD
4	,	,	,	_	9	P
5	half	half	NN	_	9	SBJ
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	8	NMOD
8	animals	animal	NNS	_	6	PMOD
9	were	be	VBD	_	0	ROOT
10	switched	switch	VBN	_	9	VC
11	from	from	IN	_	10	ADV
12	normal	normal	JJ	_	13	NMOD
13	chow	chow	NN	_	11	PMOD
14	to	to	IN	_	10	ADV
15	food	food	NN	_	14	PMOD
16	containing	contain	VBG	_	15	NMOD
17	dox	dox	NN	_	16	OBJ
18	at	at	IN	_	16	ADV
19	200	0	CD	_	20	NMOD
20	mg	mg	NN	_	18	PMOD
21	/	/	SYM	_	22	P
22	kg	kg	NN	_	20	NMOD
23	until	until	IN	_	10	TMP
24	they	they	PRP	_	25	SBJ
25	were	be	VBD	_	23	SUB
26	sacrificed	sacrifice	VBN	_	25	VC
27	at	at	IN	_	26	TMP
28	9	0	CD	_	31	NMOD
29	or	or	CC	_	28	COORD
30	12	0	CD	_	29	CONJ
31	mo	mo	NN	_	27	PMOD
32	of	of	IN	_	31	NMOD
33	age	age	NN	_	32	PMOD
34	.	.	.	_	9	P

1	The	the	DT	_	4	NMOD
2	remaining	remain	VBG	_	4	NMOD
3	control	control	NN	_	4	NMOD
4	animals	animal	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	kept	keep	VBN	_	5	VC
7	on	on	IN	_	6	ADV
8	standard	standard	JJ	_	9	NMOD
9	chow	chow	NN	_	7	PMOD
10	(	(	-LRB-	_	11	P
11	untreated	untreated	JJ	_	6	PRN
12	)	)	-RRB-	_	11	P
13	.	.	.	_	5	P

1	In	in	IN	_	6	ADV
2	all	all	DT	_	1	PMOD
3	,	,	,	_	6	P
4	four	four	CD	_	5	NMOD
5	cohorts	cohort	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	created	create	VBN	_	6	VC
8	:	:	:	_	7	P
9	6	0	CD	_	10	NMOD
10	mo	mo	NN	_	5	NMOD
11	untreated	untreated	JJ	_	10	NMOD
12	(	(	-LRB-	_	15	P
13	n	n	NN	_	15	SBJ
14	=	=	SYM	_	15	P
15	7	0	CD	_	10	PRN
16	)	)	-RRB-	_	15	P
17	,	,	,	_	10	P
18	9	0	CD	_	19	NMOD
19	mo	mo	NN	_	10	CONJ
20	untreated	untreated	JJ	_	19	NMOD
21	(	(	-LRB-	_	24	P
22	n	n	NN	_	24	SBJ
23	=	=	SYM	_	24	P
24	5	0	CD	_	19	PRN
25	)	)	-RRB-	_	24	P
26	,	,	,	_	19	P
27	6	0	CD	_	28	NMOD
28	mo	mo	NN	_	31	NMOD
29	+	+	SYM	_	31	P
30	3	0	CD	_	31	NMOD
31	mo	mo	NN	_	19	CONJ
32	treated	treat	VBN	_	31	NMOD
33	(	(	-LRB-	_	36	P
34	n	n	NN	_	36	SBJ
35	=	=	SYM	_	36	P
36	8	0	CD	_	31	PRN
37	)	)	-RRB-	_	36	P
38	,	,	,	_	31	P
39	and	and	CC	_	31	COORD
40	6	0	CD	_	41	NMOD
41	mo	mo	NN	_	44	NMOD
42	+	+	SYM	_	44	P
43	6	0	CD	_	44	NMOD
44	mo	mo	NN	_	39	CONJ
45	treated	treat	VBN	_	44	NMOD
46	(	(	-LRB-	_	49	P
47	n	n	NN	_	49	SBJ
48	=	=	SYM	_	49	P
49	5	0	CD	_	44	PRN
50	)	)	-RRB-	_	49	P
51	.	.	.	_	6	P

1	Full	full	JJ	_	2	NMOD
2	suppression	suppression	NN	_	20	SBJ
3	(	(	-LRB-	_	6	P
4	>	>	SYM	_	5	P
5	95	0	CD	_	6	NMOD
6	%	%	NN	_	2	PRN
7	)	)	-RRB-	_	6	P
8	of	of	IN	_	2	NMOD
9	transgenic	transgenic	JJ	_	13	NMOD
10	APPswe	appswe	NN	_	12	NMOD
11	/	/	HYPH	_	10	P
12	ind	ind	NN	_	13	NMOD
13	levels	level	NNS	_	8	PMOD
14	in	in	IN	_	13	LOC
15	the	the	DT	_	19	NMOD
16	dox	dox	NN	_	18	AMOD
17	-	-	HYPH	_	16	P
18	treated	treat	VBN	_	19	NMOD
19	animals	animal	NNS	_	14	PMOD
20	was	be	VBD	_	0	ROOT
21	confirmed	confirm	VBN	_	20	VC
22	by	by	IN	_	21	MNR
23	immunoblot	immunoblot	NN	_	22	PMOD
24	(	(	-LRB-	_	25	P
25	Figure	figure	NN	_	21	PRN
26	3	0	CD	_	25	NMOD
27	)	)	-RRB-	_	25	P
28	.	.	.	_	20	P

1	To	to	TO	_	31	PRP
2	ensure	ensure	VB	_	1	IM
3	that	that	IN	_	2	OBJ
4	the	the	DT	_	5	NMOD
5	transgene	transgene	NN	_	6	SBJ
6	could	could	MD	_	3	SUB
7	be	be	VB	_	6	VC
8	suppressed	suppress	VBN	_	7	VC
9	as	as	RB	_	10	AMOD
10	rapidly	rapidly	RB	_	8	ADV
11	in	in	IN	_	8	LOC
12	6	0	CD	_	14	NMOD
13	-	-	HYPH	_	12	P
14	mo	mo	NN	_	16	AMOD
15	-	-	HYPH	_	14	P
16	old	old	JJ	_	17	NMOD
17	mice	mouse	NNS	_	11	PMOD
18	with	with	IN	_	17	NMOD
19	fulminant	fulminant	JJ	_	20	NMOD
20	pathology	pathology	NN	_	18	PMOD
21	as	as	IN	_	10	AMOD
22	it	it	PRP	_	23	SBJ
23	can	can	MD	_	21	SUB
24	in	in	IN	_	23	LOC
25	young	young	JJ	_	28	NMOD
26	,	,	,	_	28	P
27	predeposit	predeposit	JJ	_	28	NMOD
28	animals	animal	NNS	_	24	PMOD
29	,	,	,	_	31	P
30	we	we	PRP	_	31	SBJ
31	treated	treat	VBD	_	0	ROOT
32	an	an	DT	_	34	NMOD
33	additional	additional	JJ	_	34	NMOD
34	set	set	NN	_	31	OBJ
35	of	of	IN	_	34	NMOD
36	6	0	CD	_	38	NMOD
37	-	-	HYPH	_	36	P
38	mo	mo	NN	_	40	AMOD
39	-	-	HYPH	_	38	P
40	old	old	JJ	_	41	NMOD
41	animals	animal	NNS	_	35	PMOD
42	with	with	IN	_	41	NMOD
43	dox	dox	NN	_	42	PMOD
44	for	for	IN	_	34	TMP
45	1	0	CD	_	46	NMOD
46	wk	wk	NN	_	44	PMOD
47	prior	prior	JJ	_	48	PMOD
48	to	to	IN	_	34	TMP
49	harvest	harvest	NN	_	48	PMOD
50	.	.	.	_	31	P

1	Importantly	importantly	RB	_	15	ADV
2	,	,	,	_	15	P
3	both	both	CC	_	6	COORD
4	APPswe	appswe	NN	_	6	NMOD
5	/	/	HYPH	_	4	P
6	ind	ind	NN	_	12	AMOD
7	and	and	CC	_	6	COORD
8	APP	app	NN	_	10	NMOD
9	–	–	HYPH	_	8	P
10	C	c	NN	_	7	CONJ
11	-	-	HYPH	_	6	P
12	terminal	terminal	JJ	_	14	NMOD
13	fragment	fragment	NN	_	14	NMOD
14	levels	level	NNS	_	15	SBJ
15	were	be	VBD	_	0	ROOT
16	fully	fully	RB	_	15	ADV
17	suppressed	suppress	VBN	_	15	VC
18	after	after	IN	_	17	ADV
19	only	only	RB	_	21	NMOD
20	1	0	CD	_	21	NMOD
21	wk	wk	NN	_	18	PMOD
22	of	of	IN	_	21	NMOD
23	treatment	treatment	NN	_	22	PMOD
24	,	,	,	_	17	P
25	indicating	indicate	VBG	_	17	ADV
26	that	that	IN	_	25	OBJ
27	the	the	DT	_	32	NMOD
28	in	in	FW	_	29	AMOD
29	vivo	vivo	FW	_	32	NMOD
30	half	half	NN	_	32	NMOD
31	-	-	HYPH	_	30	P
32	life	life	NN	_	44	SBJ
33	of	of	IN	_	32	NMOD
34	APPswe	appswe	NN	_	36	NMOD
35	/	/	HYPH	_	34	P
36	ind	ind	NN	_	33	PMOD
37	and	and	CC	_	32	COORD
38	its	its	PRP$	_	43	NMOD
39	processed	process	VBN	_	43	NMOD
40	C	c	NN	_	42	AMOD
41	-	-	HYPH	_	40	P
42	terminal	terminal	JJ	_	43	NMOD
43	fragments	fragment	NNS	_	37	CONJ
44	are	be	VBP	_	26	SUB
45	relatively	relatively	RB	_	46	AMOD
46	short	short	JJ	_	44	PRD
47	(	(	-LRB-	_	49	P
48	Figure	figure	NN	_	49	NMOD
49	3D	0d	NN	_	17	PRN
50	)	)	-RRB-	_	49	P
51	.	.	.	_	15	P

1	Tissue	tissue	NN	_	2	NMOD
2	sections	section	NNS	_	11	SBJ
3	from	from	IN	_	2	NMOD
4	each	each	DT	_	5	NMOD
5	animal	animal	NN	_	3	PMOD
6	in	in	IN	_	5	LOC
7	the	the	DT	_	10	NMOD
8	four	four	CD	_	10	NMOD
9	treatment	treatment	NN	_	10	NMOD
10	groups	group	NNS	_	6	PMOD
11	were	be	VBD	_	0	ROOT
12	stained	stain	VBN	_	11	VC
13	for	for	IN	_	12	PRP
14	amyloid	amyloid	NN	_	15	NMOD
15	pathology	pathology	NN	_	13	PMOD
16	by	by	IN	_	12	LGS
17	Hirano	hirano	NNP	_	18	NMOD
18	silver	silver	NN	_	16	PMOD
19	,	,	,	_	18	P
20	Campbell	campbell	NNP	_	22	NMOD
21	-	-	HYPH	_	20	P
22	Switzer	switzer	NNP	_	23	NMOD
23	silver	silver	NN	_	18	CONJ
24	,	,	,	_	23	P
25	thioflavin	thioflavin	NN	_	27	NMOD
26	-	-	HYPH	_	25	P
27	S	s	NN	_	23	CONJ
28	,	,	,	_	27	P
29	and	and	CC	_	27	COORD
30	Aβ	aβ	NN	_	31	NMOD
31	immunohistochemistry	immunohistochemistry	NN	_	29	CONJ
32	.	.	.	_	11	P

1	As	as	IN	_	9	ADV
2	expected	expect	VBN	_	1	SUB
3	,	,	,	_	9	P
4	the	the	DT	_	8	NMOD
5	6	0	CD	_	6	NMOD
6	mo	mo	NN	_	8	NMOD
7	untreated	untreated	JJ	_	8	NMOD
8	cohort	cohort	NN	_	9	SBJ
9	displayed	display	VBD	_	0	ROOT
10	moderate	moderate	JJ	_	12	NMOD
11	amyloid	amyloid	NN	_	12	NMOD
12	pathology	pathology	NN	_	9	OBJ
13	,	,	,	_	9	P
14	and	and	CC	_	9	COORD
15	the	the	DT	_	19	NMOD
16	9	0	CD	_	17	NMOD
17	mo	mo	NN	_	19	NMOD
18	untreated	untreated	JJ	_	19	NMOD
19	cohort	cohort	NN	_	20	SBJ
20	progressed	progress	VBD	_	14	CONJ
21	to	to	IN	_	20	ADV
22	a	a	DT	_	25	NMOD
23	severe	severe	JJ	_	25	NMOD
24	amyloid	amyloid	NN	_	25	NMOD
25	burden	burden	NN	_	21	PMOD
26	.	.	.	_	9	P

1	In	in	IN	_	28	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	28	P
4	the	the	DT	_	5	NMOD
5	extent	extent	NN	_	28	SBJ
6	of	of	IN	_	5	NMOD
7	amyloid	amyloid	NN	_	8	NMOD
8	pathology	pathology	NN	_	6	PMOD
9	in	in	IN	_	5	LOC
10	mice	mouse	NNS	_	9	PMOD
11	from	from	IN	_	10	NMOD
12	the	the	DT	_	26	NMOD
13	6	0	CD	_	14	NMOD
14	mo	mo	NN	_	17	NMOD
15	+	+	SYM	_	17	P
16	3	0	CD	_	17	NMOD
17	mo	mo	NN	_	18	AMOD
18	treated	treat	VBN	_	26	NMOD
19	or	or	CC	_	18	COORD
20	6	0	CD	_	21	NMOD
21	mo	mo	NN	_	24	NMOD
22	+	+	SYM	_	24	P
23	6	0	CD	_	24	NMOD
24	mo	mo	NN	_	25	AMOD
25	treated	treat	VBN	_	19	CONJ
26	cohorts	cohort	NNS	_	11	PMOD
27	closely	closely	RB	_	28	ADV
28	resembled	resemble	VBD	_	0	ROOT
29	that	that	DT	_	28	OBJ
30	of	of	IN	_	29	NMOD
31	the	the	DT	_	35	NMOD
32	6	0	CD	_	33	NMOD
33	mo	mo	NN	_	34	AMOD
34	untreated	untreated	JJ	_	35	NMOD
35	cohort	cohort	NN	_	30	PMOD
36	,	,	,	_	28	P
37	despite	despite	IN	_	28	ADV
38	the	the	DT	_	41	NMOD
39	significant	significant	JJ	_	41	NMOD
40	age	age	NN	_	41	NMOD
41	difference	difference	NN	_	37	PMOD
42	between	between	IN	_	41	NMOD
43	the	the	DT	_	47	NMOD
44	treated	treat	VBN	_	47	NMOD
45	and	and	CC	_	44	COORD
46	untreated	untreated	JJ	_	45	CONJ
47	groups	group	NNS	_	42	PMOD
48	(	(	-LRB-	_	49	P
49	Figures	figure	NNS	_	28	PRN
50	4	0	CD	_	49	NMOD
51	and	and	CC	_	49	COORD
52	Figure	figure	NN	_	53	NMOD
53	S3	s0	NN	_	51	CONJ
54	)	)	-RRB-	_	49	P
55	.	.	.	_	28	P

1	Well	well	RB	_	3	AMOD
2	-	-	HYPH	_	1	P
3	formed	form	VBN	_	4	NMOD
4	plaques	plaque	NNS	_	5	SBJ
5	remained	remain	VBD	_	0	ROOT
6	in	in	IN	_	5	LOC
7	the	the	DT	_	9	NMOD
8	treated	treat	VBN	_	9	NMOD
9	animals	animal	NNS	_	6	PMOD
10	after	after	IN	_	5	TMP
11	6	0	CD	_	12	NMOD
12	mo	mo	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	transgene	transgene	NN	_	15	NMOD
15	suppression	suppression	NN	_	13	PMOD
16	,	,	,	_	5	P
17	even	even	RB	_	18	ADV
18	though	though	IN	_	5	ADV
19	as	as	RB	_	20	AMOD
20	much	much	JJ	_	21	NMOD
21	time	time	NN	_	22	SBJ
22	was	be	VBD	_	18	SUB
23	given	give	VBN	_	22	VC
24	to	to	TO	_	23	PRP
25	clear	clear	VB	_	24	IM
26	the	the	DT	_	27	NMOD
27	lesions	lesion	NNS	_	25	OBJ
28	as	as	IN	_	21	NMOD
29	they	they	PRP	_	30	SBJ
30	had	have	VBD	_	28	SUB
31	taken	take	VBN	_	30	VC
32	to	to	TO	_	31	PRP
33	form	form	VB	_	32	IM
34	.	.	.	_	5	P

1	Moreover	moreover	RB	_	12	ADV
2	,	,	,	_	12	P
3	both	both	DT	_	4	NMOD
4	types	type	NNS	_	12	SBJ
5	of	of	IN	_	4	NMOD
6	amyloid	amyloid	NN	_	5	PMOD
7	,	,	,	_	4	P
8	diffuse	diffuse	JJ	_	4	NMOD
9	and	and	CC	_	8	COORD
10	fibrillar	fibrillar	JJ	_	9	CONJ
11	,	,	,	_	12	P
12	remained	remain	VBD	_	0	ROOT
13	intact	intact	JJ	_	12	PRD
14	throughout	throughout	IN	_	12	TMP
15	treatment	treatment	NN	_	14	PMOD
16	.	.	.	_	12	P

1	Using	use	VBG	_	16	MNR
2	the	the	DT	_	7	NMOD
3	Campbell	campbell	NNP	_	5	NMOD
4	-	-	HYPH	_	3	P
5	Switzer	switzer	NNP	_	7	NMOD
6	silver	silver	NN	_	7	NMOD
7	stain	stain	NN	_	1	OBJ
8	to	to	TO	_	1	PRP
9	distinguish	distinguish	VB	_	8	IM
10	different	different	JJ	_	11	NMOD
11	forms	form	NNS	_	9	OBJ
12	of	of	IN	_	11	NMOD
13	amyloid	amyloid	NN	_	12	PMOD
14	,	,	,	_	16	P
15	we	we	PRP	_	16	SBJ
16	found	find	VBD	_	0	ROOT
17	diffuse	diffuse	JJ	_	18	NMOD
18	plaques	plaque	NNS	_	19	SBJ
19	were	be	VBD	_	16	OBJ
20	as	as	RB	_	21	AMOD
21	persistent	persistent	JJ	_	19	PRD
22	as	as	IN	_	21	AMOD
23	cored	core	VBN	_	24	NMOD
24	deposits	deposit	NNS	_	22	PMOD
25	(	(	-LRB-	_	27	P
26	Figure	figure	NN	_	27	NMOD
27	S4	s0	NN	_	16	PRN
28	)	)	-RRB-	_	27	P
29	.	.	.	_	16	P

1	It	it	PRP	_	2	SBJ
2	was	be	VBD	_	0	ROOT
3	nevertheless	nevertheless	RB	_	2	ADV
4	clear	clear	JJ	_	2	PRD
5	that	that	IN	_	2	OBJ
6	dox	dox	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	induced	induce	VBN	_	9	NMOD
9	suppression	suppression	NN	_	13	SBJ
10	of	of	IN	_	9	NMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	APP	app	NN	_	10	PMOD
13	had	have	VBD	_	5	SUB
14	completely	completely	RB	_	13	ADV
15	halted	halt	VBN	_	13	VC
16	the	the	DT	_	17	NMOD
17	progression	progression	NN	_	15	OBJ
18	of	of	IN	_	17	NMOD
19	pathology	pathology	NN	_	18	PMOD
20	.	.	.	_	2	P

1	To	to	TO	_	23	PRP
2	confirm	confirm	VB	_	1	IM
3	that	that	IN	_	2	OBJ
4	the	the	DT	_	5	NMOD
5	arrest	arrest	NN	_	13	SBJ
6	of	of	IN	_	5	NMOD
7	plaques	plaque	NNS	_	6	PMOD
8	without	without	IN	_	5	NMOD
9	any	any	DT	_	10	NMOD
10	sign	sign	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	clearance	clearance	NN	_	11	PMOD
13	was	be	VBD	_	3	SUB
14	not	not	RB	_	13	ADV
15	unique	unique	JJ	_	13	PRD
16	to	to	IN	_	15	AMOD
17	the	the	DT	_	20	NMOD
18	line	line	NN	_	20	NMOD
19	107	0	CD	_	18	NMOD
20	mice	mouse	NNS	_	16	PMOD
21	,	,	,	_	23	P
22	we	we	PRP	_	23	SBJ
23	repeated	repeat	VBD	_	0	ROOT
24	the	the	DT	_	28	NMOD
25	dox	dox	NN	_	27	NMOD
26	-	-	HYPH	_	25	P
27	suppression	suppression	NN	_	28	NMOD
28	experiment	experiment	NN	_	23	OBJ
29	in	in	IN	_	23	LOC
30	a	a	DT	_	32	NMOD
31	second	$#ORD#$	JJ	_	32	NMOD
32	line	line	NN	_	29	PMOD
33	of	of	IN	_	32	NMOD
34	tet	tet	NN	_	36	NMOD
35	-	-	HYPH	_	34	P
36	off	off	NN	_	38	NMOD
37	APP	app	NN	_	38	NMOD
38	mice	mouse	NNS	_	33	PMOD
39	(	(	-LRB-	_	54	P
40	CaMKIIα	camkiiα	NN	_	48	NMOD
41	-	-	HYPH	_	40	P
42	tTA	tta	NN	_	48	NMOD
43	×	×	SYM	_	48	P
44	tet	tet	NN	_	48	NMOD
45	-	-	HYPH	_	44	P
46	APPswe	appswe	NN	_	48	NMOD
47	/	/	HYPH	_	46	P
48	ind	ind	NN	_	49	NMOD
49	line	line	NN	_	54	DEP
50	18	0	CD	_	49	NMOD
51	;	;	:	_	54	P
52	n	n	NN	_	54	SBJ
53	=	=	SYM	_	54	P
54	22	0	CD	_	23	PRN
55	)	)	-RRB-	_	54	P
56	.	.	.	_	23	P

1	Again	again	RB	_	8	ADV
2	,	,	,	_	8	P
3	long	long	JJ	_	5	NMOD
4	-	-	HYPH	_	3	P
5	term	term	NN	_	7	NMOD
6	dox	dox	NN	_	7	NMOD
7	treatment	treatment	NN	_	8	SBJ
8	was	be	VBD	_	0	ROOT
9	begun	begin	VBN	_	8	VC
10	at	at	IN	_	9	TMP
11	6	0	CD	_	12	NMOD
12	mo	mo	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	age	age	NN	_	13	PMOD
15	,	,	,	_	8	P
16	and	and	CC	_	8	COORD
17	mice	mouse	NNS	_	18	SBJ
18	were	be	VBD	_	16	CONJ
19	harvested	harvest	VBN	_	18	VC
20	after	after	IN	_	19	TMP
21	3	0	CD	_	22	NMOD
22	mo	mo	NN	_	20	PMOD
23	of	of	IN	_	22	NMOD
24	transgene	transgene	NN	_	25	NMOD
25	suppression	suppression	NN	_	23	PMOD
26	(	(	-LRB-	_	52	P
27	6	0	CD	_	28	NMOD
28	mo	mo	NN	_	29	AMOD
29	untreated	untreated	JJ	_	33	DEP
30	,	,	,	_	33	P
31	n	n	NN	_	33	SBJ
32	=	=	SYM	_	33	P
33	8	0	CD	_	52	DEP
34	;	;	:	_	52	P
35	9	0	CD	_	36	NMOD
36	mo	mo	NN	_	37	AMOD
37	untreated	untreated	JJ	_	41	DEP
38	,	,	,	_	41	P
39	n	n	NN	_	41	SBJ
40	=	=	SYM	_	41	P
41	6	0	CD	_	52	DEP
42	;	;	:	_	52	P
43	6	0	CD	_	47	NMOD
44	mo	mo	NN	_	47	NMOD
45	+	+	SYM	_	47	P
46	3	0	CD	_	47	NMOD
47	mo	mo	NN	_	48	AMOD
48	treated	treat	VBN	_	52	DEP
49	,	,	,	_	52	P
50	n	n	NN	_	52	SBJ
51	=	=	SYM	_	52	P
52	8	0	CD	_	19	PRN
53	)	)	-RRB-	_	52	P
54	.	.	.	_	8	P

1	Immunoblotting	immunoblotting	NN	_	4	SBJ
2	for	for	IN	_	1	NMOD
3	APP	app	NN	_	2	PMOD
4	confirmed	confirm	VBD	_	0	ROOT
5	full	full	JJ	_	7	NMOD
6	transgene	transgene	NN	_	7	NMOD
7	suppression	suppression	NN	_	4	OBJ
8	in	in	IN	_	4	LOC
9	the	the	DT	_	11	NMOD
10	treated	treat	VBN	_	11	NMOD
11	animals	animal	NNS	_	8	PMOD
12	(	(	-LRB-	_	14	P
13	Figure	figure	NN	_	14	NMOD
14	S5	s0	NN	_	4	PRN
15	)	)	-RRB-	_	14	P
16	.	.	.	_	4	P

1	As	as	IN	_	12	ADV
2	in	in	IN	_	1	PMOD
3	the	the	DT	_	6	NMOD
4	line	line	NN	_	6	NMOD
5	107	0	CD	_	4	NMOD
6	mice	mouse	NNS	_	2	PMOD
7	described	describe	VBN	_	6	NMOD
8	above	above	RB	_	7	ADV
9	,	,	,	_	12	P
10	amyloid	amyloid	NN	_	11	NMOD
11	burden	burden	NN	_	12	SBJ
12	worsened	worsen	VBD	_	0	ROOT
13	substantially	substantially	RB	_	12	ADV
14	in	in	IN	_	12	LOC
15	the	the	DT	_	17	NMOD
16	untreated	untreated	JJ	_	17	NMOD
17	mice	mouse	NNS	_	14	PMOD
18	between	between	IN	_	17	NMOD
19	6	0	CD	_	22	NMOD
20	and	and	CC	_	19	COORD
21	9	0	CD	_	20	CONJ
22	mo	mo	NN	_	18	PMOD
23	of	of	IN	_	22	NMOD
24	age	age	NN	_	23	PMOD
25	.	.	.	_	12	P

1	Suppression	suppression	NN	_	6	SBJ
2	of	of	IN	_	1	NMOD
3	transgene	transgene	NN	_	4	NMOD
4	expression	expression	NN	_	2	PMOD
5	abruptly	abruptly	RB	_	6	ADV
6	arrested	arrest	VBD	_	0	ROOT
7	progression	progression	NN	_	6	OBJ
8	of	of	IN	_	7	NMOD
9	pathology	pathology	NN	_	8	PMOD
10	(	(	-LRB-	_	12	P
11	Figure	figure	NN	_	12	NMOD
12	S6	s0	NN	_	6	PRN
13	)	)	-RRB-	_	12	P
14	,	,	,	_	6	P
15	but	but	CC	_	17	COORD
16	again	again	RB	_	17	TMP
17	without	without	IN	_	6	DEP
18	any	any	DT	_	19	NMOD
19	sign	sign	NN	_	17	PMOD
20	of	of	IN	_	19	NMOD
21	reduction	reduction	NN	_	20	PMOD
22	.	.	.	_	6	P

1	Both	both	CC	_	2	COORD
2	silver	silver	NN	_	9	AMOD
3	-	-	HYPH	_	2	P
4	and	and	CC	_	2	COORD
5	thioflavin	thioflavin	NN	_	7	NMOD
6	-	-	HYPH	_	5	P
7	S	s	NN	_	4	CONJ
8	-	-	HYPH	_	2	P
9	positive	positive	JJ	_	10	NMOD
10	plaques	plaque	NNS	_	11	SBJ
11	could	could	MD	_	0	ROOT
12	still	still	RB	_	11	ADV
13	be	be	VB	_	11	VC
14	found	find	VBN	_	13	VC
15	in	in	IN	_	14	LOC
16	each	each	DT	_	15	PMOD
17	of	of	IN	_	16	NMOD
18	the	the	DT	_	22	NMOD
19	dox	dox	NN	_	21	AMOD
20	-	-	HYPH	_	19	P
21	treated	treat	VBN	_	22	NMOD
22	animals	animal	NNS	_	17	PMOD
23	.	.	.	_	11	P

1	We	we	PRP	_	3	SBJ
2	biochemically	biochemically	RB	_	3	ADV
3	measured	measure	VBD	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	amount	amount	NN	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	aggregated	aggregate	VBN	_	8	NMOD
8	Aβ	aβ	NN	_	6	PMOD
9	in	in	IN	_	3	LOC
10	the	the	DT	_	11	NMOD
11	brains	brain	NNS	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	our	our	PRP$	_	14	NMOD
14	mice	mouse	NNS	_	12	PMOD
15	before	before	IN	_	3	TMP
16	and	and	CC	_	15	COORD
17	after	after	IN	_	16	CONJ
18	transgene	transgene	NN	_	19	NMOD
19	suppression	suppression	NN	_	15	PMOD
20	using	use	VBG	_	3	MNR
21	filter	filter	NN	_	22	NMOD
22	trap	trap	NN	_	23	NMOD
23	analysis	analysis	NN	_	20	OBJ
24	of	of	IN	_	23	NMOD
25	cortical	cortical	JJ	_	26	NMOD
26	tissue	tissue	NN	_	24	PMOD
27	from	from	IN	_	26	NMOD
28	each	each	DT	_	29	NMOD
29	animal	animal	NN	_	27	PMOD
30	.	.	.	_	3	P

1	In	in	IN	_	10	ADV
2	this	this	DT	_	3	NMOD
3	assay	assay	NN	_	1	PMOD
4	,	,	,	_	10	P
5	serial	serial	JJ	_	6	NMOD
6	dilutions	dilution	NNS	_	10	SBJ
7	of	of	IN	_	6	NMOD
8	protein	protein	NN	_	9	NMOD
9	homogenate	homogenate	NN	_	7	PMOD
10	are	be	VBP	_	27	DEP
11	passed	pass	VBN	_	10	VC
12	through	through	IN	_	11	DIR
13	a	a	DT	_	16	NMOD
14	cellulose	cellulose	NN	_	16	NMOD
15	acetate	acetate	NN	_	16	NMOD
16	filter	filter	NN	_	12	PMOD
17	;	;	:	_	27	P
18	particles	particle	NNS	_	27	SBJ
19	larger	large	JJR	_	18	NMOD
20	than	than	IN	_	19	AMOD
21	the	the	DT	_	23	NMOD
22	pore	pore	NN	_	23	NMOD
23	size	size	NN	_	20	PMOD
24	of	of	IN	_	23	NMOD
25	the	the	DT	_	26	NMOD
26	filter	filter	NN	_	24	PMOD
27	become	become	VBP	_	0	ROOT
28	trapped	trapped	JJ	_	27	PRD
29	in	in	IN	_	28	LOC
30	the	the	DT	_	31	NMOD
31	membrane	membrane	NN	_	29	PMOD
32	and	and	CC	_	27	COORD
33	are	be	VBP	_	32	CONJ
34	revealed	reveal	VBN	_	33	VC
35	by	by	IN	_	34	MNR
36	immunoblotting	immunoblotting	NN	_	35	PMOD
37	[	[	-LRB-	_	38	P
38	22	0	CD	_	34	PRN
39	]	]	-RRB-	_	38	P
40	.	.	.	_	27	P

1	Consistent	consistent	JJ	_	25	ADV
2	with	with	IN	_	1	AMOD
3	our	our	PRP$	_	5	NMOD
4	visual	visual	JJ	_	5	NMOD
5	analysis	analysis	NN	_	2	PMOD
6	of	of	IN	_	5	NMOD
7	the	the	DT	_	9	NMOD
8	histological	histological	JJ	_	9	NMOD
9	sections	section	NNS	_	6	PMOD
10	,	,	,	_	25	P
11	line	line	NN	_	16	NMOD
12	107	0	CD	_	11	NMOD
13	tTA	tta	NN	_	15	NMOD
14	/	/	HYPH	_	13	P
15	APP	app	NN	_	16	NMOD
16	mice	mouse	NNS	_	25	SBJ
17	treated	treat	VBN	_	16	NMOD
18	with	with	IN	_	17	MNR
19	dox	dox	NN	_	18	PMOD
20	for	for	IN	_	17	TMP
21	3	0	CD	_	24	NMOD
22	or	or	CC	_	21	COORD
23	6	0	CD	_	22	CONJ
24	mo	mo	NN	_	20	PMOD
25	had	have	VBD	_	0	ROOT
26	the	the	DT	_	28	NMOD
27	same	same	JJ	_	28	NMOD
28	amount	amount	NN	_	25	OBJ
29	of	of	IN	_	28	NMOD
30	aggregated	aggregate	VBN	_	31	NMOD
31	Aβ	aβ	NN	_	29	PMOD
32	as	as	IN	_	28	NMOD
33	when	when	WRB	_	35	TMP
34	they	they	PRP	_	35	SBJ
35	started	start	VBD	_	32	PMOD
36	treatment	treatment	NN	_	35	OBJ
37	at	at	IN	_	35	TMP
38	6	0	CD	_	39	NMOD
39	mo	mo	NN	_	37	PMOD
40	of	of	IN	_	39	NMOD
41	age	age	NN	_	40	PMOD
42	(	(	-LRB-	_	44	P
43	Figure	figure	NN	_	44	NMOD
44	4A	0a	NN	_	25	PRN
45	and	and	CC	_	44	COORD
46	4B	0b	NN	_	45	CONJ
47	)	)	-RRB-	_	44	P
48	.	.	.	_	25	P

1	In	in	IN	_	11	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	11	P
4	untreated	untreated	JJ	_	10	NMOD
5	9	0	CD	_	7	NMOD
6	-	-	HYPH	_	5	P
7	mo	mo	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	old	old	JJ	_	10	NMOD
10	mice	mouse	NNS	_	11	SBJ
11	had	have	VBD	_	0	ROOT
12	almost	almost	RB	_	13	AMOD
13	twice	twice	RB	_	15	AMOD
14	as	as	RB	_	15	AMOD
15	much	much	JJ	_	17	NMOD
16	aggregated	aggregate	VBN	_	17	NMOD
17	Aβ	aβ	NN	_	11	OBJ
18	as	as	IN	_	17	NMOD
19	either	either	DT	_	18	PMOD
20	of	of	IN	_	19	NMOD
21	the	the	DT	_	23	NMOD
22	treated	treat	VBN	_	23	NMOD
23	groups	group	NNS	_	20	PMOD
24	.	.	.	_	11	P

1	Filter	filter	NN	_	3	NMOD
2	trap	trap	NN	_	3	NMOD
3	analysis	analysis	NN	_	11	SBJ
4	of	of	IN	_	3	NMOD
5	line	line	NN	_	10	NMOD
6	18	0	CD	_	5	NMOD
7	tTA	tta	NN	_	9	NMOD
8	/	/	HYPH	_	7	P
9	APP	app	NN	_	10	NMOD
10	mice	mouse	NNS	_	4	PMOD
11	yielded	yield	VBD	_	31	DEP
12	similar	similar	JJ	_	13	NMOD
13	results	result	NNS	_	11	OBJ
14	:	:	:	_	31	P
15	the	the	DT	_	16	NMOD
16	increase	increase	NN	_	31	SBJ
17	in	in	IN	_	16	NMOD
18	aggregated	aggregate	VBN	_	19	NMOD
19	Aβ	aβ	NN	_	17	PMOD
20	observed	observe	VBN	_	16	NMOD
21	in	in	IN	_	20	LOC
22	untreated	untreated	JJ	_	23	NMOD
23	animals	animal	NNS	_	21	PMOD
24	between	between	IN	_	23	NMOD
25	6	0	CD	_	28	NMOD
26	and	and	CC	_	25	COORD
27	9	0	CD	_	26	CONJ
28	mo	mo	NN	_	24	PMOD
29	of	of	IN	_	28	NMOD
30	age	age	NN	_	29	PMOD
31	was	be	VBD	_	0	ROOT
32	completely	completely	RB	_	31	ADV
33	arrested	arrest	VBN	_	31	VC
34	by	by	IN	_	33	LGS
35	transgene	transgene	NN	_	36	NMOD
36	suppression	suppression	NN	_	34	PMOD
37	(	(	-LRB-	_	39	P
38	Figure	figure	NN	_	39	NMOD
39	S5C	s0c	NN	_	33	PRN
40	and	and	CC	_	39	COORD
41	S5D	s0d	NN	_	40	CONJ
42	)	)	-RRB-	_	39	P
43	.	.	.	_	31	P

1	We	we	PRP	_	3	SBJ
2	next	next	RB	_	3	TMP
3	used	use	VBD	_	0	ROOT
4	ELISA	elisa	NN	_	3	OBJ
5	to	to	TO	_	3	PRP
6	measure	measure	VB	_	5	IM
7	total	total	JJ	_	8	NMOD
8	Aβ	aβ	NN	_	6	OBJ
9	in	in	IN	_	6	LOC
10	the	the	DT	_	11	NMOD
11	brains	brain	NNS	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	each	each	DT	_	14	NMOD
14	group	group	NN	_	12	PMOD
15	to	to	TO	_	6	PRP
16	determine	determine	VB	_	15	IM
17	whether	whether	IN	_	16	OBJ
18	any	any	DT	_	19	NMOD
19	change	change	NN	_	27	SBJ
20	in	in	IN	_	19	NMOD
21	the	the	DT	_	22	NMOD
22	amount	amount	NN	_	20	PMOD
23	or	or	CC	_	22	COORD
24	solubility	solubility	NN	_	23	CONJ
25	of	of	IN	_	22	NMOD
26	peptide	peptide	NN	_	25	PMOD
27	occurred	occur	VBD	_	17	SUB
28	while	while	IN	_	27	TMP
29	APPswe	appswe	NN	_	31	NMOD
30	/	/	HYPH	_	29	P
31	ind	ind	NN	_	32	NMOD
32	expression	expression	NN	_	33	SBJ
33	was	be	VBD	_	28	SUB
34	suppressed	suppress	VBN	_	33	VC
35	.	.	.	_	3	P

1	Cortical	cortical	JJ	_	2	NMOD
2	homogenates	homogenate	NNS	_	3	SBJ
3	were	be	VBD	_	29	DEP
4	sequentially	sequentially	RB	_	3	MNR
5	extracted	extract	VBN	_	3	VC
6	to	to	TO	_	5	PRP
7	separate	separate	VB	_	6	IM
8	peptide	peptide	NN	_	7	OBJ
9	into	into	IN	_	7	ADV
10	PBS	pb	NN	_	19	AMOD
11	-	-	HYPH	_	10	P
12	,	,	,	_	10	P
13	SDS	sd	NN	_	10	CONJ
14	-	-	HYPH	_	13	P
15	,	,	,	_	13	P
16	and	and	CC	_	13	COORD
17	FA	fa	NN	_	16	CONJ
18	-	-	HYPH	_	10	P
19	soluble	soluble	JJ	_	20	NMOD
20	fractions	fraction	NNS	_	9	PMOD
21	,	,	,	_	29	P
22	then	then	RB	_	29	TMP
23	transgene	transgene	NN	_	25	AMOD
24	-	-	HYPH	_	23	P
25	derived	derive	VBN	_	26	NMOD
26	Aβ40	aβ0	NN	_	29	SBJ
27	and	and	CC	_	26	COORD
28	Aβ42	aβ0	NN	_	27	CONJ
29	were	be	VBD	_	0	ROOT
30	measured	measure	VBN	_	29	VC
31	by	by	IN	_	30	LGS
32	human	human	JJ	_	34	AMOD
33	-	-	HYPH	_	32	P
34	specific	specific	JJ	_	35	NMOD
35	ELISA	elisa	NN	_	31	PMOD
36	[	[	-LRB-	_	37	P
37	23	0	CD	_	30	PRN
38	]	]	-RRB-	_	37	P
39	.	.	.	_	29	P

1	In	in	IN	_	9	ADV
2	all	all	DT	_	3	NMOD
3	animals	animal	NNS	_	1	PMOD
4	harboring	harbor	VBG	_	3	NMOD
5	amyloid	amyloid	NN	_	6	NMOD
6	deposits	deposit	NNS	_	4	OBJ
7	,	,	,	_	9	P
8	we	we	PRP	_	9	SBJ
9	found	find	VBD	_	0	ROOT
10	that	that	IN	_	9	OBJ
11	the	the	DT	_	13	NMOD
12	vast	vast	JJ	_	13	NMOD
13	majority	majority	NN	_	21	SBJ
14	of	of	IN	_	13	NMOD
15	Aβ	aβ	NN	_	14	PMOD
16	(	(	-LRB-	_	19	P
17	>	>	SYM	_	18	P
18	99	0	CD	_	19	NMOD
19	%	%	NN	_	15	PRN
20	)	)	-RRB-	_	19	P
21	was	be	VBD	_	10	SUB
22	extracted	extract	VBN	_	21	VC
23	into	into	IN	_	22	LOC
24	the	the	DT	_	28	NMOD
25	SDS	sd	NN	_	28	NMOD
26	and	and	CC	_	25	COORD
27	FA	fa	NN	_	26	CONJ
28	fractions	fraction	NNS	_	23	PMOD
29	(	(	-LRB-	_	31	P
30	Figure	figure	NN	_	31	NMOD
31	5A	0a	NN	_	22	PRN
32	and	and	CC	_	31	COORD
33	5B	0b	NN	_	32	CONJ
34	)	)	-RRB-	_	31	P
35	.	.	.	_	9	P

1	Consistent	consistent	JJ	_	11	ADV
2	with	with	IN	_	1	AMOD
3	the	the	DT	_	6	NMOD
4	filter	filter	NN	_	6	NMOD
5	trap	trap	NN	_	6	NMOD
6	results	result	NNS	_	2	PMOD
7	presented	present	VBN	_	6	NMOD
8	above	above	RB	_	7	ADV
9	,	,	,	_	11	P
10	there	there	EX	_	11	SBJ
11	were	be	VBD	_	0	ROOT
12	no	no	DT	_	14	NMOD
13	significant	significant	JJ	_	14	NMOD
14	differences	difference	NNS	_	11	PRD
15	in	in	IN	_	14	LOC
16	SDS	sd	NN	_	21	AMOD
17	-	-	HYPH	_	16	P
18	or	or	CC	_	16	COORD
19	FA	fa	NN	_	18	CONJ
20	-	-	HYPH	_	16	P
21	soluble	soluble	JJ	_	22	NMOD
22	Aβ	aβ	NN	_	15	PMOD
23	between	between	IN	_	14	NMOD
24	the	the	DT	_	28	NMOD
25	6	0	CD	_	26	NMOD
26	mo	mo	NN	_	28	NMOD
27	untreated	untreated	JJ	_	28	NMOD
28	cohort	cohort	NN	_	23	PMOD
29	and	and	CC	_	28	COORD
30	either	either	CC	_	45	COORD
31	the	the	DT	_	45	NMOD
32	6	0	CD	_	33	NMOD
33	mo	mo	NN	_	36	NMOD
34	+	+	SYM	_	36	P
35	3	0	CD	_	36	NMOD
36	mo	mo	NN	_	45	NMOD
37	treated	treat	VBN	_	36	NMOD
38	or	or	CC	_	36	COORD
39	6	0	CD	_	40	NMOD
40	mo	mo	NN	_	43	NMOD
41	+	+	SYM	_	43	P
42	6	0	CD	_	43	NMOD
43	mo	mo	NN	_	38	CONJ
44	treated	treat	VBN	_	43	NMOD
45	cohorts	cohort	NNS	_	29	CONJ
46	.	.	.	_	11	P

1	However	however	RB	_	19	ADV
2	,	,	,	_	19	P
3	brains	brain	NNS	_	19	SBJ
4	of	of	IN	_	3	NMOD
5	both	both	CC	_	10	COORD
6	6	0	CD	_	7	NMOD
7	mo	mo	NN	_	10	NMOD
8	+	+	SYM	_	10	P
9	3	0	CD	_	10	NMOD
10	mo	mo	NN	_	17	AMOD
11	and	and	CC	_	10	COORD
12	6	0	CD	_	13	NMOD
13	mo	mo	NN	_	16	NMOD
14	+	+	SYM	_	16	P
15	6	0	CD	_	16	NMOD
16	mo	mo	NN	_	11	CONJ
17	treated	treat	VBN	_	18	NMOD
18	cohorts	cohort	NNS	_	4	PMOD
19	contained	contain	VBD	_	0	ROOT
20	roughly	roughly	RB	_	21	AMOD
21	twice	twice	RB	_	23	AMOD
22	as	as	RB	_	23	AMOD
23	much	much	JJ	_	27	NMOD
24	PBS	pb	NN	_	27	NMOD
25	-	-	HYPH	_	24	P
26	soluble	soluble	JJ	_	27	NMOD
27	Aβ40	aβ0	NN	_	19	OBJ
28	as	as	IN	_	27	NMOD
29	untreated	untreated	JJ	_	35	NMOD
30	6	0	CD	_	32	NMOD
31	-	-	HYPH	_	30	P
32	mo	mo	NN	_	34	AMOD
33	-	-	HYPH	_	32	P
34	old	old	JJ	_	35	NMOD
35	mice	mouse	NNS	_	28	PMOD
36	(	(	-LRB-	_	38	P
37	Figure	figure	NN	_	38	NMOD
38	5C	0c	NN	_	19	PRN
39	)	)	-RRB-	_	38	P
40	.	.	.	_	19	P

1	Levels	level	NNS	_	4	SBJ
2	of	of	IN	_	1	NMOD
3	Aβ42	aβ0	NN	_	2	PMOD
4	showed	show	VBD	_	0	ROOT
5	a	a	DT	_	7	NMOD
6	similar	similar	JJ	_	7	NMOD
7	trend	trend	NN	_	4	OBJ
8	,	,	,	_	4	P
9	but	but	CC	_	4	COORD
10	did	do	VBD	_	9	CONJ
11	not	not	RB	_	10	ADV
12	reach	reach	VB	_	10	VC
13	statistical	statistical	JJ	_	14	NMOD
14	significance	significance	NN	_	12	OBJ
15	.	.	.	_	4	P

1	In	in	IN	_	27	ADV
2	fact	fact	NN	_	1	PMOD
3	,	,	,	_	27	P
4	levels	level	NNS	_	27	SBJ
5	of	of	IN	_	4	NMOD
6	PBS	pb	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	soluble	soluble	JJ	_	9	NMOD
9	Aβ40	aβ0	NN	_	5	PMOD
10	and	and	CC	_	9	COORD
11	Aβ42	aβ0	NN	_	10	CONJ
12	in	in	IN	_	4	NMOD
13	the	the	DT	_	26	NMOD
14	6	0	CD	_	15	NMOD
15	mo	mo	NN	_	18	NMOD
16	+	+	SYM	_	18	P
17	3	0	CD	_	18	NMOD
18	mo	mo	NN	_	26	NMOD
19	and	and	CC	_	18	COORD
20	6	0	CD	_	21	NMOD
21	mo	mo	NN	_	24	NMOD
22	+	+	SYM	_	24	P
23	6	0	CD	_	24	NMOD
24	mo	mo	NN	_	19	CONJ
25	treated	treat	VBN	_	24	NMOD
26	cohorts	cohort	NNS	_	12	PMOD
27	were	be	VBD	_	0	ROOT
28	most	most	RBS	_	29	AMOD
29	similar	similar	JJ	_	27	PRD
30	to	to	IN	_	29	AMOD
31	that	that	DT	_	30	PMOD
32	of	of	IN	_	31	NMOD
33	the	the	DT	_	37	NMOD
34	9	0	CD	_	35	NMOD
35	mo	mo	NN	_	37	NMOD
36	untreated	untreated	JJ	_	37	NMOD
37	cohort	cohort	NN	_	32	PMOD
38	,	,	,	_	27	P
39	suggesting	suggest	VBG	_	27	ADV
40	that	that	IN	_	39	OBJ
41	age	age	NN	_	59	SBJ
42	,	,	,	_	41	P
43	as	as	IN	_	41	NMOD
44	opposed	oppose	VBN	_	43	PMOD
45	to	to	IN	_	44	PMOD
46	synthetic	synthetic	JJ	_	47	NMOD
47	rate	rate	NN	_	45	PMOD
48	(	(	-LRB-	_	47	P
49	which	which	WDT	_	50	SBJ
50	would	would	MD	_	47	NMOD
51	be	be	VB	_	50	VC
52	negligible	negligible	JJ	_	51	PRD
53	in	in	IN	_	51	LOC
54	the	the	DT	_	56	NMOD
55	treated	treat	VBN	_	56	NMOD
56	animals	animal	NNS	_	53	PMOD
57	)	)	-RRB-	_	59	P
58	,	,	,	_	59	P
59	may	may	MD	_	40	SUB
60	determine	determine	VB	_	59	VC
61	the	the	DT	_	62	NMOD
62	fraction	fraction	NN	_	60	OBJ
63	of	of	IN	_	62	NMOD
64	PBS	pb	NN	_	66	AMOD
65	-	-	HYPH	_	64	P
66	soluble	soluble	JJ	_	67	NMOD
67	Aβ	aβ	NN	_	63	PMOD
68	in	in	IN	_	60	LOC
69	these	these	DT	_	70	NMOD
70	animals	animal	NNS	_	68	PMOD
71	.	.	.	_	27	P

1	We	we	PRP	_	3	SBJ
2	also	also	RB	_	3	ADV
3	assessed	assess	VBD	_	0	ROOT
4	neuritic	neuritic	JJ	_	7	NMOD
5	and	and	CC	_	4	COORD
6	glial	glial	JJ	_	5	CONJ
7	pathology	pathology	NN	_	3	OBJ
8	surrounding	surround	VBG	_	7	NMOD
9	the	the	DT	_	10	NMOD
10	plaques	plaque	NNS	_	8	OBJ
11	to	to	TO	_	3	PRP
12	determine	determine	VB	_	11	IM
13	whether	whether	IN	_	12	OBJ
14	there	there	EX	_	15	SBJ
15	were	be	VBD	_	13	SUB
16	any	any	DT	_	17	NMOD
17	changes	change	NNS	_	15	PRD
18	in	in	IN	_	17	LOC
19	nearby	nearby	JJ	_	20	NMOD
20	tissue	tissue	NN	_	18	PMOD
21	following	follow	VBG	_	15	TMP
22	long	long	JJ	_	24	NMOD
23	-	-	HYPH	_	22	P
24	term	term	NN	_	26	NMOD
25	transgene	transgene	NN	_	26	NMOD
26	suppression	suppression	NN	_	21	PMOD
27	.	.	.	_	3	P

1	Both	both	CC	_	4	COORD
2	Hirano	hirano	NNP	_	4	NMOD
3	silver	silver	NN	_	4	NMOD
4	stain	stain	NN	_	8	SBJ
5	and	and	CC	_	4	COORD
6	ubiquitin	ubiquitin	NN	_	7	NMOD
7	immunostaining	immunostaining	NN	_	5	CONJ
8	showed	show	VBD	_	0	ROOT
9	neuritic	neuritic	JJ	_	10	NMOD
10	pathology	pathology	NN	_	8	OBJ
11	in	in	IN	_	8	LOC
12	all	all	DT	_	14	NMOD
13	treatment	treatment	NN	_	14	NMOD
14	groups	group	NNS	_	11	PMOD
15	(	(	-LRB-	_	16	P
16	Figure	figure	NN	_	8	PRN
17	6	0	CD	_	16	NMOD
18	)	)	-RRB-	_	16	P
19	.	.	.	_	8	P

1	Similarly	similarly	RB	_	8	ADV
2	,	,	,	_	8	P
3	activated	activate	VBN	_	4	NMOD
4	astrocytes	astrocyte	NNS	_	8	SBJ
5	immunostained	immunostained	VBN	_	4	NMOD
6	for	for	IN	_	5	ADV
7	GFAP	gfap	NN	_	6	PMOD
8	were	be	VBD	_	0	ROOT
9	found	find	VBN	_	8	VC
10	near	near	IN	_	9	LOC
11	plaques	plaque	NNS	_	10	PMOD
12	in	in	IN	_	9	LOC
13	all	all	DT	_	14	NMOD
14	animals	animal	NNS	_	12	PMOD
15	(	(	-LRB-	_	16	P
16	Figure	figure	NN	_	9	PRN
17	6	0	CD	_	16	NMOD
18	)	)	-RRB-	_	16	P
19	.	.	.	_	8	P

1	Neuritic	neuritic	JJ	_	4	NMOD
2	and	and	CC	_	1	COORD
3	glial	glial	JJ	_	2	CONJ
4	pathology	pathology	NN	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	more	more	RBR	_	7	AMOD
7	severe	severe	JJ	_	5	PRD
8	in	in	IN	_	5	LOC
9	the	the	DT	_	12	NMOD
10	older	old	JJR	_	12	NMOD
11	untreated	untreated	JJ	_	12	NMOD
12	mice	mouse	NNS	_	8	PMOD
13	.	.	.	_	5	P

1	In	in	IN	_	6	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	6	P
4	transgene	transgene	NN	_	5	NMOD
5	suppression	suppression	NN	_	6	SBJ
6	prevented	prevent	VBD	_	0	ROOT
7	the	the	DT	_	8	NMOD
8	growth	growth	NN	_	6	OBJ
9	of	of	IN	_	8	NMOD
10	individual	individual	JJ	_	11	NMOD
11	deposits	deposit	NNS	_	9	PMOD
12	apparent	apparent	JJ	_	11	NMOD
13	in	in	IN	_	12	LOC
14	untreated	untreated	JJ	_	15	NMOD
15	mice	mouse	NNS	_	13	PMOD
16	,	,	,	_	6	P
17	and	and	CC	_	6	COORD
18	limited	limit	VBD	_	17	CONJ
19	the	the	DT	_	21	NMOD
20	surrounding	surround	VBG	_	21	NMOD
21	pathology	pathology	NN	_	18	OBJ
22	to	to	IN	_	18	ADV
23	what	what	WP	_	24	SBJ
24	was	be	VBD	_	22	PMOD
25	already	already	RB	_	24	ADV
26	present	present	JJ	_	24	PRD
27	when	when	WRB	_	29	TMP
28	treatment	treatment	NN	_	29	SBJ
29	began	begin	VBD	_	24	TMP
30	.	.	.	_	6	P

1	An	an	DT	_	3	NMOD
2	obvious	obvious	JJ	_	3	NMOD
3	question	question	NN	_	8	SBJ
4	we	we	PRP	_	5	SBJ
5	sought	seek	VBD	_	3	NMOD
6	to	to	TO	_	5	OPRD
7	address	address	VB	_	6	IM
8	was	be	VBD	_	0	ROOT
9	whether	whether	IN	_	8	PRD
10	the	the	DT	_	11	NMOD
11	deposition	deposition	NN	_	14	SBJ
12	of	of	IN	_	11	NMOD
13	Aβ	aβ	NN	_	12	PMOD
14	diminished	diminish	VBD	_	9	SUB
15	cognitive	cognitive	JJ	_	16	NMOD
16	ability	ability	NN	_	14	OBJ
17	in	in	IN	_	16	LOC
18	untreated	untreated	JJ	_	19	NMOD
19	mice	mouse	NNS	_	17	PMOD
20	,	,	,	_	9	P
21	and	and	CC	_	9	COORD
22	what	what	WP	_	23	SBJ
23	might	might	MD	_	21	CONJ
24	happen	happen	VB	_	23	VC
25	to	to	IN	_	24	ADV
26	cognition	cognition	NN	_	25	PMOD
27	when	when	WRB	_	31	TMP
28	the	the	DT	_	29	NMOD
29	process	process	NN	_	30	SBJ
30	was	be	VBD	_	24	TMP
31	interrupted	interrupt	VBN	_	30	VC
32	.	.	.	_	8	P

1	Unfortunately	unfortunately	RB	_	8	ADV
2	,	,	,	_	8	P
3	efforts	effort	NNS	_	8	SBJ
4	to	to	TO	_	3	NMOD
5	characterize	characterize	VB	_	4	IM
6	cognitive	cognitive	JJ	_	7	NMOD
7	behavior	behavior	NN	_	5	OBJ
8	were	be	VBD	_	0	ROOT
9	compromised	compromise	VBN	_	8	VC
10	by	by	IN	_	9	LGS
11	severe	severe	JJ	_	12	NMOD
12	hyperactivity	hyperactivity	NN	_	10	PMOD
13	in	in	IN	_	12	LOC
14	untreated	untreated	JJ	_	17	NMOD
15	double	double	JJ	_	16	AMOD
16	transgenic	transgenic	JJ	_	17	NMOD
17	mice	mouse	NNS	_	13	PMOD
18	.	.	.	_	8	P

1	The	the	DT	_	5	NMOD
2	tTA	tta	NN	_	4	NMOD
3	/	/	HYPH	_	2	P
4	APP	app	NN	_	5	NMOD
5	animals	animal	NNS	_	6	SBJ
6	were	be	VBD	_	0	ROOT
7	often	often	RB	_	6	TMP
8	seen	see	VBN	_	6	VC
9	running	run	VBG	_	8	ADV
10	in	in	IN	_	9	ADV
11	circles	circle	NNS	_	10	PMOD
12	around	around	IN	_	9	DIR
13	the	the	DT	_	14	NMOD
14	perimeter	perimeter	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	their	their	PRP$	_	17	NMOD
17	cages	cage	NNS	_	15	PMOD
18	,	,	,	_	6	P
19	and	and	CC	_	6	COORD
20	a	a	DT	_	23	NMOD
21	similar	similar	JJ	_	23	NMOD
22	swimming	swimming	NN	_	23	NMOD
23	pattern	pattern	NN	_	24	SBJ
24	was	be	VBD	_	19	CONJ
25	noted	note	VBN	_	24	VC
26	when	when	WRB	_	30	TMP
27	the	the	DT	_	28	NMOD
28	mice	mouse	NNS	_	29	SBJ
29	were	be	VBD	_	25	TMP
30	tested	test	VBN	_	29	VC
31	in	in	IN	_	30	LOC
32	the	the	DT	_	35	NMOD
33	Morris	morris	NNP	_	35	NMOD
34	water	water	NN	_	35	NMOD
35	maze	maze	NN	_	31	PMOD
36	.	.	.	_	6	P

1	In	in	IN	_	10	LOC
2	the	the	DT	_	5	NMOD
3	radial	radial	JJ	_	5	NMOD
4	water	water	NN	_	5	NMOD
5	maze	maze	NN	_	1	PMOD
6	,	,	,	_	10	P
7	repetitive	repetitive	JJ	_	9	NMOD
8	swim	swim	NN	_	9	NMOD
9	patterns	pattern	NNS	_	10	SBJ
10	were	be	VBD	_	0	ROOT
11	noted	note	VBN	_	10	VC
12	with	with	IN	_	11	ADV
13	no	no	DT	_	14	NMOD
14	evidence	evidence	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	choice	choice	NN	_	18	AMOD
17	-	-	HYPH	_	16	P
18	motivated	motivate	VBN	_	19	NMOD
19	actions	action	NNS	_	15	PMOD
20	.	.	.	_	10	P

1	Other	other	JJ	_	2	NMOD
2	studies	study	NNS	_	3	SBJ
3	have	have	VBP	_	0	ROOT
4	dealt	deal	VBN	_	3	VC
5	with	with	IN	_	4	ADV
6	similar	similar	JJ	_	7	NMOD
7	problems	problem	NNS	_	5	PMOD
8	by	by	IN	_	4	MNR
9	excluding	exclude	VBG	_	8	PMOD
10	animals	animal	NNS	_	9	OBJ
11	that	that	WDT	_	12	SBJ
12	do	do	VBP	_	10	NMOD
13	not	not	RB	_	12	ADV
14	show	show	VB	_	12	VC
15	adequate	adequate	JJ	_	16	NMOD
16	attention	attention	NN	_	14	OBJ
17	to	to	IN	_	16	NMOD
18	the	the	DT	_	19	NMOD
19	task	task	NN	_	17	PMOD
20	,	,	,	_	14	P
21	retaining	retain	VBG	_	14	ADV
22	only	only	RB	_	24	NMOD
23	those	those	DT	_	24	NMOD
24	mice	mouse	NNS	_	21	OBJ
25	that	that	WDT	_	26	SBJ
26	meet	meet	VBP	_	24	NMOD
27	certain	certain	JJ	_	29	NMOD
28	performance	performance	NN	_	29	NMOD
29	criteria	criterion	NNS	_	26	OBJ
30	[	[	-LRB-	_	31	P
31	30	0	CD	_	4	PRN
32	]	]	-RRB-	_	31	P
33	.	.	.	_	3	P

1	In	in	IN	_	9	ADV
2	our	our	PRP$	_	3	NMOD
3	case	case	NN	_	1	PMOD
4	,	,	,	_	9	P
5	the	the	DT	_	6	NMOD
6	penetrance	penetrance	NN	_	9	SBJ
7	of	of	IN	_	6	NMOD
8	hyperactivity	hyperactivity	NN	_	7	PMOD
9	was	be	VBD	_	0	ROOT
10	close	close	JJ	_	12	QMOD
11	to	to	IN	_	12	QMOD
12	100	0	CD	_	13	NMOD
13	%	%	NN	_	9	PRD
14	,	,	,	_	9	P
15	leaving	leave	VBG	_	9	ADV
16	us	us	PRP	_	15	OBJ
17	with	with	IN	_	15	ADV
18	no	no	DT	_	20	NMOD
19	testable	testable	JJ	_	20	NMOD
20	animals	animal	NNS	_	17	PMOD
21	.	.	.	_	9	P

1	This	this	DT	_	2	NMOD
2	phenotype	phenotype	NN	_	3	SBJ
3	has	have	VBZ	_	0	ROOT
4	not	not	RB	_	3	ADV
5	affected	affect	VBN	_	3	VC
6	previous	previous	JJ	_	7	NMOD
7	lines	line	NNS	_	5	OBJ
8	of	of	IN	_	7	NMOD
9	APPswe	appswe	NN	_	10	NMOD
10	mice	mouse	NNS	_	8	PMOD
11	we	we	PRP	_	12	SBJ
12	have	have	VBP	_	7	NMOD
13	produced	produce	VBN	_	12	VC
14	,	,	,	_	7	P
15	such	such	JJ	_	16	PMOD
16	as	as	IN	_	7	NMOD
17	lines	line	NNS	_	18	NMOD
18	E1	e0	NN	_	16	PMOD
19	–	–	HYPH	_	18	P
20	2	0	CD	_	18	NMOD
21	or	or	CC	_	18	COORD
22	C3	c0	NN	_	21	CONJ
23	–	–	HYPH	_	22	P
24	3	0	CD	_	22	NMOD
25	,	,	,	_	7	P
26	that	that	WDT	_	27	SBJ
27	express	express	VBP	_	7	NMOD
28	lower	low	JJR	_	29	NMOD
29	levels	level	NNS	_	27	OBJ
30	of	of	IN	_	29	NMOD
31	transgenic	transgenic	JJ	_	32	NMOD
32	protein	protein	NN	_	30	PMOD
33	.	.	.	_	3	P

1	Indeed	indeed	RB	_	14	ADV
2	,	,	,	_	14	P
3	in	in	IN	_	14	ADV
4	past	past	JJ	_	5	NMOD
5	studies	study	NNS	_	3	PMOD
6	where	where	WRB	_	8	ADV
7	hyperactivity	hyperactivity	NN	_	8	SBJ
8	was	be	VBD	_	5	NMOD
9	not	not	RB	_	8	ADV
10	a	a	DT	_	11	NMOD
11	factor	factor	NN	_	8	PRD
12	,	,	,	_	14	P
13	we	we	PRP	_	14	SBJ
14	established	establish	VBD	_	0	ROOT
15	a	a	DT	_	17	NMOD
16	clear	clear	JJ	_	17	NMOD
17	relationship	relationship	NN	_	14	OBJ
18	between	between	IN	_	17	NMOD
19	amyloid	amyloid	NN	_	20	NMOD
20	load	load	NN	_	18	PMOD
21	and	and	CC	_	20	COORD
22	cognitive	cognitive	JJ	_	23	NMOD
23	ability	ability	NN	_	21	CONJ
24	[	[	-LRB-	_	25	P
25	31	0	CD	_	14	PRN
26	]	]	-RRB-	_	25	P
27	.	.	.	_	14	P

1	However	however	RB	_	9	ADV
2	,	,	,	_	9	P
3	in	in	IN	_	9	ADV
4	the	the	DT	_	6	NMOD
5	current	current	JJ	_	6	NMOD
6	study	study	NN	_	3	PMOD
7	,	,	,	_	9	P
8	we	we	PRP	_	9	SBJ
9	feel	feel	VBP	_	0	ROOT
10	that	that	IN	_	9	OBJ
11	although	although	IN	_	38	ADV
12	the	the	DT	_	14	NMOD
13	poor	poor	JJ	_	14	NMOD
14	performance	performance	NN	_	25	SBJ
15	of	of	IN	_	14	NMOD
16	the	the	DT	_	20	NMOD
17	tTA	tta	NN	_	19	NMOD
18	/	/	HYPH	_	17	P
19	APP	app	NN	_	20	NMOD
20	mice	mouse	NNS	_	15	PMOD
21	in	in	IN	_	14	NMOD
22	the	the	DT	_	24	NMOD
23	maze	maze	NN	_	24	NMOD
24	tests	test	NNS	_	21	PMOD
25	could	could	MD	_	11	SUB
26	technically	technically	RB	_	25	MNR
27	be	be	VB	_	25	VC
28	scored	score	VBN	_	27	VC
29	as	as	IN	_	28	ADV
30	cognitive	cognitive	JJ	_	31	NMOD
31	impairment	impairment	NN	_	29	PMOD
32	,	,	,	_	38	P
33	the	the	DT	_	34	NMOD
34	animals	animal	NNS	_	37	NMOD
35	'	'	POS	_	34	NMOD
36	severe	severe	JJ	_	37	NMOD
37	hyperactivity	hyperactivity	NN	_	38	SBJ
38	made	make	VBD	_	10	SUB
39	interpretation	interpretation	NN	_	38	OBJ
40	of	of	IN	_	39	NMOD
41	the	the	DT	_	43	NMOD
42	cognitive	cognitive	JJ	_	43	NMOD
43	tasks	task	NNS	_	40	PMOD
44	impossible	impossible	JJ	_	39	OPRD
45	.	.	.	_	9	P

1	In	in	IN	_	19	PRP
2	order	order	NN	_	1	PMOD
3	to	to	TO	_	2	NMOD
4	understand	understand	VB	_	3	IM
5	the	the	DT	_	6	NMOD
6	nature	nature	NN	_	4	OBJ
7	and	and	CC	_	6	COORD
8	extent	extent	NN	_	7	CONJ
9	of	of	IN	_	6	NMOD
10	hyperactivity	hyperactivity	NN	_	9	PMOD
11	in	in	IN	_	10	LOC
12	the	the	DT	_	16	NMOD
13	tTA	tta	NN	_	15	NMOD
14	/	/	HYPH	_	13	P
15	APP	app	NN	_	16	NMOD
16	mice	mouse	NNS	_	11	PMOD
17	,	,	,	_	19	P
18	we	we	PRP	_	19	SBJ
19	quantified	quantify	VBD	_	0	ROOT
20	daily	daily	JJ	_	22	NMOD
21	activity	activity	NN	_	22	NMOD
22	levels	level	NNS	_	19	OBJ
23	in	in	IN	_	22	LOC
24	double	double	JJ	_	25	AMOD
25	transgenic	transgenic	JJ	_	26	NMOD
26	animals	animal	NNS	_	23	PMOD
27	along	along	IN	_	22	NMOD
28	with	with	IN	_	27	PMOD
29	their	their	PRP$	_	34	NMOD
30	single	single	JJ	_	31	AMOD
31	transgenic	transgenic	JJ	_	34	NMOD
32	and	and	CC	_	31	COORD
33	nontransgenic	nontransgenic	JJ	_	32	CONJ
34	siblings	sibling	NNS	_	28	PMOD
35	using	use	VBG	_	34	NMOD
36	four	four	CD	_	38	NMOD
37	-	-	HYPH	_	36	P
38	beam	beam	NN	_	39	NMOD
39	frames	frame	NNS	_	35	OBJ
40	designed	design	VBN	_	39	NMOD
41	to	to	TO	_	40	PRP
42	monitor	monitor	VB	_	41	IM
43	ambulation	ambulation	NN	_	42	OBJ
44	within	within	IN	_	42	LOC
45	an	an	DT	_	47	NMOD
46	enclosed	enclose	VBN	_	47	NMOD
47	cage	cage	NN	_	44	PMOD
48	.	.	.	_	19	P

1	As	as	IN	_	11	ADV
2	shown	show	VBN	_	1	SUB
3	in	in	IN	_	2	ADV
4	Figure	figure	NN	_	3	PMOD
5	7	0	CD	_	4	NMOD
6	,	,	,	_	11	P
7	the	the	DT	_	10	NMOD
8	double	double	JJ	_	9	NMOD
9	transgenic	transgenic	JJ	_	10	NMOD
10	mice	mouse	NNS	_	11	SBJ
11	were	be	VBD	_	0	ROOT
12	up	up	IN	_	16	AMOD
13	to	to	IN	_	12	QMOD
14	10-fold	0-fold	RB	_	12	QMOD
15	more	more	RBR	_	16	AMOD
16	active	active	JJ	_	11	PRD
17	during	during	IN	_	11	TMP
18	the	the	DT	_	20	NMOD
19	dark	dark	NN	_	20	NMOD
20	phase	phase	NN	_	17	PMOD
21	of	of	IN	_	20	NMOD
22	the	the	DT	_	26	NMOD
23	day	day	NN	_	25	NMOD
24	–	–	HYPH	_	23	P
25	night	night	NN	_	26	NMOD
26	cycle	cycle	NN	_	21	PMOD
27	than	than	IN	_	16	AMOD
28	any	any	DT	_	27	PMOD
29	of	of	IN	_	28	NMOD
30	the	the	DT	_	32	NMOD
31	control	control	NN	_	32	NMOD
32	groups	group	NNS	_	29	PMOD
33	.	.	.	_	11	P

1	Activity	activity	NN	_	2	NMOD
2	levels	level	NNS	_	3	SBJ
3	appeared	appear	VBD	_	0	ROOT
4	to	to	TO	_	3	OPRD
5	follow	follow	VB	_	4	IM
6	a	a	DT	_	10	NMOD
7	relatively	relatively	RB	_	8	AMOD
8	normal	normal	JJ	_	10	NMOD
9	diurnal	diurnal	JJ	_	10	NMOD
10	cycle	cycle	NN	_	5	OBJ
11	,	,	,	_	5	P
12	decreasing	decrease	VBG	_	5	ADV
13	substantially	substantially	RB	_	12	MNR
14	during	during	IN	_	12	TMP
15	the	the	DT	_	17	NMOD
16	daylight	daylight	NN	_	17	NMOD
17	hours	hour	NNS	_	14	PMOD
18	.	.	.	_	3	P

1	However	however	RB	_	14	ADV
2	,	,	,	_	14	P
3	even	even	RB	_	4	PMOD
4	during	during	IN	_	14	TMP
5	the	the	DT	_	7	NMOD
6	light	light	NN	_	7	NMOD
7	phase	phase	NN	_	4	PMOD
8	,	,	,	_	14	P
9	the	the	DT	_	13	NMOD
10	tTA	tta	NN	_	12	NMOD
11	/	/	HYPH	_	10	P
12	APP	app	NN	_	13	NMOD
13	mice	mouse	NNS	_	14	SBJ
14	remained	remain	VBD	_	0	ROOT
15	many-fold	many-fold	RB	_	17	AMOD
16	more	more	RBR	_	15	AMOD
17	active	active	JJ	_	14	PRD
18	than	than	IN	_	17	AMOD
19	normal	normal	JJ	_	20	NMOD
20	controls	control	NNS	_	18	PMOD
21	.	.	.	_	14	P

1	This	this	DT	_	2	NMOD
2	behavior	behavior	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	partially	partially	RB	_	3	MNR
5	,	,	,	_	4	P
6	but	but	CC	_	4	COORD
7	not	not	RB	_	6	ADV
8	consistently	consistently	RB	_	6	CONJ
9	,	,	,	_	3	P
10	reversed	reverse	VBN	_	3	VC
11	by	by	IN	_	10	TMP
12	1	0	CD	_	13	NMOD
13	mo	mo	NN	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	transgene	transgene	NN	_	16	NMOD
16	suppression	suppression	NN	_	14	PMOD
17	beginning	begin	VBG	_	13	NMOD
18	at	at	IN	_	17	TMP
19	4	0	CD	_	22	NMOD
20	–	–	SYM	_	19	P
21	5	0	CD	_	19	QMOD
22	mo	mo	NN	_	18	PMOD
23	of	of	IN	_	22	NMOD
24	age	age	NN	_	23	PMOD
25	(	(	-LRB-	_	28	P
26	data	datum	NNS	_	28	SBJ
27	not	not	RB	_	28	ADV
28	shown	show	VBN	_	10	PRN
29	)	)	-RRB-	_	28	P
30	.	.	.	_	3	P

1	In	in	IN	_	5	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	5	P
4	hyperactivity	hyperactivity	NN	_	5	SBJ
5	was	be	VBD	_	0	ROOT
6	completely	completely	RB	_	5	ADV
7	abolished	abolish	VBN	_	5	VC
8	by	by	IN	_	7	MNR
9	rearing	rear	VBG	_	8	PMOD
10	tTA	tta	NN	_	12	NMOD
11	/	/	HYPH	_	10	P
12	APP	app	NN	_	13	NMOD
13	mice	mouse	NNS	_	9	OBJ
14	on	on	IN	_	9	ADV
15	dox	dox	NN	_	14	PMOD
16	.	.	.	_	5	P

1	Animals	animal	NNS	_	7	SBJ
2	born	bear	VBN	_	1	NMOD
3	and	and	CC	_	2	COORD
4	raised	raise	VBN	_	3	CONJ
5	on	on	IN	_	2	ADV
6	dox	dox	NN	_	5	PMOD
7	showed	show	VBD	_	0	ROOT
8	activity	activity	NN	_	9	NMOD
9	levels	level	NNS	_	7	OBJ
10	similar	similar	JJ	_	9	NMOD
11	to	to	IN	_	10	AMOD
12	the	the	DT	_	14	NMOD
13	untreated	untreated	JJ	_	14	NMOD
14	controls	control	NNS	_	11	PMOD
15	(	(	-LRB-	_	17	P
16	Figure	figure	NN	_	17	NMOD
17	7C	0c	NN	_	7	PRN
18	)	)	-RRB-	_	17	P
19	.	.	.	_	7	P

1	Intriguingly	intriguingly	RB	_	18	ADV
2	,	,	,	_	18	P
3	all	all	DT	_	18	SBJ
4	of	of	IN	_	3	NMOD
5	the	the	DT	_	9	NMOD
6	dox	dox	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	reared	rear	VBN	_	9	NMOD
9	animals	animal	NNS	_	4	PMOD
10	,	,	,	_	3	P
11	both	both	CC	_	3	NMOD
12	transgenic	transgenic	JJ	_	11	DEP
13	and	and	CC	_	12	COORD
14	wild	wild	JJ	_	16	NMOD
15	-	-	HYPH	_	14	P
16	type	type	NN	_	13	CONJ
17	,	,	,	_	18	P
18	showed	show	VBD	_	0	ROOT
19	altered	alter	VBN	_	21	NMOD
20	circadian	circadian	JJ	_	21	NMOD
21	rhythms	rhythm	NNS	_	18	OBJ
22	with	with	IN	_	21	NMOD
23	far	far	RB	_	24	AMOD
24	less	less	JJR	_	25	NMOD
25	distinction	distinction	NN	_	22	PMOD
26	between	between	IN	_	25	NMOD
27	their	their	PRP$	_	33	NMOD
28	day	day	NN	_	33	NMOD
29	-	-	HYPH	_	28	P
30	and	and	CC	_	28	COORD
31	nighttime	nighttime	NN	_	30	CONJ
32	activity	activity	NN	_	33	NMOD
33	levels	level	NNS	_	26	PMOD
34	.	.	.	_	18	P

1	Discussion	discussion	NN	_	0	ROOT

1	We	we	PRP	_	2	SBJ
2	present	present	VBP	_	0	ROOT
3	a	a	DT	_	6	NMOD
4	new	new	JJ	_	6	NMOD
5	mouse	mouse	NN	_	6	NMOD
6	model	model	NN	_	2	OBJ
7	for	for	IN	_	6	NMOD
8	AD	ad	NN	_	7	PMOD
9	that	that	WDT	_	10	SBJ
10	was	be	VBD	_	6	NMOD
11	designed	design	VBN	_	10	VC
12	to	to	TO	_	11	PRP
13	test	test	VB	_	12	IM
14	the	the	DT	_	15	NMOD
15	consequences	consequence	NNS	_	13	OBJ
16	of	of	IN	_	15	NMOD
17	inhibiting	inhibit	VBG	_	16	PMOD
18	Aβ	aβ	NN	_	19	NMOD
19	production	production	NN	_	17	OBJ
20	after	after	IN	_	17	TMP
21	the	the	DT	_	22	NMOD
22	onset	onset	NN	_	20	PMOD
23	of	of	IN	_	22	NMOD
24	amyloid	amyloid	NN	_	25	NMOD
25	pathology	pathology	NN	_	23	PMOD
26	.	.	.	_	2	P

1	New	new	JJ	_	2	NMOD
2	lines	line	NNS	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	transgenic	transgenic	JJ	_	5	NMOD
5	mice	mouse	NNS	_	3	PMOD
6	were	be	VBD	_	0	ROOT
7	developed	develop	VBN	_	6	VC
8	for	for	IN	_	7	ADV
9	this	this	DT	_	10	NMOD
10	study	study	NN	_	8	PMOD
11	that	that	WDT	_	12	SBJ
12	express	express	VBP	_	2	NMOD
13	high	high	JJ	_	14	NMOD
14	levels	level	NNS	_	12	OBJ
15	of	of	IN	_	14	NMOD
16	APPswe	appswe	NN	_	18	NMOD
17	/	/	HYPH	_	16	P
18	ind	ind	NN	_	15	PMOD
19	under	under	IN	_	12	ADV
20	the	the	DT	_	21	NMOD
21	control	control	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	a	a	DT	_	27	NMOD
24	tetracycline	tetracycline	NN	_	26	AMOD
25	-	-	HYPH	_	24	P
26	responsive	responsive	JJ	_	27	NMOD
27	promoter	promoter	NN	_	22	PMOD
28	.	.	.	_	6	P

1	We	we	PRP	_	2	SBJ
2	demonstrate	demonstrate	VBP	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	treatment	treatment	NN	_	7	SBJ
5	with	with	IN	_	4	NMOD
6	dox	dox	NN	_	5	PMOD
7	suppresses	suppress	VBZ	_	3	SUB
8	steady	steady	JJ	_	10	NMOD
9	-	-	HYPH	_	8	P
10	state	state	NN	_	11	NMOD
11	levels	level	NNS	_	7	OBJ
12	of	of	IN	_	11	NMOD
13	both	both	CC	_	16	COORD
14	APPswe	appswe	NN	_	16	NMOD
15	/	/	HYPH	_	14	P
16	ind	ind	NN	_	12	PMOD
17	and	and	CC	_	16	COORD
18	its	its	PRP$	_	22	NMOD
19	C	c	NN	_	22	NMOD
20	-	-	HYPH	_	19	P
21	terminal	terminal	JJ	_	22	NMOD
22	fragments	fragment	NNS	_	17	CONJ
23	,	,	,	_	7	P
24	indicating	indicate	VBG	_	7	ADV
25	that	that	IN	_	24	OBJ
26	the	the	DT	_	28	NMOD
27	mutant	mutant	NN	_	28	NMOD
28	proteins	protein	NNS	_	29	SBJ
29	have	have	VBP	_	25	SUB
30	a	a	DT	_	35	NMOD
31	relatively	relatively	RB	_	32	AMOD
32	short	short	JJ	_	35	NMOD
33	half	half	NN	_	35	NMOD
34	-	-	HYPH	_	33	P
35	life	life	NN	_	29	OBJ
36	in	in	FW	_	37	AMOD
37	vivo	vivo	FW	_	29	ADV
38	.	.	.	_	2	P

1	Transgenic	transgenic	JJ	_	2	NMOD
2	expression	expression	NN	_	12	SBJ
3	of	of	IN	_	2	NMOD
4	APPswe	appswe	NN	_	6	NMOD
5	/	/	HYPH	_	4	P
6	ind	ind	NN	_	3	PMOD
7	and	and	CC	_	2	COORD
8	consequent	consequent	JJ	_	9	NMOD
9	overproduction	overproduction	NN	_	7	CONJ
10	of	of	IN	_	9	NMOD
11	Aβ42	aβ0	NN	_	10	PMOD
12	cause	cause	VBP	_	0	ROOT
13	early	early	JJ	_	15	NMOD
14	-	-	HYPH	_	13	P
15	onset	onset	NN	_	17	NMOD
16	amyloid	amyloid	NN	_	17	NMOD
17	deposition	deposition	NN	_	12	OBJ
18	in	in	IN	_	12	LOC
19	untreated	untreated	JJ	_	20	NMOD
20	mice	mouse	NNS	_	18	PMOD
21	,	,	,	_	20	P
22	in	in	IN	_	25	LOC
23	which	which	WDT	_	22	PMOD
24	deposits	deposit	NNS	_	25	SBJ
25	appear	appear	VBP	_	20	NMOD
26	as	as	RB	_	27	AMOD
27	early	early	RB	_	25	TMP
28	as	as	IN	_	27	AMOD
29	2	0	CD	_	30	NMOD
30	mo	mo	NN	_	28	PMOD
31	of	of	IN	_	30	NMOD
32	age	age	NN	_	31	PMOD
33	.	.	.	_	12	P

1	Amyloid	amyloid	NN	_	2	NMOD
2	burden	burden	NN	_	3	SBJ
3	worsens	worsen	VBZ	_	0	ROOT
4	significantly	significantly	RB	_	3	ADV
5	with	with	IN	_	3	ADV
6	age	age	NN	_	5	PMOD
7	,	,	,	_	3	P
8	and	and	CC	_	3	COORD
9	by	by	IN	_	20	ADV
10	9	0	CD	_	11	NMOD
11	mo	mo	NN	_	9	PMOD
12	,	,	,	_	20	P
13	the	the	DT	_	14	NMOD
14	hippocampus	hippocampus	NN	_	20	SBJ
15	and	and	CC	_	14	COORD
16	cortex	cortex	NN	_	15	CONJ
17	of	of	IN	_	14	NMOD
18	untreated	untreated	JJ	_	19	NMOD
19	mice	mouse	NNS	_	17	PMOD
20	are	be	VBP	_	8	CONJ
21	largely	largely	RB	_	20	ADV
22	filled	fill	VBN	_	20	VC
23	with	with	IN	_	22	MNR
24	aggregated	aggregate	VBN	_	25	NMOD
25	peptide	peptide	NN	_	23	PMOD
26	.	.	.	_	3	P

1	We	we	PRP	_	2	SBJ
2	find	find	VBP	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	suppression	suppression	NN	_	14	SBJ
5	of	of	IN	_	4	NMOD
6	transgenic	transgenic	JJ	_	7	NMOD
7	APP	app	NN	_	5	PMOD
8	by	by	IN	_	4	NMOD
9	more	more	JJR	_	12	NMOD
10	than	than	IN	_	9	QMOD
11	95	0	CD	_	9	QMOD
12	%	%	NN	_	8	PMOD
13	abruptly	abruptly	RB	_	14	ADV
14	halts	halt	VBZ	_	3	SUB
15	the	the	DT	_	16	NMOD
16	progression	progression	NN	_	14	OBJ
17	of	of	IN	_	16	NMOD
18	amyloid	amyloid	NN	_	19	NMOD
19	pathology	pathology	NN	_	17	PMOD
20	.	.	.	_	2	P

1	Importantly	importantly	RB	_	5	ADV
2	,	,	,	_	5	P
3	this	this	DT	_	4	NMOD
4	outcome	outcome	NN	_	5	SBJ
5	occurs	occur	VBZ	_	0	ROOT
6	in	in	IN	_	5	LOC
7	animals	animal	NNS	_	6	PMOD
8	already	already	RB	_	9	ADV
9	harboring	harbor	VBG	_	7	NMOD
10	considerable	considerable	JJ	_	12	NMOD
11	amyloid	amyloid	NN	_	12	NMOD
12	pathology	pathology	NN	_	9	OBJ
13	,	,	,	_	5	P
14	a	a	DT	_	15	NMOD
15	situation	situation	NN	_	5	ADV
16	similar	similar	JJ	_	15	NMOD
17	to	to	IN	_	16	AMOD
18	what	what	WP	_	19	SBJ
19	might	might	MD	_	17	PMOD
20	be	be	VB	_	19	VC
21	expected	expect	VBN	_	20	VC
22	in	in	IN	_	21	LOC
23	patients	patient	NNS	_	22	PMOD
24	to	to	TO	_	23	NMOD
25	be	be	VB	_	24	IM
26	treated	treat	VBN	_	25	VC
27	with	with	IN	_	26	ADV
28	secretase	secretase	NN	_	29	NMOD
29	inhibitors	inhibitor	NNS	_	27	PMOD
30	.	.	.	_	5	P

1	Somewhat	somewhat	RB	_	2	AMOD
2	unexpectedly	unexpectedly	RB	_	5	ADV
3	,	,	,	_	5	P
4	we	we	PRP	_	5	SBJ
5	observe	observe	VBP	_	0	ROOT
6	no	no	DT	_	8	NMOD
7	appreciable	appreciable	JJ	_	8	NMOD
8	clearance	clearance	NN	_	5	OBJ
9	of	of	IN	_	8	NMOD
10	deposited	deposit	VBN	_	11	NMOD
11	amyloid	amyloid	NN	_	9	PMOD
12	even	even	RB	_	13	PMOD
13	following	follow	VBG	_	5	TMP
14	periods	period	NNS	_	13	PMOD
15	of	of	IN	_	14	NMOD
16	transgene	transgene	NN	_	17	NMOD
17	suppression	suppression	NN	_	15	PMOD
18	equal	equal	JJ	_	14	NMOD
19	to	to	IN	_	18	AMOD
20	the	the	DT	_	21	NMOD
21	time	time	NN	_	19	PMOD
22	taken	take	VBN	_	21	NMOD
23	for	for	IN	_	22	TMP
24	plaques	plaque	NNS	_	25	SBJ
25	to	to	TO	_	23	SUB
26	form	form	VB	_	25	IM
27	.	.	.	_	5	P

1	This	this	DT	_	3	NMOD
2	latter	latter	JJ	_	3	NMOD
3	finding	finding	NN	_	4	SBJ
4	indicates	indicate	VBZ	_	0	ROOT
5	that	that	IN	_	4	OBJ
6	compared	compare	VBN	_	35	ADV
7	to	to	IN	_	6	PMOD
8	other	other	JJ	_	13	NMOD
9	disease	disease	NN	_	11	AMOD
10	-	-	HYPH	_	9	P
11	associated	associate	VBN	_	13	NMOD
12	protein	protein	NN	_	13	NMOD
13	aggregates	aggregate	NNS	_	7	PMOD
14	such	such	JJ	_	15	PMOD
15	as	as	IN	_	13	NMOD
16	mutant	mutant	NN	_	17	NMOD
17	huntingtin	huntingtin	NN	_	15	PMOD
18	,	,	,	_	17	P
19	which	which	WDT	_	20	SBJ
20	clear	clear	VBP	_	17	NMOD
21	in	in	IN	_	20	TMP
22	less	less	JJR	_	25	NMOD
23	than	than	IN	_	22	QMOD
24	3	0	CD	_	22	QMOD
25	mo	mo	NN	_	21	PMOD
26	[	[	-LRB-	_	27	P
27	32	0	CD	_	20	PRN
28	]	]	-RRB-	_	27	P
29	,	,	,	_	35	P
30	the	the	DT	_	31	NMOD
31	disaggregation	disaggregation	NN	_	35	SBJ
32	of	of	IN	_	31	NMOD
33	extracellular	extracellular	JJ	_	34	NMOD
34	amyloid	amyloid	NN	_	32	PMOD
35	is	be	VBZ	_	5	SUB
36	relatively	relatively	RB	_	37	AMOD
37	slow	slow	JJ	_	35	PRD
38	.	.	.	_	4	P

1	Notably	notably	RB	_	11	ADV
2	,	,	,	_	11	P
3	pharmaceutical	pharmaceutical	JJ	_	7	NMOD
4	γ	γ	SYM	_	6	P
5	-	-	HYPH	_	6	P
6	secretase	secretase	NN	_	7	NMOD
7	inhibitors	inhibitor	NNS	_	11	SBJ
8	published	publish	VBN	_	7	NMOD
9	to	to	IN	_	8	TMP
10	date	date	NN	_	9	PMOD
11	show	show	VBP	_	0	ROOT
12	less	less	RBR	_	13	AMOD
13	strict	strict	JJ	_	14	NMOD
14	regulation	regulation	NN	_	11	OBJ
15	of	of	IN	_	14	NMOD
16	Aβ	aβ	NN	_	17	NMOD
17	production	production	NN	_	15	PMOD
18	following	follow	VBG	_	14	TMP
19	chronic	chronic	JJ	_	20	NMOD
20	administration	administration	NN	_	18	PMOD
21	than	than	IN	_	14	NMOD
22	we	we	PRP	_	23	SBJ
23	have	have	VBP	_	21	SUB
24	attained	attain	VBN	_	23	VC
25	here	here	RB	_	24	ADV
26	.	.	.	_	11	P

1	Two	two	CD	_	3	NMOD
2	independent	independent	JJ	_	3	NMOD
3	compounds	compound	NNS	_	17	SBJ
4	tested	test	VBN	_	3	NMOD
5	in	in	IN	_	4	LOC
6	Tg2576	tg0	NN	_	15	AMOD
7	[	[	-LRB-	_	8	P
8	33	0	CD	_	6	PRN
9	]	]	-RRB-	_	8	P
10	and	and	CC	_	6	COORD
11	TgCRND8	tgcrnd0	NN	_	10	CONJ
12	[	[	-LRB-	_	13	P
13	34	0	CD	_	11	PRN
14	]	]	-RRB-	_	13	P
15	transgenic	transgenic	JJ	_	16	NMOD
16	mice	mouse	NNS	_	5	PMOD
17	show	show	VBP	_	0	ROOT
18	no	no	RB	_	19	QMOD
19	more	more	JJR	_	22	NMOD
20	than	than	IN	_	19	QMOD
21	85	0	CD	_	19	QMOD
22	%	%	NN	_	23	NMOD
23	suppression	suppression	NN	_	17	OBJ
24	of	of	IN	_	23	NMOD
25	Aβ40	aβ0	NN	_	26	NMOD
26	levels	level	NNS	_	24	PMOD
27	,	,	,	_	23	P
28	and	and	CC	_	23	COORD
29	where	where	WRB	_	30	DEP
30	measured	measure	VBN	_	34	LOC
31	,	,	,	_	34	P
32	even	even	RB	_	33	AMOD
33	less	less	JJR	_	34	NMOD
34	suppression	suppression	NN	_	28	CONJ
35	of	of	IN	_	34	NMOD
36	Aβ42	aβ0	NN	_	35	PMOD
37	(	(	-LRB-	_	40	P
38	approximately	approximately	RB	_	39	QMOD
39	60	0	CD	_	40	NMOD
40	%	%	NN	_	36	PRN
41	)	)	-RRB-	_	40	P
42	[	[	-LRB-	_	45	P
43	35	0	CD	_	45	NMOD
44	,	,	,	_	45	P
45	36	0	CD	_	17	PRN
46	]	]	-RRB-	_	45	P
47	.	.	.	_	17	P

1	Thus	thus	RB	_	25	ADV
2	,	,	,	_	25	P
3	even	even	RB	_	4	PMOD
4	after	after	IN	_	25	TMP
5	accounting	account	VBG	_	4	PMOD
6	for	for	IN	_	5	ADV
7	the	the	DT	_	12	NMOD
8	much	much	RB	_	9	AMOD
9	higher	high	JJR	_	12	NMOD
10	APP	app	NN	_	12	NMOD
11	expression	expression	NN	_	12	NMOD
12	levels	level	NNS	_	6	PMOD
13	in	in	IN	_	12	LOC
14	our	our	PRP$	_	15	NMOD
15	mice	mouse	NNS	_	13	PMOD
16	than	than	IN	_	12	NMOD
17	in	in	IN	_	16	LOC
18	the	the	DT	_	22	NMOD
19	Tg2576	tg0	NN	_	22	NMOD
20	and	and	CC	_	19	COORD
21	TgCRND8	tgcrnd0	NN	_	20	CONJ
22	lines	line	NNS	_	17	PMOD
23	,	,	,	_	25	P
24	we	we	PRP	_	25	SBJ
25	have	have	VBP	_	0	ROOT
26	achieved	achieve	VBN	_	25	VC
27	better	well	RBR	_	29	NMOD
28	absolute	absolute	JJ	_	29	NMOD
29	suppression	suppression	NN	_	26	OBJ
30	of	of	IN	_	29	NMOD
31	Aβ	aβ	NN	_	32	NMOD
32	production	production	NN	_	30	PMOD
33	with	with	IN	_	29	NMOD
34	the	the	DT	_	38	NMOD
35	tet	tet	NN	_	37	NMOD
36	-	-	HYPH	_	35	P
37	off	off	NN	_	38	NMOD
38	system	system	NN	_	33	PMOD
39	than	than	IN	_	29	NMOD
40	is	be	VBZ	_	39	SUB
41	currently	currently	RB	_	40	TMP
42	possible	possible	JJ	_	40	PRD
43	with	with	IN	_	40	ADV
44	published	publish	VBN	_	48	NMOD
45	γ	γ	SYM	_	47	P
46	-	-	HYPH	_	47	P
47	secretase	secretase	NN	_	48	NMOD
48	inhibitors	inhibitor	NNS	_	43	PMOD
49	.	.	.	_	25	P

1	Since	since	IN	_	25	PRP
2	even	even	RB	_	8	NMOD
3	the	the	DT	_	8	NMOD
4	most	most	RBS	_	5	AMOD
5	advanced	advanced	JJ	_	8	NMOD
6	future	future	JJ	_	8	NMOD
7	pharmaceutical	pharmaceutical	JJ	_	8	NMOD
8	agents	agent	NNS	_	9	SBJ
9	are	be	VBP	_	1	SUB
10	unlikely	unlikely	JJ	_	9	PRD
11	to	to	TO	_	10	AMOD
12	attain	attain	VB	_	11	IM
13	more	more	RBR	_	14	AMOD
14	complete	complete	JJ	_	15	NMOD
15	control	control	NN	_	12	OBJ
16	of	of	IN	_	15	NMOD
17	Aβ	aβ	NN	_	18	NMOD
18	production	production	NN	_	16	PMOD
19	than	than	IN	_	15	NMOD
20	achieved	achieve	VBN	_	19	SUB
21	here	here	RB	_	20	ADV
22	,	,	,	_	25	P
23	this	this	DT	_	24	NMOD
24	system	system	NN	_	25	SBJ
25	provides	provide	VBZ	_	0	ROOT
26	a	a	DT	_	28	NMOD
27	salient	salient	JJ	_	28	NMOD
28	test	test	NN	_	25	OBJ
29	of	of	IN	_	28	NMOD
30	therapeutic	therapeutic	JJ	_	31	NMOD
31	intervention	intervention	NN	_	29	PMOD
32	with	with	IN	_	31	NMOD
33	Aβ	aβ	NN	_	35	AMOD
34	-	-	HYPH	_	33	P
35	lowering	lower	VBG	_	36	NMOD
36	compounds	compound	NNS	_	32	PMOD
37	.	.	.	_	25	P

1	Although	although	IN	_	15	ADV
2	the	the	DT	_	3	NMOD
3	progression	progression	NN	_	7	SBJ
4	of	of	IN	_	3	NMOD
5	amyloid	amyloid	NN	_	6	NMOD
6	deposition	deposition	NN	_	4	PMOD
7	was	be	VBD	_	1	SUB
8	sharply	sharply	RB	_	7	ADV
9	arrested	arrest	VBN	_	7	VC
10	by	by	IN	_	9	LGS
11	this	this	DT	_	12	NMOD
12	approach	approach	NN	_	10	PMOD
13	,	,	,	_	15	P
14	we	we	PRP	_	15	SBJ
15	found	find	VBD	_	0	ROOT
16	that	that	IN	_	15	OBJ
17	a	a	DT	_	20	NMOD
18	substantial	substantial	JJ	_	20	NMOD
19	amyloid	amyloid	NN	_	20	NMOD
20	burden	burden	NN	_	21	SBJ
21	remained	remain	VBD	_	16	SUB
22	even	even	RB	_	23	PMOD
23	after	after	IN	_	21	TMP
24	long	long	JJ	_	25	NMOD
25	periods	period	NNS	_	23	PMOD
26	of	of	IN	_	25	NMOD
27	transgene	transgene	NN	_	28	NMOD
28	suppression	suppression	NN	_	26	PMOD
29	.	.	.	_	15	P

1	We	we	PRP	_	2	SBJ
2	examined	examine	VBD	_	0	ROOT
3	a	a	DT	_	5	NMOD
4	small	small	JJ	_	5	NMOD
5	number	number	NN	_	2	OBJ
6	of	of	IN	_	5	NMOD
7	animals	animal	NNS	_	6	PMOD
8	after	after	IN	_	2	TMP
9	12	0	CD	_	10	NMOD
10	mo	mo	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	dox	dox	NN	_	13	NMOD
13	treatment	treatment	NN	_	11	PMOD
14	(	(	-LRB-	_	13	P
15	beginning	begin	VBG	_	13	NMOD
16	at	at	IN	_	15	TMP
17	6	0	CD	_	18	NMOD
18	mo	mo	NN	_	16	PMOD
19	of	of	IN	_	18	NMOD
20	age	age	NN	_	19	PMOD
21	)	)	-RRB-	_	13	P
22	,	,	,	_	2	P
23	and	and	CC	_	2	COORD
24	found	find	VBD	_	23	CONJ
25	that	that	IN	_	24	OBJ
26	amyloid	amyloid	NN	_	27	NMOD
27	deposits	deposit	NNS	_	28	SBJ
28	were	be	VBD	_	25	SUB
29	still	still	RB	_	28	TMP
30	relatively	relatively	RB	_	31	AMOD
31	abundant	abundant	JJ	_	28	PRD
32	.	.	.	_	2	P

1	Longer	long	JJ	_	3	NMOD
2	-	-	HYPH	_	1	P
3	term	term	NN	_	4	NMOD
4	treatments	treatment	NNS	_	5	SBJ
5	are	be	VBP	_	0	ROOT
6	now	now	RB	_	5	TMP
7	in	in	IN	_	5	PRD
8	progress	progress	NN	_	7	PMOD
9	.	.	.	_	5	P

1	At	at	IN	_	16	ADV
2	the	the	DT	_	5	NMOD
3	latest	late	JJS	_	5	NMOD
4	treatment	treatment	NN	_	5	NMOD
5	interval	interval	NN	_	1	PMOD
6	analyzed	analyze	VBN	_	5	NMOD
7	by	by	IN	_	6	LGS
8	ELISA	elisa	NN	_	7	PMOD
9	,	,	,	_	16	P
10	animals	animal	NNS	_	16	SBJ
11	administered	administer	VBN	_	10	NMOD
12	dox	dox	NN	_	11	OBJ
13	for	for	IN	_	11	TMP
14	6	0	CD	_	15	NMOD
15	mo	mo	NN	_	13	PMOD
16	showed	show	VBD	_	0	ROOT
17	elevated	elevate	VBN	_	18	NMOD
18	levels	level	NNS	_	16	OBJ
19	of	of	IN	_	18	NMOD
20	PBS	pb	NN	_	22	AMOD
21	-	-	HYPH	_	20	P
22	soluble	soluble	JJ	_	23	NMOD
23	Aβ	aβ	NN	_	19	PMOD
24	(	(	-LRB-	_	25	P
25	see	see	VB	_	23	PRN
26	Figure	figure	NN	_	25	OBJ
27	5	0	CD	_	26	NMOD
28	)	)	-RRB-	_	25	P
29	that	that	WDT	_	30	SBJ
30	could	could	MD	_	18	NMOD
31	be	be	VB	_	30	VC
32	interpreted	interpret	VBN	_	31	VC
33	as	as	IN	_	32	ADV
34	an	an	DT	_	35	NMOD
35	indication	indication	NN	_	33	PMOD
36	that	that	IN	_	35	NMOD
37	the	the	DT	_	38	NMOD
38	plaques	plaque	NNS	_	39	SBJ
39	are	be	VBP	_	36	SUB
40	slowly	slowly	RB	_	39	TMP
41	releasing	release	VBG	_	39	VC
42	peptide	peptide	NN	_	41	OBJ
43	(	(	-LRB-	_	42	P
44	or	or	CC	_	42	COORD
45	oligomeric	oligomeric	JJ	_	46	NMOD
46	Aβ	aβ	NN	_	44	CONJ
47	)	)	-RRB-	_	42	P
48	into	into	IN	_	41	LOC
49	the	the	DT	_	51	NMOD
50	soluble	soluble	JJ	_	51	NMOD
51	pool	pool	NN	_	48	PMOD
52	and	and	CC	_	39	COORD
53	might	might	MD	_	52	CONJ
54	eventually	eventually	RB	_	53	TMP
55	dissolve	dissolve	VB	_	53	VC
56	.	.	.	_	16	P

1	Whether	whether	IN	_	20	SBJ
2	inhibiting	inhibit	VBG	_	13	SBJ
3	Aβ	aβ	NN	_	4	NMOD
4	production	production	NN	_	2	OBJ
5	longer	longer	RBR	_	2	TMP
6	than	than	IN	_	5	AMOD
7	6	0	CD	_	12	NMOD
8	(	(	-LRB-	_	7	P
9	or	or	CC	_	7	COORD
10	12	0	CD	_	9	CONJ
11	)	)	-RRB-	_	12	P
12	mo	mo	NN	_	6	PMOD
13	may	may	MD	_	1	SUB
14	ultimately	ultimately	RB	_	13	ADV
15	result	result	VB	_	13	VC
16	in	in	IN	_	15	ADV
17	clearance	clearance	NN	_	16	PMOD
18	of	of	IN	_	17	NMOD
19	amyloid	amyloid	NN	_	18	PMOD
20	is	be	VBZ	_	33	DEP
21	under	under	IN	_	20	PRD
22	investigation	investigation	NN	_	21	PMOD
23	;	;	:	_	33	P
24	unfortunately	unfortunately	RB	_	33	ADV
25	,	,	,	_	33	P
26	the	the	DT	_	28	NMOD
27	life	life	NN	_	28	NMOD
28	span	span	NN	_	33	SBJ
29	of	of	IN	_	28	NMOD
30	the	the	DT	_	31	NMOD
31	model	model	NN	_	29	PMOD
32	eventually	eventually	RB	_	33	TMP
33	limits	limit	VBZ	_	0	ROOT
34	this	this	DT	_	35	NMOD
35	experiment	experiment	NN	_	33	OBJ
36	.	.	.	_	33	P

1	Therapeutics	therapeutic	NNS	_	5	SBJ
2	used	use	VBN	_	1	NMOD
3	in	in	IN	_	2	LOC
4	humans	human	NNS	_	3	PMOD
5	will	will	MD	_	0	ROOT
6	have	have	VB	_	5	VC
7	considerably	considerably	RB	_	8	AMOD
8	more	more	JJR	_	9	NMOD
9	time	time	NN	_	6	OBJ
10	to	to	TO	_	9	NMOD
11	act	act	VB	_	10	IM
12	than	than	IN	_	9	NMOD
13	is	be	VBZ	_	12	SUB
14	possible	possible	JJ	_	13	PRD
15	within	within	IN	_	13	ADV
16	the	the	DT	_	18	NMOD
17	life	life	NN	_	18	NMOD
18	span	span	NN	_	15	PMOD
19	of	of	IN	_	18	NMOD
20	rodent	rodent	NN	_	21	NMOD
21	models	model	NNS	_	19	PMOD
22	.	.	.	_	5	P

1	Long	long	JJ	_	3	NMOD
2	-	-	HYPH	_	1	P
3	term	term	NN	_	4	NMOD
4	treatments	treatment	NNS	_	5	SBJ
5	would	would	MD	_	0	ROOT
6	certainly	certainly	RB	_	5	ADV
7	be	be	VB	_	5	VC
8	possible	possible	JJ	_	7	PRD
9	and	and	CC	_	5	COORD
10	could	could	MD	_	9	CONJ
11	be	be	VB	_	10	VC
12	a	a	DT	_	13	NMOD
13	key	key	NN	_	11	PRD
14	to	to	IN	_	13	NMOD
15	effective	effective	JJ	_	16	NMOD
16	therapy	therapy	NN	_	14	PMOD
17	.	.	.	_	5	P

1	Overall	overall	RB	_	6	ADV
2	,	,	,	_	6	P
3	however	however	RB	_	6	ADV
4	,	,	,	_	6	P
5	we	we	PRP	_	6	SBJ
6	interpret	interpret	VBP	_	0	ROOT
7	our	our	PRP$	_	8	NMOD
8	findings	finding	NNS	_	6	OBJ
9	as	as	IN	_	6	ADV
10	evidence	evidence	NN	_	9	PMOD
11	that	that	IN	_	10	NMOD
12	AD	ad	NN	_	13	NMOD
13	therapies	therapy	NNS	_	32	SBJ
14	that	that	WDT	_	16	SBJ
15	significantly	significantly	RB	_	16	ADV
16	lower	lower	VBP	_	13	NMOD
17	the	the	DT	_	18	NMOD
18	production	production	NN	_	16	OBJ
19	of	of	IN	_	18	NMOD
20	Aβ	aβ	NN	_	19	PMOD
21	(	(	-LRB-	_	16	P
22	by	by	IN	_	16	MNR
23	either	either	CC	_	24	COORD
24	inhibiting	inhibit	VBG	_	22	PMOD
25	secretase	secretase	NN	_	26	NMOD
26	activity	activity	NN	_	24	OBJ
27	or	or	CC	_	24	COORD
28	inhibiting	inhibit	VBG	_	27	CONJ
29	APP	app	NN	_	30	NMOD
30	expression	expression	NN	_	28	OBJ
31	)	)	-RRB-	_	16	P
32	may	may	MD	_	11	SUB
33	not	not	RB	_	32	ADV
34	quickly	quickly	RB	_	32	TMP
35	reverse	reverse	VB	_	32	VC
36	preexisting	preexisting	JJ	_	37	NMOD
37	pathology	pathology	NN	_	35	OBJ
38	,	,	,	_	32	P
39	but	but	CC	_	32	COORD
40	should	should	MD	_	39	CONJ
41	effectively	effectively	RB	_	40	ADV
42	halt	halt	VB	_	40	VC
43	further	further	JJ	_	44	NMOD
44	deposition	deposition	NN	_	42	OBJ
45	of	of	IN	_	44	NMOD
46	amyloid	amyloid	NN	_	45	PMOD
47	.	.	.	_	6	P

1	In	in	IN	_	7	ADV
2	interpreting	interpret	VBG	_	1	PMOD
3	our	our	PRP$	_	4	NMOD
4	study	study	NN	_	2	OBJ
5	,	,	,	_	7	P
6	it	it	PRP	_	7	SBJ
7	should	should	MD	_	0	ROOT
8	be	be	VB	_	7	VC
9	remembered	remember	VBN	_	8	VC
10	that	that	IN	_	9	OBJ
11	the	the	DT	_	13	NMOD
12	earliest	early	JJS	_	13	NMOD
13	plaques	plaque	NNS	_	32	SBJ
14	to	to	TO	_	13	NMOD
15	appear	appear	VB	_	14	IM
16	in	in	IN	_	15	LOC
17	these	these	DT	_	18	NMOD
18	mice	mouse	NNS	_	16	PMOD
19	,	,	,	_	13	P
20	like	like	IN	_	13	NMOD
21	other	other	JJ	_	23	NMOD
22	APP	app	NN	_	23	NMOD
23	transgenics	transgenics	NNS	_	20	PMOD
24	harboring	harbor	VBG	_	23	NMOD
25	the	the	DT	_	27	NMOD
26	Swedish	swedish	JJ	_	27	NMOD
27	mutation	mutation	NN	_	24	OBJ
28	[	[	-LRB-	_	29	P
29	27	0	CD	_	24	PRN
30	]	]	-RRB-	_	29	P
31	,	,	,	_	32	P
32	are	be	VBP	_	10	SUB
33	predominantly	predominantly	RB	_	32	ADV
34	fibrillar	fibrillar	JJ	_	35	NMOD
35	deposits	deposit	NNS	_	32	PRD
36	,	,	,	_	35	P
37	which	which	WDT	_	38	SBJ
38	may	may	MD	_	35	NMOD
39	be	be	VB	_	38	VC
40	less	less	RBR	_	41	AMOD
41	tractable	tractable	JJ	_	39	PRD
42	than	than	IN	_	41	AMOD
43	the	the	DT	_	45	NMOD
44	diffuse	diffuse	JJ	_	45	NMOD
45	aggregates	aggregate	NNS	_	42	PMOD
46	thought	think	VBN	_	45	NMOD
47	to	to	TO	_	46	OPRD
48	come	come	VB	_	47	IM
49	first	$#ORD#$	RB	_	48	TMP
50	in	in	IN	_	48	ADV
51	the	the	DT	_	52	NMOD
52	course	course	NN	_	50	PMOD
53	of	of	IN	_	52	NMOD
54	the	the	DT	_	56	NMOD
55	human	human	JJ	_	56	NMOD
56	disease	disease	NN	_	53	PMOD
57	.	.	.	_	7	P

1	However	however	RB	_	5	ADV
2	,	,	,	_	5	P
3	our	our	PRP$	_	4	NMOD
4	data	datum	NNS	_	5	SBJ
5	suggest	suggest	VBP	_	0	ROOT
6	that	that	IN	_	5	OBJ
7	once	once	IN	_	17	TMP
8	diffuse	diffuse	JJ	_	9	NMOD
9	deposits	deposit	NNS	_	10	SBJ
10	are	be	VBP	_	7	SUB
11	formed	form	VBN	_	10	VC
12	in	in	IN	_	11	LOC
13	these	these	DT	_	14	NMOD
14	mice	mouse	NNS	_	12	PMOD
15	,	,	,	_	17	P
16	they	they	PRP	_	17	SBJ
17	are	be	VBP	_	6	SUB
18	no	no	RB	_	20	AMOD
19	more	more	RBR	_	18	AMOD
20	easily	easily	RB	_	17	MNR
21	cleared	clear	VBN	_	17	VC
22	in	in	IN	_	21	LOC
23	our	our	PRP$	_	24	NMOD
24	system	system	NN	_	22	PMOD
25	than	than	IN	_	20	AMOD
26	cored	core	VBN	_	27	NMOD
27	plaques	plaque	NNS	_	25	PMOD
28	(	(	-LRB-	_	29	P
29	see	see	VB	_	21	PRN
30	Figure	figure	NN	_	31	NMOD
31	S4	s0	NN	_	29	OBJ
32	)	)	-RRB-	_	29	P
33	.	.	.	_	5	P

1	An	an	DT	_	3	NMOD
2	additional	additional	JJ	_	3	NMOD
3	consideration	consideration	NN	_	6	SBJ
4	we	we	PRP	_	5	SBJ
5	recognize	recognize	VBP	_	3	NMOD
6	is	be	VBZ	_	0	ROOT
7	that	that	IN	_	6	PRD
8	a	a	DT	_	10	NMOD
9	small	small	JJ	_	10	NMOD
10	amount	amount	NN	_	14	SBJ
11	of	of	IN	_	10	NMOD
12	transgene	transgene	NN	_	13	NMOD
13	expression	expression	NN	_	11	PMOD
14	continues	continue	VBZ	_	7	SUB
15	in	in	IN	_	14	ADV
16	the	the	DT	_	17	NMOD
17	presence	presence	NN	_	15	PMOD
18	of	of	IN	_	17	NMOD
19	dox	dox	NN	_	18	PMOD
20	and	and	CC	_	7	COORD
21	that	that	IN	_	20	CONJ
22	endogenous	endogenous	JJ	_	24	NMOD
23	mouse	mouse	NN	_	24	NMOD
24	Aβ	aβ	NN	_	25	SBJ
25	continues	continue	VBZ	_	21	SUB
26	to	to	TO	_	25	OPRD
27	be	be	VB	_	26	IM
28	produced	produce	VBN	_	27	VC
29	.	.	.	_	6	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	possible	possible	JJ	_	2	PRD
4	that	that	IN	_	2	OBJ
5	the	the	DT	_	8	NMOD
6	combined	combine	VBN	_	8	NMOD
7	low	low	JJ	_	8	NMOD
8	levels	level	NNS	_	17	SBJ
9	of	of	IN	_	8	NMOD
10	endogenous	endogenous	JJ	_	12	NMOD
11	mouse	mouse	NN	_	12	NMOD
12	Aβ	aβ	NN	_	16	NMOD
13	and	and	CC	_	12	COORD
14	nonsuppressed	nonsuppressed	JJ	_	15	NMOD
15	human	human	JJ	_	13	CONJ
16	peptide	peptide	NN	_	9	PMOD
17	are	be	VBP	_	4	SUB
18	sufficient	sufficient	JJ	_	17	PRD
19	to	to	TO	_	18	AMOD
20	maintain	maintain	VB	_	19	IM
21	existing	exist	VBG	_	22	NMOD
22	deposits	deposit	NNS	_	20	OBJ
23	.	.	.	_	2	P

1	However	however	RB	_	8	ADV
2	,	,	,	_	8	P
3	these	these	DT	_	5	NMOD
4	low	low	JJ	_	5	NMOD
5	levels	level	NNS	_	8	SBJ
6	of	of	IN	_	5	NMOD
7	peptide	peptide	NN	_	6	PMOD
8	are	be	VBP	_	0	ROOT
9	not	not	RB	_	8	ADV
10	sufficient	sufficient	JJ	_	8	PRD
11	to	to	TO	_	10	AMOD
12	induce	induce	VB	_	11	IM
13	new	new	JJ	_	15	NMOD
14	amyloid	amyloid	NN	_	15	NMOD
15	formation	formation	NN	_	12	OBJ
16	,	,	,	_	8	P
17	as	as	IN	_	8	PRP
18	CaMKIIα	camkiiα	NN	_	24	NMOD
19	-	-	HYPH	_	18	P
20	tTA	tta	NN	_	24	NMOD
21	×	×	SYM	_	24	P
22	tetAPPswe	tetappswe	NN	_	24	NMOD
23	/	/	HYPH	_	22	P
24	ind	ind	NN	_	25	NMOD
25	mice	mouse	NNS	_	34	SBJ
26	raised	raise	VBN	_	25	NMOD
27	on	on	IN	_	26	ADV
28	dox	dox	NN	_	27	PMOD
29	for	for	IN	_	26	TMP
30	up	up	IN	_	32	QMOD
31	to	to	IN	_	32	QMOD
32	a	a	DT	_	33	NMOD
33	year	year	NN	_	29	PMOD
34	do	do	VBP	_	17	SUB
35	not	not	RB	_	34	ADV
36	develop	develop	VB	_	34	VC
37	amyloid	amyloid	NN	_	38	NMOD
38	lesions	lesion	NNS	_	36	OBJ
39	(	(	-LRB-	_	42	P
40	data	datum	NNS	_	42	SBJ
41	not	not	RB	_	42	ADV
42	shown	show	VBN	_	36	PRN
43	)	)	-RRB-	_	42	P
44	.	.	.	_	8	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	also	also	RB	_	2	ADV
4	clear	clear	JJ	_	2	PRD
5	that	that	IN	_	2	OBJ
6	in	in	IN	_	12	ADV
7	this	this	DT	_	9	NMOD
8	genetic	genetic	JJ	_	9	NMOD
9	system	system	NN	_	6	PMOD
10	,	,	,	_	12	P
11	we	we	PRP	_	12	SBJ
12	have	have	VBP	_	5	SUB
13	raised	raise	VBN	_	12	VC
14	the	the	DT	_	15	NMOD
15	production	production	NN	_	13	OBJ
16	of	of	IN	_	15	NMOD
17	Aβ	aβ	NN	_	16	PMOD
18	to	to	IN	_	13	ADV
19	levels	level	NNS	_	18	PMOD
20	not	not	RB	_	21	ADV
21	found	find	VBN	_	19	NMOD
22	in	in	IN	_	21	LOC
23	humans	human	NNS	_	22	PMOD
24	to	to	TO	_	13	PRP
25	accelerate	accelerate	VB	_	24	IM
26	pathology	pathology	NN	_	25	OBJ
27	into	into	IN	_	25	ADV
28	an	an	DT	_	32	NMOD
29	experimentally	experimentally	RB	_	30	AMOD
30	feasible	feasible	JJ	_	32	NMOD
31	time	time	NN	_	32	NMOD
32	frame	frame	NN	_	27	PMOD
33	.	.	.	_	2	P

1	This	this	DT	_	2	NMOD
2	system	system	NN	_	3	SBJ
3	allowed	allow	VBD	_	35	DEP
4	us	us	PRP	_	5	SBJ
5	to	to	TO	_	3	OPRD
6	create	create	VB	_	5	IM
7	an	an	DT	_	10	NMOD
8	approximately	approximately	RB	_	9	AMOD
9	20-fold	0-fold	JJ	_	10	NMOD
10	differential	differential	NN	_	6	OBJ
11	between	between	IN	_	10	NMOD
12	APP	app	NN	_	14	NMOD
13	/	/	HYPH	_	12	P
14	Aβ	aβ	NN	_	16	NMOD
15	synthetic	synthetic	JJ	_	16	NMOD
16	rates	rate	NNS	_	11	PMOD
17	before	before	IN	_	6	TMP
18	and	and	CC	_	17	COORD
19	after	after	IN	_	18	CONJ
20	treatment	treatment	NN	_	17	PMOD
21	,	,	,	_	35	P
22	yet	yet	RB	_	35	ADV
23	the	the	DT	_	26	NMOD
24	in	in	FW	_	25	AMOD
25	vivo	vivo	FW	_	26	NMOD
26	equilibrium	equilibrium	NN	_	35	SBJ
27	between	between	IN	_	26	NMOD
28	aggregated	aggregate	VBN	_	31	NMOD
29	and	and	CC	_	28	COORD
30	disaggregated	disaggregated	VBN	_	29	CONJ
31	states	state	NNS	_	27	PMOD
32	of	of	IN	_	31	NMOD
33	Aβ	aβ	NN	_	32	PMOD
34	still	still	RB	_	35	ADV
35	favored	favor	VBD	_	0	ROOT
36	the	the	DT	_	37	NMOD
37	maintenance	maintenance	NN	_	35	OBJ
38	of	of	IN	_	37	NMOD
39	amyloid	amyloid	NN	_	40	NMOD
40	deposits	deposit	NNS	_	38	PMOD
41	.	.	.	_	35	P

1	In	in	IN	_	6	ADV
2	our	our	PRP$	_	3	NMOD
3	opinion	opinion	NN	_	1	PMOD
4	,	,	,	_	6	P
5	it	it	PRP	_	6	SBJ
6	seems	seem	VBZ	_	0	ROOT
7	unlikely	unlikely	JJ	_	6	OPRD
8	that	that	IN	_	6	OBJ
9	amyloid	amyloid	NN	_	10	NMOD
10	deposits	deposit	NNS	_	14	SBJ
11	in	in	IN	_	10	LOC
12	human	human	JJ	_	13	NMOD
13	brain	brain	NN	_	11	PMOD
14	would	would	MD	_	8	SUB
15	be	be	VB	_	14	VC
16	inherently	inherently	RB	_	15	ADV
17	any	any	DT	_	19	AMOD
18	less	less	RBR	_	19	AMOD
19	stable	stable	JJ	_	15	PRD
20	than	than	IN	_	19	AMOD
21	those	those	DT	_	20	PMOD
22	formed	form	VBN	_	21	NMOD
23	in	in	IN	_	22	LOC
24	mouse	mouse	NN	_	25	NMOD
25	brain	brain	NN	_	23	PMOD
26	.	.	.	_	6	P

1	However	however	RB	_	6	ADV
2	,	,	,	_	6	P
3	the	the	DT	_	5	NMOD
4	human	human	JJ	_	5	NMOD
5	brain	brain	NN	_	6	SBJ
6	may	may	MD	_	0	ROOT
7	harbor	harbor	VB	_	6	VC
8	clearance	clearance	NN	_	9	NMOD
9	mechanisms	mechanism	NNS	_	7	OBJ
10	not	not	RB	_	11	ADV
11	shared	share	VBN	_	9	NMOD
12	by	by	IN	_	11	LGS
13	mice	mouse	NNS	_	12	PMOD
14	that	that	WDT	_	15	SBJ
15	would	would	MD	_	9	NMOD
16	allow	allow	VB	_	15	VC
17	more	more	RBR	_	18	AMOD
18	efficient	efficient	JJ	_	19	NMOD
19	removal	removal	NN	_	16	OBJ
20	of	of	IN	_	19	NMOD
21	preexisting	preexist	VBG	_	22	NMOD
22	amyloid	amyloid	NN	_	20	PMOD
23	.	.	.	_	6	P

1	One	one	CD	_	3	NMOD
2	potential	potential	JJ	_	3	NMOD
3	mechanism	mechanism	NN	_	21	SBJ
4	by	by	IN	_	11	MNR
5	which	which	WDT	_	4	PMOD
6	amyloid	amyloid	NN	_	7	SBJ
7	may	may	MD	_	3	NMOD
8	be	be	VB	_	7	VC
9	more	more	RBR	_	10	AMOD
10	efficiently	efficiently	RB	_	8	ADV
11	removed	remove	VBN	_	8	VC
12	in	in	IN	_	11	LOC
13	the	the	DT	_	15	NMOD
14	human	human	JJ	_	15	NMOD
15	disease	disease	NN	_	12	PMOD
16	than	than	IN	_	11	ADV
17	in	in	IN	_	16	LOC
18	the	the	DT	_	20	NMOD
19	mouse	mouse	NN	_	20	NMOD
20	models	model	NNS	_	17	PMOD
21	is	be	VBZ	_	0	ROOT
22	through	through	IN	_	21	MNR
23	microglial	microglial	JJ	_	24	NMOD
24	phagocytosis	phagocytosis	NN	_	22	PMOD
25	.	.	.	_	21	P

1	Resident	resident	JJ	_	2	NMOD
2	microglia	microglia	NNS	_	7	SBJ
3	in	in	IN	_	2	LOC
4	transgenic	transgenic	JJ	_	6	NMOD
5	mouse	mouse	NN	_	6	NMOD
6	models	model	NNS	_	3	PMOD
7	localize	localize	VBP	_	0	ROOT
8	to	to	IN	_	7	ADV
9	tissue	tissue	NN	_	8	PMOD
10	surrounding	surround	VBG	_	9	NMOD
11	plaques	plaque	NNS	_	10	OBJ
12	but	but	CC	_	7	COORD
13	show	show	VBP	_	12	CONJ
14	little	little	JJ	_	15	NMOD
15	evidence	evidence	NN	_	13	OBJ
16	of	of	IN	_	15	NMOD
17	amyloid	amyloid	NN	_	18	NMOD
18	engulfment	engulfment	NN	_	16	PMOD
19	[	[	-LRB-	_	20	P
20	37	0	CD	_	13	PRN
21	–	–	SYM	_	22	P
22	40	0	CD	_	20	NMOD
23	]	]	-RRB-	_	20	P
24	.	.	.	_	7	P

1	In	in	IN	_	11	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	11	P
4	microglia	microglia	NNS	_	11	SBJ
5	surrounding	surround	VBG	_	4	NMOD
6	amyloid	amyloid	NN	_	7	NMOD
7	plaques	plaque	NNS	_	5	OBJ
8	in	in	IN	_	5	LOC
9	human	human	JJ	_	10	NMOD
10	brain	brain	NN	_	8	PMOD
11	show	show	VBP	_	0	ROOT
12	a	a	DT	_	15	NMOD
13	much	much	RB	_	14	AMOD
14	higher	high	JJR	_	15	NMOD
15	state	state	NN	_	11	OBJ
16	of	of	IN	_	15	NMOD
17	activation	activation	NN	_	16	PMOD
18	with	with	IN	_	11	ADV
19	greater	great	JJR	_	20	NMOD
20	expression	expression	NN	_	18	PMOD
21	of	of	IN	_	20	NMOD
22	complement	complement	NN	_	23	NMOD
23	receptor	receptor	NN	_	21	PMOD
24	[	[	-LRB-	_	25	P
25	40	0	CD	_	11	PRN
26	]	]	-RRB-	_	25	P
27	.	.	.	_	11	P

1	Thus	thus	RB	_	10	ADV
2	,	,	,	_	10	P
3	the	the	DT	_	4	NMOD
4	role	role	NN	_	10	SBJ
5	of	of	IN	_	4	NMOD
6	microglia	microglia	NNS	_	5	PMOD
7	in	in	IN	_	4	NMOD
8	amyloid	amyloid	NN	_	9	NMOD
9	metabolism	metabolism	NN	_	7	PMOD
10	is	be	VBZ	_	0	ROOT
11	minor	minor	JJ	_	10	PRD
12	in	in	IN	_	10	LOC
13	transgenic	transgenic	JJ	_	14	NMOD
14	models	model	NNS	_	12	PMOD
15	compared	compare	VBN	_	10	ADV
16	to	to	IN	_	15	PMOD
17	the	the	DT	_	19	NMOD
18	human	human	JJ	_	19	NMOD
19	condition	condition	NN	_	16	PMOD
20	.	.	.	_	10	P

1	Somewhat	somewhat	RB	_	2	AMOD
2	paradoxically	paradoxically	RB	_	7	ADV
3	,	,	,	_	7	P
4	several	several	JJ	_	5	NMOD
5	studies	study	NNS	_	7	SBJ
6	further	far	RB	_	7	ADV
7	demonstrate	demonstrate	VBP	_	0	ROOT
8	that	that	IN	_	7	OBJ
9	treatment	treatment	NN	_	18	SBJ
10	with	with	IN	_	9	NMOD
11	anti-inflammatory	anti-inflammatory	JJ	_	12	NMOD
12	drugs	drug	NNS	_	10	PMOD
13	to	to	TO	_	9	PRP
14	reduce	reduce	VB	_	13	IM
15	microglial	microglial	JJ	_	16	NMOD
16	activation	activation	NN	_	14	OBJ
17	actually	actually	RB	_	18	ADV
18	lowers	lower	VBZ	_	8	SUB
19	amyloid	amyloid	NN	_	20	NMOD
20	load	load	NN	_	18	OBJ
21	in	in	IN	_	18	LOC
22	APP	app	NN	_	23	AMOD
23	transgenic	transgenic	JJ	_	24	NMOD
24	mice	mouse	NNS	_	21	PMOD
25	,	,	,	_	18	P
26	suggesting	suggest	VBG	_	18	ADV
27	a	a	DT	_	28	NMOD
28	role	role	NN	_	26	OBJ
29	for	for	IN	_	28	NMOD
30	mouse	mouse	NN	_	31	NMOD
31	microglia	microglia	NNS	_	29	PMOD
32	in	in	IN	_	28	NMOD
33	the	the	DT	_	34	NMOD
34	formation	formation	NN	_	32	PMOD
35	and	and	CC	_	34	COORD
36	maintenance	maintenance	NN	_	35	CONJ
37	of	of	IN	_	34	NMOD
38	amyloid	amyloid	NN	_	39	NMOD
39	aggregates	aggregate	NNS	_	37	PMOD
40	[	[	-LRB-	_	41	P
41	41	0	CD	_	18	PRN
42	–	–	SYM	_	43	P
43	43	0	CD	_	41	NMOD
44	]	]	-RRB-	_	41	P
45	.	.	.	_	7	P

1	However	however	RB	_	5	ADV
2	,	,	,	_	5	P
3	this	this	DT	_	4	NMOD
4	outcome	outcome	NN	_	5	SBJ
5	may	may	MD	_	0	ROOT
6	be	be	VB	_	5	VC
7	alternatively	alternatively	RB	_	6	ADV
8	explained	explain	VBN	_	6	VC
9	by	by	IN	_	8	LGS
10	direct	direct	JJ	_	11	NMOD
11	effects	effect	NNS	_	9	PMOD
12	of	of	IN	_	11	NMOD
13	many	many	JJ	_	15	NMOD
14	anti-inflammatory	anti-inflammatory	JJ	_	15	NMOD
15	drugs	drug	NNS	_	12	PMOD
16	on	on	IN	_	11	NMOD
17	γ	γ	SYM	_	19	P
18	-	-	HYPH	_	19	P
19	secretase	secretase	NN	_	20	NMOD
20	cleavage	cleavage	NN	_	16	PMOD
21	[	[	-LRB-	_	22	P
22	44	0	CD	_	8	PRN
23	–	–	SYM	_	24	P
24	47	0	CD	_	22	NMOD
25	]	]	-RRB-	_	22	P
26	.	.	.	_	5	P

1	Nonetheless	nonetheless	RB	_	16	ADV
2	,	,	,	_	16	P
3	the	the	DT	_	4	NMOD
4	role	role	NN	_	16	SBJ
5	of	of	IN	_	4	NMOD
6	microglia	microglia	NNS	_	5	PMOD
7	in	in	IN	_	4	NMOD
8	both	both	CC	_	11	COORD
9	the	the	DT	_	11	NMOD
10	human	human	JJ	_	11	NMOD
11	condition	condition	NN	_	7	PMOD
12	and	and	CC	_	11	COORD
13	the	the	DT	_	15	NMOD
14	mouse	mouse	NN	_	15	NMOD
15	models	model	NNS	_	12	CONJ
16	is	be	VBZ	_	0	ROOT
17	poorly	poorly	RB	_	18	AMOD
18	understood	understand	VBN	_	16	PRD
19	,	,	,	_	16	P
20	and	and	CC	_	16	COORD
21	differences	difference	NNS	_	28	SBJ
22	in	in	IN	_	21	NMOD
23	microglial	microglial	JJ	_	24	NMOD
24	reactivity	reactivity	NN	_	22	PMOD
25	between	between	IN	_	21	NMOD
26	the	the	DT	_	27	NMOD
27	two	two	CD	_	25	PMOD
28	could	could	MD	_	20	CONJ
29	lead	lead	VB	_	28	VC
30	to	to	IN	_	29	ADV
31	significantly	significantly	RB	_	32	AMOD
32	faster	fast	JJR	_	34	NMOD
33	amyloid	amyloid	NN	_	34	NMOD
34	clearance	clearance	NN	_	30	PMOD
35	in	in	IN	_	34	LOC
36	the	the	DT	_	37	NMOD
37	brains	brain	NNS	_	35	PMOD
38	of	of	IN	_	37	NMOD
39	patients	patient	NNS	_	38	PMOD
40	with	with	IN	_	39	NMOD
41	AD	ad	NN	_	40	PMOD
42	than	than	IN	_	34	NMOD
43	we	we	PRP	_	44	SBJ
44	observe	observe	VBP	_	42	SUB
45	in	in	IN	_	44	LOC
46	the	the	DT	_	51	NMOD
47	tet	tet	NN	_	49	NMOD
48	-	-	HYPH	_	47	P
49	off	off	NN	_	51	NMOD
50	APP	app	NN	_	51	NMOD
51	mice	mouse	NNS	_	45	PMOD
52	.	.	.	_	16	P

1	Given	give	VBN	_	17	ADV
2	the	the	DT	_	5	NMOD
3	relatively	relatively	RB	_	4	AMOD
4	minor	minor	JJ	_	5	NMOD
5	role	role	NN	_	1	PMOD
6	played	play	VBN	_	5	NMOD
7	by	by	IN	_	6	LGS
8	microglia	microglia	NNS	_	7	PMOD
9	in	in	IN	_	6	LOC
10	other	other	JJ	_	12	NMOD
11	mouse	mouse	NN	_	12	NMOD
12	models	model	NNS	_	9	PMOD
13	of	of	IN	_	12	NMOD
14	amyloidosis	amyloidosis	NN	_	13	PMOD
15	,	,	,	_	17	P
16	we	we	PRP	_	17	SBJ
17	think	think	VBP	_	0	ROOT
18	it	it	PRP	_	17	OBJ
19	unlikely	unlikely	JJ	_	18	OPRD
20	that	that	IN	_	18	ADV
21	these	these	DT	_	22	NMOD
22	cells	cell	NNS	_	23	SBJ
23	have	have	VBP	_	20	SUB
24	influenced	influence	VBN	_	23	VC
25	the	the	DT	_	26	NMOD
26	rate	rate	NN	_	24	OBJ
27	of	of	IN	_	26	NMOD
28	amyloid	amyloid	NN	_	29	NMOD
29	clearance	clearance	NN	_	27	PMOD
30	in	in	IN	_	24	LOC
31	the	the	DT	_	36	NMOD
32	tet	tet	NN	_	34	NMOD
33	-	-	HYPH	_	32	P
34	off	off	NN	_	36	NMOD
35	APP	app	NN	_	36	NMOD
36	mice	mouse	NNS	_	30	PMOD
37	.	.	.	_	17	P

1	Even	even	RB	_	2	AMOD
2	so	so	RB	_	5	ADV
3	,	,	,	_	5	P
4	we	we	PRP	_	5	SBJ
5	considered	consider	VBD	_	0	ROOT
6	the	the	DT	_	7	NMOD
7	possibility	possibility	NN	_	5	OBJ
8	that	that	IN	_	7	NMOD
9	chronic	chronic	JJ	_	11	NMOD
10	dox	dox	NN	_	11	NMOD
11	treatment	treatment	NN	_	12	SBJ
12	may	may	MD	_	8	SUB
13	have	have	VB	_	12	VC
14	altered	alter	VBN	_	13	VC
15	the	the	DT	_	17	NMOD
16	activation	activation	NN	_	17	NMOD
17	state	state	NN	_	14	OBJ
18	of	of	IN	_	17	NMOD
19	microglia	microglia	NNS	_	18	PMOD
20	in	in	IN	_	14	LOC
21	our	our	PRP$	_	23	NMOD
22	treated	treat	VBN	_	23	NMOD
23	mice	mouse	NNS	_	20	PMOD
24	.	.	.	_	5	P

1	Dox	dox	NN	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	structurally	structurally	RB	_	4	AMOD
4	similar	similar	JJ	_	2	PRD
5	to	to	IN	_	4	AMOD
6	minocycline	minocycline	NN	_	5	PMOD
7	,	,	,	_	6	P
8	a	a	DT	_	11	NMOD
9	reported	report	VBN	_	11	NMOD
10	anti-inflammatory	anti-inflammatory	JJ	_	11	NMOD
11	drug	drug	NN	_	6	APPO
12	and	and	CC	_	11	COORD
13	inhibitor	inhibitor	NN	_	12	CONJ
14	of	of	IN	_	13	NMOD
15	microglial	microglial	JJ	_	16	NMOD
16	activation	activation	NN	_	14	PMOD
17	[	[	-LRB-	_	18	P
18	48	0	CD	_	2	PRN
19	]	]	-RRB-	_	18	P
20	.	.	.	_	2	P

1	However	however	RB	_	21	ADV
2	,	,	,	_	21	P
3	if	if	IN	_	21	ADV
4	dox	dox	NN	_	5	SBJ
5	does	do	VBZ	_	3	SUB
6	have	have	VB	_	5	VC
7	anti-inflammatory	anti-inflammatory	JJ	_	8	NMOD
8	activity	activity	NN	_	6	OBJ
9	,	,	,	_	21	P
10	then	then	RB	_	21	TMP
11	,	,	,	_	21	P
12	based	base	VBN	_	21	PRP
13	on	on	IN	_	12	PMOD
14	previous	previous	JJ	_	15	NMOD
15	studies	study	NNS	_	13	PMOD
16	with	with	IN	_	15	NMOD
17	other	other	JJ	_	18	NMOD
18	anti-inflammatories	anti-inflammatories	NNS	_	16	PMOD
19	,	,	,	_	21	P
20	we	we	PRP	_	21	SBJ
21	would	would	MD	_	0	ROOT
22	have	have	VB	_	21	VC
23	expected	expect	VBN	_	22	VC
24	to	to	TO	_	23	OPRD
25	find	find	VB	_	24	IM
26	less	less	RBR	_	27	NMOD
27	amyloid	amyloid	NN	_	25	OBJ
28	in	in	IN	_	25	LOC
29	the	the	DT	_	33	NMOD
30	dox	dox	NN	_	32	AMOD
31	-	-	HYPH	_	30	P
32	treated	treat	VBN	_	33	NMOD
33	animals	animal	NNS	_	28	PMOD
34	.	.	.	_	21	P

1	Clearly	clearly	RB	_	4	ADV
2	,	,	,	_	4	P
3	that	that	DT	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	not	not	RB	_	4	ADV
6	the	the	DT	_	7	NMOD
7	case	case	NN	_	4	PRD
8	.	.	.	_	4	P

1	While	while	IN	_	21	ADV
2	it	it	PRP	_	3	SBJ
3	is	be	VBZ	_	1	SUB
4	possible	possible	JJ	_	3	PRD
5	that	that	IN	_	3	OBJ
6	dox	dox	NN	_	7	SBJ
7	acts	act	VBZ	_	5	SUB
8	in	in	IN	_	7	MNR
9	some	some	DT	_	11	NMOD
10	other	other	JJ	_	11	NMOD
11	way	way	NN	_	8	PMOD
12	to	to	TO	_	7	PRP
13	slow	slow	VB	_	12	IM
14	amyloid	amyloid	NN	_	15	NMOD
15	clearance	clearance	NN	_	13	OBJ
16	,	,	,	_	21	P
17	data	datum	NNS	_	21	SBJ
18	from	from	IN	_	17	NMOD
19	multiple	multiple	JJ	_	20	NMOD
20	studies	study	NNS	_	18	PMOD
21	demonstrate	demonstrate	VBP	_	0	ROOT
22	that	that	IN	_	21	OBJ
23	microglial	microglial	JJ	_	24	NMOD
24	responses	response	NNS	_	25	SBJ
25	are	be	VBP	_	22	SUB
26	normally	normally	RB	_	25	ADV
27	weak	weak	JJ	_	25	PRD
28	in	in	IN	_	25	LOC
29	the	the	DT	_	32	NMOD
30	mouse	mouse	NN	_	32	NMOD
31	AD	ad	NN	_	32	NMOD
32	models	model	NNS	_	28	PMOD
33	[	[	-LRB-	_	34	P
34	37	0	CD	_	25	PRN
35	–	–	SYM	_	36	P
36	40	0	CD	_	34	NMOD
37	]	]	-RRB-	_	34	P
38	,	,	,	_	25	P
39	and	and	CC	_	25	COORD
40	thus	thus	RB	_	42	ADV
41	it	it	PRP	_	42	SBJ
42	is	be	VBZ	_	39	CONJ
43	doubtful	doubtful	JJ	_	42	PRD
44	that	that	IN	_	42	OBJ
45	dox	dox	NN	_	47	AMOD
46	-	-	HYPH	_	45	P
47	mediated	mediate	VBN	_	49	NMOD
48	microglial	microglial	JJ	_	49	NMOD
49	inhibition	inhibition	NN	_	50	SBJ
50	affected	affect	VBD	_	44	SUB
51	the	the	DT	_	52	NMOD
52	outcome	outcome	NN	_	50	OBJ
53	of	of	IN	_	52	NMOD
54	our	our	PRP$	_	55	NMOD
55	study	study	NN	_	53	PMOD
56	.	.	.	_	21	P

1	The	the	DT	_	2	NMOD
2	persistence	persistence	NN	_	11	SBJ
3	and	and	CC	_	2	COORD
4	stability	stability	NN	_	3	CONJ
5	of	of	IN	_	2	NMOD
6	amyloid	amyloid	NN	_	7	NMOD
7	deposits	deposit	NNS	_	5	PMOD
8	in	in	IN	_	2	LOC
9	our	our	PRP$	_	10	NMOD
10	system	system	NN	_	8	PMOD
11	is	be	VBZ	_	0	ROOT
12	unexpected	unexpected	JJ	_	11	PRD
13	given	give	VBN	_	11	ADV
14	the	the	DT	_	15	NMOD
15	speed	speed	NN	_	13	PMOD
16	with	with	IN	_	21	MNR
17	which	which	WDT	_	16	PMOD
18	Aβ	aβ	NN	_	19	NMOD
19	aggregates	aggregate	NNS	_	20	SBJ
20	are	be	VBP	_	15	NMOD
21	cleared	clear	VBN	_	20	VC
22	in	in	IN	_	21	LOC
23	other	other	JJ	_	25	NMOD
24	mouse	mouse	NN	_	25	NMOD
25	models	model	NNS	_	22	PMOD
26	of	of	IN	_	25	NMOD
27	therapeutic	therapeutic	JJ	_	28	NMOD
28	intervention	intervention	NN	_	26	PMOD
29	.	.	.	_	11	P

1	Anti-Aβ	anti-aβ	JJ	_	2	NMOD
2	antibodies	antibody	NNS	_	8	SBJ
3	injected	inject	VBN	_	2	NMOD
4	directly	directly	RB	_	3	ADV
5	into	into	IN	_	3	LOC
6	the	the	DT	_	7	NMOD
7	brain	brain	NN	_	5	PMOD
8	have	have	VBP	_	0	ROOT
9	been	be	VBN	_	8	VC
10	shown	show	VBN	_	9	VC
11	to	to	TO	_	10	OPRD
12	eliminate	eliminate	VB	_	11	IM
13	amyloid	amyloid	NN	_	14	NMOD
14	deposits	deposit	NNS	_	12	OBJ
15	in	in	IN	_	12	TMP
16	as	as	RB	_	19	QMOD
17	little	little	JJ	_	19	QMOD
18	as	as	IN	_	19	QMOD
19	1	0	CD	_	20	NMOD
20	wk	wk	NN	_	15	PMOD
21	after	after	IN	_	20	NMOD
22	treatment	treatment	NN	_	21	PMOD
23	[	[	-LRB-	_	24	P
24	49	0	CD	_	12	PRN
25	–	–	SYM	_	26	P
26	51	0	CD	_	24	NMOD
27	]	]	-RRB-	_	24	P
28	.	.	.	_	8	P

1	Peripheral	peripheral	JJ	_	3	NMOD
2	antibody	antibody	NN	_	3	NMOD
3	injection	injection	NN	_	4	SBJ
4	decreases	decrease	VBZ	_	0	ROOT
5	amyloid	amyloid	NN	_	6	NMOD
6	load	load	NN	_	4	OBJ
7	more	more	RBR	_	8	AMOD
8	broadly	broadly	RB	_	4	ADV
9	,	,	,	_	4	P
10	and	and	CC	_	4	COORD
11	although	although	IN	_	24	ADV
12	it	it	PRP	_	13	SBJ
13	does	do	VBZ	_	11	SUB
14	not	not	RB	_	13	ADV
15	appear	appear	VB	_	13	VC
16	to	to	TO	_	15	OPRD
17	act	act	VB	_	16	IM
18	as	as	RB	_	19	AMOD
19	quickly	quickly	RB	_	17	TMP
20	as	as	IN	_	19	AMOD
21	local	local	JJ	_	22	NMOD
22	injection	injection	NN	_	20	PMOD
23	,	,	,	_	24	P
24	can	can	MD	_	10	CONJ
25	significantly	significantly	RB	_	24	ADV
26	reduce	reduce	VB	_	24	VC
27	amyloid	amyloid	NN	_	28	NMOD
28	load	load	NN	_	26	OBJ
29	within	within	IN	_	26	TMP
30	2	0	CD	_	31	NMOD
31	mo	mo	NN	_	29	PMOD
32	of	of	IN	_	31	NMOD
33	initial	initial	JJ	_	34	NMOD
34	treatment	treatment	NN	_	32	PMOD
35	[	[	-LRB-	_	38	P
36	52	0	CD	_	38	NMOD
37	,	,	,	_	38	P
38	53	0	CD	_	26	PRN
39	]	]	-RRB-	_	38	P
40	.	.	.	_	4	P

1	More	more	RBR	_	2	AMOD
2	recently	recently	RB	_	7	TMP
3	,	,	,	_	7	P
4	an	an	DT	_	6	NMOD
5	alternative	alternative	JJ	_	6	NMOD
6	approach	approach	NN	_	7	SBJ
7	has	have	VBZ	_	0	ROOT
8	shown	show	VBN	_	7	VC
9	that	that	IN	_	8	OBJ
10	lentiviral	lentiviral	JJ	_	11	NMOD
11	transfer	transfer	NN	_	14	SBJ
12	of	of	IN	_	11	NMOD
13	neprilysin	neprilysin	NN	_	12	PMOD
14	can	can	MD	_	9	SUB
15	also	also	RB	_	14	ADV
16	reduce	reduce	VB	_	14	VC
17	the	the	DT	_	18	NMOD
18	number	number	NN	_	16	OBJ
19	of	of	IN	_	18	NMOD
20	aggregates	aggregate	NNS	_	19	PMOD
21	in	in	IN	_	16	LOC
22	the	the	DT	_	23	NMOD
23	area	area	NN	_	21	PMOD
24	of	of	IN	_	23	NMOD
25	the	the	DT	_	27	NMOD
26	injection	injection	NN	_	27	NMOD
27	site	site	NN	_	24	PMOD
28	[	[	-LRB-	_	29	P
29	54	0	CD	_	16	PRN
30	]	]	-RRB-	_	29	P
31	.	.	.	_	7	P

1	Careful	careful	JJ	_	2	NMOD
2	study	study	NN	_	14	SBJ
3	of	of	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	mechanism	mechanism	NN	_	3	PMOD
6	behind	behind	IN	_	5	NMOD
7	several	several	JJ	_	6	PMOD
8	of	of	IN	_	7	NMOD
9	the	the	DT	_	13	NMOD
10	antibody	antibody	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	mediated	mediate	VBN	_	13	NMOD
13	therapies	therapy	NNS	_	8	PMOD
14	has	have	VBZ	_	0	ROOT
15	suggested	suggest	VBN	_	14	VC
16	that	that	IN	_	15	OBJ
17	activated	activate	VBN	_	18	NMOD
18	microglia	microglia	NNS	_	19	SBJ
19	play	play	VBP	_	16	SUB
20	an	an	DT	_	22	NMOD
21	important	important	JJ	_	22	NMOD
22	role	role	NN	_	19	OBJ
23	in	in	IN	_	19	ADV
24	the	the	DT	_	25	NMOD
25	removal	removal	NN	_	23	PMOD
26	of	of	IN	_	25	NMOD
27	fibrillar	fibrillar	JJ	_	28	NMOD
28	plaques	plaque	NNS	_	26	PMOD
29	after	after	IN	_	19	TMP
30	immunization	immunization	NN	_	29	PMOD
31	[	[	-LRB-	_	36	P
32	50	0	CD	_	36	NMOD
33	,	,	,	_	36	P
34	52	0	CD	_	36	NMOD
35	,	,	,	_	36	P
36	55	0	CD	_	15	PRN
37	]	]	-RRB-	_	36	P
38	.	.	.	_	14	P

1	However	however	RB	_	4	ADV
2	,	,	,	_	4	P
3	it	it	PRP	_	4	SBJ
4	has	have	VBZ	_	0	ROOT
5	been	be	VBN	_	4	VC
6	noted	note	VBN	_	5	VC
7	that	that	IN	_	6	OBJ
8	deletion	deletion	NN	_	31	SBJ
9	of	of	IN	_	8	NMOD
10	the	the	DT	_	12	NMOD
11	Fc	fc	NN	_	12	NMOD
12	receptor	receptor	NN	_	16	NMOD
13	(	(	-LRB-	_	16	P
14	the	the	DT	_	16	NMOD
15	primary	primary	JJ	_	16	NMOD
16	receptor	receptor	NN	_	9	PMOD
17	for	for	IN	_	16	NMOD
18	microglial	microglial	JJ	_	19	NMOD
19	opsinization	opsinization	NN	_	17	PMOD
20	of	of	IN	_	19	NMOD
21	antibody	antibody	NN	_	23	NMOD
22	–	–	HYPH	_	21	P
23	antigen	antigen	NN	_	24	NMOD
24	complexes	complex	NNS	_	20	PMOD
25	)	)	-RRB-	_	8	P
26	in	in	IN	_	8	LOC
27	APP	app	NN	_	28	AMOD
28	transgenic	transgenic	JJ	_	30	NMOD
29	mouse	mouse	NN	_	30	NMOD
30	models	model	NNS	_	26	PMOD
31	has	have	VBZ	_	7	SUB
32	no	no	DT	_	33	NMOD
33	impact	impact	NN	_	31	OBJ
34	on	on	IN	_	33	NMOD
35	the	the	DT	_	36	NMOD
36	effectiveness	effectiveness	NN	_	34	PMOD
37	of	of	IN	_	36	NMOD
38	antibody	antibody	NN	_	40	AMOD
39	-	-	HYPH	_	38	P
40	mediated	mediate	VBN	_	41	NMOD
41	therapy	therapy	NN	_	37	PMOD
42	[	[	-LRB-	_	45	P
43	56	0	CD	_	45	NMOD
44	,	,	,	_	45	P
45	57	0	CD	_	31	PRN
46	]	]	-RRB-	_	45	P
47	.	.	.	_	4	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	,	,	,	_	2	P
4	nevertheless	nevertheless	RB	_	2	ADV
5	,	,	,	_	2	P
6	possible	possible	JJ	_	2	PRD
7	that	that	IN	_	2	OBJ
8	lack	lack	NN	_	12	SBJ
9	of	of	IN	_	8	NMOD
10	microglia	microglia	NNS	_	11	NMOD
11	activation	activation	NN	_	9	PMOD
12	is	be	VBZ	_	7	SUB
13	the	the	DT	_	15	NMOD
14	major	major	JJ	_	15	NMOD
15	difference	difference	NN	_	12	PRD
16	between	between	IN	_	15	NMOD
17	the	the	DT	_	19	NMOD
18	slow	slow	JJ	_	19	NMOD
19	clearance	clearance	NN	_	16	PMOD
20	described	describe	VBN	_	19	NMOD
21	here	here	RB	_	20	ADV
22	,	,	,	_	19	P
23	where	where	WRB	_	31	LOC
24	no	no	DT	_	25	NMOD
25	perturbation	perturbation	NN	_	30	SBJ
26	of	of	IN	_	25	NMOD
27	the	the	DT	_	29	NMOD
28	immune	immune	JJ	_	29	NMOD
29	system	system	NN	_	26	PMOD
30	is	be	VBZ	_	19	NMOD
31	expected	expect	VBN	_	30	VC
32	,	,	,	_	19	P
33	and	and	CC	_	19	COORD
34	the	the	DT	_	36	NMOD
35	rapid	rapid	JJ	_	36	NMOD
36	clearance	clearance	NN	_	33	CONJ
37	described	describe	VBN	_	36	NMOD
38	in	in	IN	_	37	ADV
39	studies	study	NNS	_	38	PMOD
40	involving	involve	VBG	_	39	NMOD
41	antibody	antibody	NN	_	44	NMOD
42	or	or	CC	_	41	COORD
43	viral	viral	JJ	_	42	CONJ
44	injection	injection	NN	_	40	OBJ
45	.	.	.	_	2	P

1	In	in	IN	_	13	ADV
2	isolation	isolation	NN	_	1	PMOD
3	,	,	,	_	13	P
4	mild	mild	JJ	_	5	NMOD
5	activation	activation	NN	_	13	SBJ
6	of	of	IN	_	5	NMOD
7	microglia	microglia	NNS	_	6	PMOD
8	by	by	IN	_	5	NMOD
9	injection	injection	NN	_	10	NMOD
10	damage	damage	NN	_	8	PMOD
11	or	or	CC	_	10	COORD
12	opsinization	opsinization	NN	_	11	CONJ
13	may	may	MD	_	0	ROOT
14	not	not	RB	_	13	ADV
15	be	be	VB	_	13	VC
16	adequate	adequate	JJ	_	15	PRD
17	to	to	TO	_	15	PRP
18	induce	induce	VB	_	17	IM
19	substantial	substantial	JJ	_	20	NMOD
20	phagocytosis	phagocytosis	NN	_	18	OBJ
21	,	,	,	_	13	P
22	but	but	CC	_	13	COORD
23	when	when	WRB	_	24	TMP
24	combined	combine	VBN	_	43	TMP
25	with	with	IN	_	24	ADV
26	an	an	DT	_	30	NMOD
27	Aβ	aβ	NN	_	29	AMOD
28	-	-	HYPH	_	27	P
29	lowering	lower	VBG	_	30	NMOD
30	agent	agent	NN	_	25	PMOD
31	,	,	,	_	30	P
32	such	such	JJ	_	33	PMOD
33	as	as	IN	_	30	NMOD
34	neprilysin	neprilysin	NN	_	38	AMOD
35	or	or	CC	_	34	COORD
36	Aβ	aβ	NN	_	35	CONJ
37	-	-	HYPH	_	34	P
38	targeted	target	VBN	_	39	NMOD
39	antibodies	antibody	NNS	_	33	PMOD
40	,	,	,	_	43	P
41	the	the	DT	_	42	NMOD
42	two	two	CD	_	43	SBJ
43	may	may	MD	_	22	CONJ
44	work	work	VB	_	43	VC
45	in	in	IN	_	44	MNR
46	concert	concert	NN	_	45	PMOD
47	to	to	TO	_	44	PRP
48	clear	clear	VB	_	47	IM
49	peptide	peptide	NN	_	50	NMOD
50	deposits	deposit	NNS	_	48	OBJ
51	.	.	.	_	13	P

1	Consistent	consistent	JJ	_	28	ADV
2	with	with	IN	_	1	AMOD
3	this	this	DT	_	4	NMOD
4	hypothesis	hypothesis	NN	_	2	PMOD
5	,	,	,	_	28	P
6	strong	strong	JJ	_	7	NMOD
7	activation	activation	NN	_	28	SBJ
8	of	of	IN	_	7	NMOD
9	microglia	microglia	NNS	_	8	PMOD
10	through	through	IN	_	7	NMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	expression	expression	NN	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	TGFβ	tgfβ	NN	_	13	PMOD
15	[	[	-LRB-	_	16	P
16	58	0	CD	_	14	PRN
17	]	]	-RRB-	_	16	P
18	or	or	CC	_	12	COORD
19	central	central	JJ	_	20	NMOD
20	injection	injection	NN	_	18	CONJ
21	of	of	IN	_	20	NMOD
22	lipopolysaccharide	lipopolysaccharide	NN	_	21	PMOD
23	[	[	-LRB-	_	26	P
24	59	0	CD	_	26	NMOD
25	,	,	,	_	26	P
26	60	0	CD	_	22	PRN
27	]	]	-RRB-	_	26	P
28	can	can	MD	_	0	ROOT
29	by	by	IN	_	28	MNR
30	itself	itself	PRP	_	29	PMOD
31	substantially	substantially	RB	_	28	ADV
32	reduce	reduce	VB	_	28	VC
33	plaque	plaque	NN	_	34	NMOD
34	burden	burden	NN	_	32	OBJ
35	in	in	IN	_	32	LOC
36	APP	app	NN	_	37	AMOD
37	transgenic	transgenic	JJ	_	38	NMOD
38	mice	mouse	NNS	_	35	PMOD
39	.	.	.	_	28	P

1	But	but	CC	_	39	COORD
2	in	in	IN	_	39	ADV
3	the	the	DT	_	4	NMOD
4	case	case	NN	_	2	PMOD
5	of	of	IN	_	4	NMOD
6	acute	acute	JJ	_	15	NMOD
7	antibody	antibody	NN	_	14	AMOD
8	-	-	HYPH	_	7	P
9	and	and	CC	_	7	COORD
10	/	/	HYPH	_	9	P
11	or	or	CC	_	9	COORD
12	injury	injury	NN	_	9	CONJ
13	-	-	HYPH	_	7	P
14	mediated	mediate	VBN	_	15	NMOD
15	activation	activation	NN	_	5	PMOD
16	,	,	,	_	39	P
17	once	once	IN	_	39	TMP
18	the	the	DT	_	19	NMOD
19	inflammation	inflammation	NN	_	20	SBJ
20	has	have	VBZ	_	17	SUB
21	passed	pass	VBN	_	20	VC
22	,	,	,	_	20	P
23	and	and	CC	_	20	COORD
24	the	the	DT	_	25	NMOD
25	antibody	antibody	NN	_	29	SBJ
26	and	and	CC	_	25	COORD
27	bound	bind	VBN	_	28	NMOD
28	peptide	peptide	NN	_	26	CONJ
29	have	have	VBP	_	23	CONJ
30	been	be	VBN	_	29	VC
31	cleared	clear	VBN	_	30	VC
32	and	and	CC	_	31	COORD
33	degraded	degrade	VBN	_	32	CONJ
34	,	,	,	_	39	P
35	the	the	DT	_	37	NMOD
36	remaining	remain	VBG	_	37	NMOD
37	Aβ	aβ	NN	_	39	SBJ
38	quickly	quickly	RB	_	39	TMP
39	reaggregates	reaggregates	VBZ	_	0	ROOT
40	and	and	CC	_	39	COORD
41	amyloid	amyloid	NN	_	42	NMOD
42	pathology	pathology	NN	_	43	SBJ
43	is	be	VBZ	_	40	CONJ
44	reestablished	reestablish	VBN	_	43	VC
45	[	[	-LRB-	_	46	P
46	49	0	CD	_	44	PRN
47	]	]	-RRB-	_	46	P
48	.	.	.	_	39	P

1	This	this	DT	_	2	NMOD
2	finding	finding	NN	_	3	SBJ
3	reinforces	reinforce	VBZ	_	0	ROOT
4	the	the	DT	_	5	NMOD
5	notion	notion	NN	_	3	OBJ
6	that	that	IN	_	5	NMOD
7	without	without	IN	_	15	ADV
8	continued	continue	VBN	_	9	NMOD
9	stimulation	stimulation	NN	_	7	PMOD
10	,	,	,	_	15	P
11	microglia	microglia	NNS	_	15	SBJ
12	in	in	IN	_	11	NMOD
13	mouse	mouse	NN	_	14	NMOD
14	models	model	NNS	_	12	PMOD
15	do	do	VBP	_	6	SUB
16	not	not	RB	_	15	ADV
17	maintain	maintain	VB	_	15	VC
18	the	the	DT	_	20	NMOD
19	same	same	JJ	_	20	NMOD
20	level	level	NN	_	17	OBJ
21	of	of	IN	_	20	NMOD
22	sustained	sustain	VBN	_	23	NMOD
23	activation	activation	NN	_	21	PMOD
24	that	that	WDT	_	25	SBJ
25	may	may	MD	_	20	NMOD
26	occur	occur	VB	_	25	VC
27	in	in	IN	_	26	LOC
28	humans	human	NNS	_	27	PMOD
29	.	.	.	_	3	P

1	SantaCruz	santacruz	NNP	_	5	SBJ
2	et	et	FW	_	3	AMOD
3	al.	al.	FW	_	1	NMOD
4	recently	recently	RB	_	5	TMP
5	published	publish	VBD	_	0	ROOT
6	a	a	DT	_	7	NMOD
7	study	study	NN	_	5	OBJ
8	of	of	IN	_	7	NMOD
9	mice	mouse	NNS	_	8	PMOD
10	that	that	WDT	_	11	SBJ
11	express	express	VBP	_	9	NMOD
12	P301L	p0l	NN	_	14	NMOD
13	human	human	JJ	_	14	NMOD
14	tau	tau	NN	_	11	OBJ
15	via	via	IN	_	11	ADV
16	a	a	DT	_	19	NMOD
17	similar	similar	JJ	_	19	NMOD
18	vector	vector	NN	_	19	NMOD
19	system	system	NN	_	15	PMOD
20	[	[	-LRB-	_	21	P
21	61	0	CD	_	5	PRN
22	]	]	-RRB-	_	21	P
23	.	.	.	_	5	P

1	As	as	IN	_	13	ADV
2	in	in	IN	_	1	LOC
3	our	our	PRP$	_	8	NMOD
4	tet	tet	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	off	off	NN	_	8	NMOD
7	APP	app	NN	_	8	NMOD
8	mice	mouse	NNS	_	2	PMOD
9	,	,	,	_	13	P
10	SantaCruz	santacruz	NNP	_	13	SBJ
11	et	et	FW	_	12	AMOD
12	al.	al.	FW	_	10	NMOD
13	found	find	VBD	_	0	ROOT
14	that	that	IN	_	13	OBJ
15	tau	tau	NN	_	17	NMOD
16	neurofibrillary	neurofibrillary	JJ	_	17	NMOD
17	tangles	tangle	NNS	_	23	SBJ
18	,	,	,	_	17	P
19	like	like	IN	_	17	NMOD
20	amyloid	amyloid	NN	_	21	NMOD
21	plaques	plaque	NNS	_	19	PMOD
22	,	,	,	_	23	P
23	are	be	VBP	_	14	SUB
24	not	not	RB	_	23	ADV
25	cleared	clear	VBN	_	23	VC
26	efficiently	efficiently	RB	_	25	MNR
27	following	follow	VBG	_	25	TMP
28	transgene	transgene	NN	_	29	NMOD
29	suppression	suppression	NN	_	27	PMOD
30	.	.	.	_	13	P

1	The	the	DT	_	2	NMOD
2	lack	lack	NN	_	11	SBJ
3	of	of	IN	_	2	NMOD
4	clearance	clearance	NN	_	3	PMOD
5	in	in	IN	_	2	NMOD
6	both	both	DT	_	7	NMOD
7	models	model	NNS	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	AD	ad	NN	_	10	NMOD
10	pathology	pathology	NN	_	8	PMOD
11	comes	come	VBZ	_	0	ROOT
12	as	as	IN	_	11	ADV
13	a	a	DT	_	15	NMOD
14	stark	stark	JJ	_	15	NMOD
15	contrast	contrast	NN	_	12	PMOD
16	to	to	IN	_	15	NMOD
17	the	the	DT	_	19	NMOD
18	rapid	rapid	JJ	_	19	NMOD
19	removal	removal	NN	_	16	PMOD
20	of	of	IN	_	19	NMOD
21	protein	protein	NN	_	22	NMOD
22	aggregates	aggregate	NNS	_	20	PMOD
23	found	find	VBN	_	19	NMOD
24	in	in	IN	_	23	ADV
25	similar	similar	JJ	_	30	NMOD
26	tet	tet	NN	_	28	NMOD
27	-	-	HYPH	_	26	P
28	off	off	NN	_	30	NMOD
29	mouse	mouse	NN	_	30	NMOD
30	models	model	NNS	_	24	PMOD
31	of	of	IN	_	30	NMOD
32	Huntington	huntington	NNP	_	38	NMOD
33	[	[	-LRB-	_	34	P
34	32	0	CD	_	32	PRN
35	]	]	-RRB-	_	34	P
36	and	and	CC	_	32	COORD
37	prion	prion	NN	_	36	CONJ
38	disease	disease	NN	_	31	PMOD
39	[	[	-LRB-	_	40	P
40	62	0	CD	_	38	PRN
41	]	]	-RRB-	_	40	P
42	.	.	.	_	11	P

1	In	in	IN	_	20	ADV
2	these	these	DT	_	3	NMOD
3	cases	case	NNS	_	1	PMOD
4	,	,	,	_	20	P
5	disrupting	disrupt	VBG	_	20	SBJ
6	the	the	DT	_	7	NMOD
7	input	input	NN	_	5	OBJ
8	of	of	IN	_	7	NMOD
9	new	new	JJ	_	10	NMOD
10	monomer	monomer	NN	_	8	PMOD
11	to	to	IN	_	7	NMOD
12	the	the	DT	_	13	NMOD
13	system	system	NN	_	11	PMOD
14	via	via	IN	_	5	MNR
15	dox	dox	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	mediated	mediate	VBN	_	19	NMOD
18	transgene	transgene	NN	_	19	NMOD
19	suppression	suppression	NN	_	14	PMOD
20	led	lead	VBD	_	0	ROOT
21	to	to	IN	_	20	ADV
22	relatively	relatively	RB	_	23	AMOD
23	rapid	rapid	JJ	_	24	NMOD
24	clearance	clearance	NN	_	21	PMOD
25	of	of	IN	_	24	NMOD
26	protein	protein	NN	_	27	NMOD
27	aggregates	aggregate	NNS	_	25	PMOD
28	.	.	.	_	20	P

1	By	by	IN	_	12	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	12	P
4	our	our	PRP$	_	5	NMOD
5	study	study	NN	_	12	SBJ
6	and	and	CC	_	5	COORD
7	that	that	DT	_	6	CONJ
8	of	of	IN	_	7	NMOD
9	SantaCruz	santacruz	NNP	_	8	PMOD
10	et	et	FW	_	11	AMOD
11	al.	al.	FW	_	9	NMOD
12	suggest	suggest	VBP	_	0	ROOT
13	that	that	IN	_	12	OBJ
14	protein	protein	NN	_	15	NMOD
15	aggregates	aggregate	NNS	_	18	SBJ
16	in	in	IN	_	15	LOC
17	AD	ad	NN	_	16	PMOD
18	may	may	MD	_	13	SUB
19	be	be	VB	_	18	VC
20	more	more	RBR	_	21	AMOD
21	tenacious	tenacious	JJ	_	19	PRD
22	than	than	IN	_	21	AMOD
23	in	in	IN	_	22	LOC
24	other	other	JJ	_	26	NMOD
25	neurodegenerative	neurodegenerative	JJ	_	26	NMOD
26	disorders	disorder	NNS	_	23	PMOD
27	.	.	.	_	12	P

1	Perhaps	perhaps	RB	_	8	ADV
2	once	once	IN	_	8	TMP
3	aggregated	aggregate	VBN	_	2	SUB
4	,	,	,	_	8	P
5	Aβ	aβ	NN	_	8	SBJ
6	and	and	CC	_	5	COORD
7	tau	tau	NN	_	6	CONJ
8	are	be	VBP	_	0	ROOT
9	either	either	RB	_	12	AMOD
10	inherently	inherently	RB	_	12	AMOD
11	more	more	RBR	_	12	AMOD
12	stable	stable	JJ	_	8	PRD
13	than	than	IN	_	12	AMOD
14	other	other	JJ	_	16	NMOD
15	protein	protein	NN	_	16	NMOD
16	aggregates	aggregate	NNS	_	13	PMOD
17	or	or	CC	_	12	COORD
18	more	more	RBR	_	19	AMOD
19	resistant	resistant	JJ	_	17	CONJ
20	to	to	IN	_	19	AMOD
21	intra	intra	AFX	_	26	NMOD
22	-	-	HYPH	_	21	P
23	and	and	CC	_	21	COORD
24	extracellular	extracellular	JJ	_	23	CONJ
25	clearance	clearance	NN	_	26	NMOD
26	mechanisms	mechanism	NNS	_	20	PMOD
27	.	.	.	_	8	P

1	One	one	CD	_	2	NMOD
2	question	question	NN	_	12	SBJ
3	we	we	PRP	_	4	SBJ
4	were	be	VBD	_	2	NMOD
5	not	not	RB	_	4	ADV
6	able	able	JJ	_	4	PRD
7	to	to	TO	_	6	AMOD
8	address	address	VB	_	7	IM
9	in	in	IN	_	8	ADV
10	this	this	DT	_	11	NMOD
11	study	study	NN	_	9	PMOD
12	is	be	VBZ	_	0	ROOT
13	whether	whether	IN	_	12	PRD
14	abrogating	abrogate	VBG	_	19	SBJ
15	synthesis	synthesis	NN	_	14	OBJ
16	of	of	IN	_	15	NMOD
17	new	new	JJ	_	18	NMOD
18	Aβ	aβ	NN	_	16	PMOD
19	halts	halt	VBZ	_	13	SUB
20	the	the	DT	_	21	NMOD
21	progression	progression	NN	_	19	OBJ
22	of	of	IN	_	21	NMOD
23	cognitive	cognitive	JJ	_	24	NMOD
24	decline	decline	NN	_	22	PMOD
25	.	.	.	_	12	P

1	Studies	study	NNS	_	9	SBJ
2	from	from	IN	_	1	NMOD
3	the	the	DT	_	8	NMOD
4	tet	tet	NN	_	6	NMOD
5	-	-	HYPH	_	4	P
6	off	off	NN	_	8	NMOD
7	tau	tau	NN	_	8	NMOD
8	mice	mouse	NNS	_	2	PMOD
9	suggest	suggest	VBP	_	0	ROOT
10	that	that	IN	_	9	OBJ
11	protein	protein	NN	_	12	NMOD
12	clearance	clearance	NN	_	13	SBJ
13	may	may	MD	_	10	SUB
14	in	in	IN	_	13	ADV
15	fact	fact	NN	_	14	PMOD
16	not	not	RB	_	13	ADV
17	be	be	VB	_	13	VC
18	required	require	VBN	_	17	VC
19	for	for	IN	_	18	PRP
20	cognitive	cognitive	JJ	_	21	NMOD
21	improvement	improvement	NN	_	19	PMOD
22	following	follow	VBG	_	18	TMP
23	transgene	transgene	NN	_	24	NMOD
24	suppression	suppression	NN	_	22	PMOD
25	[	[	-LRB-	_	26	P
26	61	0	CD	_	18	PRN
27	]	]	-RRB-	_	26	P
28	.	.	.	_	9	P

1	At	at	IN	_	12	TMP
2	present	present	JJ	_	1	PMOD
3	,	,	,	_	12	P
4	because	because	IN	_	12	ADV
5	of	of	IN	_	4	PMOD
6	unexpected	unexpected	JJ	_	9	NMOD
7	noncognitive	noncognitive	JJ	_	9	NMOD
8	behavioral	behavioral	JJ	_	9	NMOD
9	abnormalities	abnormality	NNS	_	4	PMOD
10	,	,	,	_	12	P
11	it	it	PRP	_	12	SBJ
12	is	be	VBZ	_	0	ROOT
13	not	not	RB	_	12	ADV
14	clear	clear	JJ	_	12	PRD
15	whether	whether	IN	_	12	OBJ
16	the	the	DT	_	21	NMOD
17	tet	tet	NN	_	19	NMOD
18	-	-	HYPH	_	17	P
19	off	off	NN	_	21	NMOD
20	APP	app	NN	_	21	NMOD
21	mice	mouse	NNS	_	22	SBJ
22	can	can	MD	_	15	SUB
23	be	be	VB	_	22	VC
24	used	use	VBN	_	23	VC
25	to	to	TO	_	24	PRP
26	address	address	VB	_	25	IM
27	the	the	DT	_	29	NMOD
28	same	same	JJ	_	29	NMOD
29	question	question	NN	_	26	OBJ
30	in	in	IN	_	26	ADV
31	the	the	DT	_	32	NMOD
32	context	context	NN	_	30	PMOD
33	of	of	IN	_	32	NMOD
34	amyloid	amyloid	NN	_	35	NMOD
35	pathology	pathology	NN	_	33	PMOD
36	.	.	.	_	12	P

1	Both	both	DT	_	2	NMOD
2	lines	line	NNS	_	11	SBJ
3	of	of	IN	_	2	NMOD
4	tTA	tta	NN	_	6	NMOD
5	/	/	HYPH	_	4	P
6	APP	app	NN	_	7	NMOD
7	mice	mouse	NNS	_	3	PMOD
8	we	we	PRP	_	9	SBJ
9	studied	study	VBN	_	2	NMOD
10	here	here	RB	_	9	LOC
11	display	display	VBP	_	0	ROOT
12	extreme	extreme	JJ	_	13	NMOD
13	hyperactivity	hyperactivity	NN	_	11	OBJ
14	visible	visible	JJ	_	13	NMOD
15	as	as	IN	_	14	AMOD
16	cage	cage	NN	_	17	NMOD
17	circling	circling	NN	_	15	PMOD
18	and	and	CC	_	14	COORD
19	quantified	quantify	VBN	_	18	CONJ
20	by	by	IN	_	19	LGS
21	activity	activity	NN	_	22	NMOD
22	monitoring	monitoring	NN	_	20	PMOD
23	(	(	-LRB-	_	24	P
24	see	see	VB	_	11	PRN
25	Figure	figure	NN	_	24	OBJ
26	7	0	CD	_	25	NMOD
27	)	)	-RRB-	_	24	P
28	.	.	.	_	11	P

1	Many	many	JJ	_	7	SBJ
2	of	of	IN	_	1	NMOD
3	the	the	DT	_	6	NMOD
4	double	double	JJ	_	5	AMOD
5	transgenic	transgenic	JJ	_	6	NMOD
6	mice	mouse	NNS	_	2	PMOD
7	showed	show	VBD	_	0	ROOT
8	similar	similar	JJ	_	10	NMOD
9	circular	circular	JJ	_	10	NMOD
10	patterns	pattern	NNS	_	7	OBJ
11	of	of	IN	_	10	NMOD
12	swimming	swimming	NN	_	11	PMOD
13	near	near	IN	_	10	LOC
14	the	the	DT	_	15	NMOD
15	edge	edge	NN	_	13	PMOD
16	of	of	IN	_	15	NMOD
17	the	the	DT	_	18	NMOD
18	tank	tank	NN	_	16	PMOD
19	when	when	WRB	_	20	TMP
20	tested	test	VBN	_	7	TMP
21	in	in	IN	_	20	LOC
22	the	the	DT	_	25	NMOD
23	Morris	morris	NNP	_	25	NMOD
24	water	water	NN	_	25	NMOD
25	maze	maze	NN	_	21	PMOD
26	.	.	.	_	7	P

1	Expression	expression	NN	_	5	SBJ
2	of	of	IN	_	1	NMOD
3	this	this	DT	_	4	NMOD
4	phenotype	phenotype	NN	_	2	PMOD
5	makes	make	VBZ	_	0	ROOT
6	standard	standard	JJ	_	7	NMOD
7	tests	test	NNS	_	5	OBJ
8	of	of	IN	_	7	NMOD
9	learning	learning	NN	_	8	PMOD
10	and	and	CC	_	9	COORD
11	memory	memory	NN	_	10	CONJ
12	uninterpretable	uninterpretable	JJ	_	7	OPRD
13	.	.	.	_	5	P

1	Hyperactivity	hyperactivity	NN	_	3	SBJ
2	nonspecifically	nonspecifically	RB	_	3	MNR
3	inhibits	inhibit	VBZ	_	0	ROOT
4	choice	choice	NN	_	6	AMOD
5	-	-	HYPH	_	4	P
6	driven	drive	VBN	_	7	NMOD
7	changes	change	NNS	_	3	OBJ
8	in	in	IN	_	7	NMOD
9	movement	movement	NN	_	8	PMOD
10	,	,	,	_	7	P
11	the	the	DT	_	13	NMOD
12	key	key	JJ	_	13	NMOD
13	element	element	NN	_	7	APPO
14	behind	behind	IN	_	13	NMOD
15	all	all	DT	_	18	NMOD
16	cognitive	cognitive	JJ	_	18	NMOD
17	behavioral	behavioral	JJ	_	18	NMOD
18	paradigms	paradigm	NNS	_	14	PMOD
19	.	.	.	_	3	P

1	We	we	PRP	_	2	SBJ
2	are	be	VBP	_	0	ROOT
3	currently	currently	RB	_	2	TMP
4	working	work	VBG	_	2	VC
5	to	to	TO	_	4	OPRD
6	determine	determine	VB	_	5	IM
7	whether	whether	IN	_	6	OBJ
8	hyperactivity	hyperactivity	NN	_	9	SBJ
9	correlates	correlate	VBZ	_	7	SUB
10	with	with	IN	_	9	ADV
11	expression	expression	NN	_	10	PMOD
12	of	of	IN	_	11	NMOD
13	the	the	DT	_	17	NMOD
14	APPswe	appswe	NN	_	16	NMOD
15	/	/	HYPH	_	14	P
16	ind	ind	NN	_	17	NMOD
17	holoprotein	holoprotein	NN	_	12	PMOD
18	or	or	CC	_	11	COORD
19	its	its	PRP$	_	21	NMOD
20	proteolytic	proteolytic	JJ	_	21	NMOD
21	derivatives	derivative	NNS	_	18	CONJ
22	.	.	.	_	2	P

1	Preliminary	preliminary	JJ	_	2	NMOD
2	studies	study	NNS	_	3	SBJ
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	hyperactivity	hyperactivity	NN	_	6	SBJ
6	does	do	VBZ	_	4	SUB
7	not	not	RB	_	6	ADV
8	appear	appear	VB	_	6	VC
9	quickly	quickly	RB	_	8	TMP
10	when	when	WRB	_	16	TMP
11	dox	dox	NN	_	13	AMOD
12	-	-	HYPH	_	11	P
13	reared	rear	VBN	_	14	NMOD
14	mice	mouse	NNS	_	15	SBJ
15	are	be	VBP	_	8	TMP
16	shifted	shift	VBN	_	15	VC
17	to	to	IN	_	16	ADV
18	nonmedicated	nonmedicated	JJ	_	19	NMOD
19	diets	diet	NNS	_	17	PMOD
20	(	(	-LRB-	_	26	P
21	J.	j.	NNP	_	23	NMOD
22	L.	l.	NNP	_	23	NMOD
23	J.	j.	NNP	_	26	DEP
24	,	,	,	_	26	P
25	unpublished	unpublished	JJ	_	26	NMOD
26	data	datum	NNS	_	16	PRN
27	)	)	-RRB-	_	26	P
28	.	.	.	_	3	P

1	These	these	DT	_	2	NMOD
2	data	datum	NNS	_	3	SBJ
3	may	may	MD	_	0	ROOT
4	indicate	indicate	VB	_	3	VC
5	that	that	IN	_	4	OBJ
6	the	the	DT	_	8	NMOD
7	neuroactive	neuroactive	JJ	_	8	NMOD
8	culprit	culprit	NN	_	9	SBJ
9	is	be	VBZ	_	5	SUB
10	not	not	RB	_	11	AMOD
11	immediately	immediately	RB	_	9	TMP
12	present	present	JJ	_	9	PRD
13	after	after	IN	_	9	TMP
14	transgenic	transgenic	JJ	_	16	NMOD
15	APP	app	NN	_	16	NMOD
16	synthesis	synthesis	NN	_	17	SBJ
17	is	be	VBZ	_	13	SUB
18	initiated	initiate	VBN	_	17	VC
19	,	,	,	_	9	P
20	but	but	CC	_	9	COORD
21	requires	require	VBZ	_	20	CONJ
22	additional	additional	JJ	_	23	NMOD
23	time	time	NN	_	21	OBJ
24	to	to	TO	_	23	NMOD
25	develop	develop	VB	_	24	IM
26	.	.	.	_	3	P

1	Alternatively	alternatively	RB	_	4	ADV
2	,	,	,	_	4	P
3	hyperactivity	hyperactivity	NN	_	4	SBJ
4	may	may	MD	_	0	ROOT
5	be	be	VB	_	4	VC
6	caused	cause	VBN	_	5	VC
7	by	by	IN	_	6	LGS
8	neuronal	neuronal	JJ	_	9	NMOD
9	alterations	alteration	NNS	_	7	PMOD
10	due	due	IN	_	6	PRP
11	to	to	IN	_	10	PMOD
12	transgene	transgene	NN	_	13	NMOD
13	expression	expression	NN	_	10	PMOD
14	during	during	IN	_	13	TMP
15	early	early	JJ	_	16	AMOD
16	postnatal	postnatal	JJ	_	17	NMOD
17	development	development	NN	_	14	PMOD
18	.	.	.	_	4	P

1	Further	further	JJ	_	2	NMOD
2	experiments	experiment	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	needed	need	VBN	_	3	VC
5	to	to	TO	_	4	PRP
6	distinguish	distinguish	VB	_	5	IM
7	between	between	IN	_	6	ADV
8	these	these	DT	_	9	NMOD
9	possibilities	possibility	NNS	_	7	PMOD
10	.	.	.	_	3	P

1	In	in	IN	_	5	ADV
2	summary	summary	NN	_	1	PMOD
3	,	,	,	_	5	P
4	we	we	PRP	_	5	SBJ
5	demonstrate	demonstrate	VBP	_	0	ROOT
6	that	that	IN	_	5	OBJ
7	abrogating	abrogate	VBG	_	10	SBJ
8	Aβ	aβ	NN	_	9	NMOD
9	production	production	NN	_	7	OBJ
10	halts	halt	VBZ	_	6	SUB
11	the	the	DT	_	12	NMOD
12	progression	progression	NN	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	pathologic	pathologic	JJ	_	15	NMOD
15	changes	change	NNS	_	13	PMOD
16	in	in	IN	_	12	LOC
17	a	a	DT	_	20	NMOD
18	transgenic	transgenic	JJ	_	20	NMOD
19	mouse	mouse	NN	_	20	NMOD
20	model	model	NN	_	16	PMOD
21	of	of	IN	_	20	NMOD
22	Alzheimer	alzheimer	NNP	_	24	NMOD
23	-	-	HYPH	_	22	P
24	type	type	NN	_	25	NMOD
25	amyloidosis	amyloidosis	NN	_	21	PMOD
26	.	.	.	_	5	P

1	However	however	RB	_	12	ADV
2	,	,	,	_	12	P
3	despite	despite	IN	_	12	ADV
4	dramatic	dramatic	JJ	_	5	NMOD
5	reductions	reduction	NNS	_	3	PMOD
6	in	in	IN	_	5	NMOD
7	Aβ	aβ	NN	_	8	NMOD
8	synthesis	synthesis	NN	_	6	PMOD
9	,	,	,	_	12	P
10	neuritic	neuritic	JJ	_	11	NMOD
11	plaques	plaque	NNS	_	12	SBJ
12	are	be	VBP	_	0	ROOT
13	stable	stable	JJ	_	14	NMOD
14	structures	structure	NNS	_	12	PRD
15	in	in	FW	_	16	AMOD
16	vivo	vivo	FW	_	14	NMOD
17	that	that	WDT	_	18	SBJ
18	do	do	VBP	_	14	NMOD
19	not	not	RB	_	18	ADV
20	quickly	quickly	RB	_	18	TMP
21	disaggregate	disaggregate	VB	_	18	VC
22	.	.	.	_	12	P

1	It	it	PRP	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	possible	possible	JJ	_	2	PRD
4	that	that	IN	_	2	OBJ
5	a	a	DT	_	6	NMOD
6	combination	combination	NN	_	24	SBJ
7	of	of	IN	_	6	NMOD
8	therapies	therapy	NNS	_	7	PMOD
9	to	to	TO	_	8	NMOD
10	limit	limit	VB	_	9	IM
11	Aβ	aβ	NN	_	12	NMOD
12	production	production	NN	_	10	OBJ
13	,	,	,	_	10	P
14	increase	increase	VB	_	10	CONJ
15	Aβ	aβ	NN	_	16	NMOD
16	degradation	degradation	NN	_	14	OBJ
17	,	,	,	_	14	P
18	and	and	CC	_	14	COORD
19	enhance	enhance	VBP	_	18	CONJ
20	phagocytosis	phagocytosis	NN	_	19	OBJ
21	of	of	IN	_	20	NMOD
22	deposited	deposit	VBN	_	23	NMOD
23	amyloid	amyloid	NN	_	21	PMOD
24	may	may	MD	_	4	SUB
25	be	be	VB	_	24	VC
26	required	require	VBN	_	25	VC
27	to	to	TO	_	26	PRP
28	reverse	reverse	VB	_	27	IM
29	damage	damage	NN	_	28	OBJ
30	associated	associate	VBN	_	29	NMOD
31	with	with	IN	_	30	ADV
32	AD	ad	NN	_	31	PMOD
33	.	.	.	_	2	P

1	However	however	RB	_	16	ADV
2	,	,	,	_	16	P
3	if	if	IN	_	16	ADV
4	started	start	VBN	_	3	SUB
5	early	early	RB	_	6	AMOD
6	enough	enough	RB	_	4	TMP
7	in	in	IN	_	4	ADV
8	the	the	DT	_	9	NMOD
9	course	course	NN	_	7	PMOD
10	of	of	IN	_	9	NMOD
11	disease	disease	NN	_	10	PMOD
12	,	,	,	_	16	P
13	secretase	secretase	NN	_	14	NMOD
14	inhibitors	inhibitor	NNS	_	16	SBJ
15	alone	alone	RB	_	14	NMOD
16	could	could	MD	_	0	ROOT
17	provide	provide	VB	_	16	VC
18	substantial	substantial	JJ	_	19	NMOD
19	benefit	benefit	NN	_	17	OBJ
20	in	in	IN	_	19	NMOD
21	slowing	slow	VBG	_	20	PMOD
22	pathogenic	pathogenic	JJ	_	23	NMOD
23	processes	process	NNS	_	21	OBJ
24	linked	link	VBN	_	23	NMOD
25	to	to	IN	_	24	ADV
26	amyloid	amyloid	NN	_	27	NMOD
27	deposition	deposition	NN	_	25	PMOD
28	.	.	.	_	16	P

1	Even	even	RB	_	2	PMOD
2	at	at	IN	_	21	TMP
3	later	late	JJR	_	4	NMOD
4	stages	stage	NNS	_	2	PMOD
5	in	in	IN	_	4	NMOD
6	the	the	DT	_	7	NMOD
7	disease	disease	NN	_	5	PMOD
8	,	,	,	_	21	P
9	the	the	DT	_	10	NMOD
10	presence	presence	NN	_	21	SBJ
11	of	of	IN	_	10	NMOD
12	substantial	substantial	JJ	_	14	NMOD
13	microglial	microglial	JJ	_	14	NMOD
14	activation	activation	NN	_	11	PMOD
15	in	in	IN	_	10	LOC
16	human	human	JJ	_	17	NMOD
17	AD	ad	NN	_	15	PMOD
18	[	[	-LRB-	_	19	P
19	40	0	CD	_	17	PRN
20	]	]	-RRB-	_	19	P
21	suggests	suggest	VBZ	_	0	ROOT
22	that	that	IN	_	21	OBJ
23	simply	simply	RB	_	24	ADV
24	slowing	slow	VBG	_	31	SBJ
25	the	the	DT	_	26	NMOD
26	formation	formation	NN	_	24	OBJ
27	of	of	IN	_	26	NMOD
28	new	new	JJ	_	30	NMOD
29	amyloid	amyloid	NN	_	30	NMOD
30	deposits	deposit	NNS	_	27	PMOD
31	may	may	MD	_	22	SUB
32	allow	allow	VB	_	31	VC
33	ongoing	ongoing	JJ	_	34	NMOD
34	phagocytosis	phagocytosis	NN	_	35	SBJ
35	to	to	TO	_	32	OPRD
36	diminish	diminish	VB	_	35	IM
37	preexisting	preexisting	JJ	_	38	NMOD
38	lesions	lesion	NNS	_	36	OBJ
39	.	.	.	_	21	P

1	However	however	RB	_	11	ADV
2	,	,	,	_	11	P
3	the	the	DT	_	4	NMOD
4	development	development	NN	_	11	SBJ
5	of	of	IN	_	4	NMOD
6	safe	safe	JJ	_	10	NMOD
7	and	and	CC	_	6	COORD
8	effective	effective	JJ	_	7	CONJ
9	secretase	secretase	NN	_	10	NMOD
10	inhibitors	inhibitor	NNS	_	5	PMOD
11	will	will	MD	_	0	ROOT
12	ultimately	ultimately	RB	_	11	TMP
13	be	be	VB	_	11	VC
14	required	require	VBN	_	13	VC
15	to	to	TO	_	14	PRP
16	determine	determine	VB	_	15	IM
17	whether	whether	IN	_	16	OBJ
18	the	the	DT	_	20	NMOD
19	human	human	JJ	_	20	NMOD
20	brain	brain	NN	_	21	SBJ
21	has	have	VBZ	_	17	SUB
22	the	the	DT	_	23	NMOD
23	capacity	capacity	NN	_	21	OBJ
24	to	to	TO	_	23	NMOD
25	repair	repair	VB	_	24	IM
26	amyloid	amyloid	NN	_	28	AMOD
27	-	-	HYPH	_	26	P
28	associated	associate	VBN	_	29	NMOD
29	damage	damage	NN	_	25	OBJ
30	of	of	IN	_	29	NMOD
31	AD	ad	NN	_	30	PMOD
32	once	once	IN	_	25	TMP
33	the	the	DT	_	34	NMOD
34	progression	progression	NN	_	37	SBJ
35	of	of	IN	_	34	NMOD
36	pathology	pathology	NN	_	35	PMOD
37	is	be	VBZ	_	32	SUB
38	arrested	arrest	VBN	_	37	VC
39	.	.	.	_	11	P

1	Supporting	support	VBG	_	2	NMOD
2	Information	information	NN	_	0	ROOT

1	Figure	figure	NN	_	2	NMOD
2	S1	s0	NN	_	0	ROOT

1	Transgenic	transgenic	JJ	_	3	NMOD
2	APP	app	NN	_	3	NMOD
3	Expression	expression	NN	_	0	ROOT
4	and	and	CC	_	3	COORD
5	Suppression	suppression	NN	_	4	CONJ
6	by	by	IN	_	3	NMOD
7	Dox	dox	NN	_	6	PMOD
8	in	in	IN	_	3	LOC
9	the	the	DT	_	16	NMOD
10	Four	four	CD	_	16	NMOD
11	New	new	JJ	_	16	NMOD
12	Tet	tet	NN	_	14	NMOD
13	-	-	HYPH	_	12	P
14	Off	off	NN	_	16	NMOD
15	APP	app	NN	_	16	NMOD
16	Lines	line	NNS	_	8	PMOD

1	Western	western	NNP	_	2	NMOD
2	blotting	blotting	NN	_	9	SBJ
3	with	with	IN	_	2	NMOD
4	human	human	JJ	_	6	AMOD
5	-	-	HYPH	_	4	P
6	specific	specific	JJ	_	8	NMOD
7	antibody	antibody	NN	_	8	NMOD
8	6E10	0e0	NN	_	3	PMOD
9	reveals	reveal	VBZ	_	0	ROOT
10	transgene	transgene	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	derived	derive	VBN	_	16	NMOD
13	full	full	JJ	_	15	NMOD
14	-	-	HYPH	_	13	P
15	length	length	NN	_	16	NMOD
16	APP	app	NN	_	9	OBJ
17	in	in	IN	_	9	ADV
18	cortical	cortical	JJ	_	19	NMOD
19	homogenates	homogenate	NNS	_	17	PMOD
20	from	from	IN	_	19	NMOD
21	untreated	untreated	JJ	_	22	NMOD
22	animals	animal	NNS	_	20	PMOD
23	(	(	-LRB-	_	25	P
24	left	left	JJ	_	25	NMOD
25	lanes	lane	NNS	_	9	PRN
26	of	of	IN	_	25	NMOD
27	each	each	DT	_	28	NMOD
28	panel	panel	NN	_	26	PMOD
29	)	)	-RRB-	_	25	P
30	.	.	.	_	9	P

1	The	the	DT	_	3	NMOD
2	new	new	JJ	_	3	NMOD
3	lines	line	NNS	_	4	SBJ
4	produce	produce	VBP	_	24	DEP
5	exceptionally	exceptionally	RB	_	6	AMOD
6	high	high	JJ	_	7	NMOD
7	levels	level	NNS	_	4	OBJ
8	of	of	IN	_	7	NMOD
9	transgene	transgene	NN	_	10	NMOD
10	expression	expression	NN	_	8	PMOD
11	;	;	:	_	24	P
12	an	an	DT	_	14	NMOD
13	equal	equal	JJ	_	14	NMOD
14	amount	amount	NN	_	24	SBJ
15	of	of	IN	_	14	NMOD
16	brain	brain	NN	_	17	NMOD
17	homogenate	homogenate	NN	_	15	PMOD
18	from	from	IN	_	17	NMOD
19	a	a	DT	_	23	NMOD
20	standard	standard	JJ	_	23	NMOD
21	transgenic	transgenic	JJ	_	23	NMOD
22	APP	app	NN	_	23	NMOD
23	line	line	NN	_	18	PMOD
24	is	be	VBZ	_	0	ROOT
25	shown	show	VBN	_	24	VC
26	for	for	IN	_	25	ADV
27	comparison	comparison	NN	_	26	PMOD
28	(	(	-LRB-	_	43	P
29	extreme	extreme	JJ	_	31	NMOD
30	left	left	JJ	_	31	NMOD
31	lane	lane	NN	_	43	DEP
32	,	,	,	_	43	P
33	Standard	standard	JJ	_	36	NMOD
34	Tg	tg	NN	_	36	NMOD
35	line	line	NN	_	36	NMOD
36	C3	c0	NN	_	43	DEP
37	–	–	HYPH	_	36	P
38	3	0	CD	_	36	NMOD
39	;	;	:	_	43	P
40	[	[	-LRB-	_	43	P
41	15	0	CD	_	43	NMOD
42	,	,	,	_	43	P
43	63	0	CD	_	25	PRN
44	]	]	-RRB-	_	43	P
45	)	)	-RRB-	_	43	P
46	.	.	.	_	24	P

1	After	after	IN	_	19	TMP
2	1	0	CD	_	3	NMOD
3	mo	mo	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	dox	dox	NN	_	6	NMOD
6	treatment	treatment	NN	_	4	PMOD
7	,	,	,	_	19	P
8	transgenic	transgenic	JJ	_	9	NMOD
9	protein	protein	NN	_	19	SBJ
10	in	in	IN	_	9	NMOD
11	all	all	DT	_	18	NMOD
12	four	four	CD	_	18	NMOD
13	new	new	JJ	_	18	NMOD
14	tet	tet	NN	_	16	NMOD
15	-	-	HYPH	_	14	P
16	off	off	NN	_	18	NMOD
17	APP	app	NN	_	18	NMOD
18	lines	line	NNS	_	10	PMOD
19	is	be	VBZ	_	0	ROOT
20	reduced	reduce	VBN	_	19	VC
21	to	to	IN	_	20	ADV
22	residual	residual	JJ	_	23	NMOD
23	levels	level	NNS	_	21	PMOD
24	(	(	-LRB-	_	29	P
25	+	+	SYM	_	26	P
26	dox	dox	NN	_	29	DEP
27	;	;	:	_	29	P
28	right	right	JJ	_	29	NMOD
29	lanes	lane	NNS	_	20	PRN
30	of	of	IN	_	29	NMOD
31	each	each	DT	_	32	NMOD
32	panel	panel	NN	_	30	PMOD
33	)	)	-RRB-	_	29	P
34	.	.	.	_	19	P

1	(	(	-LRB-	_	4	P
2	474	0	CD	_	3	NMOD
3	KB	kb	NN	_	4	NMOD
4	TIF	tif	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	LOC
3	for	for	IN	_	1	ADV
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Figure	figure	NN	_	2	NMOD
2	S2	s0	NN	_	0	ROOT

1	Transgenic	transgenic	JJ	_	3	NMOD
2	APP	app	NN	_	3	NMOD
3	mRNA	mrna	NN	_	4	SBJ
4	Is	be	VBZ	_	0	ROOT
5	Brain	brain	NN	_	7	AMOD
6	-	-	HYPH	_	5	P
7	Specific	specific	JJ	_	4	PRD

1	A	a	DT	_	3	NMOD
2	slot	slot	NN	_	3	NMOD
3	blot	blot	NN	_	25	SBJ
4	of	of	IN	_	3	NMOD
5	mRNA	mrna	NN	_	4	PMOD
6	harvested	harvest	VBN	_	5	NMOD
7	from	from	IN	_	6	ADV
8	various	various	JJ	_	9	NMOD
9	tissues	tissue	NNS	_	7	PMOD
10	in	in	IN	_	6	LOC
11	three	three	CD	_	10	PMOD
12	of	of	IN	_	11	NMOD
13	the	the	DT	_	20	NMOD
14	four	four	CD	_	20	NMOD
15	new	new	JJ	_	20	NMOD
16	tet	tet	NN	_	18	NMOD
17	-	-	HYPH	_	16	P
18	off	off	NN	_	20	NMOD
19	APP	app	NN	_	20	NMOD
20	lines	line	NNS	_	12	PMOD
21	and	and	CC	_	20	COORD
22	a	a	DT	_	24	NMOD
23	nontransgenic	nontransgenic	JJ	_	24	NMOD
24	control	control	NN	_	21	CONJ
25	was	be	VBD	_	0	ROOT
26	used	use	VBN	_	25	VC
27	to	to	TO	_	26	PRP
28	examine	examine	VB	_	27	IM
29	transgenic	transgenic	JJ	_	31	NMOD
30	mRNA	mrna	NN	_	31	NMOD
31	expression	expression	NN	_	28	OBJ
32	.	.	.	_	25	P

1	Hybridization	hybridization	NN	_	2	SBJ
2	is	be	VBZ	_	13	DEP
3	seen	see	VBN	_	2	VC
4	only	only	RB	_	5	PMOD
5	in	in	IN	_	3	LOC
6	the	the	DT	_	7	NMOD
7	brain	brain	NN	_	5	PMOD
8	;	;	:	_	13	P
9	no	no	DT	_	10	NMOD
10	signal	signal	NN	_	13	SBJ
11	above	above	IN	_	10	NMOD
12	background	background	NN	_	11	PMOD
13	is	be	VBZ	_	0	ROOT
14	seen	see	VBN	_	13	VC
15	in	in	IN	_	14	LOC
16	any	any	DT	_	18	NMOD
17	other	other	JJ	_	18	NMOD
18	tissue	tissue	NN	_	15	PMOD
19	.	.	.	_	13	P

1	(	(	-LRB-	_	4	P
2	781	0	CD	_	3	NMOD
3	KB	kb	NN	_	4	NMOD
4	PSD	psd	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	LOC
3	for	for	IN	_	1	ADV
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Figure	figure	NN	_	2	NMOD
2	S3	s0	NN	_	0	ROOT

1	Amyloid	amyloid	NN	_	2	NMOD
2	Pathology	pathology	NN	_	6	SBJ
3	in	in	IN	_	2	NMOD
4	the	the	DT	_	5	NMOD
5	Cortex	cortex	NN	_	3	PMOD
6	Reiterates	reiterate	VBZ	_	0	ROOT
7	That	that	DT	_	6	OBJ
8	in	in	IN	_	7	NMOD
9	the	the	DT	_	10	NMOD
10	Hippocampus	hippocampus	NN	_	8	PMOD

1	Amyloid	amyloid	NN	_	2	NMOD
2	histology	histology	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	performed	perform	VBN	_	3	VC
5	on	on	IN	_	4	ADV
6	sections	section	NNS	_	5	PMOD
7	from	from	IN	_	6	NMOD
8	line	line	NN	_	12	NMOD
9	107	0	CD	_	12	NMOD
10	double	double	JJ	_	11	AMOD
11	transgenic	transgenic	JJ	_	12	NMOD
12	mice	mouse	NNS	_	7	PMOD
13	by	by	IN	_	4	LGS
14	Hirano	hirano	NNP	_	16	NMOD
15	silver	silver	NN	_	16	NMOD
16	stain	stain	NN	_	13	PMOD
17	(	(	-LRB-	_	19	P
18	top	top	JJ	_	19	NMOD
19	row	row	NN	_	16	PRN
20	)	)	-RRB-	_	19	P
21	,	,	,	_	16	P
22	thioflavin	thioflavin	NN	_	24	NMOD
23	-	-	HYPH	_	22	P
24	S	s	NN	_	16	CONJ
25	(	(	-LRB-	_	27	P
26	middle	middle	JJ	_	27	NMOD
27	row	row	NN	_	24	PRN
28	)	)	-RRB-	_	27	P
29	,	,	,	_	24	P
30	and	and	CC	_	24	COORD
31	Aβ	aβ	NN	_	32	NMOD
32	immunohistochemistry	immunohistochemistry	NN	_	30	CONJ
33	(	(	-LRB-	_	35	P
34	bottom	bottom	JJ	_	35	NMOD
35	row	row	NN	_	32	PRN
36	)	)	-RRB-	_	35	P
37	to	to	TO	_	4	PRP
38	examine	examine	VB	_	37	IM
39	the	the	DT	_	40	NMOD
40	persistence	persistence	NN	_	38	OBJ
41	of	of	IN	_	40	NMOD
42	pathology	pathology	NN	_	41	PMOD
43	following	follow	VBG	_	40	TMP
44	transgene	transgene	NN	_	45	NMOD
45	suppression	suppression	NN	_	43	PMOD
46	.	.	.	_	3	P

1	As	as	IN	_	21	ADV
2	in	in	IN	_	1	LOC
3	the	the	DT	_	4	NMOD
4	hippocampus	hippocampus	NN	_	2	PMOD
5	(	(	-LRB-	_	6	P
6	see	see	VB	_	4	PRN
7	Figure	figure	NN	_	6	OBJ
8	4	0	CD	_	7	NMOD
9	and	and	CC	_	7	COORD
10	text	text	NN	_	9	CONJ
11	)	)	-RRB-	_	6	P
12	,	,	,	_	21	P
13	the	the	DT	_	14	NMOD
14	progression	progression	NN	_	21	SBJ
15	of	of	IN	_	14	NMOD
16	amyloid	amyloid	NN	_	17	NMOD
17	pathology	pathology	NN	_	15	PMOD
18	in	in	IN	_	14	LOC
19	the	the	DT	_	20	NMOD
20	cortex	cortex	NN	_	18	PMOD
21	worsens	worsen	VBZ	_	0	ROOT
22	substantially	substantially	RB	_	21	ADV
23	between	between	IN	_	21	TMP
24	6	0	CD	_	27	NMOD
25	and	and	CC	_	24	COORD
26	9	0	CD	_	25	CONJ
27	mo	mo	NN	_	23	PMOD
28	of	of	IN	_	27	NMOD
29	age	age	NN	_	28	PMOD
30	in	in	IN	_	21	LOC
31	untreated	untreated	JJ	_	32	NMOD
32	mice	mouse	NNS	_	30	PMOD
33	.	.	.	_	21	P

1	This	this	DT	_	2	NMOD
2	progression	progression	NN	_	3	SBJ
3	is	be	VBZ	_	0	ROOT
4	completely	completely	RB	_	3	ADV
5	prevented	prevent	VBN	_	3	VC
6	by	by	IN	_	5	LGS
7	suppression	suppression	NN	_	6	PMOD
8	of	of	IN	_	7	NMOD
9	the	the	DT	_	10	NMOD
10	transgene	transgene	NN	_	8	PMOD
11	with	with	IN	_	7	NMOD
12	dox	dox	NN	_	11	PMOD
13	.	.	.	_	3	P

1	For	for	IN	_	6	ADV
2	comparison	comparison	NN	_	1	PMOD
3	,	,	,	_	6	P
4	normal	normal	JJ	_	5	NMOD
5	neurohistology	neurohistology	NN	_	6	SBJ
6	is	be	VBZ	_	0	ROOT
7	shown	show	VBN	_	6	VC
8	in	in	IN	_	7	LOC
9	an	an	DT	_	19	NMOD
10	age	age	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	matched	match	VBN	_	19	NMOD
13	single	single	JJ	_	14	AMOD
14	transgenic	transgenic	JJ	_	19	NMOD
15	(	(	-LRB-	_	16	P
16	tTA	tta	NN	_	14	PRN
17	only	only	RB	_	16	NMOD
18	)	)	-RRB-	_	16	P
19	animal	animal	NN	_	8	PMOD
20	.	.	.	_	6	P

1	No	no	DT	_	3	NMOD
2	amyloid	amyloid	NN	_	3	NMOD
3	pathology	pathology	NN	_	4	SBJ
4	has	have	VBZ	_	0	ROOT
5	been	be	VBN	_	4	VC
6	detected	detect	VBN	_	5	VC
7	in	in	IN	_	6	LOC
8	either	either	CC	_	9	COORD
9	APP	app	NN	_	14	NMOD
10	or	or	CC	_	9	COORD
11	tTA	tta	NN	_	10	CONJ
12	single	single	JJ	_	13	AMOD
13	transgenic	transgenic	JJ	_	14	NMOD
14	animals	animal	NNS	_	7	PMOD
15	up	up	IN	_	17	QMOD
16	to	to	IN	_	17	QMOD
17	15	0	CD	_	18	NMOD
18	mo	mo	NN	_	14	TMP
19	of	of	IN	_	18	NMOD
20	age	age	NN	_	19	PMOD
21	.	.	.	_	4	P

1	(	(	-LRB-	_	4	P
2	4.8	0	CD	_	3	NMOD
3	MB	mb	NN	_	4	NMOD
4	PSD	psd	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	ADV
3	for	for	IN	_	1	ADV
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Figure	figure	NN	_	2	NMOD
2	S4	s0	NN	_	0	ROOT

1	Diffuse	diffuse	NN	_	2	NMOD
2	Deposits	deposit	NNS	_	3	SBJ
3	Do	do	VBP	_	0	ROOT
4	Not	not	RB	_	3	ADV
5	Disperse	disperse	VB	_	3	VC
6	During	during	IN	_	5	TMP
7	Aβ	aβ	NN	_	8	NMOD
8	Suppression	suppression	NN	_	6	PMOD

1	Campbell	campbell	NNP	_	3	NMOD
2	–	–	HYPH	_	1	P
3	Switzer	switzer	NNP	_	5	NMOD
4	silver	silver	NN	_	5	NMOD
5	stain	stain	NN	_	6	SBJ
6	was	be	VBD	_	0	ROOT
7	used	use	VBN	_	6	VC
8	to	to	TO	_	7	PRP
9	differentiate	differentiate	VB	_	8	IM
10	cored	core	VBN	_	9	OPRD
11	(	(	-LRB-	_	12	P
12	brown	brown	JJ	_	10	PRN
13	)	)	-RRB-	_	12	P
14	from	from	IN	_	9	ADV
15	diffuse	diffuse	JJ	_	19	NMOD
16	(	(	-LRB-	_	17	P
17	black	black	JJ	_	15	PRN
18	)	)	-RRB-	_	17	P
19	deposits	deposit	NNS	_	14	PMOD
20	in	in	IN	_	9	LOC
21	line	line	NN	_	26	NMOD
22	107	0	CD	_	21	NMOD
23	tTA	tta	NN	_	25	NMOD
24	/	/	HYPH	_	23	P
25	APP	app	NN	_	26	NMOD
26	mice	mouse	NNS	_	20	PMOD
27	.	.	.	_	6	P

1	This	this	DT	_	2	NMOD
2	stain	stain	NN	_	3	SBJ
3	demonstrates	demonstrate	VBZ	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	both	both	DT	_	6	NMOD
6	types	type	NNS	_	9	SBJ
7	of	of	IN	_	6	NMOD
8	deposit	deposit	NN	_	7	PMOD
9	persist	persist	VBP	_	4	SUB
10	throughout	throughout	IN	_	9	TMP
11	long	long	JJ	_	12	NMOD
12	periods	period	NNS	_	10	PMOD
13	of	of	IN	_	12	NMOD
14	transgene	transgene	NN	_	15	NMOD
15	suppression	suppression	NN	_	13	PMOD
16	.	.	.	_	3	P

1	The	the	DT	_	3	NMOD
2	lower	low	JJ	_	3	NMOD
3	panels	panel	NNS	_	21	SBJ
4	,	,	,	_	3	P
5	showing	show	VBG	_	3	NMOD
6	low	low	JJ	_	8	NMOD
7	-	-	HYPH	_	6	P
8	power	power	NN	_	9	NMOD
9	images	image	NNS	_	5	OBJ
10	(	(	-LRB-	_	11	P
11	10	0	CD	_	9	PRN
12	×	×	SYM	_	11	P
13	)	)	-RRB-	_	11	P
14	of	of	IN	_	9	NMOD
15	frontal	frontal	JJ	_	16	NMOD
16	cortex	cortex	NN	_	14	PMOD
17	from	from	IN	_	9	NMOD
18	each	each	DT	_	19	NMOD
19	condition	condition	NN	_	17	PMOD
20	,	,	,	_	21	P
21	reveal	reveal	VBP	_	0	ROOT
22	little	little	JJ	_	23	NMOD
23	change	change	NN	_	21	OBJ
24	in	in	IN	_	23	NMOD
25	the	the	DT	_	26	NMOD
26	extent	extent	NN	_	24	PMOD
27	of	of	IN	_	26	NMOD
28	diffuse	diffuse	JJ	_	29	NMOD
29	amyloid	amyloid	NN	_	27	PMOD
30	following	follow	VBG	_	21	TMP
31	up	up	IN	_	33	QMOD
32	to	to	IN	_	33	QMOD
33	6	0	CD	_	34	NMOD
34	mo	mo	NN	_	30	PMOD
35	of	of	IN	_	34	NMOD
36	Aβ	aβ	NN	_	37	NMOD
37	suppression	suppression	NN	_	35	PMOD
38	.	.	.	_	21	P

1	High	high	JJ	_	3	NMOD
2	-	-	HYPH	_	1	P
3	power	power	NN	_	4	NMOD
4	images	image	NNS	_	13	SBJ
5	(	(	-LRB-	_	6	P
6	40	0	CD	_	4	PRN
7	×	×	SYM	_	6	P
8	)	)	-RRB-	_	6	P
9	in	in	IN	_	4	NMOD
10	the	the	DT	_	12	NMOD
11	upper	upper	JJ	_	12	NMOD
12	panels	panel	NNS	_	9	PMOD
13	show	show	VBP	_	0	ROOT
14	that	that	IN	_	13	OBJ
15	the	the	DT	_	17	NMOD
16	diffuse	diffuse	JJ	_	17	NMOD
17	halo	halo	NN	_	22	SBJ
18	surrounding	surround	VBG	_	17	NMOD
19	individual	individual	JJ	_	21	NMOD
20	cored	core	VBN	_	21	NMOD
21	deposits	deposit	NNS	_	18	OBJ
22	remains	remain	VBZ	_	14	SUB
23	relatively	relatively	RB	_	24	AMOD
24	unchanged	unchanged	JJ	_	22	PRD
25	in	in	IN	_	22	LOC
26	treated	treat	VBN	_	27	NMOD
27	mice	mouse	NNS	_	25	PMOD
28	.	.	.	_	13	P

1	Untreated	untreated	JJ	_	5	NMOD
2	tTA	tta	NN	_	5	NMOD
3	single	single	JJ	_	4	AMOD
4	transgenic	transgenic	JJ	_	5	NMOD
5	animals	animal	NNS	_	6	SBJ
6	are	be	VBP	_	0	ROOT
7	shown	show	VBN	_	6	VC
8	as	as	IN	_	7	ADV
9	a	a	DT	_	11	NMOD
10	negative	negative	JJ	_	11	NMOD
11	control	control	NN	_	8	PMOD
12	.	.	.	_	6	P

1	Protocol	protocol	NN	_	10	SBJ
2	for	for	IN	_	1	NMOD
3	the	the	DT	_	9	NMOD
4	Campbell	campbell	NNP	_	6	NMOD
5	-	-	HYPH	_	4	P
6	Switzer	switzer	NNP	_	9	NMOD
7	Alzheimer	alzheimer	NNP	_	9	NMOD
8	's	's	POS	_	7	NMOD
9	Method	method	NN	_	2	PMOD
10	was	be	VBD	_	0	ROOT
11	kindly	kindly	RB	_	10	ADV
12	shared	share	VBN	_	10	VC
13	by	by	IN	_	12	LGS
14	Robert	robert	NNP	_	15	NMOD
15	Switzer	switzer	NNP	_	13	PMOD
16	,	,	,	_	15	P
17	III	iii	CD	_	15	NMOD
18	(	(	-LRB-	_	20	P
19	NeuroScience	neuroscience	NNP	_	20	NMOD
20	Associates	associate	NNPS	_	15	PRN
21	,	,	,	_	20	P
22	Knoxville	knoxville	NNP	_	20	APPO
23	,	,	,	_	22	P
24	Tennessee	tennessee	NNP	_	22	APPO
25	,	,	,	_	24	P
26	United	united	NNP	_	27	NMOD
27	States	state	NNP	_	24	APPO
28	)	)	-RRB-	_	20	P
29	,	,	,	_	10	P
30	and	and	CC	_	10	COORD
31	can	can	MD	_	30	CONJ
32	be	be	VB	_	31	VC
33	downloaded	download	VBN	_	32	VC
34	at	at	IN	_	33	LOC
35	http://www.nsalabs.com/Documents/publications/campbell-switzer_protocol.htm	http://www.nsalabs.com/documents/publications/campbell-switzer_protocol.htm	NN	_	34	PMOD
36	[	[	-LRB-	_	39	P
37	64	0	CD	_	39	NMOD
38	,	,	,	_	39	P
39	65	0	CD	_	35	PRN
40	]	]	-RRB-	_	39	P
41	.	.	.	_	10	P

1	(	(	-LRB-	_	4	P
2	923	0	CD	_	3	NMOD
3	KB	kb	NN	_	4	NMOD
4	JPG	jpg	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	ADV
3	for	for	IN	_	1	PRP
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Figure	figure	NN	_	2	NMOD
2	S5	s0	NN	_	0	ROOT

1	Chronic	chronic	JJ	_	3	NMOD
2	Transgene	transgene	NN	_	3	NMOD
3	Suppression	suppression	NN	_	0	ROOT
4	and	and	CC	_	3	COORD
5	Arrest	arrest	NN	_	4	CONJ
6	of	of	IN	_	3	NMOD
7	Aβ	aβ	NN	_	9	NMOD
8	Aggregate	aggregate	NN	_	9	NMOD
9	Formation	formation	NN	_	6	PMOD
10	in	in	IN	_	9	NMOD
11	an	an	DT	_	13	NMOD
12	Independent	independent	JJ	_	13	NMOD
13	Line	line	NN	_	10	PMOD
14	of	of	IN	_	13	NMOD
15	Tet	tet	NN	_	17	NMOD
16	-	-	HYPH	_	15	P
17	Off	off	NN	_	19	NMOD
18	APP	app	NN	_	19	NMOD
19	Mice	mouse	NNS	_	14	PMOD
20	(	(	-LRB-	_	30	P
21	CaMKIIα	camkiiα	NN	_	29	NMOD
22	-	-	HYPH	_	21	P
23	tTA	tta	NN	_	29	NMOD
24	×	×	SYM	_	29	P
25	tet	tet	NN	_	29	NMOD
26	-	-	HYPH	_	25	P
27	APPswe	appswe	NN	_	29	NMOD
28	/	/	HYPH	_	27	P
29	ind	ind	NN	_	30	NMOD
30	Line	line	NN	_	19	PRN
31	18	0	CD	_	30	NMOD
32	)	)	-RRB-	_	30	P

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	17	DEP
3	)	)	-RRB-	_	2	P
4	The	the	DT	_	5	NMOD
5	experiment	experiment	NN	_	17	SBJ
6	presented	present	VBN	_	5	NMOD
7	in	in	IN	_	6	ADV
8	the	the	DT	_	9	NMOD
9	text	text	NN	_	7	PMOD
10	for	for	IN	_	6	ADV
11	line	line	NN	_	16	NMOD
12	107	0	CD	_	11	NMOD
13	tet	tet	NN	_	15	NMOD
14	-	-	HYPH	_	13	P
15	off	off	NN	_	16	NMOD
16	APP	app	NN	_	10	PMOD
17	was	be	VBD	_	0	ROOT
18	repeated	repeat	VBN	_	17	VC
19	with	with	IN	_	18	ADV
20	a	a	DT	_	26	NMOD
21	second	$#ORD#$	JJ	_	26	NMOD
22	tet	tet	NN	_	24	NMOD
23	-	-	HYPH	_	22	P
24	off	off	NN	_	26	NMOD
25	APP	app	NN	_	26	NMOD
26	line	line	NN	_	19	PMOD
27	(	(	-LRB-	_	28	P
28	line	line	NN	_	26	PRN
29	18	0	CD	_	28	NMOD
30	)	)	-RRB-	_	28	P
31	to	to	TO	_	18	PRP
32	control	control	VB	_	31	IM
33	for	for	IN	_	32	ADV
34	integration	integration	NN	_	35	NMOD
35	site	site	NN	_	36	NMOD
36	artifacts	artifact	NNS	_	33	PMOD
37	.	.	.	_	17	P

1	Cortical	cortical	JJ	_	2	NMOD
2	homogenates	homogenate	NNS	_	13	SBJ
3	from	from	IN	_	2	NMOD
4	untreated	untreated	JJ	_	5	NMOD
5	control	control	NN	_	12	NMOD
6	and	and	CC	_	5	COORD
7	dox	dox	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	treated	treat	VBN	_	11	AMOD
10	double	double	JJ	_	11	AMOD
11	transgenic	transgenic	JJ	_	6	CONJ
12	mice	mouse	NNS	_	3	PMOD
13	were	be	VBD	_	0	ROOT
14	immunoblotted	immunoblotted	VBN	_	13	VC
15	for	for	IN	_	14	PRP
16	full	full	JJ	_	18	NMOD
17	-	-	HYPH	_	16	P
18	length	length	NN	_	19	NMOD
19	APP	app	NN	_	15	PMOD
20	with	with	IN	_	14	ADV
21	the	the	DT	_	26	NMOD
22	human	human	JJ	_	24	AMOD
23	-	-	HYPH	_	22	P
24	specific	specific	JJ	_	26	NMOD
25	antibody	antibody	NN	_	26	NMOD
26	6E10	0e0	NN	_	20	PMOD
27	to	to	TO	_	14	PRP
28	confirm	confirm	VB	_	27	IM
29	transgene	transgene	NN	_	30	NMOD
30	suppression	suppression	NN	_	28	OBJ
31	at	at	IN	_	28	ADV
32	the	the	DT	_	33	NMOD
33	time	time	NN	_	31	PMOD
34	of	of	IN	_	33	NMOD
35	harvest	harvest	NN	_	34	PMOD
36	.	.	.	_	13	P

1	Immunostaining	immunostaining	NN	_	9	SBJ
2	for	for	IN	_	1	NMOD
3	endogenous	endogenous	JJ	_	5	NMOD
4	superoxide	superoxide	NN	_	5	NMOD
5	dismutase	dismutase	NN	_	2	PMOD
6	(	(	-LRB-	_	7	P
7	SOD1	sod0	NN	_	5	PRN
8	)	)	-RRB-	_	7	P
9	was	be	VBD	_	0	ROOT
10	included	include	VBN	_	9	VC
11	as	as	IN	_	10	ADV
12	a	a	DT	_	14	NMOD
13	loading	loading	NN	_	14	NMOD
14	control	control	NN	_	11	PMOD
15	.	.	.	_	9	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	16	DEP
3	)	)	-RRB-	_	2	P
4	Quantitation	quantitation	NN	_	16	SBJ
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	from	from	IN	_	4	NMOD
9	the	the	DT	_	11	NMOD
10	Western	western	NNP	_	11	NMOD
11	blot	blot	NN	_	8	PMOD
12	in	in	IN	_	4	NMOD
13	(	(	-LRB-	_	12	P
14	A	a	NN	_	12	PMOD
15	)	)	-RRB-	_	16	P
16	shows	show	VBZ	_	0	ROOT
17	transgenic	transgenic	JJ	_	19	NMOD
18	APP	app	NN	_	19	NMOD
19	levels	level	NNS	_	23	SBJ
20	in	in	IN	_	19	NMOD
21	line	line	NN	_	20	PMOD
22	18	0	CD	_	21	NMOD
23	are	be	VBP	_	16	OBJ
24	suppressed	suppress	VBN	_	23	VC
25	by	by	IN	_	24	EXT
26	more	more	JJR	_	29	NMOD
27	than	than	IN	_	26	QMOD
28	98	0	CD	_	26	QMOD
29	%	%	NN	_	25	PMOD
30	following	follow	VBG	_	24	TMP
31	3	0	CD	_	32	NMOD
32	mo	mo	NN	_	30	PMOD
33	of	of	IN	_	32	NMOD
34	dox	dox	NN	_	35	NMOD
35	treatment	treatment	NN	_	33	PMOD
36	(	(	-LRB-	_	50	P
37	significant	significant	JJ	_	38	NMOD
38	effect	effect	NN	_	50	DEP
39	of	of	IN	_	38	NMOD
40	group	group	NN	_	41	NMOD
41	ANOVA	anova	NN	_	39	PMOD
42	F2	f0	NN	_	46	SBJ
43	,	,	,	_	42	P
44	8	0	CD	_	42	NMOD
45	=	=	SYM	_	46	P
46	1559.7	0	CD	_	50	DEP
47	,	,	,	_	50	P
48	p	p	NN	_	50	SBJ
49	<	<	SYM	_	50	P
50	0.001	0	CD	_	24	PRN
51	)	)	-RRB-	_	50	P
52	.	.	.	_	16	P

1	This	this	DT	_	2	NMOD
2	level	level	NN	_	5	SBJ
3	of	of	IN	_	2	NMOD
4	suppression	suppression	NN	_	3	PMOD
5	was	be	VBD	_	0	ROOT
6	equal	equal	JJ	_	5	PRD
7	to	to	IN	_	6	AMOD
8	or	or	CC	_	6	COORD
9	better	good	JJR	_	8	CONJ
10	than	than	IN	_	9	AMOD
11	that	that	DT	_	10	PMOD
12	attained	attain	VBN	_	11	NMOD
13	in	in	IN	_	12	ADV
14	line	line	NN	_	13	PMOD
15	107	0	CD	_	14	NMOD
16	(	(	-LRB-	_	17	P
17	see	see	VB	_	5	PRN
18	Figure	figure	NN	_	19	NMOD
19	3B	0b	NN	_	17	OBJ
20	)	)	-RRB-	_	17	P
21	.	.	.	_	5	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	9	DEP
3	)	)	-RRB-	_	2	P
4	Serial	serial	JJ	_	5	NMOD
5	dilution	dilution	NN	_	7	NMOD
6	filter	filter	NN	_	7	NMOD
7	trap	trap	NN	_	8	NMOD
8	assay	assay	NN	_	9	SBJ
9	was	be	VBD	_	0	ROOT
10	used	use	VBN	_	9	VC
11	to	to	TO	_	10	PRP
12	quantify	quantify	VB	_	11	IM
13	aggregated	aggregate	VBN	_	14	NMOD
14	Aβ	aβ	NN	_	12	OBJ
15	in	in	IN	_	12	LOC
16	cortical	cortical	JJ	_	17	NMOD
17	homogenates	homogenate	NNS	_	15	PMOD
18	.	.	.	_	9	P

1	(	(	-LRB-	_	2	P
2	D	d	LS	_	4	NMOD
3	)	)	-RRB-	_	2	P
4	Quantitation	quantitation	NN	_	0	ROOT
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	in	in	IN	_	4	NMOD
9	the	the	DT	_	11	NMOD
10	linear	linear	JJ	_	11	NMOD
11	range	range	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	the	the	DT	_	15	NMOD
14	dilution	dilution	NN	_	15	NMOD
15	series	series	NN	_	12	PMOD
16	shown	show	VBN	_	11	NMOD
17	in	in	IN	_	16	ADV
18	(	(	-LRB-	_	17	P
19	C	c	NN	_	17	PMOD
20	)	)	-RRB-	_	4	P
21	.	.	.	_	4	P

1	Consistent	consistent	JJ	_	13	ADV
2	with	with	IN	_	1	AMOD
3	the	the	DT	_	5	NMOD
4	amyloid	amyloid	NN	_	5	NMOD
5	histology	histology	NN	_	2	PMOD
6	shown	show	VBN	_	5	NMOD
7	in	in	IN	_	6	ADV
8	Figure	figure	NN	_	9	NMOD
9	S5	s0	NN	_	7	PMOD
10	,	,	,	_	13	P
11	aggregate	aggregate	NN	_	12	NMOD
12	formation	formation	NN	_	13	SBJ
13	was	be	VBD	_	0	ROOT
14	significantly	significantly	RB	_	15	AMOD
15	increased	increase	VBN	_	13	PRD
16	between	between	IN	_	13	TMP
17	6	0	CD	_	20	NMOD
18	and	and	CC	_	17	COORD
19	9	0	CD	_	18	CONJ
20	mo	mo	NN	_	16	PMOD
21	of	of	IN	_	20	NMOD
22	age	age	NN	_	21	PMOD
23	in	in	IN	_	13	LOC
24	untreated	untreated	JJ	_	25	NMOD
25	mice	mouse	NNS	_	23	PMOD
26	(	(	-LRB-	_	40	P
27	significant	significant	JJ	_	28	NMOD
28	effect	effect	NN	_	36	SBJ
29	of	of	IN	_	28	NMOD
30	group	group	NN	_	32	NMOD
31	ANOVA	anova	NN	_	32	NMOD
32	F2	f0	NN	_	29	PMOD
33	,	,	,	_	32	P
34	18	0	CD	_	32	NMOD
35	=	=	SYM	_	36	P
36	12.14	0	CD	_	40	DEP
37	,	,	,	_	40	P
38	p	p	NN	_	40	SBJ
39	<	<	SYM	_	40	P
40	0.001	0	CD	_	13	PRN
41	)	)	-RRB-	_	40	P
42	.	.	.	_	13	P

1	Aggregate	aggregate	NN	_	2	NMOD
2	formation	formation	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	completely	completely	RB	_	3	ADV
5	arrested	arrest	VBN	_	3	VC
6	by	by	IN	_	5	ADV
7	transgene	transgene	NN	_	8	NMOD
8	suppression	suppression	NN	_	6	PMOD
9	,	,	,	_	3	P
10	and	and	CC	_	3	COORD
11	is	be	VBZ	_	10	CONJ
12	identical	identical	JJ	_	11	PRD
13	in	in	IN	_	11	LOC
14	9	0	CD	_	16	NMOD
15	-	-	HYPH	_	14	P
16	mo	mo	NN	_	18	AMOD
17	-	-	HYPH	_	16	P
18	old	old	JJ	_	19	NMOD
19	mice	mouse	NNS	_	13	PMOD
20	treated	treat	VBN	_	19	NMOD
21	with	with	IN	_	20	MNR
22	dox	dox	NN	_	21	PMOD
23	for	for	IN	_	20	TMP
24	3	0	CD	_	25	NMOD
25	mo	mo	NN	_	23	PMOD
26	as	as	IN	_	20	ADV
27	in	in	IN	_	26	LOC
28	untreated	untreated	JJ	_	29	NMOD
29	animals	animal	NNS	_	27	PMOD
30	harvested	harvest	VBN	_	29	NMOD
31	when	when	WRB	_	33	TMP
32	treatment	treatment	NN	_	33	SBJ
33	began	begin	VBD	_	30	TMP
34	(	(	-LRB-	_	43	P
35	p	p	NN	_	37	SBJ
36	>	>	SYM	_	37	P
37	0.5	0	CD	_	43	DEP
38	,	,	,	_	43	P
39	Tukey	tukey	NNP	_	43	NMOD
40	post	post	FW	_	42	NMOD
41	-	-	HYPH	_	40	P
42	hoc	hoc	FW	_	43	NMOD
43	test	test	NN	_	33	PRN
44	)	)	-RRB-	_	43	P
45	.	.	.	_	3	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.05	0	CD	_	17	DEP
6	;	;	:	_	17	P
7	**	**	SYM	_	11	DEP
8	,	,	,	_	11	P
9	p	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.005	0	CD	_	17	DEP
12	;	;	:	_	17	P
13	***	***	SYM	_	17	DEP
14	,	,	,	_	17	P
15	p	p	NN	_	17	SBJ
16	<	<	SYM	_	17	P
17	0.001	0	CD	_	31	DEP
18	versus	versus	CC	_	17	COORD
19	9	0	CD	_	21	NMOD
20	-	-	HYPH	_	19	P
21	mo	mo	NN	_	23	AMOD
22	-	-	HYPH	_	21	P
23	old	old	JJ	_	25	NMOD
24	untreated	untreated	JJ	_	25	NMOD
25	mice	mouse	NNS	_	18	CONJ
26	,	,	,	_	31	P
27	Tukey	tukey	NNP	_	31	NMOD
28	post	post	FW	_	30	NMOD
29	-	-	HYPH	_	28	P
30	hoc	hoc	FW	_	31	NMOD
31	test	test	NN	_	0	ROOT
32	.	.	.	_	31	P

1	(	(	-LRB-	_	4	P
2	962	0	CD	_	3	NMOD
3	KB	kb	NN	_	4	NMOD
4	TIF	tif	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	ADV
3	for	for	IN	_	1	ADV
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Figure	figure	NN	_	2	NMOD
2	S6	s0	NN	_	0	ROOT

1	Arrest	arrest	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	Amyloid	amyloid	NN	_	4	NMOD
4	Progression	progression	NN	_	2	PMOD
5	by	by	IN	_	1	NMOD
6	Chronic	chronic	JJ	_	8	NMOD
7	Transgene	transgene	NN	_	8	NMOD
8	Suppression	suppression	NN	_	5	PMOD
9	in	in	IN	_	1	LOC
10	Line	line	NN	_	16	NMOD
11	18	0	CD	_	10	NMOD
12	Tet	tet	NN	_	14	NMOD
13	-	-	HYPH	_	12	P
14	Off	off	NN	_	16	NMOD
15	APP	app	NN	_	16	NMOD
16	Mice	mouse	NNS	_	9	PMOD

1	Amyloid	amyloid	NN	_	2	NMOD
2	histology	histology	NN	_	26	SBJ
3	in	in	IN	_	2	NMOD
4	cortical	cortical	JJ	_	19	NMOD
5	(	(	-LRB-	_	9	P
6	first	$#ORD#$	JJ	_	9	NMOD
7	and	and	CC	_	6	COORD
8	third	$#ORD#$	JJ	_	7	CONJ
9	rows	row	NNS	_	4	PRN
10	)	)	-RRB-	_	9	P
11	and	and	CC	_	4	COORD
12	hippocampal	hippocampal	JJ	_	11	CONJ
13	(	(	-LRB-	_	17	P
14	second	$#ORD#$	JJ	_	17	NMOD
15	and	and	CC	_	14	COORD
16	fourth	$#ORD#$	JJ	_	15	CONJ
17	rows	row	NNS	_	12	PRN
18	)	)	-RRB-	_	17	P
19	sections	section	NNS	_	3	PMOD
20	from	from	IN	_	19	NMOD
21	untreated	untreated	JJ	_	25	NMOD
22	tTA	tta	NN	_	24	NMOD
23	/	/	HYPH	_	22	P
24	APP	app	NN	_	25	NMOD
25	mice	mouse	NNS	_	20	PMOD
26	shows	show	VBZ	_	0	ROOT
27	a	a	DT	_	29	NMOD
28	dramatic	dramatic	JJ	_	29	NMOD
29	progression	progression	NN	_	26	OBJ
30	of	of	IN	_	29	NMOD
31	pathology	pathology	NN	_	30	PMOD
32	between	between	IN	_	26	TMP
33	6	0	CD	_	36	NMOD
34	and	and	CC	_	33	COORD
35	9	0	CD	_	34	CONJ
36	mo	mo	NN	_	32	PMOD
37	of	of	IN	_	36	NMOD
38	age	age	NN	_	37	PMOD
39	.	.	.	_	26	P

1	Suppression	suppression	NN	_	6	SBJ
2	of	of	IN	_	1	NMOD
3	transgenic	transgenic	JJ	_	5	NMOD
4	APP	app	NN	_	5	NMOD
5	expression	expression	NN	_	2	PMOD
6	arrests	arrest	VBZ	_	0	ROOT
7	this	this	DT	_	8	NMOD
8	progression	progression	NN	_	6	OBJ
9	,	,	,	_	6	P
10	although	although	IN	_	6	ADV
11	without	without	IN	_	10	SUB
12	any	any	DT	_	13	NMOD
13	sign	sign	NN	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	plaque	plaque	NN	_	16	NMOD
16	clearance	clearance	NN	_	14	PMOD
17	(	(	-LRB-	_	23	P
18	6	0	CD	_	19	NMOD
19	mo	mo	NN	_	22	NMOD
20	+	+	SYM	_	22	P
21	3	0	CD	_	22	NMOD
22	mo	mo	NN	_	23	NMOD
23	dox	dox	NN	_	6	PRN
24	)	)	-RRB-	_	23	P
25	.	.	.	_	6	P

1	Hirano	hirano	NNP	_	3	NMOD
2	silver	silver	NN	_	3	NMOD
3	stain	stain	NN	_	11	NMOD
4	(	(	-LRB-	_	6	P
5	top	top	JJ	_	6	NMOD
6	panels	panel	NNS	_	3	PRN
7	)	)	-RRB-	_	6	P
8	;	;	:	_	11	P
9	thioflavin	thioflavin	NN	_	11	NMOD
10	-	-	HYPH	_	9	P
11	S	s	NN	_	0	ROOT
12	(	(	-LRB-	_	14	P
13	bottom	bottom	JJ	_	14	NMOD
14	panels	panel	NNS	_	11	PRN
15	)	)	-RRB-	_	14	P
16	.	.	.	_	11	P

1	(	(	-LRB-	_	4	P
2	5.8	0	CD	_	3	NMOD
3	MB	mb	NN	_	4	NMOD
4	PSD	psd	NN	_	0	ROOT
5	)	)	-RRB-	_	4	P
6	.	.	.	_	4	P

1	Click	click	VB	_	0	ROOT
2	here	here	RB	_	1	LOC
3	for	for	IN	_	1	ADV
4	additional	additional	JJ	_	6	NMOD
5	data	datum	NNS	_	6	NMOD
6	file	file	NN	_	3	PMOD
7	.	.	.	_	1	P

1	Patient	patient	NN	_	2	NMOD
2	Summary	summary	NN	_	0	ROOT

1	Background	background	NN	_	0	ROOT

1	Patients	patient	NNS	_	8	SBJ
2	with	with	IN	_	1	NMOD
3	Alzheimer	alzheimer	NNP	_	4	NMOD
4	disease	disease	NN	_	6	NMOD
5	(	(	-LRB-	_	6	P
6	AD	ad	NN	_	2	PMOD
7	)	)	-RRB-	_	8	P
8	have	have	VBP	_	0	ROOT
9	elevated	elevate	VBN	_	8	VC
10	levels	level	NNS	_	9	OBJ
11	of	of	IN	_	10	NMOD
12	a	a	DT	_	14	NMOD
13	small	small	JJ	_	14	NMOD
14	protein	protein	NN	_	11	PMOD
15	called	call	VBN	_	14	NMOD
16	amyloid	amyloid	NN	_	18	NMOD
17	-	-	HYPH	_	16	P
18	β	β	NN	_	19	NMOD
19	peptide	peptide	NN	_	15	OPRD
20	that	that	WDT	_	21	SBJ
21	sticks	stick	VBZ	_	14	NMOD
22	together	together	RB	_	21	ADV
23	to	to	TO	_	21	PRP
24	form	form	VB	_	23	IM
25	what	what	WP	_	26	SBJ
26	are	be	VBP	_	24	OBJ
27	known	know	VBN	_	26	VC
28	as	as	IN	_	27	ADV
29	amyloid	amyloid	NN	_	30	NMOD
30	plaques	plaque	NNS	_	28	PMOD
31	in	in	IN	_	27	LOC
32	their	their	PRP$	_	33	NMOD
33	brains	brain	NNS	_	31	PMOD
34	.	.	.	_	8	P

1	This	this	DT	_	2	NMOD
2	peptide	peptide	NN	_	3	SBJ
3	is	be	VBZ	_	0	ROOT
4	normally	normally	RB	_	3	ADV
5	made	make	VBN	_	3	VC
6	at	at	IN	_	5	ADV
7	low	low	JJ	_	8	NMOD
8	levels	level	NNS	_	6	PMOD
9	in	in	IN	_	5	LOC
10	healthy	healthy	JJ	_	11	NMOD
11	individuals	individual	NNS	_	9	PMOD
12	,	,	,	_	3	P
13	and	and	CC	_	3	COORD
14	is	be	VBZ	_	13	CONJ
15	made	make	VBN	_	14	VC
16	when	when	WRB	_	28	TMP
17	a	a	DT	_	19	NMOD
18	larger	large	JJR	_	19	NMOD
19	protein	protein	NN	_	27	SBJ
20	called	call	VBN	_	19	NMOD
21	amyloid	amyloid	NN	_	23	NMOD
22	precursor	precursor	NN	_	23	NMOD
23	protein	protein	NN	_	25	NMOD
24	(	(	-LRB-	_	25	P
25	APP	app	NN	_	20	OPRD
26	)	)	-RRB-	_	27	P
27	is	be	VBZ	_	15	TMP
28	cut	cut	VBN	_	27	VC
29	down	down	RP	_	28	PRT
30	in	in	IN	_	28	ADV
31	size	size	NN	_	30	PMOD
32	.	.	.	_	3	P

1	New	new	JJ	_	2	NMOD
2	treatments	treatment	NNS	_	3	SBJ
3	are	be	VBP	_	0	ROOT
4	now	now	RB	_	3	TMP
5	being	be	VBG	_	3	VC
6	developed	develop	VBN	_	5	VC
7	that	that	WDT	_	8	SBJ
8	will	will	MD	_	2	NMOD
9	decrease	decrease	VB	_	8	VC
10	the	the	DT	_	11	NMOD
11	amount	amount	NN	_	9	OBJ
12	of	of	IN	_	11	NMOD
13	Aβ	aβ	NN	_	12	PMOD
14	produced	produce	VBN	_	11	NMOD
15	from	from	IN	_	14	ADV
16	APP	app	NN	_	15	PMOD
17	.	.	.	_	3	P

1	However	however	RB	_	4	ADV
2	,	,	,	_	4	P
3	it	it	PRP	_	4	SBJ
4	is	be	VBZ	_	0	ROOT
5	not	not	RB	_	4	ADV
6	clear	clear	JJ	_	4	PRD
7	whether	whether	IN	_	4	OBJ
8	lowering	lower	VBG	_	13	SBJ
9	the	the	DT	_	10	NMOD
10	production	production	NN	_	8	OBJ
11	of	of	IN	_	8	ADV
12	Aβ	aβ	NN	_	11	PMOD
13	will	will	MD	_	7	SUB
14	allow	allow	VB	_	13	VC
15	the	the	DT	_	16	NMOD
16	brain	brain	NN	_	17	SBJ
17	to	to	TO	_	14	OPRD
18	heal	heal	VB	_	17	IM
19	itself	itself	PRP	_	18	OBJ
20	by	by	IN	_	18	MNR
21	clearing	clear	VBG	_	20	PMOD
22	the	the	DT	_	24	NMOD
23	amyloid	amyloid	NN	_	24	NMOD
24	plaques	plaque	NNS	_	21	OBJ
25	.	.	.	_	4	P

1	The	the	DT	_	2	NMOD
2	answer	answer	NN	_	6	SBJ
3	to	to	IN	_	2	NMOD
4	this	this	DT	_	5	NMOD
5	question	question	NN	_	3	PMOD
6	may	may	MD	_	0	ROOT
7	be	be	VB	_	6	VC
8	important	important	JJ	_	7	PRD
9	for	for	IN	_	8	AMOD
10	deciding	decide	VBG	_	9	PMOD
11	when	when	WRB	_	18	TMP
12	Aβ	aβ	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	lowering	lower	VBG	_	15	NMOD
15	drugs	drug	NNS	_	16	SBJ
16	should	should	MD	_	10	TMP
17	be	be	VB	_	16	VC
18	started	start	VBN	_	17	VC
19	,	,	,	_	10	P
20	and	and	CC	_	10	COORD
21	may	may	MD	_	20	CONJ
22	also	also	RB	_	21	ADV
23	determine	determine	VB	_	21	VC
24	how	how	WRB	_	25	AMOD
25	effective	effective	JJ	_	27	PRD
26	they	they	PRP	_	27	SBJ
27	are	be	VBP	_	23	OBJ
28	in	in	IN	_	27	ADV
29	reversing	reverse	VBG	_	28	PMOD
30	the	the	DT	_	32	NMOD
31	mental	mental	JJ	_	32	NMOD
32	symptoms	symptom	NNS	_	29	OBJ
33	of	of	IN	_	32	NMOD
34	AD	ad	NN	_	33	PMOD
35	.	.	.	_	6	P

1	What	what	WP	_	5	OBJ
2	Did	do	VBD	_	0	ROOT
3	the	the	DT	_	4	NMOD
4	Researchers	researcher	NNS	_	2	SBJ
5	Do	do	VB	_	2	VC
6	and	and	CC	_	5	COORD
7	Find	find	VB	_	6	CONJ
8	?	?	.	_	2	P

1	Because	because	IN	_	15	PRP
2	new	new	JJ	_	3	NMOD
3	drugs	drug	NNS	_	9	SBJ
4	designed	design	VBN	_	3	NMOD
5	to	to	TO	_	4	PRP
6	lower	lower	VB	_	5	IM
7	Aβ	aβ	NN	_	8	NMOD
8	levels	level	NNS	_	6	OBJ
9	are	be	VBP	_	1	SUB
10	still	still	RB	_	9	ADV
11	in	in	IN	_	9	LOC
12	development	development	NN	_	11	PMOD
13	,	,	,	_	15	P
14	they	they	PRP	_	15	SBJ
15	are	be	VBP	_	0	ROOT
16	not	not	RB	_	15	ADV
17	available	available	JJ	_	15	PRD
18	for	for	IN	_	17	AMOD
19	testing	testing	NN	_	18	PMOD
20	in	in	IN	_	15	LOC
21	animal	animal	NN	_	22	NMOD
22	models	model	NNS	_	20	PMOD
23	of	of	IN	_	22	NMOD
24	the	the	DT	_	25	NMOD
25	disease	disease	NN	_	23	PMOD
26	.	.	.	_	15	P

1	Instead	instead	RB	_	13	ADV
2	,	,	,	_	13	P
3	basic	basic	JJ	_	4	NMOD
4	questions	question	NNS	_	13	SBJ
5	about	about	IN	_	4	NMOD
6	the	the	DT	_	7	NMOD
7	effectiveness	effectiveness	NN	_	5	PMOD
8	of	of	IN	_	7	NMOD
9	this	this	DT	_	10	NMOD
10	type	type	NN	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	treatment	treatment	NN	_	11	PMOD
13	must	must	MD	_	0	ROOT
14	be	be	VB	_	13	VC
15	answered	answer	VBN	_	14	VC
16	using	use	VBG	_	15	MNR
17	systems	system	NNS	_	16	OBJ
18	that	that	WDT	_	19	DEP
19	mimic	mimic	VBP	_	17	NMOD
20	how	how	WRB	_	23	ADV
21	the	the	DT	_	22	NMOD
22	drugs	drug	NNS	_	23	SBJ
23	work	work	VBP	_	19	OBJ
24	.	.	.	_	13	P

1	To	to	TO	_	7	PRP
2	do	do	VB	_	1	IM
3	this	this	DT	_	2	OBJ
4	,	,	,	_	7	P
5	the	the	DT	_	6	NMOD
6	authors	author	NNS	_	7	SBJ
7	created	create	VBD	_	0	ROOT
8	mice	mouse	NNS	_	7	OBJ
9	that	that	WDT	_	10	SBJ
10	produce	produce	VBP	_	8	NMOD
11	too	too	RB	_	12	AMOD
12	much	much	JJ	_	13	NMOD
13	APP	app	NN	_	10	OBJ
14	and	and	CC	_	10	COORD
15	that	that	WDT	_	16	SBJ
16	develop	develop	VBP	_	14	CONJ
17	the	the	DT	_	20	NMOD
18	same	same	JJ	_	20	NMOD
19	amyloid	amyloid	NN	_	20	NMOD
20	lesions	lesion	NNS	_	16	OBJ
21	as	as	IN	_	20	NMOD
22	do	do	VBP	_	21	SUB
23	human	human	JJ	_	24	NMOD
24	patients	patient	NNS	_	22	SBJ
25	with	with	IN	_	24	NMOD
26	AD	ad	NN	_	25	PMOD
27	.	.	.	_	7	P

1	Unlike	unlike	IN	_	8	ADV
2	normal	normal	JJ	_	3	NMOD
3	mice	mouse	NNS	_	1	PMOD
4	,	,	,	_	8	P
5	these	these	DT	_	6	NMOD
6	mice	mouse	NNS	_	8	SBJ
7	also	also	RB	_	8	ADV
8	carried	carry	VBD	_	0	ROOT
9	a	a	DT	_	13	NMOD
10	“	“	``	_	13	P
11	switch	switch	NN	_	13	NMOD
12	”	”	''	_	13	P
13	gene	gene	NN	_	8	OBJ
14	that	that	WDT	_	15	SBJ
15	allowed	allow	VBD	_	13	NMOD
16	the	the	DT	_	17	NMOD
17	researchers	researcher	NNS	_	18	SBJ
18	to	to	TO	_	15	OPRD
19	turn	turn	VB	_	18	IM
20	off	off	RP	_	19	PRT
21	APP	app	NN	_	19	OBJ
22	by	by	IN	_	19	MNR
23	feeding	feed	VBG	_	22	PMOD
24	the	the	DT	_	25	NMOD
25	mice	mouse	NNS	_	23	OBJ
26	special	special	JJ	_	27	NMOD
27	food	food	NN	_	23	OBJ
28	.	.	.	_	8	P

1	Turning	turn	VBG	_	7	SBJ
2	off	off	RP	_	1	PRT
3	APP	app	NN	_	1	OBJ
4	in	in	IN	_	1	LOC
5	these	these	DT	_	6	NMOD
6	mice	mouse	NNS	_	4	PMOD
7	had	have	VBD	_	0	ROOT
8	the	the	DT	_	10	NMOD
9	same	same	JJ	_	10	NMOD
10	effect	effect	NN	_	7	OBJ
11	as	as	IN	_	10	NMOD
12	treating	treat	VBG	_	11	PMOD
13	them	them	PRP	_	12	OBJ
14	with	with	IN	_	12	MNR
15	Aβ	aβ	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	lowering	lower	VBG	_	18	NMOD
18	drugs	drug	NNS	_	14	PMOD
19	,	,	,	_	7	P
20	and	and	CC	_	7	COORD
21	so	so	IN	_	20	DEP
22	the	the	DT	_	23	NMOD
23	researchers	researcher	NNS	_	24	SBJ
24	were	be	VBD	_	20	CONJ
25	able	able	JJ	_	24	PRD
26	to	to	TO	_	25	AMOD
27	ask	ask	VB	_	26	IM
28	what	what	WP	_	29	SBJ
29	happened	happen	VBD	_	27	OBJ
30	to	to	IN	_	29	ADV
31	the	the	DT	_	33	NMOD
32	amyloid	amyloid	NN	_	33	NMOD
33	plaques	plaque	NNS	_	30	PMOD
34	after	after	IN	_	29	TMP
35	Aβ	aβ	NN	_	36	NMOD
36	production	production	NN	_	37	SBJ
37	was	be	VBD	_	34	SUB
38	shut	shut	VBN	_	37	VC
39	down	down	RP	_	38	PRT
40	.	.	.	_	7	P

1	They	they	PRP	_	2	SBJ
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	lowering	lower	VBG	_	7	SBJ
5	Aβ	aβ	NN	_	6	NMOD
6	production	production	NN	_	4	OBJ
7	prevents	prevent	VBZ	_	3	SUB
8	the	the	DT	_	10	NMOD
9	amyloid	amyloid	NN	_	10	NMOD
10	lesions	lesion	NNS	_	7	OBJ
11	from	from	IN	_	7	ADV
12	getting	get	VBG	_	11	PMOD
13	worse	bad	JJR	_	12	OPRD
14	as	as	IN	_	12	TMP
15	the	the	DT	_	16	NMOD
16	disease	disease	NN	_	17	SBJ
17	progresses	progress	VBZ	_	14	SUB
18	.	.	.	_	2	P

1	This	this	DT	_	2	SBJ
2	means	mean	VBZ	_	0	ROOT
3	that	that	IN	_	2	OBJ
4	treatment	treatment	NN	_	10	SBJ
5	with	with	IN	_	4	NMOD
6	Aβ	aβ	NN	_	8	AMOD
7	-	-	HYPH	_	6	P
8	lowering	lower	VBG	_	9	NMOD
9	drugs	drug	NNS	_	5	PMOD
10	may	may	MD	_	3	SUB
11	be	be	VB	_	10	VC
12	able	able	JJ	_	11	PRD
13	to	to	TO	_	12	AMOD
14	stop	stop	VB	_	13	IM
15	the	the	DT	_	16	NMOD
16	disease	disease	NN	_	14	OBJ
17	from	from	IN	_	14	ADV
18	filling	fill	VBG	_	17	PMOD
19	the	the	DT	_	20	NMOD
20	brain	brain	NN	_	18	OBJ
21	with	with	IN	_	18	MNR
22	plaques	plaque	NNS	_	21	PMOD
23	.	.	.	_	2	P

1	However	however	RB	_	6	ADV
2	,	,	,	_	6	P
3	the	the	DT	_	4	NMOD
4	researchers	researcher	NNS	_	6	SBJ
5	also	also	RB	_	6	ADV
6	found	find	VBD	_	0	ROOT
7	that	that	IN	_	6	OBJ
8	the	the	DT	_	10	NMOD
9	amyloid	amyloid	NN	_	10	NMOD
10	lesions	lesion	NNS	_	18	SBJ
11	that	that	WDT	_	12	SBJ
12	had	have	VBD	_	10	NMOD
13	formed	form	VBN	_	12	VC
14	before	before	IN	_	13	TMP
15	treatment	treatment	NN	_	16	SBJ
16	was	be	VBD	_	14	SUB
17	started	start	VBN	_	16	VC
18	remained	remain	VBD	_	7	SUB
19	intact	intact	JJ	_	18	PRD
20	throughout	throughout	IN	_	18	TMP
21	the	the	DT	_	22	NMOD
22	experiment	experiment	NN	_	20	PMOD
23	.	.	.	_	6	P

1	What	what	WP	_	5	OBJ
2	Do	do	VBP	_	0	ROOT
3	These	these	DT	_	4	NMOD
4	Findings	finding	NNS	_	2	SBJ
5	Mean	mean	VB	_	2	VC
6	?	?	.	_	2	P

1	These	these	DT	_	2	NMOD
2	results	result	NNS	_	3	SBJ
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	treatments	treatment	NNS	_	13	SBJ
6	designed	design	VBN	_	5	NMOD
7	to	to	TO	_	6	PRP
8	lower	lower	VB	_	7	IM
9	the	the	DT	_	10	NMOD
10	production	production	NN	_	8	OBJ
11	of	of	IN	_	10	NMOD
12	Aβ	aβ	NN	_	11	PMOD
13	may	may	MD	_	4	SUB
14	be	be	VB	_	13	VC
15	an	an	DT	_	17	NMOD
16	important	important	JJ	_	17	NMOD
17	part	part	NN	_	14	PRD
18	of	of	IN	_	17	NMOD
19	future	future	JJ	_	21	NMOD
20	AD	ad	NN	_	21	NMOD
21	treatment	treatment	NN	_	18	PMOD
22	,	,	,	_	14	P
23	as	as	IN	_	14	ADV
24	this	this	DT	_	25	NMOD
25	approach	approach	NN	_	26	SBJ
26	seems	seem	VBZ	_	23	SUB
27	to	to	TO	_	26	OPRD
28	prevents	prevent	VB	_	27	IM
29	additional	additional	JJ	_	31	NMOD
30	amyloid	amyloid	NN	_	31	NMOD
31	plaques	plaque	NNS	_	28	OBJ
32	from	from	IN	_	28	ADV
33	forming	form	VBG	_	32	PMOD
34	in	in	IN	_	33	LOC
35	the	the	DT	_	37	NMOD
36	mouse	mouse	NN	_	37	NMOD
37	brain	brain	NN	_	34	PMOD
38	.	.	.	_	3	P

1	However	however	RB	_	8	ADV
2	,	,	,	_	8	P
3	by	by	IN	_	8	ADV
4	itself	itself	PRP	_	3	PMOD
5	,	,	,	_	8	P
6	this	this	DT	_	7	NMOD
7	strategy	strategy	NN	_	8	SBJ
8	may	may	MD	_	0	ROOT
9	not	not	RB	_	8	ADV
10	be	be	VB	_	8	VC
11	able	able	JJ	_	10	PRD
12	to	to	TO	_	11	AMOD
13	rid	rid	VB	_	12	IM
14	the	the	DT	_	15	NMOD
15	brain	brain	NN	_	13	OBJ
16	of	of	IN	_	13	ADV
17	plaques	plaque	NNS	_	16	PMOD
18	that	that	WDT	_	19	SBJ
19	have	have	VBP	_	17	NMOD
20	already	already	RB	_	19	ADV
21	formed	form	VBN	_	19	VC
22	in	in	IN	_	21	LOC
23	the	the	DT	_	24	NMOD
24	brain	brain	NN	_	22	PMOD
25	before	before	IN	_	21	TMP
26	treatment	treatment	NN	_	27	SBJ
27	is	be	VBZ	_	25	SUB
28	started	start	VBN	_	27	VC
29	.	.	.	_	8	P

1	The	the	DT	_	2	NMOD
2	findings	finding	NNS	_	3	SBJ
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	early	early	JJ	_	6	NMOD
6	treatment	treatment	NN	_	7	SBJ
7	may	may	MD	_	4	SUB
8	be	be	VB	_	7	VC
9	important	important	JJ	_	8	PRD
10	for	for	IN	_	8	PRP
11	this	this	DT	_	12	NMOD
12	approach	approach	NN	_	13	SBJ
13	to	to	TO	_	10	SUB
14	succeed	succeed	VB	_	13	IM
15	.	.	.	_	3	P

1	Where	where	WRB	_	4	LOC
2	Can	can	MD	_	0	ROOT
3	I	i	PRP	_	2	SBJ
4	Get	get	VB	_	2	VC
5	More	more	JJR	_	6	NMOD
6	Information	information	NN	_	4	OBJ
7	Online	online	RB	_	4	ADV
8	?	?	.	_	2	P

1	MedlinePlus	medlineplus	NNP	_	2	SBJ
2	has	have	VBZ	_	0	ROOT
3	several	several	JJ	_	5	NMOD
4	Web	web	NN	_	5	NMOD
5	pages	page	NNS	_	12	NMOD
6	of	of	IN	_	5	NMOD
7	information	information	NN	_	6	PMOD
8	on	on	IN	_	7	NMOD
9	Alzheimer	alzheimer	NNP	_	10	NMOD
10	disease	disease	NN	_	8	PMOD
11	:	:	:	_	12	P
12	http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html	http://www.nlm.nih.gov/medlineplus/alzheimersdisease.html	NN	_	2	OBJ

1	The	the	DT	_	3	NMOD
2	ADEAR	adear	NNP	_	3	NMOD
3	Center	center	NNP	_	14	SBJ
4	of	of	IN	_	3	NMOD
5	the	the	DT	_	7	NMOD
6	US	u	NNP	_	7	NMOD
7	Government	government	NNP	_	10	NMOD
8	's	's	POS	_	7	NMOD
9	National	national	NNP	_	10	NMOD
10	Institute	institute	NNP	_	4	PMOD
11	on	on	IN	_	10	NMOD
12	Aging	aging	NNP	_	11	PMOD
13	also	also	RB	_	14	ADV
14	has	have	VBZ	_	0	ROOT
15	information	information	NN	_	20	NMOD
16	on	on	IN	_	15	NMOD
17	Alzheimer	alzheimer	NNP	_	18	NMOD
18	disease	disease	NN	_	16	PMOD
19	:	:	:	_	20	P
20	http://www.alzheimers.org/	http://www.alzheimers.org/	NN	_	14	OBJ

1	The	the	DT	_	2	NMOD
2	Alzheimer	alzheimer	NNP	_	4	NMOD
3	's	's	POS	_	2	NMOD
4	Association	association	NNP	_	6	NMOD
5	Web	web	NN	_	6	NMOD
6	site	site	NN	_	7	SBJ
7	contains	contain	VBZ	_	0	ROOT
8	information	information	NN	_	7	OBJ
9	on	on	IN	_	8	NMOD
10	both	both	CC	_	11	COORD
11	caregiving	caregiving	NN	_	9	PMOD
12	and	and	CC	_	11	COORD
13	research	research	NN	_	12	CONJ
14	:	:	:	_	7	P
15	http://www.alz.org	http://www.alz.org	NN	_	6	NMOD

1	Acknowledgements	acknowledgement	NNS	_	0	ROOT

1	We	we	PRP	_	2	SBJ
2	thank	thank	VBP	_	0	ROOT
3	Patrick	patrick	NNP	_	4	NMOD
4	Tremblay	tremblay	NNP	_	2	OBJ
5	for	for	IN	_	2	PRP
6	helpful	helpful	JJ	_	7	NMOD
7	advice	advice	NN	_	5	PMOD
8	on	on	IN	_	7	NMOD
9	the	the	DT	_	11	NMOD
10	tet	tet	NN	_	11	NMOD
11	system	system	NN	_	8	PMOD
12	at	at	IN	_	7	TMP
13	a	a	DT	_	15	NMOD
14	critical	critical	JJ	_	15	NMOD
15	time	time	NN	_	12	PMOD
16	in	in	IN	_	15	NMOD
17	the	the	DT	_	18	NMOD
18	project	project	NN	_	16	PMOD
19	,	,	,	_	2	P
20	and	and	CC	_	2	COORD
21	Mark	mark	NNP	_	22	NMOD
22	Mayford	mayford	NNP	_	20	GAP
23	for	for	IN	_	22	PRP
24	sharing	share	VBG	_	23	PMOD
25	the	the	DT	_	29	NMOD
26	CaMKIIα	camkiiα	NN	_	29	NMOD
27	-	-	HYPH	_	26	P
28	tTA	tta	NN	_	29	NMOD
29	mice	mouse	NNS	_	24	OBJ
30	through	through	IN	_	24	ADV
31	Jackson	jackson	NNP	_	32	NMOD
32	Laboratory	laboratory	NNP	_	30	PMOD
33	.	.	.	_	2	P

1	We	we	PRP	_	3	SBJ
2	also	also	RB	_	3	ADV
3	thank	thank	VBP	_	0	ROOT
4	Fraser	fraser	NNP	_	5	NMOD
5	Moss	moss	NNP	_	3	OBJ
6	for	for	IN	_	3	ADV
7	saving	save	VBG	_	6	PMOD
8	several	several	JJ	_	9	NMOD
9	immunoblots	immunoblots	NNS	_	7	OBJ
10	with	with	IN	_	7	ADV
11	last	last	JJ	_	13	NMOD
12	-	-	HYPH	_	11	P
13	minute	minute	NN	_	14	NMOD
14	shipments	shipment	NNS	_	10	PMOD
15	,	,	,	_	3	P
16	Andy	andy	NNP	_	17	NMOD
17	Groves	grove	NNP	_	3	GAP
18	for	for	IN	_	17	ADV
19	many	many	JJ	_	21	NMOD
20	thoughtful	thoughtful	JJ	_	21	NMOD
21	discussions	discussion	NNS	_	18	PMOD
22	,	,	,	_	17	P
23	Neil	neil	NNP	_	24	NMOD
24	Segil	segil	NNP	_	17	GAP
25	for	for	IN	_	24	ADV
26	generously	generously	RB	_	27	MNR
27	sharing	share	VBG	_	25	PMOD
28	his	his	PRP$	_	29	NMOD
29	laboratory	laboratory	NN	_	27	OBJ
30	and	and	CC	_	29	COORD
31	equipment	equipment	NN	_	30	CONJ
32	,	,	,	_	24	P
33	Beth	beth	NNP	_	34	NMOD
34	Olson	olson	NNP	_	24	GAP
35	,	,	,	_	34	P
36	Natasha	natasha	NNP	_	37	NMOD
37	Bouey	bouey	NNP	_	34	CONJ
38	,	,	,	_	37	P
39	and	and	CC	_	37	COORD
40	Yolanda	yolanda	NNP	_	41	NMOD
41	Jackson	jackson	NNP	_	39	CONJ
42	for	for	IN	_	34	ADV
43	outstanding	outstanding	JJ	_	45	NMOD
44	animal	animal	NN	_	45	NMOD
45	care	care	NN	_	42	PMOD
46	,	,	,	_	34	P
47	Debbie	debbie	NNP	_	48	NMOD
48	Swing	swing	NNP	_	34	GAP
49	for	for	IN	_	48	ADV
50	expert	expert	JJ	_	51	NMOD
51	microinjection	microinjection	NN	_	49	PMOD
52	,	,	,	_	48	P
53	and	and	CC	_	48	COORD
54	Dave	dave	NNP	_	55	NMOD
55	Fromholt	fromholt	NNP	_	53	GAP
56	for	for	IN	_	55	ADV
57	genotyping	genotyping	NN	_	56	PMOD
58	and	and	CC	_	57	COORD
59	dissection	dissection	NN	_	58	CONJ
60	.	.	.	_	3	P

1	We	we	PRP	_	3	SBJ
2	gratefully	gratefully	RB	_	3	ADV
3	acknowledge	acknowledge	VBP	_	0	ROOT
4	Takeda	takeda	NNP	_	6	NMOD
5	Chemical	chemical	NNP	_	6	NMOD
6	Industries	industry	NNPS	_	3	OBJ
7	for	for	IN	_	3	ADV
8	providing	provide	VBG	_	7	PMOD
9	antibodies	antibody	NNS	_	10	NMOD
10	BAN50	ban0	NN	_	8	OBJ
11	,	,	,	_	10	P
12	BA27	ba0	NN	_	10	CONJ
13	,	,	,	_	12	P
14	and	and	CC	_	12	COORD
15	BC05	bc0	NN	_	14	CONJ
16	,	,	,	_	3	P
17	Konrad	konrad	NNP	_	18	NMOD
18	Beyreuther	beyreuther	NNP	_	3	GAP
19	and	and	CC	_	18	COORD
20	Andreas	andreas	NNP	_	21	NMOD
21	Weidemann	weidemann	NNP	_	19	CONJ
22	for	for	IN	_	18	ADV
23	providing	provide	VBG	_	22	PMOD
24	22C11	0c0	NN	_	25	NMOD
25	antibody	antibody	NN	_	23	OBJ
26	,	,	,	_	18	P
27	and	and	CC	_	18	COORD
28	Ed	ed	NNP	_	29	NMOD
29	Koo	koo	NNP	_	27	GAP
30	for	for	IN	_	29	ADV
31	sharing	share	VBG	_	30	PMOD
32	CT15	ct0	NN	_	33	NMOD
33	antibody	antibody	NN	_	31	OBJ
34	.	.	.	_	3	P

1	This	this	DT	_	2	NMOD
2	work	work	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	supported	support	VBN	_	3	VC
5	by	by	IN	_	4	LGS
6	grants	grant	NNS	_	5	PMOD
7	from	from	IN	_	6	NMOD
8	the	the	DT	_	15	NMOD
9	Johns	john	NNP	_	10	NMOD
10	Hopkins	hopkins	NNP	_	15	NMOD
11	Alzheimer	alzheimer	NNP	_	13	NMOD
12	's	's	POS	_	11	NMOD
13	Disease	disease	NNP	_	15	NMOD
14	Research	research	NNP	_	15	NMOD
15	Center	center	NNP	_	7	PMOD
16	(	(	-LRB-	_	17	P
17	JLJ	jlj	NNP	_	15	PRN
18	)	)	-RRB-	_	17	P
19	,	,	,	_	6	P
20	the	the	DT	_	22	NMOD
21	National	national	NNP	_	22	NMOD
22	Alliance	alliance	NNP	_	6	CONJ
23	for	for	IN	_	22	NMOD
24	Research	research	NNP	_	23	PMOD
25	on	on	IN	_	24	NMOD
26	Schizophrenia	schizophrenia	NNP	_	25	PMOD
27	and	and	CC	_	26	COORD
28	Depression	depression	NNP	_	27	CONJ
29	(	(	-LRB-	_	34	P
30	Young	young	NNP	_	32	NMOD
31	Investigator	investigator	NNP	_	32	NMOD
32	Award	award	NNP	_	34	DEP
33	[	[	-LRB-	_	34	P
34	JLJ	jlj	NNP	_	22	PRN
35	]	]	-RRB-	_	34	P
36	)	)	-RRB-	_	34	P
37	,	,	,	_	22	P
38	the	the	DT	_	41	NMOD
39	Rose	rose	NNP	_	41	NMOD
40	Hills	hill	NNP	_	41	NMOD
41	Foundation	foundation	NNP	_	22	CONJ
42	(	(	-LRB-	_	43	P
43	JLJ	jlj	NNP	_	41	PRN
44	)	)	-RRB-	_	43	P
45	,	,	,	_	41	P
46	the	the	DT	_	47	NMOD
47	Alzheimer	alzheimer	NNP	_	49	NMOD
48	's	's	POS	_	47	NMOD
49	Association	association	NNP	_	41	CONJ
50	(	(	-LRB-	_	54	P
51	Zenith	zenith	NNP	_	52	NMOD
52	Award	award	NNP	_	54	DEP
53	[	[	-LRB-	_	54	P
54	DRB	drb	NN	_	49	PRN
55	]	]	-RRB-	_	54	P
56	)	)	-RRB-	_	54	P
57	,	,	,	_	49	P
58	the	the	DT	_	60	NMOD
59	National	national	NNP	_	60	NMOD
60	Institute	institute	NNP	_	49	CONJ
61	of	of	IN	_	60	NMOD
62	Aging	aging	NNP	_	61	PMOD
63	(	(	-LRB-	_	65	P
64	K01	k0	NN	_	65	NMOD
65	AG26144	ag0	NN	_	62	PRN
66	–	–	HYPH	_	65	P
67	01	0	CD	_	65	NMOD
68	[	[	-LRB-	_	65	P
69	JLJ	jlj	NNP	_	65	DEP
70	]	]	-RRB-	_	65	P
71	,	,	,	_	65	P
72	P50	p0	NN	_	73	NMOD
73	AGO5146	ago0	NN	_	65	CONJ
74	–	–	HYPH	_	73	P
75	20	0	CD	_	73	NMOD
76	[	[	-LRB-	_	73	P
77	DRB	drb	NN	_	73	DEP
78	]	]	-RRB-	_	73	P
79	,	,	,	_	73	P
80	R01	r0	NN	_	81	NMOD
81	AG006656	ag0	NN	_	73	CONJ
82	–	–	HYPH	_	81	P
83	16	0	CD	_	81	NMOD
84	[	[	-LRB-	_	81	P
85	SGY	sgy	NN	_	81	DEP
86	]	]	-RRB-	_	81	P
87	,	,	,	_	81	P
88	and	and	CC	_	81	COORD
89	P01	p0	NN	_	90	NMOD
90	AG015453	ag0	NN	_	88	CONJ
91	[	[	-LRB-	_	90	P
92	SGY	sgy	NNP	_	90	DEP
93	]	]	-RRB-	_	90	P
94	)	)	-RRB-	_	65	P
95	,	,	,	_	60	P
96	the	the	DT	_	98	NMOD
97	National	national	NNP	_	98	NMOD
98	Institute	institute	NNP	_	60	CONJ
99	of	of	IN	_	98	NMOD
100	Neurologic	neurologic	JJ	_	101	NMOD
101	Disease	disease	NN	_	99	PMOD
102	and	and	CC	_	101	COORD
103	Stoke	stoke	NN	_	102	CONJ
104	(	(	-LRB-	_	109	P
105	R01	r0	NN	_	106	NMOD
106	NS	n	NN	_	109	DEP
107	047225	0	CD	_	106	NMOD
108	[	[	-LRB-	_	109	P
109	DRB	drb	NNP	_	101	PRN
110	]	]	-RRB-	_	109	P
111	)	)	-RRB-	_	109	P
112	,	,	,	_	98	P
113	and	and	CC	_	98	COORD
114	the	the	DT	_	117	NMOD
115	National	national	NNP	_	117	NMOD
116	Cancer	cancer	NNP	_	117	NMOD
117	Institute	institute	NNP	_	113	CONJ
118	(	(	-LRB-	_	119	P
119	NAJ	naj	NNP	_	117	PRN
120	and	and	CC	_	119	COORD
121	NGC	ngc	NNP	_	120	CONJ
122	)	)	-RRB-	_	119	P
123	.	.	.	_	3	P

1	The	the	DT	_	3	NMOD
2	funding	funding	NN	_	3	NMOD
3	agencies	agency	NNS	_	5	SBJ
4	generously	generously	RB	_	5	ADV
5	provided	provide	VBN	_	22	DEP
6	for	for	IN	_	5	ADV
7	research	research	NN	_	8	NMOD
8	supplies	supply	NNS	_	6	PMOD
9	,	,	,	_	8	P
10	animal	animal	NN	_	11	NMOD
11	care	care	NN	_	8	CONJ
12	,	,	,	_	11	P
13	and	and	CC	_	11	COORD
14	salary	salary	NN	_	15	NMOD
15	support	support	NN	_	13	CONJ
16	;	;	:	_	22	P
17	the	the	DT	_	18	NMOD
18	funders	funders	NNS	_	22	SBJ
19	of	of	IN	_	18	NMOD
20	this	this	DT	_	21	NMOD
21	work	work	NN	_	19	PMOD
22	had	have	VBD	_	0	ROOT
23	no	no	DT	_	24	NMOD
24	role	role	NN	_	22	OBJ
25	in	in	IN	_	24	NMOD
26	study	study	NN	_	27	NMOD
27	design	design	NN	_	25	PMOD
28	,	,	,	_	27	P
29	data	datum	NNS	_	30	NMOD
30	collection	collection	NN	_	27	CONJ
31	and	and	CC	_	30	COORD
32	analysis	analysis	NN	_	31	CONJ
33	,	,	,	_	30	P
34	decision	decision	NN	_	30	CONJ
35	to	to	TO	_	34	NMOD
36	publish	publish	VB	_	35	IM
37	,	,	,	_	34	P
38	or	or	CC	_	34	COORD
39	preparation	preparation	NN	_	38	CONJ
40	of	of	IN	_	39	NMOD
41	the	the	DT	_	42	NMOD
42	manuscript	manuscript	NN	_	40	PMOD
43	.	.	.	_	22	P

1	Abbreviations	abbreviation	NNS	_	0	ROOT

1	Aβ	aβ	NN	_	5	NMOD
2	-	-	:	_	5	P
3	amyloid	amyloid	NN	_	5	NMOD
4	-	-	HYPH	_	3	P
5	β	β	NN	_	0	ROOT

1	AD	ad	NN	_	4	NMOD
2	-	-	:	_	4	P
3	Alzheimer	alzheimer	NNP	_	4	NMOD
4	disease	disease	NN	_	0	ROOT

1	APLP	aplp	NN	_	5	NMOD
2	-	-	:	_	5	P
3	amyloid	amyloid	NN	_	5	NMOD
4	precursor–like	precursor–like	JJ	_	5	NMOD
5	protein	protein	NN	_	0	ROOT

1	APP	app	NN	_	5	NMOD
2	-	-	:	_	5	P
3	amyloid	amyloid	NN	_	5	NMOD
4	precursor	precursor	NN	_	5	NMOD
5	protein	protein	NN	_	0	ROOT

1	CaMKIIα	camkiiα	NN	_	7	NMOD
2	-	-	:	_	7	P
3	calcium	calcium	NN	_	5	NMOD
4	-	-	HYPH	_	3	P
5	calmodulin	calmodulin	NN	_	7	NMOD
6	kinase	kinase	NN	_	7	NMOD
7	IIα	iiα	NN	_	0	ROOT

1	dox	dox	NN	_	3	NMOD
2	-	-	:	_	3	P
3	doxycycline	doxycycline	NN	_	0	ROOT

1	FA	fa	NN	_	4	NMOD
2	-	-	:	_	4	P
3	formic	formic	JJ	_	4	NMOD
4	acid	acid	NN	_	0	ROOT

1	GFAP	gfap	NN	_	6	NMOD
2	-	-	:	_	6	P
3	glial	glial	JJ	_	6	NMOD
4	fibrillary	fibrillary	JJ	_	6	NMOD
5	acidic	acidic	JJ	_	6	NMOD
6	protein	protein	NN	_	0	ROOT

1	mo	mo	NN	_	3	NMOD
2	/	/	HYPH	_	1	P
3	huAPP695	huapp0	NN	_	6	NMOD
4	-	-	:	_	6	P
5	mouse	mouse	NN	_	6	NMOD
6	APP	app	NN	_	0	ROOT
7	with	with	IN	_	6	NMOD
8	a	a	DT	_	11	NMOD
9	humanized	humanize	VBN	_	11	NMOD
10	Aβ	aβ	NN	_	11	NMOD
11	domain	domain	NN	_	7	PMOD

1	PBS	pb	NN	_	6	NMOD
2	-	-	:	_	6	P
3	phosphate	phosphate	NN	_	5	AMOD
4	-	-	HYPH	_	3	P
5	buffered	buffer	VBN	_	6	NMOD
6	saline	saline	NN	_	0	ROOT

1	SDS	sd	NN	_	5	NMOD
2	-	-	:	_	5	P
3	sodium	sodium	NN	_	5	NMOD
4	dodecyl	dodecyl	NN	_	5	NMOD
5	sulfate	sulfate	NN	_	0	ROOT

1	swe	swe	NN	_	3	NMOD
2	/	/	HYPH	_	1	P
3	ind	ind	NN	_	7	NMOD
4	-	-	:	_	7	P
5	Swedish	swedish	JJ	_	7	NMOD
6	/	/	HYPH	_	5	P
7	Indiana	indiana	NNP	_	0	ROOT

1	tTA	tta	NN	_	4	NMOD
2	-	-	:	_	4	P
3	tetracycline	tetracycline	NN	_	4	NMOD
4	transactivator	transactivator	NN	_	0	ROOT

1	Figures	figure	NNS	_	0	ROOT
2	and	and	CC	_	1	COORD
3	Tables	table	NNS	_	2	CONJ

1	Figure	figure	NN	_	0	ROOT
2	1	0	CD	_	1	NMOD

1	Control	control	NN	_	0	ROOT
2	of	of	IN	_	1	NMOD
3	Transgenic	transgenic	JJ	_	5	NMOD
4	APP	app	NN	_	5	NMOD
5	Expression	expression	NN	_	2	PMOD
6	by	by	IN	_	1	NMOD
7	Dox	dox	NN	_	6	PMOD

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	16	DEP
3	)	)	-RRB-	_	2	P
4	Western	western	NNP	_	5	NMOD
5	blotting	blotting	NN	_	16	SBJ
6	for	for	IN	_	5	NMOD
7	transgenic	transgenic	JJ	_	8	NMOD
8	APP	app	NN	_	6	PMOD
9	using	use	VBG	_	5	NMOD
10	the	the	DT	_	15	NMOD
11	human	human	JJ	_	13	AMOD
12	-	-	HYPH	_	11	P
13	specific	specific	JJ	_	15	NMOD
14	6E10	0e0	NN	_	15	NMOD
15	antibody	antibody	NN	_	9	OBJ
16	shows	show	VBZ	_	0	ROOT
17	expression	expression	NN	_	16	OBJ
18	of	of	IN	_	17	NMOD
19	full	full	JJ	_	21	NMOD
20	-	-	HYPH	_	19	P
21	length	length	NN	_	22	NMOD
22	protein	protein	NN	_	18	PMOD
23	in	in	IN	_	17	LOC
24	forebrain	forebrain	NN	_	25	NMOD
25	tissue	tissue	NN	_	23	PMOD
26	from	from	IN	_	25	NMOD
27	young	young	JJ	_	31	NMOD
28	predeposit	predeposit	JJ	_	31	NMOD
29	double	double	JJ	_	30	AMOD
30	transgenic	transgenic	JJ	_	31	NMOD
31	animals	animal	NNS	_	26	PMOD
32	(	(	-LRB-	_	33	P
33	line	line	NN	_	31	PRN
34	107	0	CD	_	33	NMOD
35	)	)	-RRB-	_	33	P
36	and	and	CC	_	31	COORD
37	its	its	PRP$	_	38	NMOD
38	suppression	suppression	NN	_	36	CONJ
39	following	follow	VBG	_	38	TMP
40	dox	dox	NN	_	41	NMOD
41	treatment	treatment	NN	_	39	PMOD
42	.	.	.	_	16	P

1	Untreated	untreated	JJ	_	2	NMOD
2	animals	animal	NNS	_	3	SBJ
3	show	show	VBP	_	12	DEP
4	high	high	JJ	_	5	NMOD
5	levels	level	NNS	_	3	OBJ
6	of	of	IN	_	5	NMOD
7	transgene	transgene	NN	_	8	NMOD
8	expression	expression	NN	_	6	PMOD
9	;	;	:	_	12	P
10	protein	protein	NN	_	11	NMOD
11	levels	level	NNS	_	12	SBJ
12	drop	drop	VBP	_	0	ROOT
13	dramatically	dramatically	RB	_	12	ADV
14	in	in	IN	_	12	LOC
15	animals	animal	NNS	_	14	PMOD
16	acutely	acutely	RB	_	17	ADV
17	treated	treat	VBN	_	15	NMOD
18	with	with	IN	_	17	MNR
19	dox	dox	NN	_	18	PMOD
20	for	for	IN	_	17	TMP
21	2	0	CD	_	22	NMOD
22	wk	wk	NN	_	20	PMOD
23	.	.	.	_	12	P

1	A	a	DT	_	6	NMOD
2	faint	faint	NN	_	6	NMOD
3	,	,	,	_	2	P
4	but	but	CC	_	2	COORD
5	detectable	detectable	JJ	_	4	CONJ
6	band	band	NN	_	12	SBJ
7	of	of	IN	_	6	NMOD
8	full	full	JJ	_	10	NMOD
9	-	-	HYPH	_	8	P
10	length	length	NN	_	11	NMOD
11	protein	protein	NN	_	7	PMOD
12	remains	remain	VBZ	_	0	ROOT
13	in	in	IN	_	12	LOC
14	acutely	acutely	RB	_	16	NMOD
15	treated	treat	VBN	_	16	NMOD
16	animals	animal	NNS	_	13	PMOD
17	that	that	WDT	_	18	SBJ
18	can	can	MD	_	16	NMOD
19	be	be	VB	_	18	VC
20	eliminated	eliminate	VBN	_	19	VC
21	in	in	IN	_	20	LOC
22	mice	mouse	NNS	_	21	PMOD
23	born	bear	VBN	_	22	NMOD
24	and	and	CC	_	23	COORD
25	raised	raise	VBN	_	24	CONJ
26	on	on	IN	_	23	ADV
27	dox	dox	NN	_	26	PMOD
28	.	.	.	_	12	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	19	DEP
3	)	)	-RRB-	_	2	P
4	Immunoblotting	immunoblotting	NN	_	19	SBJ
5	with	with	IN	_	4	NMOD
6	the	the	DT	_	10	NMOD
7	N	n	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	terminal	terminal	JJ	_	10	NMOD
10	antibody	antibody	NN	_	11	NMOD
11	22C11	0c0	NN	_	5	PMOD
12	to	to	TO	_	4	NMOD
13	detect	detect	VB	_	12	IM
14	both	both	CC	_	18	COORD
15	transgenic	transgenic	JJ	_	18	NMOD
16	and	and	CC	_	15	COORD
17	endogenous	endogenous	JJ	_	16	CONJ
18	protein	protein	NN	_	13	OBJ
19	shows	show	VBZ	_	0	ROOT
20	that	that	IN	_	19	OBJ
21	dox	dox	NN	_	22	NMOD
22	treatment	treatment	NN	_	23	SBJ
23	reduces	reduce	VBZ	_	20	SUB
24	APP	app	NN	_	26	NMOD
25	/	/	HYPH	_	24	P
26	APLP	aplp	NN	_	23	OBJ
27	to	to	IN	_	23	ADV
28	levels	level	NNS	_	27	PMOD
29	found	find	VBN	_	28	NMOD
30	in	in	IN	_	29	LOC
31	nontransgenic	nontransgenic	JJ	_	32	NMOD
32	mice	mouse	NNS	_	30	PMOD
33	.	.	.	_	19	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	16	DEP
3	)	)	-RRB-	_	2	P
4	Measurement	measurement	NN	_	16	SBJ
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	from	from	IN	_	4	NMOD
9	the	the	DT	_	11	NMOD
10	Western	western	NNP	_	11	NMOD
11	blot	blot	NN	_	8	PMOD
12	in	in	IN	_	4	NMOD
13	(	(	-LRB-	_	12	P
14	A	a	NN	_	12	PMOD
15	)	)	-RRB-	_	16	P
16	shows	show	VBZ	_	0	ROOT
17	transgenic	transgenic	JJ	_	19	NMOD
18	APP	app	NN	_	19	NMOD
19	levels	level	NNS	_	20	SBJ
20	are	be	VBP	_	16	OBJ
21	decreased	decrease	VBN	_	20	VC
22	more	more	JJR	_	25	NMOD
23	than	than	IN	_	22	QMOD
24	95	0	CD	_	22	QMOD
25	%	%	NN	_	21	EXT
26	by	by	IN	_	21	MNR
27	dox	dox	NN	_	26	PMOD
28	in	in	IN	_	21	LOC
29	both	both	CC	_	30	COORD
30	acutely	acutely	RB	_	33	AMOD
31	and	and	CC	_	30	COORD
32	chronically	chronically	RB	_	31	CONJ
33	treated	treat	VBN	_	34	NMOD
34	animals	animal	NNS	_	28	PMOD
35	(	(	-LRB-	_	70	P
36	97.2	0	CD	_	37	NMOD
37	%	%	NN	_	70	DEP
38	for	for	IN	_	37	NMOD
39	4	0	CD	_	40	NMOD
40	wk	wk	NN	_	43	NMOD
41	+	+	SYM	_	43	P
42	2	0	CD	_	43	NMOD
43	wk	wk	NN	_	44	NMOD
44	dox	dox	NN	_	38	PMOD
45	,	,	,	_	37	P
46	98.0	0	CD	_	47	NMOD
47	%	%	NN	_	37	APPO
48	for	for	IN	_	47	NMOD
49	reared	rear	VBN	_	48	PMOD
50	on	on	IN	_	49	ADV
51	dox	dox	NN	_	50	PMOD
52	versus	versus	CC	_	49	COORD
53	4	0	CD	_	54	NMOD
54	wk	wk	NN	_	55	AMOD
55	untreated	untreated	JJ	_	52	CONJ
56	;	;	:	_	70	P
57	ANOVA	anova	NN	_	58	NMOD
58	effect	effect	NN	_	66	SBJ
59	of	of	IN	_	58	NMOD
60	treatment	treatment	NN	_	62	NMOD
61	group	group	NN	_	62	NMOD
62	F4	f0	NN	_	59	PMOD
63	,	,	,	_	62	P
64	15	0	CD	_	62	NMOD
65	=	=	SYM	_	66	P
66	85.55	0	CD	_	70	DEP
67	,	,	,	_	70	P
68	p	p	NN	_	70	SBJ
69	<	<	SYM	_	70	P
70	0.001	0	CD	_	21	PRN
71	)	)	-RRB-	_	70	P
72	.	.	.	_	16	P

1	APP	app	NN	_	2	NMOD
2	levels	level	NNS	_	20	SBJ
3	in	in	IN	_	2	LOC
4	4	0	CD	_	5	NMOD
5	wk	wk	NN	_	8	NMOD
6	+	+	SYM	_	8	P
7	2	0	CD	_	8	NMOD
8	wk	wk	NN	_	9	NMOD
9	dox	dox	NN	_	11	NMOD
10	,	,	,	_	11	P
11	reared	rear	VBN	_	3	PMOD
12	on	on	IN	_	11	ADV
13	dox	dox	NN	_	12	PMOD
14	,	,	,	_	11	P
15	and	and	CC	_	11	COORD
16	nontransgenic	nontransgenic	JJ	_	18	NMOD
17	(	(	-LRB-	_	18	P
18	NTg	ntg	NN	_	15	CONJ
19	)	)	-RRB-	_	2	P
20	were	be	VBD	_	0	ROOT
21	not	not	RB	_	20	ADV
22	significantly	significantly	RB	_	23	AMOD
23	different	different	JJ	_	20	PRD
24	(	(	-LRB-	_	33	P
25	p	p	NN	_	27	SBJ
26	>	>	SYM	_	27	P
27	0.9	0	CD	_	33	DEP
28	,	,	,	_	33	P
29	Tukey	tukey	NNP	_	33	NMOD
30	post	post	FW	_	32	NMOD
31	-	-	HYPH	_	30	P
32	hoc	hoc	FW	_	33	NMOD
33	test	test	NN	_	23	PRN
34	)	)	-RRB-	_	33	P
35	.	.	.	_	20	P

1	(	(	-LRB-	_	2	P
2	D	d	LS	_	16	DEP
3	)	)	-RRB-	_	2	P
4	Measurement	measurement	NN	_	16	SBJ
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	from	from	IN	_	4	NMOD
9	the	the	DT	_	11	NMOD
10	Western	western	NNP	_	11	NMOD
11	blot	blot	NN	_	8	PMOD
12	in	in	IN	_	11	NMOD
13	(	(	-LRB-	_	12	P
14	B	b	NN	_	12	PMOD
15	)	)	-RRB-	_	16	P
16	shows	show	VBZ	_	0	ROOT
17	total	total	JJ	_	21	NMOD
18	APP	app	NN	_	20	NMOD
19	/	/	HYPH	_	18	P
20	APLP	aplp	NN	_	21	NMOD
21	levels	level	NNS	_	30	SBJ
22	in	in	IN	_	21	NMOD
23	dox	dox	NN	_	25	AMOD
24	-	-	HYPH	_	23	P
25	treated	treat	VBN	_	29	NMOD
26	tTA	tta	NN	_	28	NMOD
27	/	/	HYPH	_	26	P
28	APP	app	NN	_	29	NMOD
29	mice	mouse	NNS	_	22	PMOD
30	are	be	VBP	_	16	OBJ
31	significantly	significantly	RB	_	32	AMOD
32	lower	low	JJR	_	30	PRD
33	than	than	IN	_	32	AMOD
34	in	in	IN	_	33	LOC
35	4	0	CD	_	37	NMOD
36	-	-	HYPH	_	35	P
37	wk	wk	NN	_	39	AMOD
38	-	-	HYPH	_	37	P
39	old	old	JJ	_	41	NMOD
40	untreated	untreated	JJ	_	41	NMOD
41	mice	mouse	NNS	_	34	PMOD
42	(	(	-LRB-	_	56	P
43	ANOVA	anova	NN	_	44	NMOD
44	effect	effect	NN	_	52	SBJ
45	of	of	IN	_	44	NMOD
46	treatment	treatment	NN	_	48	NMOD
47	group	group	NN	_	48	NMOD
48	F4	f0	NN	_	45	PMOD
49	,	,	,	_	48	P
50	15	0	CD	_	48	NMOD
51	=	=	SYM	_	52	P
52	84.41	0	CD	_	56	DEP
53	,	,	,	_	56	P
54	p	p	NN	_	56	SBJ
55	<	<	SYM	_	56	P
56	0.001	0	CD	_	41	PRN
57	)	)	-RRB-	_	56	P
58	and	and	CC	_	32	COORD
59	indistinguishable	indistinguishable	JJ	_	58	CONJ
60	from	from	IN	_	59	AMOD
61	those	those	DT	_	60	PMOD
62	of	of	IN	_	61	NMOD
63	nontransgenic	nontransgenic	JJ	_	64	NMOD
64	animals	animal	NNS	_	62	PMOD
65	(	(	-LRB-	_	74	P
66	p	p	NN	_	68	SBJ
67	>	>	SYM	_	68	P
68	0.9	0	CD	_	74	DEP
69	,	,	,	_	74	P
70	Tukey	tukey	NNP	_	74	NMOD
71	post	post	FW	_	73	NMOD
72	-	-	HYPH	_	71	P
73	hoc	hoc	FW	_	74	NMOD
74	test	test	NN	_	64	PRN
75	)	)	-RRB-	_	74	P
76	.	.	.	_	16	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.001	0	CD	_	0	ROOT
6	versus	versus	IN	_	5	ADV
7	untreated	untreated	JJ	_	13	NMOD
8	4	0	CD	_	10	NMOD
9	-	-	HYPH	_	8	P
10	wk	wk	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	old	old	JJ	_	13	NMOD
13	mice	mouse	NNS	_	6	PMOD
14	,	,	,	_	5	P
15	Tukey	tukey	NNP	_	19	NMOD
16	post	post	FW	_	18	NMOD
17	-	-	HYPH	_	16	P
18	hoc	hoc	FW	_	19	NMOD
19	test	test	NN	_	5	ADV
20	applied	apply	VBN	_	19	NMOD
21	to	to	IN	_	20	ADV
22	significant	significant	JJ	_	23	NMOD
23	effect	effect	NN	_	21	PMOD
24	of	of	IN	_	23	NMOD
25	group	group	NN	_	26	NMOD
26	ANOVA	anova	NN	_	24	PMOD
27	.	.	.	_	5	P

1	Figure	figure	NN	_	0	ROOT
2	2	0	CD	_	1	NMOD

1	Aβ	aβ	NN	_	2	NMOD
2	Levels	level	NNS	_	3	SBJ
3	Are	be	VBP	_	0	ROOT
4	Dramatically	dramatically	RB	_	3	ADV
5	Reduced	reduce	VBN	_	3	VC
6	by	by	IN	_	5	LGS
7	Transgene	transgene	NN	_	8	NMOD
8	Suppression	suppression	NN	_	6	PMOD

1	Cortical	cortical	JJ	_	2	NMOD
2	homogenates	homogenate	NNS	_	22	SBJ
3	from	from	IN	_	2	NMOD
4	young	young	JJ	_	10	NMOD
5	,	,	,	_	10	P
6	predeposit	predeposit	JJ	_	10	NMOD
7	tTA	tta	NN	_	9	NMOD
8	/	/	HYPH	_	7	P
9	APP	app	NN	_	10	NMOD
10	mice	mouse	NNS	_	3	PMOD
11	used	use	VBN	_	10	NMOD
12	for	for	IN	_	11	ADV
13	Western	western	NNP	_	14	NMOD
14	blot	blot	NN	_	12	PMOD
15	in	in	IN	_	11	ADV
16	Figure	figure	NN	_	15	PMOD
17	1	0	CD	_	16	NMOD
18	(	(	-LRB-	_	19	P
19	line	line	NN	_	11	PRN
20	107	0	CD	_	19	NMOD
21	)	)	-RRB-	_	19	P
22	were	be	VBD	_	0	ROOT
23	fractionated	fractionate	VBN	_	22	VC
24	by	by	IN	_	23	MNR
25	sequential	sequential	JJ	_	27	NMOD
26	multi-step	multi-step	JJ	_	27	NMOD
27	extraction	extraction	NN	_	24	PMOD
28	with	with	IN	_	27	NMOD
29	PBS	pb	NN	_	28	PMOD
30	,	,	,	_	29	P
31	2	0	CD	_	32	NMOD
32	%	%	NN	_	33	NMOD
33	SDS	sd	NN	_	29	CONJ
34	,	,	,	_	33	P
35	and	and	CC	_	33	COORD
36	70	0	CD	_	37	NMOD
37	%	%	NN	_	38	NMOD
38	FA	fa	NN	_	35	CONJ
39	followed	follow	VBN	_	27	NMOD
40	by	by	IN	_	39	LGS
41	human	human	JJ	_	43	AMOD
42	-	-	HYPH	_	41	P
43	specific	specific	JJ	_	45	NMOD
44	Aβ	aβ	NN	_	45	NMOD
45	ELISA	elisa	NN	_	40	PMOD
46	to	to	TO	_	39	PRP
47	measure	measure	VB	_	46	IM
48	transgene	transgene	NN	_	50	AMOD
49	-	-	HYPH	_	48	P
50	derived	derive	VBN	_	51	NMOD
51	peptide	peptide	NN	_	47	OBJ
52	in	in	IN	_	47	ADV
53	each	each	DT	_	54	NMOD
54	fraction	fraction	NN	_	52	PMOD
55	.	.	.	_	22	P

1	Aβ40	aβ0	NN	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	shown	show	VBN	_	2	VC
4	in	in	IN	_	3	ADV
5	white	white	JJ	_	4	PMOD
6	,	,	,	_	3	P
7	Aβ42	aβ0	NN	_	3	GAP-SBJ
8	in	in	IN	_	7	ADV
9	black	black	JJ	_	8	PMOD
10	.	.	.	_	2	P

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	9	DEP
3	)	)	-RRB-	_	2	P
4	PBS	pb	NN	_	6	AMOD
5	-	-	HYPH	_	4	P
6	soluble	soluble	JJ	_	8	NMOD
7	Aβ	aβ	NN	_	8	NMOD
8	levels	level	NNS	_	9	SBJ
9	are	be	VBP	_	0	ROOT
10	substantially	substantially	RB	_	9	ADV
11	reduced	reduce	VBN	_	9	VC
12	by	by	IN	_	11	LGS
13	both	both	CC	_	18	COORD
14	acute	acute	JJ	_	18	NMOD
15	and	and	CC	_	14	COORD
16	chronic	chronic	JJ	_	15	CONJ
17	dox	dox	NN	_	18	NMOD
18	treatment	treatment	NN	_	12	PMOD
19	(	(	-LRB-	_	36	P
20	ANOVA	anova	NN	_	36	DEP
21	,	,	,	_	36	P
22	effect	effect	NN	_	30	SBJ
23	of	of	IN	_	22	NMOD
24	treatment	treatment	NN	_	25	NMOD
25	group	group	NN	_	26	NMOD
26	F4	f0	NN	_	23	PMOD
27	,	,	,	_	26	P
28	24	0	CD	_	26	NMOD
29	=	=	SYM	_	30	P
30	137.10	0	CD	_	36	DEP
31	and	and	CC	_	30	COORD
32	386.01	0	CD	_	31	CONJ
33	,	,	,	_	36	P
34	p	p	NN	_	36	SBJ
35	<	<	SYM	_	36	P
36	0.001	0	CD	_	11	PRN
37	,	,	,	_	36	P
38	for	for	IN	_	36	ADV
39	Aβ40	aβ0	NN	_	38	PMOD
40	and	and	CC	_	39	COORD
41	Aβ42	aβ0	NN	_	40	CONJ
42	,	,	,	_	36	P
43	respectively	respectively	RB	_	36	ADV
44	)	)	-RRB-	_	36	P
45	.	.	.	_	9	P

1	Aβ	aβ	NN	_	2	NMOD
2	levels	level	NNS	_	6	SBJ
3	in	in	IN	_	2	NMOD
4	treated	treat	VBN	_	5	NMOD
5	animals	animal	NNS	_	3	PMOD
6	are	be	VBP	_	0	ROOT
7	indistinguishable	indistinguishable	JJ	_	6	PRD
8	from	from	IN	_	7	AMOD
9	nontransgenic	nontransgenic	JJ	_	13	NMOD
10	(	(	-LRB-	_	11	P
11	NTg	ntg	NN	_	9	PRN
12	)	)	-RRB-	_	11	P
13	animals	animal	NNS	_	8	PMOD
14	(	(	-LRB-	_	23	P
15	p	p	NN	_	17	SBJ
16	>	>	SYM	_	17	P
17	0.3	0	CD	_	23	DEP
18	,	,	,	_	23	P
19	Tukey	tukey	NNP	_	23	NMOD
20	post	post	FW	_	22	NMOD
21	-	-	HYPH	_	20	P
22	hoc	hoc	FW	_	23	NMOD
23	test	test	NN	_	6	PRN
24	)	)	-RRB-	_	23	P
25	.	.	.	_	6	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	21	DEP
3	)	)	-RRB-	_	2	P
4	In	in	IN	_	21	LOC
5	the	the	DT	_	7	NMOD
6	young	young	JJ	_	7	NMOD
7	animals	animal	NNS	_	4	PMOD
8	tested	test	VBN	_	7	NMOD
9	here	here	RB	_	8	ADV
10	prior	prior	JJ	_	11	PMOD
11	to	to	IN	_	8	TMP
12	the	the	DT	_	13	NMOD
13	formation	formation	NN	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	visible	visible	JJ	_	17	NMOD
16	amyloid	amyloid	NN	_	17	NMOD
17	deposits	deposit	NNS	_	14	PMOD
18	,	,	,	_	21	P
19	most	most	JJS	_	20	NMOD
20	Aβ	aβ	NN	_	21	SBJ
21	is	be	VBZ	_	0	ROOT
22	extracted	extract	VBN	_	21	VC
23	into	into	IN	_	22	ADV
24	the	the	DT	_	26	NMOD
25	SDS	sd	NN	_	26	NMOD
26	fraction	fraction	NN	_	23	PMOD
27	(	(	-LRB-	_	42	P
28	84	0	CD	_	29	NMOD
29	%	%	NN	_	42	DEP
30	and	and	CC	_	29	COORD
31	76	0	CD	_	32	NMOD
32	%	%	NN	_	30	CONJ
33	of	of	IN	_	29	NMOD
34	all	all	DT	_	38	NMOD
35	transgene	transgene	JJ	_	37	AMOD
36	-	-	HYPH	_	35	P
37	derived	derive	VBN	_	38	NMOD
38	Aβ40	aβ0	NN	_	33	PMOD
39	and	and	CC	_	38	COORD
40	Aβ42	aβ0	NN	_	39	CONJ
41	,	,	,	_	42	P
42	respectively	respectively	RB	_	22	PRN
43	)	)	-RRB-	_	42	P
44	.	.	.	_	21	P

1	As	as	IN	_	15	ADV
2	in	in	IN	_	1	PMOD
3	the	the	DT	_	7	NMOD
4	PBS	pb	NN	_	6	AMOD
5	-	-	HYPH	_	4	P
6	soluble	soluble	JJ	_	7	NMOD
7	fraction	fraction	NN	_	2	PMOD
8	,	,	,	_	15	P
9	Aβ	aβ	NN	_	10	NMOD
10	levels	level	NNS	_	15	SBJ
11	in	in	IN	_	10	NMOD
12	the	the	DT	_	14	NMOD
13	SDS	sd	NN	_	14	NMOD
14	fraction	fraction	NN	_	11	PMOD
15	are	be	VBP	_	0	ROOT
16	significantly	significantly	RB	_	15	ADV
17	lowered	lower	VBN	_	15	VC
18	by	by	IN	_	17	LGS
19	dox	dox	NN	_	20	NMOD
20	treatment	treatment	NN	_	18	PMOD
21	compared	compare	VBN	_	17	ADV
22	to	to	IN	_	21	PMOD
23	untreated	untreated	JJ	_	24	NMOD
24	animals	animal	NNS	_	22	PMOD
25	(	(	-LRB-	_	40	P
26	ANOVA	anova	NN	_	27	NMOD
27	effect	effect	NN	_	34	SBJ
28	of	of	IN	_	27	NMOD
29	group	group	NN	_	30	NMOD
30	F4	f0	NN	_	28	PMOD
31	,	,	,	_	30	P
32	24	0	CD	_	30	NMOD
33	=	=	SYM	_	34	P
34	197.57	0	CD	_	40	DEP
35	and	and	CC	_	34	COORD
36	163.48	0	CD	_	35	CONJ
37	,	,	,	_	40	P
38	p	p	NN	_	40	SBJ
39	<	<	SYM	_	40	P
40	0.001	0	CD	_	24	PRN
41	,	,	,	_	40	P
42	for	for	IN	_	40	ADV
43	Aβ40	aβ0	NN	_	42	PMOD
44	and	and	CC	_	43	COORD
45	Aβ42	aβ0	NN	_	44	CONJ
46	,	,	,	_	40	P
47	respectively	respectively	RB	_	40	ADV
48	)	)	-RRB-	_	40	P
49	.	.	.	_	15	P

1	Acutely	acutely	RB	_	2	AMOD
2	treated	treat	VBN	_	3	NMOD
3	animals	animal	NNS	_	4	SBJ
4	retained	retain	VBD	_	0	ROOT
5	a	a	DT	_	11	NMOD
6	small	small	JJ	_	11	NMOD
7	(	(	-LRB-	_	8	P
8	although	although	IN	_	6	PRN
9	significant	significant	JJ	_	8	SUB
10	)	)	-RRB-	_	8	P
11	amount	amount	NN	_	4	OBJ
12	of	of	IN	_	11	NMOD
13	residual	residual	JJ	_	14	NMOD
14	peptide	peptide	NN	_	12	PMOD
15	(	(	-LRB-	_	27	P
16	p	p	NN	_	18	SBJ
17	<	<	SYM	_	18	P
18	0.001	0	CD	_	27	DEP
19	compared	compare	VBN	_	18	ADV
20	to	to	IN	_	19	PMOD
21	nontransgeinc	nontransgeinc	JJ	_	20	PMOD
22	,	,	,	_	27	P
23	Tukey	tukey	NNP	_	27	NMOD
24	post	post	FW	_	26	NMOD
25	-	-	HYPH	_	24	P
26	hoc	hoc	FW	_	27	NMOD
27	test	test	NN	_	4	PRN
28	)	)	-RRB-	_	27	P
29	,	,	,	_	4	P
30	whereas	whereas	IN	_	4	ADV
31	Aβ	aβ	NN	_	32	NMOD
32	levels	level	NNS	_	40	SBJ
33	in	in	IN	_	32	LOC
34	mice	mouse	NNS	_	33	PMOD
35	born	bear	VBN	_	34	NMOD
36	and	and	CC	_	35	COORD
37	raised	raise	VBN	_	36	CONJ
38	on	on	IN	_	35	ADV
39	dox	dox	NN	_	38	PMOD
40	were	be	VBD	_	30	SUB
41	reduced	reduce	VBN	_	40	VC
42	to	to	IN	_	41	ADV
43	levels	level	NNS	_	42	PMOD
44	indistinguishable	indistinguishable	JJ	_	43	NMOD
45	from	from	IN	_	44	AMOD
46	nontransgenic	nontransgenic	JJ	_	45	PMOD
47	(	(	-LRB-	_	56	P
48	p	p	NN	_	50	SBJ
49	>	>	SYM	_	50	P
50	0.8	0	CD	_	56	DEP
51	,	,	,	_	56	P
52	Tukey	tukey	NNP	_	56	NMOD
53	post	post	FW	_	55	NMOD
54	-	-	HYPH	_	53	P
55	hoc	hoc	FW	_	56	NMOD
56	test	test	NN	_	41	PRN
57	)	)	-RRB-	_	56	P
58	.	.	.	_	4	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	10	DEP
3	)	)	-RRB-	_	2	P
4	The	the	DT	_	8	NMOD
5	FA	fa	NN	_	7	AMOD
6	-	-	HYPH	_	5	P
7	soluble	soluble	JJ	_	8	NMOD
8	fraction	fraction	NN	_	10	SBJ
9	already	already	RB	_	10	ADV
10	contains	contain	VBZ	_	0	ROOT
11	a	a	DT	_	15	NMOD
12	small	small	JJ	_	15	NMOD
13	but	but	CC	_	12	COORD
14	significant	significant	JJ	_	13	CONJ
15	pool	pool	NN	_	10	OBJ
16	of	of	IN	_	15	NMOD
17	aggregated	aggregate	VBN	_	18	NMOD
18	Aβ42	aβ0	NN	_	16	PMOD
19	in	in	IN	_	10	LOC
20	untreated	untreated	JJ	_	21	NMOD
21	animals	animal	NNS	_	19	PMOD
22	by	by	IN	_	10	TMP
23	4	0	CD	_	24	NMOD
24	wk	wk	NN	_	22	PMOD
25	of	of	IN	_	24	NMOD
26	age	age	NN	_	25	PMOD
27	(	(	-LRB-	_	54	P
28	p	p	NN	_	30	SBJ
29	<	<	SYM	_	30	P
30	0.05	0	CD	_	54	DEP
31	versus	versus	IN	_	30	ADV
32	nontransgenic	nontransgenic	JJ	_	31	PMOD
33	;	;	:	_	54	P
34	Tukey	tukey	NNP	_	38	NMOD
35	post	post	FW	_	37	NMOD
36	-	-	HYPH	_	35	P
37	hoc	hoc	FW	_	38	NMOD
38	test	test	NN	_	50	SBJ
39	applied	apply	VBN	_	38	NMOD
40	to	to	IN	_	39	ADV
41	significant	significant	JJ	_	42	NMOD
42	effect	effect	NN	_	40	PMOD
43	of	of	IN	_	42	NMOD
44	group	group	NN	_	46	NMOD
45	ANOVA	anova	NN	_	46	NMOD
46	F4	f0	NN	_	43	PMOD
47	,	,	,	_	46	P
48	24	0	CD	_	46	NMOD
49	=	=	SYM	_	50	P
50	17.11	0	CD	_	54	DEP
51	,	,	,	_	54	P
52	p	p	NN	_	54	SBJ
53	<	<	SYM	_	54	P
54	0.001	0	CD	_	10	PRN
55	)	)	-RRB-	_	54	P
56	.	.	.	_	10	P

1	By	by	IN	_	15	TMP
2	6	0	CD	_	3	NMOD
3	wk	wk	NN	_	1	PMOD
4	of	of	IN	_	3	NMOD
5	age	age	NN	_	4	PMOD
6	,	,	,	_	15	P
7	the	the	DT	_	8	NMOD
8	amount	amount	NN	_	15	SBJ
9	of	of	IN	_	8	NMOD
10	Aβ	aβ	NN	_	9	PMOD
11	in	in	IN	_	8	LOC
12	the	the	DT	_	14	NMOD
13	FA	fa	NN	_	14	NMOD
14	fraction	fraction	NN	_	11	PMOD
15	is	be	VBZ	_	0	ROOT
16	increased	increase	VBN	_	15	VC
17	significantly	significantly	RB	_	16	ADV
18	preceding	precede	VBG	_	16	TMP
19	the	the	DT	_	20	NMOD
20	appearance	appearance	NN	_	18	OBJ
21	of	of	IN	_	20	NMOD
22	visible	visible	JJ	_	23	NMOD
23	deposits	deposit	NNS	_	21	PMOD
24	2	0	CD	_	25	NMOD
25	wk	wk	NN	_	26	AMOD
26	later	later	RB	_	18	TMP
27	.	.	.	_	15	P

1	The	the	DT	_	3	NMOD
2	FA	fa	NN	_	3	NMOD
3	pool	pool	NN	_	4	SBJ
4	is	be	VBZ	_	0	ROOT
5	the	the	DT	_	8	NMOD
6	only	only	JJ	_	8	NMOD
7	peptide	peptide	NN	_	8	NMOD
8	fraction	fraction	NN	_	4	PRD
9	not	not	RB	_	10	ADV
10	lowered	lower	VBN	_	8	NMOD
11	by	by	IN	_	10	LGS
12	acute	acute	JJ	_	14	NMOD
13	dox	dox	NN	_	14	NMOD
14	treatment	treatment	NN	_	11	PMOD
15	(	(	-LRB-	_	29	P
16	4	0	CD	_	17	NMOD
17	wk	wk	NN	_	25	SBJ
18	untreated	untreated	JJ	_	17	NMOD
19	=	=	SYM	_	25	P
20	4	0	CD	_	21	NMOD
21	wk	wk	NN	_	24	NMOD
22	+	+	SYM	_	24	P
23	2	0	CD	_	24	NMOD
24	wk	wk	NN	_	25	NMOD
25	dox	dox	NN	_	29	DEP
26	,	,	,	_	29	P
27	p	p	NN	_	29	SBJ
28	>	>	SYM	_	29	P
29	0.9	0	CD	_	14	PRN
30	,	,	,	_	29	P
31	Tukey	tukey	NNP	_	35	NMOD
32	post	post	FW	_	34	AMOD
33	-	-	HYPH	_	32	P
34	hoc	hoc	FW	_	35	NMOD
35	test	test	NN	_	29	ADV
36	)	)	-RRB-	_	29	P
37	,	,	,	_	4	P
38	consistent	consistent	JJ	_	4	ADV
39	with	with	IN	_	38	AMOD
40	poor	poor	JJ	_	41	NMOD
41	turnover	turnover	NN	_	39	PMOD
42	of	of	IN	_	41	NMOD
43	aggregated	aggregate	VBN	_	45	NMOD
44	Aβ	aβ	NN	_	45	NMOD
45	species	specie	NNS	_	42	PMOD
46	.	.	.	_	4	P

1	(	(	-LRB-	_	2	P
2	D	d	LS	_	18	DEP
3	)	)	-RRB-	_	2	P
4	Measurements	measurement	NNS	_	18	SBJ
5	of	of	IN	_	4	NMOD
6	total	total	JJ	_	7	NMOD
7	Aβ	aβ	NN	_	5	PMOD
8	,	,	,	_	4	P
9	including	include	VBG	_	4	NMOD
10	both	both	CC	_	11	COORD
11	endogenous	endogenous	JJ	_	16	NMOD
12	and	and	CC	_	11	COORD
13	transgene	transgene	NN	_	15	AMOD
14	-	-	HYPH	_	13	P
15	derived	derive	VBN	_	12	CONJ
16	peptides	peptide	NNS	_	9	PMOD
17	,	,	,	_	18	P
18	show	show	VBP	_	0	ROOT
19	that	that	IN	_	18	OBJ
20	animals	animal	NNS	_	26	SBJ
21	born	bear	VBN	_	20	NMOD
22	and	and	CC	_	21	COORD
23	raised	raise	VBN	_	22	CONJ
24	on	on	IN	_	21	ADV
25	dox	dox	NN	_	24	PMOD
26	harbor	harbor	VBP	_	19	SUB
27	Aβ	aβ	NN	_	28	NMOD
28	levels	level	NNS	_	26	OBJ
29	identical	identical	JJ	_	28	NMOD
30	to	to	IN	_	29	AMOD
31	nontransgenic	nontransgenic	JJ	_	32	NMOD
32	animals	animal	NNS	_	30	PMOD
33	(	(	-LRB-	_	58	P
34	p	p	NN	_	36	SBJ
35	>	>	SYM	_	36	P
36	0.9	0	CD	_	58	DEP
37	,	,	,	_	36	P
38	Tukey	tukey	NNP	_	42	NMOD
39	post	post	FW	_	41	AMOD
40	-	-	HYPH	_	39	P
41	hoc	hoc	FW	_	42	NMOD
42	test	test	NN	_	36	ADV
43	,	,	,	_	36	P
44	effect	effect	NN	_	52	SBJ
45	of	of	IN	_	44	NMOD
46	group	group	NN	_	48	NMOD
47	ANOVA	anova	NN	_	48	NMOD
48	F4	f0	NN	_	45	PMOD
49	,	,	,	_	48	P
50	24	0	CD	_	48	NMOD
51	=	=	SYM	_	52	P
52	39.13	0	CD	_	58	DEP
53	and	and	CC	_	52	COORD
54	35.29	0	CD	_	53	CONJ
55	,	,	,	_	58	P
56	p	p	NN	_	58	SBJ
57	<	<	SYM	_	58	P
58	0.001	0	CD	_	26	PRN
59	,	,	,	_	58	P
60	for	for	IN	_	58	ADV
61	Aβ40	aβ0	NN	_	60	PMOD
62	and	and	CC	_	61	COORD
63	Aβ42	aβ0	NN	_	62	CONJ
64	,	,	,	_	58	P
65	respectively	respectively	RB	_	58	ADV
66	)	)	-RRB-	_	58	P
67	.	.	.	_	18	P

1	Whereas	whereas	IN	_	16	ADV
2	chronic	chronic	JJ	_	4	NMOD
3	transgene	transgene	NN	_	4	NMOD
4	suppression	suppression	NN	_	6	SBJ
5	fully	fully	RB	_	6	ADV
6	prevents	prevent	VBZ	_	1	SUB
7	synthesis	synthesis	NN	_	6	OBJ
8	of	of	IN	_	7	NMOD
9	both	both	DT	_	10	NMOD
10	peptides	peptide	NNS	_	8	PMOD
11	,	,	,	_	16	P
12	acute	acute	JJ	_	14	NMOD
13	dox	dox	NN	_	14	NMOD
14	treatment	treatment	NN	_	16	SBJ
15	fully	fully	RB	_	16	ADV
16	suppresses	suppress	VBZ	_	0	ROOT
17	Aβ40	aβ0	NN	_	18	NMOD
18	levels	level	NNS	_	16	OBJ
19	(	(	-LRB-	_	28	P
20	p	p	NN	_	22	SBJ
21	>	>	SYM	_	22	P
22	0.8	0	CD	_	28	DEP
23	,	,	,	_	28	P
24	Tukey	tukey	NNP	_	28	NMOD
25	post	post	FW	_	27	AMOD
26	-	-	HYPH	_	25	P
27	hoc	hoc	FW	_	28	NMOD
28	test	test	NN	_	16	PRN
29	)	)	-RRB-	_	28	P
30	,	,	,	_	16	P
31	but	but	CC	_	16	COORD
32	leaves	leave	VBZ	_	31	CONJ
33	a	a	DT	_	35	NMOD
34	small	small	JJ	_	35	NMOD
35	amount	amount	NN	_	32	OBJ
36	of	of	IN	_	35	NMOD
37	nonsuppressed	nonsuppressed	JJ	_	38	NMOD
38	Aβ42	aβ0	NN	_	36	PMOD
39	.	.	.	_	16	P

1	The	the	DT	_	3	NMOD
2	residual	residual	JJ	_	3	NMOD
3	Aβ42	aβ0	NN	_	10	SBJ
4	observed	observe	VBN	_	3	NMOD
5	in	in	IN	_	4	LOC
6	acutely	acutely	RB	_	7	AMOD
7	treated	treat	VBN	_	9	NMOD
8	young	young	JJ	_	9	NMOD
9	animals	animal	NNS	_	5	PMOD
10	derives	derive	VBZ	_	0	ROOT
11	from	from	IN	_	10	ADV
12	uncleared	uncleared	JJ	_	13	NMOD
13	aggregates	aggregate	NNS	_	11	PMOD
14	extracted	extract	VBN	_	13	NMOD
15	in	in	IN	_	10	LOC
16	the	the	DT	_	20	NMOD
17	SDS	sd	NN	_	20	NMOD
18	and	and	CC	_	17	COORD
19	FA	fa	NN	_	18	CONJ
20	fractions	fraction	NNS	_	15	PMOD
21	.	.	.	_	10	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.05	0	CD	_	17	DEP
6	;	;	:	_	17	P
7	**	**	SYM	_	11	DEP
8	,	,	,	_	11	P
9	p	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.005	0	CD	_	17	DEP
12	;	;	:	_	17	P
13	***	***	SYM	_	17	DEP
14	,	,	,	_	17	P
15	p	p	NN	_	17	SBJ
16	<	<	SYM	_	17	P
17	0.001	0	CD	_	0	ROOT
18	versus	versus	IN	_	17	ADV
19	4	0	CD	_	21	NMOD
20	-	-	HYPH	_	19	P
21	wk	wk	NN	_	23	AMOD
22	-	-	HYPH	_	21	P
23	old	old	JJ	_	25	NMOD
24	untreated	untreated	JJ	_	25	NMOD
25	mice	mouse	NNS	_	18	PMOD
26	,	,	,	_	17	P
27	Tukey	tukey	NNP	_	17	ADV
28	post	post	FW	_	27	NMOD
29	-	-	HYPH	_	28	P
30	hoc	hoc	FW	_	27	NMOD
31	applied	apply	VBN	_	27	NMOD
32	to	to	IN	_	31	ADV
33	significant	significant	JJ	_	34	NMOD
34	effect	effect	NN	_	32	PMOD
35	of	of	IN	_	34	NMOD
36	group	group	NN	_	37	NMOD
37	ANOVA	anova	NN	_	35	PMOD
38	.	.	.	_	17	P

1	Figure	figure	NN	_	0	ROOT
2	3	0	CD	_	1	NMOD

1	Robust	robust	JJ	_	3	NMOD
2	Transgene	transgene	NN	_	3	NMOD
3	Suppression	suppression	NN	_	0	ROOT
4	in	in	IN	_	3	LOC
5	Older	old	JJ	_	6	NMOD
6	Mice	mouse	NNS	_	4	PMOD
7	with	with	IN	_	6	NMOD
8	Preexisting	preexist	VBG	_	10	NMOD
9	Amyloid	amyloid	NN	_	10	NMOD
10	Pathology	pathology	NN	_	7	PMOD

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	26	DEP
3	)	)	-RRB-	_	2	P
4	Cortical	cortical	JJ	_	5	NMOD
5	homogenates	homogenate	NNS	_	26	SBJ
6	from	from	IN	_	5	NMOD
7	6	0	CD	_	12	NMOD
8	-	-	HYPH	_	7	P
9	to	to	IN	_	7	QMOD
10	12	0	CD	_	7	QMOD
11	-	-	HYPH	_	7	P
12	mo	mo	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	old	old	JJ	_	15	NMOD
15	animals	animal	NNS	_	6	PMOD
16	used	use	VBN	_	15	NMOD
17	for	for	IN	_	16	ADV
18	pathology	pathology	NN	_	19	NMOD
19	studies	study	NNS	_	17	PMOD
20	described	describe	VBN	_	19	NMOD
21	below	below	RB	_	20	ADV
22	(	(	-LRB-	_	23	P
23	line	line	NN	_	20	PRN
24	107	0	CD	_	23	NMOD
25	)	)	-RRB-	_	23	P
26	were	be	VBD	_	0	ROOT
27	immunoblotted	immunoblotted	VBN	_	26	VC
28	with	with	IN	_	27	MNR
29	human	human	JJ	_	31	AMOD
30	-	-	HYPH	_	29	P
31	specific	specific	JJ	_	33	NMOD
32	antibody	antibody	NN	_	33	NMOD
33	6E10	0e0	NN	_	28	PMOD
34	to	to	TO	_	27	PRP
35	examine	examine	VB	_	34	IM
36	transgene	transgene	NN	_	37	NMOD
37	suppression	suppression	NN	_	35	OBJ
38	following	follow	VBG	_	35	ADV
39	3	0	CD	_	42	NMOD
40	or	or	CC	_	39	COORD
41	6	0	CD	_	40	CONJ
42	mo	mo	NN	_	38	PMOD
43	of	of	IN	_	42	NMOD
44	dox	dox	NN	_	45	NMOD
45	treatment	treatment	NN	_	43	PMOD
46	.	.	.	_	26	P

1	The	the	DT	_	2	NMOD
2	blot	blot	NN	_	3	SBJ
3	was	be	VBD	_	0	ROOT
4	co-immunostained	co-immunostained	VBN	_	3	VC
5	for	for	IN	_	4	ADV
6	endogenous	endogenous	JJ	_	8	NMOD
7	superoxide	superoxide	NN	_	8	NMOD
8	dismutase	dismutase	NN	_	11	NMOD
9	1	0	CD	_	8	NMOD
10	(	(	-LRB-	_	11	P
11	SOD1	sod0	NN	_	5	PMOD
12	)	)	-RRB-	_	4	P
13	as	as	IN	_	4	ADV
14	a	a	DT	_	15	NMOD
15	control	control	NN	_	13	PMOD
16	for	for	IN	_	15	NMOD
17	loading	loading	NN	_	16	PMOD
18	.	.	.	_	3	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	4	NMOD
3	)	)	-RRB-	_	2	P
4	Quantitation	quantitation	NN	_	0	ROOT
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	from	from	IN	_	4	NMOD
9	the	the	DT	_	11	NMOD
10	Western	western	NNP	_	11	NMOD
11	blot	blot	NN	_	8	PMOD
12	shown	show	VBN	_	11	NMOD
13	in	in	IN	_	12	ADV
14	(	(	-LRB-	_	13	P
15	A	a	NN	_	13	PMOD
16	)	)	-RRB-	_	4	P
17	.	.	.	_	4	P

1	Transgenic	transgenic	JJ	_	3	NMOD
2	APP	app	NN	_	3	NMOD
3	levels	level	NNS	_	4	SBJ
4	are	be	VBP	_	0	ROOT
5	significantly	significantly	RB	_	4	ADV
6	suppressed	suppress	VBN	_	4	VC
7	following	follow	VBG	_	6	TMP
8	3	0	CD	_	11	NMOD
9	or	or	CC	_	8	COORD
10	6	0	CD	_	9	CONJ
11	mo	mo	NN	_	7	PMOD
12	of	of	IN	_	11	NMOD
13	dox	dox	NN	_	14	NMOD
14	treatment	treatment	NN	_	12	PMOD
15	(	(	-LRB-	_	22	P
16	96.9	0	CD	_	17	NMOD
17	%	%	NN	_	22	DEP
18	and	and	CC	_	17	COORD
19	97.6	0	CD	_	20	NMOD
20	%	%	NN	_	18	CONJ
21	,	,	,	_	22	P
22	respectively	respectively	RB	_	6	PRN
23	)	)	-RRB-	_	22	P
24	.	.	.	_	4	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.001	0	CD	_	36	DEP
6	compared	compare	VBN	_	5	ADV
7	to	to	IN	_	6	PMOD
8	6	0	CD	_	10	NMOD
9	-	-	HYPH	_	8	P
10	mo	mo	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	old	old	JJ	_	14	NMOD
13	untreated	untreated	JJ	_	14	NMOD
14	animals	animal	NNS	_	7	PMOD
15	,	,	,	_	36	P
16	Tukey	tukey	NNP	_	20	NMOD
17	post	post	FW	_	19	AMOD
18	-	-	HYPH	_	17	P
19	hoc	hoc	FW	_	20	NMOD
20	test	test	NN	_	32	SBJ
21	applied	apply	VBN	_	20	NMOD
22	to	to	IN	_	21	ADV
23	significant	significant	JJ	_	24	NMOD
24	effect	effect	NN	_	22	PMOD
25	of	of	IN	_	24	NMOD
26	group	group	NN	_	28	NMOD
27	ANOVA	anova	NN	_	28	NMOD
28	F3	f0	NN	_	25	PMOD
29	,	,	,	_	28	P
30	12	0	CD	_	28	NMOD
31	=	=	SYM	_	32	P
32	107.22	0	CD	_	36	DEP
33	,	,	,	_	36	P
34	p	p	NN	_	36	SBJ
35	<	<	SYM	_	36	P
36	0.001	0	CD	_	0	ROOT
37	.	.	.	_	36	P

1	These	these	DT	_	2	NMOD
2	data	datum	NNS	_	3	SBJ
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	that	that	IN	_	3	OBJ
5	strong	strong	JJ	_	7	NMOD
6	transgene	transgene	NN	_	7	NMOD
7	suppression	suppression	NN	_	8	SBJ
8	is	be	VBZ	_	4	SUB
9	attained	attain	VBN	_	8	VC
10	both	both	CC	_	11	COORD
11	before	before	IN	_	9	TMP
12	and	and	CC	_	11	COORD
13	after	after	IN	_	12	CONJ
14	the	the	DT	_	15	NMOD
15	onset	onset	NN	_	11	PMOD
16	of	of	IN	_	15	NMOD
17	amyloid	amyloid	NN	_	18	NMOD
18	pathology	pathology	NN	_	16	PMOD
19	(	(	-LRB-	_	20	P
20	see	see	VB	_	9	PRN
21	Figure	figure	NN	_	20	OBJ
22	1	0	CD	_	21	NMOD
23	for	for	IN	_	20	ADV
24	predeposit	predeposit	JJ	_	25	NMOD
25	experiments	experiment	NNS	_	23	PMOD
26	)	)	-RRB-	_	20	P
27	.	.	.	_	3	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	5	NMOD
3	)	)	-RRB-	_	2	P
4	Experimental	experimental	JJ	_	5	NMOD
5	design	design	NN	_	0	ROOT
6	.	.	.	_	5	P

1	To	to	TO	_	19	PRP
2	examine	examine	VB	_	1	IM
3	the	the	DT	_	4	NMOD
4	effects	effect	NNS	_	2	OBJ
5	of	of	IN	_	4	NMOD
6	chronic	chronic	JJ	_	8	NMOD
7	Aβ	aβ	NN	_	8	NMOD
8	suppression	suppression	NN	_	5	PMOD
9	on	on	IN	_	4	NMOD
10	amyloid	amyloid	NN	_	11	NMOD
11	pathology	pathology	NN	_	9	PMOD
12	after	after	IN	_	2	TMP
13	the	the	DT	_	14	NMOD
14	onset	onset	NN	_	12	PMOD
15	of	of	IN	_	14	NMOD
16	deposition	deposition	NN	_	15	PMOD
17	,	,	,	_	19	P
18	we	we	PRP	_	19	SBJ
19	compared	compare	VBD	_	0	ROOT
20	untreated	untreated	JJ	_	21	NMOD
21	controls	control	NNS	_	19	OBJ
22	harvested	harvest	VBN	_	21	NMOD
23	at	at	IN	_	22	TMP
24	6	0	CD	_	27	NMOD
25	and	and	CC	_	24	COORD
26	9	0	CD	_	25	CONJ
27	mo	mo	NN	_	23	PMOD
28	of	of	IN	_	27	NMOD
29	age	age	NN	_	28	PMOD
30	to	to	IN	_	22	ADV
31	animals	animal	NNS	_	30	PMOD
32	placed	place	VBN	_	31	NMOD
33	on	on	IN	_	32	ADV
34	dox	dox	NN	_	33	PMOD
35	at	at	IN	_	32	TMP
36	6	0	CD	_	37	NMOD
37	mo	mo	NN	_	35	PMOD
38	of	of	IN	_	37	NMOD
39	age	age	NN	_	38	PMOD
40	and	and	CC	_	32	COORD
41	harvested	harvest	VBN	_	40	CONJ
42	after	after	IN	_	41	TMP
43	3	0	CD	_	46	NMOD
44	or	or	CC	_	43	COORD
45	6	0	CD	_	44	CONJ
46	mo	mo	NN	_	42	PMOD
47	of	of	IN	_	46	NMOD
48	treatment	treatment	NN	_	47	PMOD
49	.	.	.	_	19	P

1	(	(	-LRB-	_	2	P
2	D	d	LS	_	6	DEP
3	)	)	-RRB-	_	2	P
4	Dox	dox	NN	_	5	NMOD
5	treatment	treatment	NN	_	6	SBJ
6	leads	lead	VBZ	_	0	ROOT
7	to	to	IN	_	6	ADV
8	rapid	rapid	JJ	_	10	NMOD
9	transgene	transgene	NN	_	10	NMOD
10	suppression	suppression	NN	_	7	PMOD
11	even	even	RB	_	12	PMOD
12	in	in	IN	_	6	LOC
13	6	0	CD	_	15	NMOD
14	-	-	HYPH	_	13	P
15	mo	mo	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	old	old	JJ	_	21	NMOD
18	tTA	tta	NN	_	20	NMOD
19	/	/	HYPH	_	18	P
20	APP	app	NN	_	21	NMOD
21	mice	mouse	NNS	_	12	PMOD
22	.	.	.	_	6	P

1	Immunostaining	immunostaining	NN	_	9	SBJ
2	with	with	IN	_	1	NMOD
3	6E10	0e0	NN	_	2	PMOD
4	shows	show	VBZ	_	1	NMOD
5	APPswe	appswe	NN	_	7	NMOD
6	/	/	HYPH	_	5	P
7	ind	ind	NN	_	8	NMOD
8	levels	level	NNS	_	4	OBJ
9	are	be	VBP	_	0	ROOT
10	dramatically	dramatically	RB	_	9	ADV
11	reduced	reduce	VBN	_	9	VC
12	in	in	IN	_	11	LOC
13	6	0	CD	_	15	NMOD
14	-	-	HYPH	_	13	P
15	mo	mo	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	old	old	JJ	_	18	NMOD
18	mice	mouse	NNS	_	12	PMOD
19	treated	treat	VBN	_	18	NMOD
20	for	for	IN	_	19	EXT
21	1	0	CD	_	22	NMOD
22	wk	wk	NN	_	20	PMOD
23	with	with	IN	_	19	MNR
24	dox	dox	NN	_	23	PMOD
25	(	(	-LRB-	_	27	P
26	upper	upper	JJ	_	27	NMOD
27	panel	panel	NN	_	19	PRN
28	)	)	-RRB-	_	27	P
29	.	.	.	_	9	P

1	A	a	DT	_	3	NMOD
2	separate	separate	JJ	_	3	NMOD
3	blot	blot	NN	_	4	SBJ
4	was	be	VBD	_	0	ROOT
5	immunostained	immunostained	VBN	_	4	VC
6	for	for	IN	_	5	ADV
7	APP	app	NN	_	8	NMOD
8	C	c	NN	_	10	AMOD
9	-	-	HYPH	_	8	P
10	terminal	terminal	JJ	_	11	NMOD
11	fragments	fragment	NNS	_	6	PMOD
12	with	with	IN	_	5	MNR
13	CT15	ct0	NN	_	14	NMOD
14	antibody	antibody	NN	_	12	PMOD
15	to	to	TO	_	5	PRP
16	show	show	VB	_	15	IM
17	that	that	IN	_	16	OBJ
18	the	the	DT	_	19	NMOD
19	precursors	precursor	NNS	_	23	SBJ
20	to	to	IN	_	19	NMOD
21	Aβ	aβ	NN	_	22	NMOD
22	cleavage	cleavage	NN	_	20	PMOD
23	are	be	VBP	_	17	SUB
24	decreased	decrease	VBN	_	23	VC
25	in	in	IN	_	24	ADV
26	parallel	parallel	NN	_	25	PMOD
27	with	with	IN	_	26	NMOD
28	the	the	DT	_	32	NMOD
29	full	full	JJ	_	31	NMOD
30	-	-	HYPH	_	29	P
31	length	length	NN	_	32	NMOD
32	protein	protein	NN	_	27	PMOD
33	(	(	-LRB-	_	35	P
34	middle	middle	JJ	_	35	NMOD
35	panel	panel	NN	_	5	PRN
36	)	)	-RRB-	_	35	P
37	.	.	.	_	4	P

1	Costaining	costaining	NN	_	6	SBJ
2	for	for	IN	_	1	NMOD
3	superoxide	superoxide	NN	_	4	NMOD
4	dismutase	dismutase	NN	_	2	PMOD
5	1	0	CD	_	4	NMOD
6	was	be	VBD	_	0	ROOT
7	used	use	VBN	_	6	VC
8	as	as	IN	_	7	ADV
9	an	an	DT	_	11	NMOD
10	internal	internal	JJ	_	11	NMOD
11	control	control	NN	_	8	PMOD
12	for	for	IN	_	11	NMOD
13	loading	loading	NN	_	12	PMOD
14	(	(	-LRB-	_	16	P
15	lower	low	JJ	_	16	NMOD
16	panel	panel	NN	_	7	PRN
17	,	,	,	_	16	P
18	taken	take	VBN	_	16	NMOD
19	from	from	IN	_	18	ADV
20	bottom	bottom	JJ	_	21	NMOD
21	half	half	NN	_	19	PMOD
22	of	of	IN	_	21	NMOD
23	6E10	0e0	NN	_	24	NMOD
24	blot	blot	NN	_	22	PMOD
25	)	)	-RRB-	_	16	P
26	.	.	.	_	6	P

1	Figure	figure	NN	_	0	ROOT
2	4	0	CD	_	1	NMOD

1	Suppression	suppression	NN	_	5	SBJ
2	of	of	IN	_	1	NMOD
3	Transgenic	transgenic	JJ	_	4	NMOD
4	APP	app	NN	_	2	PMOD
5	Arrests	arrest	VBZ	_	0	ROOT
6	Progression	progression	NN	_	5	OBJ
7	of	of	IN	_	6	NMOD
8	Amyloid	amyloid	NN	_	9	NMOD
9	Pathology	pathology	NN	_	7	PMOD

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	6	DEP
3	)	)	-RRB-	_	2	P
4	Aggregated	aggregate	VBN	_	5	NMOD
5	Aβ	aβ	NN	_	6	SBJ
6	was	be	VBD	_	0	ROOT
7	quantified	quantify	VBN	_	6	VC
8	in	in	IN	_	7	LOC
9	cortical	cortical	JJ	_	10	NMOD
10	tissue	tissue	NN	_	8	PMOD
11	from	from	IN	_	10	NMOD
12	dox	dox	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	treated	treat	VBN	_	20	NMOD
15	and	and	CC	_	14	COORD
16	control	control	NN	_	15	CONJ
17	tTA	tta	NN	_	19	NMOD
18	/	/	HYPH	_	17	P
19	APP	app	NN	_	20	NMOD
20	mice	mouse	NNS	_	11	PMOD
21	(	(	-LRB-	_	22	P
22	line	line	NN	_	20	PRN
23	107	0	CD	_	22	NMOD
24	)	)	-RRB-	_	22	P
25	using	use	VBG	_	7	MNR
26	a	a	DT	_	29	NMOD
27	filter	filter	NN	_	29	NMOD
28	trap	trap	NN	_	29	NMOD
29	assay	assay	NN	_	25	OBJ
30	.	.	.	_	6	P

1	Serial	serial	JJ	_	2	NMOD
2	dilutions	dilution	NNS	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	protein	protein	NN	_	5	NMOD
5	homogenate	homogenate	NN	_	3	PMOD
6	were	be	VBD	_	21	DEP
7	passed	pass	VBN	_	6	VC
8	through	through	IN	_	7	ADV
9	a	a	DT	_	12	NMOD
10	cellulose	cellulose	NN	_	12	NMOD
11	acetate	acetate	NN	_	12	NMOD
12	filter	filter	NN	_	8	PMOD
13	;	;	:	_	21	P
14	protein	protein	NN	_	15	NMOD
15	aggregates	aggregate	NNS	_	21	SBJ
16	larger	large	JJR	_	15	NMOD
17	than	than	IN	_	16	AMOD
18	the	the	DT	_	20	NMOD
19	pore	pore	NN	_	20	NMOD
20	size	size	NN	_	17	PMOD
21	were	be	VBD	_	0	ROOT
22	trapped	trap	VBN	_	21	VC
23	and	and	CC	_	22	COORD
24	immunostained	immunostained	VBN	_	23	CONJ
25	for	for	IN	_	22	ADV
26	Aβ	aβ	NN	_	25	PMOD
27	.	.	.	_	21	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	25	DEP
3	)	)	-RRB-	_	2	P
4	Quantitation	quantitation	NN	_	25	SBJ
5	of	of	IN	_	4	NMOD
6	signal	signal	NN	_	7	NMOD
7	intensity	intensity	NN	_	5	PMOD
8	in	in	IN	_	4	LOC
9	the	the	DT	_	11	NMOD
10	linear	linear	JJ	_	11	NMOD
11	range	range	NN	_	8	PMOD
12	of	of	IN	_	11	NMOD
13	each	each	DT	_	17	NMOD
14	filter	filter	NN	_	15	NMOD
15	trap	trap	NN	_	17	NMOD
16	dilution	dilution	NN	_	17	NMOD
17	series	series	NNS	_	12	PMOD
18	(	(	-LRB-	_	19	P
19	arrow	arrow	NN	_	17	PRN
20	in	in	IN	_	19	NMOD
21	[	[	-LRB-	_	20	P
22	A	a	NN	_	20	PMOD
23	]	]	-RRB-	_	19	P
24	)	)	-RRB-	_	19	P
25	was	be	VBD	_	0	ROOT
26	used	use	VBN	_	25	VC
27	to	to	TO	_	26	PRP
28	compare	compare	VB	_	27	IM
29	aggregate	aggregate	JJ	_	30	NMOD
30	load	load	NN	_	28	OBJ
31	across	across	IN	_	28	ADV
32	treatment	treatment	NN	_	33	NMOD
33	groups	group	NNS	_	31	PMOD
34	.	.	.	_	25	P

1	Aggregated	aggregate	VBN	_	2	NMOD
2	Aβ	aβ	NN	_	3	SBJ
3	increased	increase	VBD	_	0	ROOT
4	significantly	significantly	RB	_	3	EXT
5	between	between	IN	_	3	TMP
6	6	0	CD	_	9	NMOD
7	and	and	CC	_	6	COORD
8	9	0	CD	_	7	CONJ
9	mo	mo	NN	_	5	PMOD
10	of	of	IN	_	9	NMOD
11	age	age	NN	_	10	PMOD
12	in	in	IN	_	3	LOC
13	untreated	untreated	JJ	_	14	NMOD
14	mice	mouse	NNS	_	12	PMOD
15	(	(	-LRB-	_	29	P
16	significant	significant	JJ	_	17	NMOD
17	effect	effect	NN	_	25	SBJ
18	of	of	IN	_	17	NMOD
19	group	group	NN	_	21	NMOD
20	ANOVA	anova	NN	_	21	NMOD
21	F3	f0	NN	_	18	PMOD
22	,	,	,	_	21	P
23	18	0	CD	_	21	NMOD
24	=	=	SYM	_	25	P
25	7.85	0	CD	_	29	DEP
26	,	,	,	_	29	P
27	p	p	NN	_	29	SBJ
28	<	<	SYM	_	29	P
29	0.002	0	CD	_	3	PRN
30	)	)	-RRB-	_	29	P
31	.	.	.	_	3	P

1	This	this	DT	_	2	NMOD
2	progression	progression	NN	_	5	SBJ
3	of	of	IN	_	2	NMOD
4	pathology	pathology	NN	_	3	PMOD
5	was	be	VBD	_	0	ROOT
6	completely	completely	RB	_	5	ADV
7	prevented	prevent	VBN	_	5	VC
8	by	by	IN	_	7	LGS
9	transgene	transgene	NN	_	10	NMOD
10	suppression	suppression	NN	_	8	PMOD
11	.	.	.	_	5	P

1	The	the	DT	_	2	NMOD
2	amount	amount	NN	_	6	SBJ
3	of	of	IN	_	2	NMOD
4	aggregated	aggregate	VBN	_	5	NMOD
5	Aβ	aβ	NN	_	3	PMOD
6	was	be	VBD	_	0	ROOT
7	identical	identical	JJ	_	6	PRD
8	in	in	IN	_	6	LOC
9	untreated	untreated	JJ	_	10	NMOD
10	mice	mouse	NNS	_	8	PMOD
11	at	at	IN	_	6	TMP
12	6	0	CD	_	13	NMOD
13	mo	mo	NN	_	11	PMOD
14	of	of	IN	_	13	NMOD
15	age	age	NN	_	14	PMOD
16	to	to	IN	_	6	ADV
17	that	that	DT	_	16	PMOD
18	in	in	IN	_	17	LOC
19	9	0	CD	_	24	NMOD
20	-	-	HYPH	_	19	P
21	or	or	CC	_	19	COORD
22	12	0	CD	_	21	CONJ
23	-	-	HYPH	_	19	P
24	mo	mo	NN	_	26	AMOD
25	-	-	HYPH	_	24	P
26	old	old	JJ	_	27	NMOD
27	animals	animal	NNS	_	18	PMOD
28	treated	treat	VBN	_	27	NMOD
29	with	with	IN	_	28	MNR
30	dox	dox	NN	_	29	PMOD
31	(	(	-LRB-	_	40	P
32	p	p	NN	_	34	SBJ
33	>	>	SYM	_	34	P
34	0.9	0	CD	_	40	DEP
35	,	,	,	_	40	P
36	Tukey	tukey	NNP	_	40	NMOD
37	post	post	FW	_	39	AMOD
38	-	-	HYPH	_	37	P
39	hoc	hoc	FW	_	40	NMOD
40	test	test	NN	_	28	PRN
41	)	)	-RRB-	_	40	P
42	.	.	.	_	6	P

1	Single	single	JJ	_	2	AMOD
2	transgenic	transgenic	JJ	_	4	NMOD
3	tTA	tta	NN	_	4	NMOD
4	samples	sample	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	included	include	VBN	_	5	VC
7	as	as	IN	_	6	ADV
8	negative	negative	JJ	_	9	NMOD
9	controls	control	NNS	_	7	PMOD
10	and	and	CC	_	6	COORD
11	showed	show	VBD	_	10	CONJ
12	no	no	DT	_	13	NMOD
13	signal	signal	NN	_	11	OBJ
14	above	above	IN	_	13	NMOD
15	background	background	NN	_	14	PMOD
16	.	.	.	_	5	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.01	0	CD	_	31	DEP
6	;	;	:	_	31	P
7	**	**	SYM	_	11	DEP
8	,	,	,	_	11	P
9	p	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.005	0	CD	_	31	DEP
12	versus	versus	IN	_	11	ADV
13	9	0	CD	_	15	NMOD
14	-	-	HYPH	_	13	P
15	mo	mo	NN	_	17	AMOD
16	-	-	HYPH	_	15	P
17	old	old	JJ	_	19	NMOD
18	untreated	untreated	JJ	_	19	NMOD
19	mice	mouse	NNS	_	12	PMOD
20	,	,	,	_	11	P
21	Tukey	tukey	NNP	_	25	NMOD
22	post	post	FW	_	24	AMOD
23	-	-	HYPH	_	22	P
24	hoc	hoc	FW	_	25	NMOD
25	test	test	NN	_	11	ADV
26	;	;	:	_	31	P
27	***	***	SYM	_	31	DEP
28	,	,	,	_	31	P
29	p	p	NN	_	31	SBJ
30	<	<	SYM	_	31	P
31	0.001	0	CD	_	0	ROOT
32	versus	versus	IN	_	31	ADV
33	9	0	CD	_	35	NMOD
34	-	-	HYPH	_	33	P
35	mo	mo	NN	_	37	AMOD
36	-	-	HYPH	_	35	P
37	old	old	JJ	_	39	NMOD
38	untreated	untreated	JJ	_	39	NMOD
39	mice	mouse	NNS	_	32	PMOD
40	,	,	,	_	31	P
41	Student	student	NNP	_	45	NMOD
42	's	's	POS	_	41	NMOD
43	t	t	NN	_	45	NMOD
44	-	-	HYPH	_	43	P
45	test	test	NN	_	31	ADV
46	.	.	.	_	31	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	5	NMOD
3	)	)	-RRB-	_	2	P
4	Amyloid	amyloid	NN	_	5	NMOD
5	pathology	pathology	NN	_	0	ROOT
6	in	in	IN	_	5	NMOD
7	the	the	DT	_	8	NMOD
8	hippocampus	hippocampus	NN	_	6	PMOD
9	of	of	IN	_	8	NMOD
10	representative	representative	JJ	_	11	NMOD
11	mice	mouse	NNS	_	9	PMOD
12	from	from	IN	_	11	NMOD
13	each	each	DT	_	15	NMOD
14	treatment	treatment	NN	_	15	NMOD
15	group	group	NN	_	19	NMOD
16	:	:	:	_	19	P
17	Hirano	hirano	NNP	_	19	NMOD
18	silver	silver	NN	_	19	NMOD
19	stain	stain	NN	_	12	PMOD
20	(	(	-LRB-	_	22	P
21	top	top	JJ	_	22	NMOD
22	row	row	NN	_	19	PRN
23	)	)	-RRB-	_	22	P
24	,	,	,	_	19	P
25	thioflavin	thioflavin	NN	_	27	NMOD
26	-	-	HYPH	_	25	P
27	S	s	NN	_	19	CONJ
28	(	(	-LRB-	_	30	P
29	middle	middle	JJ	_	30	NMOD
30	row	row	NN	_	27	PRN
31	)	)	-RRB-	_	30	P
32	,	,	,	_	27	P
33	and	and	CC	_	27	COORD
34	Aβ	aβ	NN	_	35	NMOD
35	immunohistochemistry	immunohistochemistry	NN	_	33	CONJ
36	(	(	-LRB-	_	38	P
37	bottom	bottom	JJ	_	38	NMOD
38	row	row	NN	_	35	PRN
39	)	)	-RRB-	_	38	P
40	.	.	.	_	5	P

1	Amyloid	amyloid	NN	_	2	NMOD
2	burden	burden	NN	_	3	SBJ
3	increases	increase	VBZ	_	0	ROOT
4	dramatically	dramatically	RB	_	3	ADV
5	between	between	IN	_	3	ADV
6	6	0	CD	_	9	NMOD
7	and	and	CC	_	6	COORD
8	9	0	CD	_	7	CONJ
9	mo	mo	NN	_	5	PMOD
10	of	of	IN	_	9	NMOD
11	age	age	NN	_	10	PMOD
12	in	in	IN	_	3	LOC
13	untreated	untreated	JJ	_	14	NMOD
14	animals	animal	NNS	_	12	PMOD
15	,	,	,	_	3	P
16	but	but	CC	_	3	COORD
17	remains	remain	VBZ	_	16	CONJ
18	stable	stable	JJ	_	17	PRD
19	in	in	IN	_	17	LOC
20	transgene	transgene	NN	_	22	AMOD
21	-	-	HYPH	_	20	P
22	suppressed	suppress	VBN	_	23	NMOD
23	mice	mouse	NNS	_	19	PMOD
24	over	over	IN	_	17	TMP
25	the	the	DT	_	27	NMOD
26	same	same	JJ	_	27	NMOD
27	period	period	NN	_	24	PMOD
28	(	(	-LRB-	_	34	P
29	6	0	CD	_	30	NMOD
30	mo	mo	NN	_	33	NMOD
31	+	+	SYM	_	33	P
32	3	0	CD	_	33	NMOD
33	mo	mo	NN	_	34	NMOD
34	dox	dox	NN	_	17	PRN
35	and	and	CC	_	34	COORD
36	6	0	CD	_	37	NMOD
37	mo	mo	NN	_	40	NMOD
38	+	+	SYM	_	40	P
39	6	0	CD	_	40	NMOD
40	mo	mo	NN	_	41	NMOD
41	dox	dox	NN	_	35	CONJ
42	)	)	-RRB-	_	34	P
43	.	.	.	_	3	P

1	Single	single	JJ	_	2	AMOD
2	transgenic	transgenic	JJ	_	3	NMOD
3	animals	animal	NNS	_	10	SBJ
4	(	(	-LRB-	_	7	P
5	tTA	tta	NN	_	7	SBJ
6	only	only	RB	_	7	ADV
7	shown	show	VBN	_	3	PRN
8	here	here	RB	_	7	ADV
9	)	)	-RRB-	_	7	P
10	show	show	VBP	_	0	ROOT
11	no	no	DT	_	12	NMOD
12	sign	sign	NN	_	10	OBJ
13	of	of	IN	_	12	NMOD
14	amyloid	amyloid	NN	_	15	NMOD
15	pathology	pathology	NN	_	13	PMOD
16	at	at	IN	_	10	TMP
17	any	any	DT	_	18	NMOD
18	age	age	NN	_	16	PMOD
19	tested	test	VBN	_	18	NMOD
20	.	.	.	_	10	P

1	Figure	figure	NN	_	0	ROOT
2	5	0	CD	_	1	NMOD

1	Aβ	aβ	NN	_	2	NMOD
2	ELISA	elisa	NN	_	3	SBJ
3	Confirms	confirm	VBZ	_	0	ROOT
4	Arrest	arrest	NN	_	3	OBJ
5	of	of	IN	_	4	NMOD
6	Progression	progression	NN	_	5	PMOD
7	without	without	IN	_	3	ADV
8	Clearance	clearance	NN	_	7	PMOD
9	of	of	IN	_	8	NMOD
10	Peptide	peptide	NN	_	9	PMOD
11	in	in	IN	_	3	LOC
12	Mice	mouse	NNS	_	11	PMOD
13	with	with	IN	_	12	NMOD
14	Preexisting	preexist	VBG	_	15	NMOD
15	Aggregates	aggregate	NNS	_	13	PMOD

1	Aβ	aβ	NN	_	2	NMOD
2	levels	level	NNS	_	25	SBJ
3	in	in	IN	_	2	LOC
4	untreated	untreated	JJ	_	18	NMOD
5	6	0	CD	_	10	NMOD
6	-	-	HYPH	_	5	P
7	and	and	CC	_	5	COORD
8	9	0	CD	_	7	CONJ
9	-	-	HYPH	_	5	P
10	mo	mo	NN	_	12	AMOD
11	-	-	HYPH	_	10	P
12	old	old	JJ	_	18	NMOD
13	tTA	tta	NN	_	15	NMOD
14	/	/	HYPH	_	13	P
15	APP	app	NN	_	18	NMOD
16	line	line	NN	_	18	NMOD
17	107	0	CD	_	16	NMOD
18	mice	mouse	NNS	_	3	PMOD
19	(	(	-LRB-	_	20	P
20	shown	show	VBN	_	18	PRN
21	in	in	IN	_	20	ADV
22	Figure	figure	NN	_	21	PMOD
23	4	0	CD	_	22	NMOD
24	)	)	-RRB-	_	20	P
25	were	be	VBD	_	0	ROOT
26	compared	compare	VBN	_	25	VC
27	to	to	IN	_	26	ADV
28	those	those	DT	_	27	PMOD
29	in	in	IN	_	28	LOC
30	9	0	CD	_	35	NMOD
31	-	-	HYPH	_	30	P
32	and	and	CC	_	30	COORD
33	12	0	CD	_	32	CONJ
34	-	-	HYPH	_	30	P
35	mo	mo	NN	_	37	AMOD
36	-	-	HYPH	_	35	P
37	old	old	JJ	_	38	NMOD
38	animals	animal	NNS	_	29	PMOD
39	treated	treat	VBN	_	38	NMOD
40	with	with	IN	_	39	MNR
41	dox	dox	NN	_	40	PMOD
42	from	from	IN	_	39	TMP
43	the	the	DT	_	44	NMOD
44	age	age	NN	_	42	PMOD
45	of	of	IN	_	44	NMOD
46	6	0	CD	_	47	NMOD
47	mo	mo	NN	_	45	PMOD
48	.	.	.	_	25	P

1	Single	single	JJ	_	2	AMOD
2	transgenic	transgenic	JJ	_	4	NMOD
3	APP	app	NN	_	4	NMOD
4	samples	sample	NNS	_	5	SBJ
5	were	be	VBD	_	0	ROOT
6	included	include	VBN	_	5	VC
7	as	as	IN	_	6	ADV
8	negative	negative	JJ	_	9	NMOD
9	controls	control	NNS	_	7	PMOD
10	.	.	.	_	5	P

1	Cortical	cortical	JJ	_	2	NMOD
2	homogenates	homogenate	NNS	_	3	SBJ
3	were	be	VBD	_	0	ROOT
4	fractionated	fractionate	VBN	_	3	VC
5	by	by	IN	_	4	MNR
6	sequential	sequential	JJ	_	8	NMOD
7	multi-step	multi-step	JJ	_	8	NMOD
8	extraction	extraction	NN	_	5	PMOD
9	with	with	IN	_	4	MNR
10	PBS	pb	NN	_	9	PMOD
11	,	,	,	_	10	P
12	2	0	CD	_	13	NMOD
13	%	%	NN	_	14	NMOD
14	SDS	sd	NN	_	10	CONJ
15	,	,	,	_	14	P
16	and	and	CC	_	14	COORD
17	70	0	CD	_	18	NMOD
18	%	%	NN	_	19	NMOD
19	FA	fa	NN	_	16	CONJ
20	followed	follow	VBN	_	10	NMOD
21	by	by	IN	_	20	LGS
22	human	human	JJ	_	24	AMOD
23	-	-	HYPH	_	22	P
24	specific	specific	JJ	_	26	NMOD
25	Aβ	aβ	NN	_	26	NMOD
26	ELISA	elisa	NN	_	21	PMOD
27	to	to	TO	_	4	PRP
28	measure	measure	VB	_	27	IM
29	transgene	transgene	NN	_	31	AMOD
30	-	-	HYPH	_	29	P
31	derived	derive	VBN	_	32	NMOD
32	peptide	peptide	NN	_	28	OBJ
33	in	in	IN	_	28	ADV
34	each	each	DT	_	35	NMOD
35	fraction	fraction	NN	_	33	PMOD
36	.	.	.	_	3	P

1	Aβ40	aβ0	NN	_	2	SBJ
2	is	be	VBZ	_	0	ROOT
3	shown	show	VBN	_	2	VC
4	in	in	IN	_	3	ADV
5	white	white	JJ	_	4	PMOD
6	,	,	,	_	3	P
7	Aβ42	aβ0	NN	_	3	GAP-SBJ
8	in	in	IN	_	7	ADV
9	black	black	JJ	_	8	PMOD
10	.	.	.	_	2	P

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	16	DEP
3	and	and	CC	_	2	COORD
4	B	b	LS	_	3	CONJ
5	)	)	-RRB-	_	2	P
6	Most	most	JJS	_	7	NMOD
7	Aβ	aβ	NN	_	16	SBJ
8	in	in	IN	_	7	LOC
9	the	the	DT	_	10	NMOD
10	brains	brain	NNS	_	8	PMOD
11	of	of	IN	_	10	NMOD
12	plaque	plaque	NN	_	14	AMOD
13	-	-	HYPH	_	12	P
14	bearing	bear	VBG	_	15	NMOD
15	mice	mouse	NNS	_	11	PMOD
16	is	be	VBZ	_	0	ROOT
17	extracted	extract	VBN	_	16	VC
18	into	into	IN	_	17	ADV
19	the	the	DT	_	23	NMOD
20	FA	fa	NN	_	23	NMOD
21	and	and	CC	_	20	COORD
22	SDS	sd	NN	_	21	CONJ
23	fractions	fraction	NNS	_	18	PMOD
24	.	.	.	_	16	P

1	Consistent	consistent	JJ	_	29	ADV
2	with	with	IN	_	1	AMOD
3	amyloid	amyloid	NN	_	4	NMOD
4	burden	burden	NN	_	2	PMOD
5	(	(	-LRB-	_	6	P
6	Figures	figure	NNS	_	4	PRN
7	4	0	CD	_	6	NMOD
8	and	and	CC	_	6	COORD
9	Figure	figure	NN	_	10	NMOD
10	S3	s0	NN	_	8	CONJ
11	)	)	-RRB-	_	6	P
12	,	,	,	_	29	P
13	SDS	sd	NN	_	18	AMOD
14	-	-	HYPH	_	13	P
15	and	and	CC	_	13	COORD
16	FA	fa	NN	_	15	CONJ
17	-	-	HYPH	_	13	P
18	extracted	extract	VBN	_	20	NMOD
19	Aβ	aβ	NN	_	20	NMOD
20	levels	level	NNS	_	29	SBJ
21	in	in	IN	_	20	LOC
22	untreated	untreated	JJ	_	28	NMOD
23	9	0	CD	_	25	NMOD
24	-	-	HYPH	_	23	P
25	mo	mo	NN	_	27	AMOD
26	-	-	HYPH	_	25	P
27	old	old	JJ	_	28	NMOD
28	mice	mouse	NNS	_	21	PMOD
29	were	be	VBD	_	0	ROOT
30	significantly	significantly	RB	_	31	AMOD
31	higher	high	JJR	_	29	PRD
32	than	than	IN	_	31	AMOD
33	in	in	IN	_	32	LOC
34	untreated	untreated	JJ	_	40	NMOD
35	6	0	CD	_	37	NMOD
36	-	-	HYPH	_	35	P
37	mo	mo	NN	_	39	AMOD
38	-	-	HYPH	_	37	P
39	old	old	JJ	_	40	NMOD
40	mice	mouse	NNS	_	33	PMOD
41	(	(	-LRB-	_	69	P
42	Tukey	tukey	NNP	_	46	NMOD
43	post	post	FW	_	45	AMOD
44	-	-	HYPH	_	43	P
45	hoc	hoc	FW	_	46	NMOD
46	test	test	NN	_	69	DEP
47	applied	apply	VBN	_	46	NMOD
48	to	to	IN	_	47	ADV
49	significant	significant	JJ	_	50	NMOD
50	effect	effect	NN	_	48	PMOD
51	of	of	IN	_	50	NMOD
52	group	group	NN	_	53	NMOD
53	ANOVA	anova	NN	_	51	PMOD
54	for	for	IN	_	50	NMOD
55	SDS	sd	NN	_	58	NMOD
56	and	and	CC	_	55	COORD
57	FA	fa	NN	_	56	CONJ
58	fractions	fraction	NNS	_	54	PMOD
59	F3	f0	NN	_	63	SBJ
60	,	,	,	_	59	P
61	18	0	CD	_	59	NMOD
62	=	=	SYM	_	63	P
63	4.72	0	CD	_	69	DEP
64	–	–	SYM	_	63	P
65	12.92	0	CD	_	63	QMOD
66	,	,	,	_	69	P
67	p	p	NN	_	69	SBJ
68	<	<	SYM	_	69	P
69	0.02	0	CD	_	29	PRN
70	)	)	-RRB-	_	69	P
71	.	.	.	_	29	P

1	In	in	IN	_	11	ADV
2	contrast	contrast	NN	_	1	PMOD
3	,	,	,	_	11	P
4	3	0	CD	_	7	NMOD
5	or	or	CC	_	4	COORD
6	6	0	CD	_	5	CONJ
7	mo	mo	NN	_	11	SBJ
8	of	of	IN	_	7	NMOD
9	transgene	transgene	NN	_	10	NMOD
10	suppression	suppression	NN	_	8	PMOD
11	held	hold	VBD	_	0	ROOT
12	Aβ	aβ	NN	_	11	OBJ
13	at	at	IN	_	11	ADV
14	levels	level	NNS	_	13	PMOD
15	equivalent	equivalent	JJ	_	14	NMOD
16	to	to	IN	_	15	AMOD
17	those	those	DT	_	16	PMOD
18	harbored	harbor	VBN	_	17	NMOD
19	when	when	WRB	_	22	ADV
20	treatment	treatment	NN	_	21	SBJ
21	was	be	VBD	_	18	TMP
22	started	start	VBN	_	21	VC
23	(	(	-LRB-	_	26	P
24	p	p	NN	_	26	SBJ
25	>	>	SYM	_	26	P
26	0.2	0	CD	_	11	PRN
27	compared	compare	VBN	_	26	ADV
28	to	to	IN	_	27	PMOD
29	6	0	CD	_	30	NMOD
30	mo	mo	NN	_	32	NMOD
31	untreated	untreated	JJ	_	32	NMOD
32	mice	mouse	NNS	_	28	PMOD
33	,	,	,	_	26	P
34	Tukey	tukey	NNP	_	38	NMOD
35	post	post	FW	_	37	AMOD
36	-	-	HYPH	_	35	P
37	hoc	hoc	FW	_	38	NMOD
38	test	test	NN	_	26	ADV
39	)	)	-RRB-	_	26	P
40	.	.	.	_	11	P

1	*	*	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.05	0	CD	_	17	DEP
6	;	;	:	_	17	P
7	**	**	SYM	_	11	DEP
8	,	,	,	_	11	P
9	p	p	NN	_	11	SBJ
10	<	<	SYM	_	11	P
11	0.005	0	CD	_	17	DEP
12	;	;	:	_	17	P
13	***	***	SYM	_	17	DEP
14	,	,	,	_	17	P
15	p	p	NN	_	17	SBJ
16	<	<	SYM	_	17	P
17	0.001	0	CD	_	0	ROOT
18	versus	versus	IN	_	17	ADV
19	9	0	CD	_	21	NMOD
20	-	-	HYPH	_	19	P
21	mo	mo	NN	_	23	AMOD
22	-	-	HYPH	_	21	P
23	old	old	JJ	_	25	NMOD
24	untreated	untreated	JJ	_	25	NMOD
25	mice	mouse	NNS	_	18	PMOD
26	,	,	,	_	17	P
27	Tukey	tukey	NNP	_	31	NMOD
28	post	post	FW	_	30	AMOD
29	-	-	HYPH	_	28	P
30	hoc	hoc	FW	_	31	NMOD
31	test	test	NN	_	17	ADV
32	.	.	.	_	17	P

1	Significance	significance	NN	_	12	SBJ
2	for	for	IN	_	1	NMOD
3	APP	app	NN	_	2	PMOD
4	versus	versus	CC	_	3	COORD
5	9	0	CD	_	7	NMOD
6	-	-	HYPH	_	5	P
7	mo	mo	NN	_	9	AMOD
8	-	-	HYPH	_	7	P
9	old	old	JJ	_	11	NMOD
10	untreated	untreated	JJ	_	11	NMOD
11	mice	mouse	NNS	_	4	CONJ
12	is	be	VBZ	_	0	ROOT
13	based	base	VBN	_	12	VC
14	on	on	IN	_	13	ADV
15	Student	student	NNP	_	19	NMOD
16	's	's	POS	_	15	NMOD
17	t	t	NN	_	19	NMOD
18	-	-	HYPH	_	17	P
19	test	test	NN	_	14	PMOD
20	.	.	.	_	12	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	7	DEP
3	)	)	-RRB-	_	2	P
4	The	the	DT	_	6	NMOD
5	PBS	pb	NN	_	6	NMOD
6	fraction	fraction	NN	_	7	SBJ
7	represents	represent	VBZ	_	36	DEP
8	less	less	JJR	_	11	NMOD
9	than	than	IN	_	8	QMOD
10	0.1	0	CD	_	8	QMOD
11	%	%	NN	_	7	OBJ
12	of	of	IN	_	11	NMOD
13	total	total	JJ	_	14	NMOD
14	Aβ	aβ	NN	_	12	PMOD
15	(	(	-LRB-	_	16	P
16	note	note	VB	_	14	PRN
17	the	the	DT	_	18	NMOD
18	change	change	NN	_	16	OBJ
19	in	in	IN	_	16	ADV
20	y	y	NN	_	22	NMOD
21	-	-	HYPH	_	20	P
22	axis	ax	NN	_	19	PMOD
23	from	from	IN	_	16	ADV
24	[	[	-LRB-	_	23	P
25	A	a	NN	_	23	PMOD
26	]	]	-RRB-	_	25	P
27	and	and	CC	_	25	COORD
28	[	[	-LRB-	_	29	P
29	B	b	NN	_	27	CONJ
30	]	]	-RRB-	_	16	P
31	)	)	-RRB-	_	16	P
32	,	,	,	_	36	P
33	but	but	CC	_	36	COORD
34	only	only	RB	_	35	AMOD
35	here	here	RB	_	36	ADV
36	do	do	VB	_	0	ROOT
37	Aβ	aβ	NN	_	38	NMOD
38	levels	level	NNS	_	36	SBJ
39	in	in	IN	_	38	LOC
40	the	the	DT	_	44	NMOD
41	dox	dox	NN	_	43	AMOD
42	-	-	HYPH	_	41	P
43	treated	treat	VBN	_	44	NMOD
44	mice	mouse	NNS	_	39	PMOD
45	differ	differ	VBP	_	36	VC
46	from	from	IN	_	45	ADV
47	those	those	DT	_	46	PMOD
48	in	in	IN	_	45	LOC
49	younger	young	JJR	_	51	NMOD
50	untreated	untreated	JJ	_	51	NMOD
51	mice	mouse	NNS	_	48	PMOD
52	.	.	.	_	36	P

1	Although	although	IN	_	23	ADV
2	both	both	DT	_	3	NMOD
3	peptides	peptide	NNS	_	4	SBJ
4	appear	appear	VBP	_	1	SUB
5	elevated	elevated	JJ	_	4	OPRD
6	in	in	IN	_	4	ADV
7	the	the	DT	_	9	NMOD
8	treated	treat	VBN	_	9	NMOD
9	groups	group	NNS	_	6	PMOD
10	compared	compare	VBN	_	4	ADV
11	to	to	IN	_	10	PMOD
12	the	the	DT	_	19	NMOD
13	untreated	untreated	JJ	_	19	NMOD
14	6	0	CD	_	16	NMOD
15	-	-	HYPH	_	14	P
16	mo	mo	NN	_	18	AMOD
17	-	-	HYPH	_	16	P
18	old	old	JJ	_	19	NMOD
19	mice	mouse	NNS	_	11	PMOD
20	,	,	,	_	23	P
21	only	only	RB	_	22	NMOD
22	Aβ40	aβ0	NN	_	23	SBJ
23	reaches	reach	VBZ	_	0	ROOT
24	statistical	statistical	JJ	_	25	NMOD
25	significance	significance	NN	_	23	OBJ
26	(	(	-LRB-	_	53	P
27	p	p	NN	_	29	SBJ
28	<	<	SYM	_	29	P
29	0.05	0	CD	_	53	DEP
30	,	,	,	_	53	P
31	Tukey	tukey	NNP	_	35	NMOD
32	post	post	FW	_	34	AMOD
33	-	-	HYPH	_	32	P
34	hoc	hoc	FW	_	35	NMOD
35	test	test	NN	_	53	DEP
36	applied	apply	VBN	_	35	NMOD
37	to	to	IN	_	36	ADV
38	significant	significant	JJ	_	39	NMOD
39	effect	effect	NN	_	37	PMOD
40	of	of	IN	_	39	NMOD
41	group	group	NN	_	42	NMOD
42	ANOVA	anova	NN	_	40	PMOD
43	for	for	IN	_	39	NMOD
44	Aβ40	aβ0	NN	_	43	PMOD
45	F3	f0	NN	_	49	SBJ
46	,	,	,	_	45	P
47	18	0	CD	_	45	NMOD
48	=	=	SYM	_	49	P
49	4.60	0	CD	_	53	DEP
50	,	,	,	_	53	P
51	p	p	NN	_	53	SBJ
52	<	<	SYM	_	53	P
53	0.02	0	CD	_	23	PRN
54	)	)	-RRB-	_	53	P
55	.	.	.	_	23	P

1	A	a	DT	_	3	NMOD
2	similar	similar	JJ	_	3	NMOD
3	trend	trend	NN	_	4	SBJ
4	was	be	VBD	_	36	DEP
5	seen	see	VBN	_	4	VC
6	for	for	IN	_	5	ADV
7	Aβ42	aβ0	NN	_	6	PMOD
8	,	,	,	_	5	P
9	where	where	WRB	_	11	ADV
10	ANOVA	anova	NN	_	11	SBJ
11	yielded	yield	VBD	_	5	ADV
12	a	a	DT	_	14	NMOD
13	significant	significant	JJ	_	14	NMOD
14	effect	effect	NN	_	11	OBJ
15	of	of	IN	_	11	ADV
16	group	group	NN	_	15	PMOD
17	for	for	IN	_	11	ADV
18	PBS	pb	NN	_	20	AMOD
19	-	-	HYPH	_	18	P
20	soluble	soluble	JJ	_	21	NMOD
21	Aβ42	aβ0	NN	_	17	PMOD
22	(	(	-LRB-	_	31	P
23	F3	f0	NN	_	27	SBJ
24	,	,	,	_	23	P
25	18	0	CD	_	23	NMOD
26	=	=	SYM	_	27	P
27	3.75	0	CD	_	31	DEP
28	,	,	,	_	31	P
29	p	p	NN	_	31	SBJ
30	<	<	SYM	_	31	P
31	0.03	0	CD	_	11	PRN
32	)	)	-RRB-	_	31	P
33	,	,	,	_	36	P
34	however	however	RB	_	36	ADV
35	this	this	DT	_	36	SBJ
36	was	be	VBD	_	0	ROOT
37	due	due	IN	_	36	PRD
38	only	only	RB	_	37	PMOD
39	to	to	IN	_	37	PMOD
40	differences	difference	NNS	_	37	PMOD
41	between	between	IN	_	40	NMOD
42	the	the	DT	_	52	NMOD
43	untreated	untreated	JJ	_	52	NMOD
44	6	0	CD	_	49	NMOD
45	-	-	HYPH	_	44	P
46	and	and	CC	_	44	COORD
47	9	0	CD	_	46	CONJ
48	-	-	HYPH	_	44	P
49	mo	mo	NN	_	51	AMOD
50	-	-	HYPH	_	49	P
51	old	old	JJ	_	52	NMOD
52	groups	group	NNS	_	41	PMOD
53	.	.	.	_	36	P

1	•	•	SYM	_	5	DEP
2	,	,	,	_	5	P
3	p	p	NN	_	5	SBJ
4	<	<	SYM	_	5	P
5	0.05	0	CD	_	25	DEP
6	versus	versus	IN	_	5	ADV
7	6	0	CD	_	9	NMOD
8	-	-	HYPH	_	7	P
9	mo	mo	NN	_	11	AMOD
10	-	-	HYPH	_	9	P
11	old	old	JJ	_	13	NMOD
12	untreated	untreated	JJ	_	13	NMOD
13	mice	mouse	NNS	_	6	PMOD
14	,	,	,	_	5	P
15	Tukey	tukey	NNP	_	19	NMOD
16	post	post	FW	_	18	AMOD
17	-	-	HYPH	_	16	P
18	hoc	hoc	FW	_	19	NMOD
19	test	test	NN	_	5	ADV
20	;	;	:	_	25	P
21	•••	•••	SYM	_	25	DEP
22	,	,	,	_	25	P
23	p	p	NN	_	25	SBJ
24	<	<	SYM	_	25	P
25	0.001	0	CD	_	0	ROOT
26	versus	versus	IN	_	25	ADV
27	6	0	CD	_	29	NMOD
28	-	-	HYPH	_	27	P
29	mo	mo	NN	_	31	AMOD
30	-	-	HYPH	_	29	P
31	old	old	JJ	_	33	NMOD
32	untreated	untreated	JJ	_	33	NMOD
33	mice	mouse	NNS	_	26	PMOD
34	,	,	,	_	25	P
35	Student	student	NNP	_	39	NMOD
36	's	's	POS	_	35	NMOD
37	t	t	NN	_	39	NMOD
38	-	-	HYPH	_	37	P
39	test	test	NN	_	25	ADV
40	.	.	.	_	25	P

1	Figure	figure	NN	_	0	ROOT
2	6	0	CD	_	1	NMOD

1	Neuritic	neuritic	JJ	_	4	NMOD
2	and	and	CC	_	1	COORD
3	Glial	glial	JJ	_	2	CONJ
4	Pathology	pathology	NN	_	5	SBJ
5	Are	be	VBP	_	0	ROOT
6	Unchanged	unchanged	JJ	_	5	PRD
7	following	follow	VBG	_	5	TMP
8	Transgene	transgene	NN	_	9	NMOD
9	Suppression	suppression	NN	_	7	PMOD

1	Dystrophic	dystrophic	JJ	_	2	NMOD
2	neurites	neurites	NNS	_	6	SBJ
3	and	and	CC	_	2	COORD
4	activated	activate	VBN	_	5	NMOD
5	astrocytes	astrocyte	NNS	_	3	CONJ
6	surround	surround	VBP	_	0	ROOT
7	most	most	JJS	_	9	NMOD
8	compact	compact	JJ	_	9	NMOD
9	plaques	plaque	NNS	_	6	OBJ
10	in	in	IN	_	6	LOC
11	tet	tet	NN	_	13	NMOD
12	-	-	HYPH	_	11	P
13	off	off	NN	_	15	NMOD
14	APP	app	NN	_	15	NMOD
15	mice	mouse	NNS	_	10	PMOD
16	(	(	-LRB-	_	17	P
17	line	line	NN	_	6	PRN
18	107	0	CD	_	17	NMOD
19	)	)	-RRB-	_	17	P
20	.	.	.	_	6	P

1	Dark	dark	NN	_	3	AMOD
2	-	-	HYPH	_	1	P
3	stained	stain	VBN	_	8	NMOD
4	,	,	,	_	8	P
5	ubiquitin	ubiquitin	NN	_	7	AMOD
6	-	-	HYPH	_	5	P
7	filled	fill	VBN	_	8	NMOD
8	neurites	neurites	NNS	_	12	SBJ
9	and	and	CC	_	8	COORD
10	reactive	reactive	JJ	_	11	NMOD
11	astrocytes	astrocyte	NNS	_	9	CONJ
12	form	form	VBP	_	0	ROOT
13	a	a	DT	_	14	NMOD
14	halo	halo	NN	_	12	OBJ
15	around	around	IN	_	12	LOC
16	cored	core	VBN	_	19	NMOD
17	,	,	,	_	19	P
18	fibrillar	fibrillar	JJ	_	19	NMOD
19	deposits	deposit	NNS	_	15	PMOD
20	by	by	IN	_	12	TMP
21	6	0	CD	_	22	NMOD
22	mo	mo	NN	_	20	PMOD
23	of	of	IN	_	22	NMOD
24	age	age	NN	_	23	PMOD
25	that	that	WDT	_	26	SBJ
26	worsens	worsen	VBZ	_	14	NMOD
27	with	with	IN	_	26	ADV
28	time	time	NN	_	27	PMOD
29	in	in	IN	_	12	LOC
30	untreated	untreated	JJ	_	31	NMOD
31	mice	mouse	NNS	_	29	PMOD
32	.	.	.	_	12	P

1	Both	both	DT	_	5	NMOD
2	plaque	plaque	NN	_	4	AMOD
3	-	-	HYPH	_	2	P
4	associated	associate	VBN	_	5	NMOD
5	pathologies	pathology	NNS	_	6	SBJ
6	are	be	VBP	_	0	ROOT
7	arrested	arrest	VBN	_	6	VC
8	,	,	,	_	7	P
9	although	although	IN	_	7	ADV
10	not	not	RB	_	9	SUB
11	reversed	reverse	VBN	_	10	DEP
12	,	,	,	_	7	P
13	by	by	IN	_	7	LGS
14	transgene	transgene	NN	_	15	NMOD
15	suppression	suppression	NN	_	13	PMOD
16	.	.	.	_	6	P

1	Hirano	hirano	NNP	_	3	NMOD
2	silver	silver	NN	_	3	NMOD
3	stain	stain	NN	_	17	NMOD
4	(	(	-LRB-	_	6	P
5	top	top	JJ	_	6	NMOD
6	row	row	NN	_	3	PRN
7	)	)	-RRB-	_	6	P
8	;	;	:	_	17	P
9	GFAP	gfap	NN	_	10	NMOD
10	immunohistochemistry	immunohistochemistry	NN	_	17	NMOD
11	(	(	-LRB-	_	13	P
12	middle	middle	JJ	_	13	NMOD
13	row	row	NN	_	10	PRN
14	)	)	-RRB-	_	13	P
15	;	;	:	_	17	P
16	ubiquitin	ubiquitin	NN	_	17	NMOD
17	immunohistochemistry	immunohistochemistry	NN	_	0	ROOT
18	(	(	-LRB-	_	20	P
19	bottom	bottom	JJ	_	20	NMOD
20	row	row	NN	_	17	PRN
21	)	)	-RRB-	_	20	P
22	.	.	.	_	17	P

1	Figure	figure	NN	_	0	ROOT
2	7	0	CD	_	1	NMOD

1	Transgene	transgene	NN	_	2	NMOD
2	Suppression	suppression	NN	_	3	SBJ
3	Attenuates	attenuate	VBZ	_	0	ROOT
4	Hyperactivity	hyperactivity	NN	_	3	OBJ
5	in	in	IN	_	3	LOC
6	tTA	tta	NN	_	8	NMOD
7	/	/	HYPH	_	6	P
8	APP	app	NN	_	9	NMOD
9	Mice	mouse	NNS	_	5	PMOD

1	(	(	-LRB-	_	2	P
2	A	a	LS	_	11	DEP
3	)	)	-RRB-	_	2	P
4	A	a	DT	_	8	NMOD
5	48	0	CD	_	7	NMOD
6	-	-	HYPH	_	5	P
7	h	h	NN	_	8	NMOD
8	measure	measure	NN	_	11	SBJ
9	of	of	IN	_	8	NMOD
10	ambulation	ambulation	NN	_	9	PMOD
11	records	record	VBZ	_	0	ROOT
12	extreme	extreme	JJ	_	13	NMOD
13	hyperactivity	hyperactivity	NN	_	11	OBJ
14	in	in	IN	_	11	LOC
15	untreated	untreated	JJ	_	18	NMOD
16	double	double	JJ	_	17	AMOD
17	transgenic	transgenic	JJ	_	18	NMOD
18	mice	mouse	NNS	_	14	PMOD
19	compared	compare	VBN	_	11	ADV
20	to	to	IN	_	19	PMOD
21	single	single	JJ	_	22	AMOD
22	transgenic	transgenic	JJ	_	25	NMOD
23	and	and	CC	_	22	COORD
24	nontransgenic	nontransgenic	JJ	_	23	CONJ
25	controls	control	NNS	_	20	PMOD
26	(	(	-LRB-	_	27	P
27	line	line	NN	_	11	PRN
28	107	0	CD	_	27	NMOD
29	)	)	-RRB-	_	27	P
30	.	.	.	_	11	P

1	This	this	DT	_	2	NMOD
2	phenotype	phenotype	NN	_	3	SBJ
3	is	be	VBZ	_	0	ROOT
4	completely	completely	RB	_	3	ADV
5	eliminated	eliminate	VBN	_	3	VC
6	by	by	IN	_	5	LGS
7	rearing	rear	VBG	_	6	PMOD
8	the	the	DT	_	11	NMOD
9	double	double	JJ	_	10	AMOD
10	transgenic	transgenic	JJ	_	11	NMOD
11	mice	mouse	NNS	_	7	OBJ
12	on	on	IN	_	7	ADV
13	dox	dox	NN	_	12	PMOD
14	.	.	.	_	3	P

1	(	(	-LRB-	_	2	P
2	B	b	LS	_	12	DEP
3	)	)	-RRB-	_	2	P
4	The	the	DT	_	6	NMOD
5	same	same	JJ	_	6	NMOD
6	data	datum	NNS	_	12	SBJ
7	shown	show	VBN	_	6	NMOD
8	in	in	IN	_	7	ADV
9	(	(	-LRB-	_	8	P
10	A	a	NN	_	8	PMOD
11	)	)	-RRB-	_	12	P
12	are	be	VBP	_	0	ROOT
13	replotted	replotted	VBN	_	12	VC
14	to	to	TO	_	13	PRP
15	magnify	magnify	VB	_	14	IM
16	data	datum	NNS	_	15	OBJ
17	from	from	IN	_	16	NMOD
18	untreated	untreated	JJ	_	19	NMOD
19	control	control	NN	_	24	NMOD
20	and	and	CC	_	19	COORD
21	dox	dox	NN	_	23	AMOD
22	-	-	HYPH	_	21	P
23	treated	treat	VBN	_	20	CONJ
24	groups	group	NNS	_	17	PMOD
25	.	.	.	_	12	P

1	(	(	-LRB-	_	2	P
2	C	c	LS	_	21	DEP
3	and	and	CC	_	2	COORD
4	D	d	LS	_	3	CONJ
5	)	)	-RRB-	_	2	P
6	Activity	activity	NN	_	7	NMOD
7	levels	level	NNS	_	21	SBJ
8	in	in	IN	_	7	NMOD
9	the	the	DT	_	12	NMOD
10	combined	combine	VBN	_	12	NMOD
11	control	control	NN	_	12	NMOD
12	groups	group	NNS	_	8	PMOD
13	of	of	IN	_	12	NMOD
14	(	(	-LRB-	_	13	P
15	A	a	NN	_	13	PMOD
16	)	)	-RRB-	_	15	P
17	and	and	CC	_	15	COORD
18	(	(	-LRB-	_	19	P
19	B	b	NN	_	17	CONJ
20	)	)	-RRB-	_	21	P
21	are	be	VBP	_	0	ROOT
22	here	here	RB	_	21	LOC
23	separated	separate	VBN	_	21	VC
24	by	by	IN	_	23	ADV
25	genotype	genotype	NN	_	24	PMOD
26	.	.	.	_	21	P

1	None	none	NN	_	10	SBJ
2	of	of	IN	_	1	NMOD
3	the	the	DT	_	9	NMOD
4	single	single	JJ	_	5	AMOD
5	transgenic	transgenic	JJ	_	9	NMOD
6	or	or	CC	_	5	COORD
7	nontransgenic	nontransgenic	JJ	_	8	NMOD
8	control	control	NN	_	6	CONJ
9	groups	group	NNS	_	2	PMOD
10	display	display	VBP	_	0	ROOT
11	the	the	DT	_	12	NMOD
12	hyperactivity	hyperactivity	NN	_	10	OBJ
13	present	present	JJ	_	12	NMOD
14	in	in	IN	_	10	LOC
15	untreated	untreated	JJ	_	19	NMOD
16	tTA	tta	NN	_	18	NMOD
17	/	/	HYPH	_	16	P
18	APP	app	NN	_	19	NMOD
19	animals	animal	NNS	_	14	PMOD
20	.	.	.	_	10	P

1	Again	again	RB	_	3	ADV
2	,	,	,	_	3	P
3	note	note	VBP	_	0	ROOT
4	the	the	DT	_	7	NMOD
5	y	y	NN	_	7	NMOD
6	-	-	HYPH	_	5	P
7	axes	ax	NNS	_	8	SBJ
8	have	have	VBP	_	3	OBJ
9	been	be	VBN	_	8	VC
10	enlarged	enlarge	VBN	_	9	VC
11	for	for	IN	_	10	ADV
12	detail	detail	NN	_	11	PMOD
13	compared	compare	VBN	_	10	ADV
14	to	to	IN	_	13	PMOD
15	(	(	-LRB-	_	14	P
16	A	a	NN	_	14	PMOD
17	)	)	-RRB-	_	3	P
18	.	.	.	_	3	P

1	Footnotes	footnote	NNS	_	0	ROOT

1	Citation	citation	NN	_	0	ROOT
2	:	:	:	_	1	P
3	Jankowsky	jankowsky	NNP	_	1	CIT
4	JL	jl	NNP	_	3	DEP
5	,	,	,	_	3	P
6	Slunt	slunt	NNP	_	3	DEP
7	HH	hh	NNP	_	3	DEP
8	,	,	,	_	3	P
9	Gonzales	gonzales	NNP	_	3	DEP
10	V	v	NNP	_	3	DEP
11	,	,	,	_	3	P
12	Savonenko	savonenko	NNP	_	3	DEP
13	AV	av	NNP	_	3	DEP
14	,	,	,	_	3	P
15	Wen	wen	NNP	_	3	DEP
16	JC	jc	NNP	_	3	DEP
17	,	,	,	_	3	P
18	et	et	FW	_	3	DEP
19	al.	al.	FW	_	3	DEP
20	(	(	-LRB-	_	3	P
21	2005	0	CD	_	3	DEP
22	)	)	-RRB-	_	3	P
23	Persistent	persistent	JJ	_	24	NMOD
24	amyloidosis	amyloidosis	NN	_	1	DEP
25	following	follow	VBG	_	24	TMP
26	suppression	suppression	NN	_	25	PMOD
27	of	of	IN	_	26	NMOD
28	Aβ	aβ	NN	_	29	NMOD
29	production	production	NN	_	27	PMOD
30	in	in	IN	_	24	NMOD
31	a	a	DT	_	33	NMOD
32	transgenic	transgenic	JJ	_	33	NMOD
33	model	model	NN	_	30	PMOD
34	of	of	IN	_	33	NMOD
35	Alzheimer	alzheimer	NNP	_	36	NMOD
36	disease	disease	NN	_	34	PMOD
37	.	.	.	_	1	P

1	PLoS	plo	NNP	_	0	ROOT
2	Med	med	NNP	_	1	DEP
3	2	0	CD	_	1	DEP
4	(	(	-LRB-	_	1	P
5	12	0	CD	_	1	DEP
6	)	)	-RRB-	_	1	P
7	:	:	:	_	1	P
8	e355	e0	NN	_	1	DEP
9	.	.	.	_	1	P

